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General introduction 
 
 
  
 
  Chapter 1 
Streptococcus pneumoniae was discovered by Sternberg and Pasteur in 1880. It took 
another six years to discover that this microorganism, called the pneumococcus, was the 
actual cause of bacterial pneumonia 1. Subsequently, this bacterium has been shown to 
provoke an impressive number of diseases, which can be roughly classified in respiratory 
and invasive. Respiratory diseases by S. pneumoniae are sinusitis, otitis media, bronchitis 
and pneumonia, of which the latter one may be complicated by septicemia 2. Disseminated 
invasive infections caused by the pneumococcus include sepsis, meningitis, endocarditis 
and arthritis 2. Morbidity and mortality are high both in the developing and the developed 
world: annually 3 million people die worldwide of pneumococcal infections. Approximately 1 
million are children under the age of five years 3. Risk groups for pneumococcal disease are 
children younger than 2 years, elderly people and immunocompromised patients 2. In 
children, the increased risk for pneumococcal infections is mainly due to a relatively 
immature immune response to type II T-cell independent (TI-2) antigens such as capsular 
polysaccharides 4. In the elderly, the ability of both the innate as well as the adaptive 
immunity to respond to pneumococcal infection are thought to decline 5. In addition, higher 
rates of pneumococcal invasive diseases have been observed among populations such as 
Alaskan Natives, American Indians and African Americans 6. Patient groups who are at risk 
for particular variants of pneumococcal diseases are well defined. For example functional 
asplenia as in sickle cell disease as well as anatomic asplenia are serious risk factors for 
pneumococcal sepsis. This is due to the absence or dysfunction of the spleen, which is 
involved in systemic clearance of S. pneumoniae 2. In addition, complement deficiency and 
lower levels of circulating antibodies are thought to contribute to the increased susceptibility 
to pneumococcal infections in patients with sickle cell disease and other 
haemoglobinopathies 6. A relatively new risk group for pneumococcal meningitis are children 
with a cochlear implantation 7. Disease in these patients is thought to occur by the presence 
of a continuum between the outer ear and the inner skull. In general, patients with 
cerebrospinal fluid leakage, immunodeficiencies, chronic cardiovascular and pulmonary 
disease, HIV infections and diabetes mellitus are considered at risk for pneumococcal 
invasive disease 2,6.  
Nasopharyngeal carriage of S. pneumoniae is common. The majority of infants become 
colonized at least once early in life. Pneumococcal colonization is mostly asymptomatic and 
not followed by disease. However, in situations of disturbance of the host-pathogen balance, 
for example through viral infection, malnutrition or local damage of the mucosa, 
asymptomatic colonization can proceed to (invasive) disease (Figure 1) 8-10. In addition, 
healthy individuals with asymptomatic pneumococcal carriage may spread this pathogen 
within the community. Especially crowding of individuals as occurs in hospitals, day-care 
centers and jails has been shown to enhance the horizontal spread of pneumococci 11-13. 
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Because the highest incidence in pneumococcal colonization and the highest crowding 
index is found in young children, this risk group is believed to be the most important vector 
for horizontal dissemination of pneumococcal strains within the community 14. The 
nasopharynx is also believed to be the main reservoir and thus source of acquisition, 
exchange and spread of antibiotic resistance among pneumococcal isolates 15. Penicillin- 
and multidrug-resistant pneumococci have emerged in several countries over the last 
decades. In some of these countries, up to 60% of the pneumococci are resistant to one or 
more antibiotics 16-18. A significant proportion of pneumococcal resistance is the result of 
worldwide spread of a limited number of multidrug-resistant clones 19-22.  
Until recently, intervention strategies by means of vaccination failed in the major risk group 
of young children. Recently, a 7-valent conjugate vaccine has shown to be highly efficacious 
against pneumococcal invasive disease caused by the predominant serotypes in young 
children. Moreover, the vaccine partially protects against diseases such as pneumonia and 
otitis media 23-26. Unfortunately, the coverage of the conjugate vaccine is limited to 7 of the 
more than 90 known pneumococcal serotypes, which may result in replacement of vaccine 
serotypes by non-vaccine serotypes after vaccination. Several studies have shown that this 
replacement phenomenon occurs at the nasopharyngeal level 27. Whether this observation 
will also occur with respect to disease remains unclear. 
In conclusion, nasopharyngeal colonization is of crucial importance in the pathogenesis of 
infection with, resistance to, spread of and intervention against S. pneumoniae and, 
therefore, important to study in more detail. Though many studies have investigated overall 
pneumococcal colonization and serotype distributions in young children, few of these have 
extended the age group until adulthood. Therefore no data are available on the natural 
dynamics of pneumococcal colonization and serotype distribution with increasing age. In 
addition, few studies have been performed on the molecular epidemiology of pneumococci 
with respect to colonization and infection, although these are extremely important to 
generate knowledge about pneumococci, especially in the context of vaccination. Moreover, 
only a limited number of studies have investigated the effect of conjugate vaccination on 
colonization. Therefore, in this thesis we asked ourselves the following questions: a) what is 
the prevalence and which are the determinants of nasopharyngeal colonization with S. 
pneumoniae and other pathogenic bacteria in children, b) is nasopharyngeal colonization 
with S. pneumoniae during health and (mucosal) infection a static or dynamic process, and 
c) how efficiently do antibiotic-resistant pneumococci spread within the population and which 
events are involved in the acquisition and spread of resistance and resistance genes in 
pneumococci? In addition we asked d) what the effect of pneumococcal vaccination is on 
colonization and infection with S. pneumoniae and e) what the response of the host immune 
system is and what  type  of  response  occurs with  respect  to  pneumococcal  colonization, 
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infection and vaccination.  
In Chapter 2, we discuss the mechanism of pneumococcal colonization and the importance 
of colonization for pneumococcal disease. In Chapter 3, the epidemiology and determinants 
for pneumococcal colonization and the interaction with other nosocomial pathogens are 
described. In Chapter 4, we specifically focus on the molecular behavior of drug-resistant 
pneumococci in Greece and The Netherlands. In Chapter 5, the molecular dynamics of 
colonization and infection with S. pneumoniae, especially the acquisition and spread of 
resistance is investigated. In Chapter 6, an update on the current vaccination strategies is 
provided, followed by the description of the impact of pneumococcal conjugate vaccination 
on colonization and infection with Streptococcus pneumoniae in Chapter 7. Finally, in 
Chapter 8 our most recent studies regarding the host immune response to pneumococcal 
infection and vaccination are presented.  
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ABSTRACT 
Streptococcus pneumoniae is an important pathogen causing invasive diseases such as 
sepsis, meningitis and pneumonia. The burden of disease is highest in the youngest and 
oldest parts of the population in both developed and developing countries. The therapy of 
pneumococcal infections is complicated by the worldwide emergence of resistance to 
penicillin and other antibiotics. Especially in children pneumococcal disease is preceded by 
asymptomatic colonisation.  
The current 7-valent conjugate vaccine is highly efficacious against invasive disease caused 
by the vaccine type strains. However, the vaccine coverage is limited and replacement by 
non-vaccine serotypes resulting in disease is a serious threat for the near future. Therefore, 
the search for new vaccine candidates that elicit protection against a broader range of 
pneumococcal strains is still an important field of investigation.  To this respect, several 
surface-associated protein vaccines are currently studied. Another important matter of 
debate is whether to prevent pneumococcal disease by eradication of nasopharyngeal 
colonisation, or whether to aim for the prevention of bacterial invasion leaving colonisation 
relatively unaffected and hence, preventing the occurrence of replacement colonisation and 
disease.   
To illustrate the importance of pneumococcal colonisation in relation to pneumococcal 
disease and prevention of disease we will discuss in detail the mechanism and epidemiology 
of colonisation, the complexity of inter- and intra-species relations, and the consequences of 
the different preventive strategies for pneumococcal colonisation. 
                                            Streptococcus pneumoniae colonisation 
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INTRODUCTION 
Streptococcus pneumoniae is a common cause of invasive disease and respiratory tract 
infections in developing as well as developed countries. Risk groups for pneumococcal 
infections such as meningitis, sepsis and pneumonia include young children, the elderly and 
patients with immunodeficiencies 1. Annually, 1 million children under the age of 5 years die 
due to pneumonia and invasive diseases. In the United States, the yearly incidence of fatal 
pneumococcal infection is 40.000 deaths 2. Community-acquired pneumococcal meningitis 
has a very high case-fatality rate (20% and 50% in developed and developing countries, 
respectively). Depending on the age, 30%-60% of the survivors develop long-term sequelae 
including hearing-loss, neurological deficits and neuropsychological impairment 3.  
Protection against pneumococcal infections is mediated by opsonin-dependent 
phagocytosis. This antibody-initiated complement-dependent opsonisation, which activates 
the classical complement pathway, is considered to be the major immune mechanism 
protecting the host against infections with pneumococci 4. The mechanism of clearance 
depends on the interaction of type-specific antibodies (IgA, IgM, IgG), complement and 
neutrophils or phagocytic cells from lung, liver and spleen. The absence of the spleen or 
cirrhosis of the liver predisposes for severe pneumococal infection. Congenital deficiencies 
in immunoglobulin or complement are also associated with predisposition to pneumococcal 
infection 5. S. pneumoniae is part of the commensal flora of the upper respiratory tract. 
Together with Moraxella cattarrhalis, Haemophilus influenzae, Neisseria meningitidis, 
Staphylococcus aureus and various haemolytic streptococci, they colonise the 
nasopharyngeal niche. Though colonisation with pneumococci is mostly asymptomatic, it 
can progress to respiratory or even systemic disease (Figure 1). Importantly, pneumococcal 
disease will not occur without being preceded by nasopharyngeal colonisation with the 
homologous strain 6,7. In addition, pneumococcal carriage is believed to be an important 
source of horizontal spread of this pathogen within the community. Especially, crowding like 
in hospitals, day-care centres and jails has shown to enhance horizontal spread of 
pneumococcal strains 8-16. Because the highest incidence in pneumococcal colonisation and 
the highest crowding index is found in young children, this risk group is believed to be the 
most important vector for horizontal dissemination of pneumococcal strains within the 
community 17. Therefore, part of the prevention strategies for pneumococcal disease focus 
on prevention of nasopharyngeal colonisation, especially in children. 
Because of the key role for nasopharyngeal colonisation in pneumococcal disease and 
pneumococcal spread, we will focus in this review on the different aspects of 
nasopharyngeal colonisation in children. In order to gain insight into the route of 
pneumococcal disease we will discuss the current knowledge on the mechanism of 
18   Chapter 2 
 
colonisation, the epidemiology and determinants of pneumococcal carriage, and the actual 
status of prevention of colonisation by means of vaccination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pathogenic route for S. pneumoniae infection (adapted from Obaro et al., J. Med. Microbiol. 2002;51: 98-
104). In dark and light grey the organs infected through the hematogenic and airborn route, respectively, are depicted.  
 
 
SEARCH STRATEGY AND SELECTION CRITERIA 
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English language papers were reviewed.  
 
 
DYNAMICS OF NASOPHARYNGEAL COLONISATION 
The upper respiratory tract is the ecological niche for many bacterial species. In children, the 
nasopharyngeal flora becomes established during the first months of life 18,19. A broad 
variety of microorganisms including S. pneumoniae, H. influenzae and M. catarrhalis may 
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colonise the nasopharyngeal niche. It is estimated that all humans are colonised with these 
pathogens at least once during life. In most cases, this concerns asymptomatic carriage, but 
occasionally colonisation is followed by disease 20,21. Colonisation is commonly followed by 
horizontal dissemination of these pathogens to individuals in the direct environment leading 
to spread within the community 22-24. The reported rates of bacterial acquisition and carriage 
depend on age, geographical area, genetic background and socio-economic conditions 11,24-
27. The local host immune response plays an important regulatory role in the trafficking of 
pathogens in the upper respiratory tract 28. A poor mucosal immune response may lead to 
persistent and recurrent colonisation and consequently infection, whereas a brisk local 
immune response to the pathogen will eliminate colonisation and prevent re-colonisation 
29,30. In general, mucosal immunity matures earlier than systemic immunity, and is detected 
from the age of 6 months 29. IgG as well as secretory IgA antibodies directed against 
capsular polysaccharides and surface-associated proteins have been observed in saliva of 
children in response to colonisation with S. pneumoniae 31,32.  
Nasopharyngeal colonisation is a dynamical process regarding the turnover of colonising 
species and serotypes. Moreover, interspecies competition is believed to be present and to 
interfere with the composition of the nasopharyngeal flora. First of all, the balance between 
the resident flora and transient invaders is important. To this purpose, the resident flora 
including α-haemolytic streptococci have shown to inhibit S. pneumoniae, H. influenzae, S. 
aureus as well as M. catarrhalis 23,29,33,34. The importance of this inhibitory role has been 
shown by Ghaffar et al., who found a competitive balance between α-haemolytic 
streptococci and S. pneumoniae and H. influenzae, which could be altered by antibiotics. 
Faden et al. reported a negative correlation between viridans streptococci and S. 
pneumoniae, H. influenzae and M. catarrhalis with the last three becoming predominant 
during upper respiratory tract infections 23,35.  
In addition, a competitive relation between the different pathogenic species exists. In vitro 
studies of Pericone et al. have shown a significant correlation between N. meningitidis and 
S. pneumoniae. S. pneumoniae growth did increase in the presence of meningococci, a 
process probably mediated by meningococcal catalase. However, meningococcal growth 
was decreased in the presence of pneumococci or pneumococcal culture supernatant. The 
authors attributed the latter effect to the presence of pneumococcal peroxide 36. This 
inhibitory effect of S. pneumoniae was also observed in co-cultures with H. influenzae and 
M. catarrhalis. Moreover, S. pneumoniae may interfere with the growth of S. aureus, which 
has also been assigned to pneumococcal hydrogen peroxide 37,38. Bogaert et al. showed in 
a cross-sectional carriage study among 3200 children that this interspecies competition 
between S. aureus and S. pneumoniae significantly contributes to the age-related dynamics 
of nasopharyngeal colonisation in children 39, which was recently confirmed by data of 
20     Chapter 2 
Regev-Yochay et al. 40. Bogaert et al. found parallel to the age-related decline of 
pneumococcal colonisation, caused by the maturation of the immune system, a 
simultaneous increase in S. aureus ranging from 10% in the first years of life to a maximum 
carriage rate of 50% at the age of ten years was found. In addition to these ecological 
interactions, the composition of the nasopharyngeal niche was influenced by environmental 
factors such as crowding and smoking 39. Finally, limited evidence is available for the 
competition between the different pneumococcal serotypes. For example, Lipsitch et al. 
have used a mouse model of intranasal carriage of pneumococci to test whether competition 
occurs between different pneumococcal strains. They have found reduced levels of 
colonization with a serotype 6B strain when challenged intranasally with a serotype 23F 
pneumococcus. This inhibitory effect could be overcome by increasing the dose of the 
challenge strain 41. We have to realise, that interference in this complex pattern of interaction 
and inhibition by means of vaccination may have serious and unpredictable consequences 
for the composition of the entire nasopharyngeal population.  
 
 
MECHANISM OF COLONISATION 
The pneumococcal outer surface is covered by a polysaccharide capsule. Capsular 
polysaccharides are highly heterogeneous, and thus far, almost 100 different capsular 
serotypes have been described 5. The polysaccharide capsule is the most important 
virulence factor of the pneumococcus since it protects the bacteria from phagocytosis 42. 
Reduced expression results in greater access of antibodies and complement to the 
pneumococcal surface 43, and hence, increased clearance by the immune system. Capsular 
polysaccharides are highly immunogenic and antibodies against these polysaccharides 
protect against infection with the homologous serotype by induction of opsonophagocytosis. 
The antigenicity of the capsule is type-specific, however, cross-reaction can occur because 
of shared polysaccharide epitopes 5. 
The layer underneath the capsule, the cell wall, consists of polysaccharides and teichoic 
acid and serves as an anchor for cell wall associated surface proteins (CBPs). The cell wall 
is responsible for the intense inflammatory reaction that accompanies pneumococcal 
infection as it stimulates the influx of inflammatory cells and activates the complement 
cascade, and cytokine production 44. The cell wall is believed to be protected from the host 
response by the surrounding polysaccharide capsule.  
Colonisation of S. pneumoniae requires adherence to the epithelial lining of the respiratory 
tract. Asymptomatic colonisation involves pneumococcal binding to cell-surface 
carbohydrates (GlcNAc) on non-inflamed resting epithelium. Adherence to these sugars is 
mediated  by CBPs, like pneumococcal  surface adhesion  A  (PsaA) (Figure 2). In  addition, 
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Figure 2. Interaction between S. pneumoniae and epithelial cells. Neuraminidase (NanA) decreases the viscosity of the 
mucus and exposes the N-acetyl-glycosamine (GlcNAc) receptors on the epithelial cells, which are able to interact with 
pneumococcal surface associated proteins like PsaA. In response to cytokine stimulation, host epithelial cells 
upregulate the platelet activating receptors (PAFr). The pneumococcus has increased affinity via its cell-wall 
phosphocholine (ChoP) for PAFr. Moreover, a second choline binding protein, CbpA, displays increased affinity for 
immobilised sialic acid and lacto-N-neotreatose, and binds directly to the polymeric Ig receptor (pIgR), which enhances 
migration through the mucosal barrier (transcytosis). Pneumococcal IgA1 protease cleaves opsonizing IgA, which 
results in a change (neutralisation) of surface charge and increases the physical proximity of ChoP to the PAF 
receptor. 
 
CPBs contribute to the hydrophobic and electrostatic surface characteristics of pneumococci 
and may facilitate adherence to host cells partially through non-specific, physiochemical 
interactions 45. In general, colonisation is not followed by symptomatic disease. Conversion 
of asymptomatic colonisation to invasive disease requires the local generation of 
inflammatory factors like interleukin-1 and tumor necrosis factor, as seen in the presence of 
viral infections 46. This inflammatory cascade changes the type and number of receptors on 
target epithelial and endothelial cells. Pneumococcal cell wall choline (ChoP) shows 
increased affinity for one of these upregulated receptors, the platelet activating factor (PAF) 
receptor. Binding to the PAF receptor induces internalisation of pneumococci and promotes 
the transcellular migration through respiratory epithelium as well as vascular endothelium, 
pneumococcus
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resulting in invasion of living bacteria (Figure 2) 47,48. In addition, one of the CBPs, choline 
binding protein A (CbpA) shows increased affinity for immobilised sialic acid and lacto-N-
neotetraose on cytokine-activated human cells 49. Moreover, CbpA directly interacts with the 
polymeric Ig receptor (pIgR) which enhances migration through the mucosal barrier 50. How 
the pneumococcus escapes endocytosis-mediated killing remains unclear 46,51. The function 
of IgA1 protease has recently been unravelled by Weiser et al. They showed an enhanced 
adherence of pneumococci to lung epithelial cells in the presence of human IgA. This effect 
is thought to occur due to the cleavage of opsonising IgA by IgA1 protease, which results in 
change of surface charge and increased physical proximity of ChoP to the PAF receptor 
52,53. In addition, CbpA binds to the secretory component of IgA and interacts with the 
complement pathway, thus interfering with the human immune-response 50,54. Another 
pneumococcal enzyme neuraminidase (NanA), enhances colonisation by cleaving N-
acetylneuraminic acid from mucin decreasing the viscosity of the mucus. NanA also cleaves 
glycolipids, glycoproteins and oligosaccharides, and thus is thought to be responsible for 
exposing the N-acetyl-glycosamine receptors on the host epithelial cells 55. In this way, the 
neuraminidase activity of viruses like influenza and parainfluenza viruses may contribute to 
the increased adherence of pneumococci observed during viral infections 56. Variability in 
the composition, expression or exposure of surface-associated proteins may explain 
differences in colonisation and invasion capacities between strains. The complexity of this 
process is underlined by previous studies of Weiser et al., in which they identified a 
reversible phenotypic variation within pneumococcal strains and its role in host interaction. 
Transparent phase variants show enhanced adherence compared to opaque variants. This 
phenotypic variation is associated with the lower expression of capsule polysaccharides, 
and higher expression of certain cell surface proteins and carbohydrate containing cell wall 
structures 57-59.  
With increasing knowledge about the mechanisms of colonisation, the surface-associated 
proteins have become of major interest as potential vaccine candidates. Although surface-
associated proteins like pneumolysin and PspA have shown to elicit protection against 
systemic diseases, PsaA and CbpA have proven to be promising candidates for prevention 
of colonisation 50,60. Theoretically, enhanced protection against colonisation and infection 
with S. pneumoniae may be expected when a combination of proteins with distinct roles in 
bacterial virulence is used. 
 
 
PNEUMOCOCCAL COLONISATION IN CHILDREN 
Nasopharyngeal colonisation of S. pneumoniae in children is primarily age dependent. 
Recently,  the age-dependent  carriage  rate  was  investigated  in  a  large cohort of healthy  
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children ranging from 1 to 19 years of age. The peak-incidence of pneumococcal 
colonisation was 55% at the age of 3 years. This was followed by a steady decline until a 
stable prevalence was observed of 8% after the age of 10 years 39. Although most other 
colonisation studies have not extended the age of children until adulthood, the few studies 
that did study this show a comparable decline 61-63. In contrast, in the first year of life the 
nasopharyngeal niche will become colonised. Therefore, pneumococcal carriage shows an 
increase before the age of two years (Table 1)73,82.  For example, in a Finnish study the 
incidence of nasopharyngeal carriage in children 2 to 24 months of age increased from 13% 
under 6 months of age to 43% in children older than 19 months of age 67. This percentage 
increased during respiratory infections to 22-45%, supporting the theory of enhanced 
adherence during (viral) infections.  
In the healthy population, risk factors also seem to determine the incidence of 
pneumococcal carriage. Independent determinants for nasopharyngeal colonisation are 
ethnicity, crowding, environmental and socio-economic factors. Socio-economic and 
environmental risk factors include family size, specifically the number of older siblings, 
income, smoking (passive and active) and recent antibiotic use 11,17,29,64,84. Crowding is a 
major factor in colonisation and in spread of pneumococcal strains. In young children, 
especially day-care visits are correlated to significant increased colonisation rates (Table 1) 
24,39,75,82-87. In a day-care study in The Netherlands a 1.6-fold increased risk of 
nasopharyngeal colonisation of pneumococci in day-care centre attendees was found 
compared to children who were taken care for at home 24. In addition, this study has shown 
increased genetic clustering among pneumococcal isolates, which is in line with previous 
reports 87-89. This supports the hypothesis of increased horizontal spread of specific 
pneumococcal strains among day-care centre attendees 24. In agreement with these 
findings, Raymond et al. reported a colonisation rate of up to 82% in infants living in an 
orphanage 80. Furthermore, close relatedness between the pneumococcal isolates was 
found in this study, suggesting frequent horizontal spread.  
According to ethnicity, risk-groups for pneumococcal colonisation as well as invasive 
disease are African American, native American (Apache and Navajo) and Alaskan native 
populations 90. The risk for invasive pneumococcal diseases in children 24-35 months of age 
is 64.7 cases per 100.000, whereas African American citizens in the USA have a risk 
incidence of 116.4 per 100.000 and native Americans 73-227 cases per 100.000 90. For 
example, the risk for invasive disease in American native population is increased to such a 
degree that the Advisory Committee for Immunization Practices (ACIP; USA) has 
recommended  pneumococcal   vaccination  for  this  population  in all age groups 1. Also for 
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children attending day-care centres the risk of pneumococcal infection is so high that 
immunisation with a 7-valent pneumococcal conjugate vaccine (Prevnar, Wyeth, USA) 
covering the most prevalent serotypes 4, 6B, 9V, 14, 18C, 19F and 23F is advised. 
Pneumococcal colonisation, especially colonisation with antibiotic-resistant pneumococci is 
also increased as a result of recent antibiotic treatment 35,84. It is commonly assumed that 
the selection of antibiotic-resistant pneumococci at the nasopharynx causes the spread of 
resistant pneumococcal strains within the comunity 78. Consequently, several multidrug-
resistant clones have already spread throughout the world 91,92. 
Not all risk groups for pneumococcal diseases show increased prevalences of colonisation 
compared to the general population. For example children with HIV and sickle cell disease 
have similar colonisation rates compared to healthy children (Table 1) 71,93. Their 
predisposition is presumably caused by the underlying immune disorder: instead of a defect 
or augmented challenge of the primary defence mechanism against pneumococal invasion, 
an immune disorder is present related to an impaired response to or clearance mechanism 
for pneumococci after invasion has occurred. For children with HIV/AIDS, CD4 positive T-
cells, necessary for an appropriate anti-polysaccharide response, are decreased, whereas 
for children with sickle cell disease the 
splenic function, involved in direct 
phagocytosis and initiation of the anti-
polysaccharide response, is impaired. 
However, the primary mucosal barrier 
including the mucosal immune response 
is still intact in these patients 93,94.  
In Table 1 recent colonisation studies in 
different areas of the world are 
summarised. Though variable 
colonisation rates have been observed, 
the colonisation rates are higher during 
respiratory tract infections and otitis 
media and in risk groups like day-care 
centre attendees compared to healthy 
populations. An additional difference is 
the tendency towards lower colonisation 
rates when nasopharyngeal samples 
were obtained via the oropharynx 
compared with the transnasal approach, 
though this was more obvious in  healthy  
Figure 3. A nasopharyngeal swab is taken from a 10-year 
old girl during a large cohort study in Rotterdam, The 
Netherlands (September 2002). The nasopharynx is 
approached via the nasal route: the swab is passed gently 
back from one nostril along the floor of the nasal cavity until 
it touches the posterior wall of the nasopharynx. After 
gentle rubbing or twisting for 1-2 seconds the swab is 
withdrawn. The swab is stored in stuart transport medium 
and plated within 6 hours onto gentamycin blood agar 
plates. 
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children than in risk groups. For future research, we believe the transnasal route for 
approaching the nasopharynx will be preferable (Figure 3). 
 
SEROTYPE DISTRIBUTION AMONG PNEUMOCOCCAL ISOLATES  
The serotype distribution among nasopharyngeal carriage isolates shows slightly variable 
results depending on the country, age group and type of cohort. First of all, Europe and the 
United States show comparable serotype distributions with minor differences regarding 
several serotypes. For example, in The Netherlands serotype 19F (19%), 6B (16%), 6A 
(13%), 9V (7%) and 23F (7%) are most frequently found among children under 3 years of 
age 24. Comparable results originate from Greece where the most predominant serotypes 
among children younger than 2 years of age are 6B, 19F, 23F, 14 and 18C 65, and from 
Finland where the serotypes 6B (16%), 23F (14%), 19F (14%) and 6A (9%) are most 
prevalent 67. In the United States, the serotypes 6B, 14, 19F and 23F are also highly 
prevalent 95. In Asia, similar serotypes and serogroups have been found among 
nasopharyngeal isolates in healthy children. For example, in India the most common 
serogroups are 6, 14, 19 and 15 64,66 and in Vietnam the serogroups 19, 23, 14, 6 and 18 72. 
The serogroup distribution in Indonesia is slightly different, with the most common 
serogroups being 6 (25%) and 23 (21%) followed by 15 (8%), 33 (8%), 19 (6%), 12 (5%) 
and 3 (4%) 68. In Kenya, serotype 13 was besides the serotypes 15, 14, 6B and 19F most 
predominantly present 69. In South Africa a similar distribution was found with the exception 
of serotype 13 which was not found at all 96. 
No major differences were found in the serotype distribution among children with risk factors 
such as day care centre attendance and upper respiratory tract infections compared to 
healthy children 24,67,75.  
In contrast, a major variable is the age group investigated. In general, the incidence of 
vaccine serotypes is declining with age 97. In a recent study in The Netherlands, 
nasopharyngeal carriage of vaccine-type strains generally declined from 30% at the age of 
one year to 3% at the age of eight years, after which a stable prevalence was observed until 
the age of 19 years. In contrast, non-conjugate vaccine serotypes, especially serotype 3, 8, 
10, 11 and 15 show an initial increase till the age of 7-10 years after which a delayed decline 
compared to the vaccine serotypes was observed 39.  
In general the serotype distribution among nasopharyngeal isolates from different parts of 
the world is rather similar. This is also reflected by the potential conjugate vaccine coverage 
(Table 1). As shown by Lloyd-Evans et al., invasive disease originates from nasopharyngeal 
colonisation with the homologous serotype 98. Therefore, the serotype distribution of 
colonisation isolates should be representative for invasive disease, antibiotic resistance 
profiles and potential vaccine coverage. Alternatively, certain serotypes and genotypes 
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seem to cause invasive diseases more often when corrected for prevalence of 
nasopharyngeal colonisation 98. This is recently shown by Brueggemann et al. who found 
serotype and clone-specific differences in invasive disease potential with an increased 
capacity to cause disease for specific serotype 14 and 18C clones 99. In contrast, the most 
commonly carried serotypes 6B, 19F and 23F are least invasive, whereas certain non-
vaccine serotypes (8, 38, 33F) are infrequent colonisers but appear to be more invasive. 
This counts in particular for the serotypes 5, 7F and 1 100,101. This knowledge is extremely 
important in view of the replacement of colonising strains observed after conjugate 
vaccination. Therefore, surveillance of pneumococcal invasive disease and colonisation 
isolates remains a necessity in those countries where large-scale pneumococcal vaccination 
is initiated. 
 
 
CURRENT VACCINE STRATEGIES 
The ACIP has recommended vaccination against pneumococcal infections for several risk 
groups. Although the 23-valent vaccine, with a theoretical coverage of 85-90% of the 
circulating strains, has shown to be immunogenic in adults and children > 5 years of age, 
children < 2 years of age have a severely impaired antibody response upon polysaccharide 
vaccination 94,102-104. Therefore, the recommendations of the ACIP in 1997 excluded the 
major risk group of children under 2 years of age. The remaining groups were 
immunocompetent children above 2 years of age at increased risk for illness and death 
associated with pneumococcal disease because of chronic cardiac and pulmonary diseases, 
persons older than 2 years with functional or anatomic asplenia and immunocompromised 
patients above 2 years of age 1. Fortunately, the new generation of conjugate vaccines is 
highly immunogenic in children under 2 years of age. Moreover, these vaccines elicit 
immunological memory 105. In several large recent studies, a 7-valent conjugate vaccine had 
an almost 100% efficacy against invasive diseases caused by the serotypes included 106,107. 
The new vaccines contain polysaccharides of 7-11 pneumococcal serotypes conjugated to a 
carrier protein inducing a T-cell-dependent immune response which is already present in 
humans from birth on. The ACIP therefore changed the childhood recommendations for 
pneumococcal vaccination in 2000. Vaccination with the 7-valent conjugate vaccine Prevnar 
(Wyeth, USA) for all children under two years of age and in children 2-5 years of age at 
increased risk of pneumococcal disease is advised. In the latter case, conjugate vaccination 
is followed by a polysaccharide booster because this has been shown to improve 
pneumococcal antibody titers in this age group 108. The conjugate vaccine is highly effective 
against invasive disease caused by vaccine serotype strains. The efficacy against mucosal 
diseases such as pneumonia and otitis media is much lower and more difficult to measure 
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because culture based proof of diagnosis are often missing 106,107,109,110. Moreover, several 
investigators have shown a significant reduction in nasopharyngeal carriage of vaccine type 
pneumococci as a result of conjugate vaccination 96,97,111-113. In addition to individual 
protection, diminished colonisation is thought to elicit protection against pneumococcal 
colonisation and disease in the vaccinated community, i.e. herd immunity. Dagan and co-
workers for example have shown a decreased colonisation rate in siblings of day-care 
centre attendees who were vaccinated with a 9-valent conjugate vaccine 114. Moreover, 
penicillin and multidrug resistance is common among pneumococcal strains, especially 
among the conjugate vaccine serotypes. Therefore, it has been suggested that conjugate 
vaccination will also reduce resistance among pneumococcal strains in vaccinated 
individuals as well as the open community as a result of herd immunity 90. Recently, Dagan 
et al. have proven a significant reduction in penicillin- and multidrug resistance among 
carriage strains as a result of vaccination with a nine-valent conjugate vaccine 115. 
Unfortunately, the 7-11 valent vaccines cover a limited number of serotypes. Protection is 
also dependent on the geographic area with a potential coverage of the 7-valent conjugate 
vaccine for invasive strains of over 85% for the USA, 60-70% for Europe and around 55% 
for Asia 90, although a large proportion of these differences might be explained by variation 
in blood-culture practices 116. In addition to the limited coverage of these conjugate vaccines, 
another long-term risk needs to be considered. Because of the limited coverage of 
circulating pneumococcal strains by the conjugate-vaccine, the remaining non-vaccine 
serotype strains will actually benefit from this selective immunological pressure. A 
phenomenon called replacement may occur, causing a shift in serotype strains circulating in 
the population and, consequently, in disease. Since the start of large-scale vaccination trials, 
replacement has been observed in subjects colonised with pneumococci as well as in 
patients with acute otitis media 79,96,110. So far, the effect of this phenomenon on invasive 
diseases remains unclear. However, though not yet significant, the first alarming findings 
have been reported on partial replacement of invasive strains with non-vaccine serotypes in 
vivo 117. In addition, Brueggemann et al. have shown a high invasive capacity for certain 
non-vaccine serotypes, which may also imply that replacement of carriage will lead to 
replacement of disease 99. Thus, close monitoring of serotype distribution among invasive as 
well as colonisation strains remains of major importance. In Table 2, the seven studies that 
investigated the impact of conjugate vaccination on nasopharyngeal colonisation are 
summarised. In two studies, no significant effect was observed on the overall pneumococcal 
colonisation nor on vaccine type carriage 95,111. In the remaining studies, a positive effect of 
vaccination was found on colonisation of vaccine serotype pneumococci. However, 
replacement of these strains with non-vaccine serotypes reduced the effect on overall 
pneumococcal colonisation. 
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NEW VACCINE STRATEGIES 
New vaccine strategies focus on the use of pneumococcal surface-associated proteins. This 
approach has several potential advantages. First of all, the production of protein vaccines is 
expected to be cheaper thus within reach of developing countries. Secondly, a protein-
based vaccine is expected to elicit protection in all age groups, including children under 2 
years of age. Finally, in case highly conserved proteins or protein epitopes will be used as 
vaccine components, broad and serotype-independent protection can be expected. 
However, the level and type of protection will be influenced by the function of the protein(s) 
included in the vaccine. We will illustrate this by discussing the most promising protein 
vaccine candidates. 
Pneumococcal surface protein A (PspA) belongs to the family of structurally related choline-
binding surface proteins and is able to interfere with complement fixation by blocking 
recruitment of the alternative pathway through reduction of the amount of C3b, deposited on 
the pneumococci, thereby reducing the effectiveness of the complement receptor mediated 
pathways of clearance 121-124. This is particularly important when bacterial invasion has 
occurred and suggests a significant role for PspA in the maintenance of invasive 
pneumococcal disease. Active immunisation data with PspA in animal models yields a 
protective effect against invasive infections and to a lesser extent against mucosal disease 
and nasopharyngeal carriage 125-128. The first phase I vaccination trial with a single 
recombinant PspA variant in humans showed induction of cross-reactive antibodies to 
heterologous PspA molecules 129, which were found to protect mice challenged 
intraperitoneally with pneumococci 130. 
Another candidate is pneumococcal surface adhesin A (PsaA), a member of the family of 
metal binding lipoproteins, part of an ABC transporter complex thought to be involved in the 
transport of manganese into pneumococci 131,132. This protein is mainly involved in 
asymptomatic colonisation 46. The first immunisation studies with PsaA have shown 
significant protection against colonisation but limited to modest protection against invasive 
infections 60,133-135. Recently, Seo et al. have shown that oral vaccination of mice with PsaA 
encapsulated in microalginate microspheres elicits significant protection against 
colonisation, pneumonia as well as septicaemia when challenged orally 136. These data 
suggest that vaccination with PsaA elicits primary protection against colonisation with 
secondary protection against invasive disease. However, clinical studies on the correlation 
between anti-PsaA antibodies and the risk of pneumococcal AOM have shown contradictory 
results. Rapola et al. have shown an association between a higher anti-PsaA antibody titer 
and lower risk of pneumococcal AOM, but only in children older then 9 months of age, 
whereas in children younger than 9 months of age the risk was increased with higher anti-
PsaA concentration 137,138. These data suggest a basic difference between age-groups with 
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respect to protectivity of anti-PsaA antibodies, and perhaps to the origin of the antibody 
response. A higher anti-PsaA antibody titer might be associated with increased 
pneumococcal contacts in the past, i.e. through colonisation as well as through infection. 
Consequently, this might explain the correlation with the underlying increased susceptibility 
to pneumococcal AOM rather than a decreased risk of infections. 
Pneumolysin is a protein that also contains a choline-binding domain, and is suggested to 
interfere with host immunity and inflammatory responses by a variety of functions, including 
complement fixation and inhibition of phagocyte function. It also inhibits ciliary activity in the 
bronchus and is thus important in pathogenesis of pulmonary infection 139. Knock-out 
mutagenesis of genes encoding pneumolysin has suggested its role in virulence, in 
colonisation as well as in infection 140-142. Several investigators described the protective 
properties of pneumolysin against challenge with pneumococci in mice, albeit only against 
invasive diseases 143,144. The combination of PspA and pneumolysin yields complementary 
protection to invasive diseases in animal models 60,126. Additionally, the combination of PsaA 
and PspA has been shown to prevent colonisation and otitis media in animal models 126,132. 
Hence, depending on the target, a different combination of vaccine components may be 
used. The optimal combination of proteins for vaccination remains to be determined.  
Alternative routes of vaccination are also explored. Several recent studies suggest that 
administration of a vaccine via the oral or nasal route is as effective as systemic application 
125,128,136. In addition, a recent study by Lynch et al. has shown that intranasal administration 
of a conjugate vaccine plus interleukin-12 not only elicits protection against invasive disease 
but, in contrast to intramuscular administration, also induces protection against nasal 
carriage 145. The latter effect occurs through the induction of significant mucosal IgA 
responses. A mucosal route of administration is highly preferable because it is less invasive 
and the number of vaccines already administered intramuscularly to children, as part of 
community vaccination programs is high. Moreover, in contrast to pneumococcal conjugate 
vaccines and polysaccharide vaccines, protection is also expected in children with 
HIV/AIDS, even during progression of disease, because of the intact mucosal immune 
response in these patients 136.  
 
 
DISCUSSION 
Nasopharyngeal colonisation provides an important key to the burden of pneumococcal 
disease and its prevention. Nasopharyngeal colonisation is not only obligatory for invasive 
disease, it also provides the basis for horizontal spread of the species.  
Although the major goal of all vaccine strategies is to reduce the burden of pneumococcal 
disease, it implicates also the prevention of pneumococcal colonisation. Opinions about 
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reduction in colonisation differ from ‘secondary aim’ to ‘fortunate side effect’. However, the 
importance of this essential link in pathogenesis has seldom received full attention.   
The natural route of infection with S. pneumoniae starts with colonisation, which may 
progress to (invasive) disease by crossing of natural immunological barriers. Therefore, it 
seems rational to aim for prevention of colonisation thus eliciting protection against 
(invasive) diseases. Moreover, by preventing nasopharyngeal colonisation of S. 
pneumoniae, horizontal spread of pneumococcal strains may also diminish thus enhancing 
herd immunity 2,114,146. This supports the use of polysaccharide-based vaccines such as the 
23-valent polysaccharide vaccine and the 7-valent conjugate vaccine, or future protein-
based vaccines comprising surface-exposed proteins involved in colonisation and 
adherence such as PsaA, CbpA and neuraminidase. An alternative to vaccination could be 
the use of anti-attachment agents such as receptor analogues or agents like xylitol, N-
acetylcysteine or the recently found S-carboxymethylcysteine 147. Unfortunately, none of 
these agents results in a complete eradication of pneumococcal colonisation. However, the 
same counts for vaccination: by prevention of colonisation without complete eradication of 
pneumococcal carriage, the immunological pressure will skew selection of non-covered 
serotypes or genotypes. Moreover, by clearing the nasopharyngeal niche for pneumococci, 
replacement with other species may occur. This is supported by findings of Veenhoven et al. 
who observed that pneumococcal conjugate vaccination resulted in fewer middle ear fluid 
cultures with vaccine serotype pneumococci, but in a 3-fold increase in S. aureus positive 
cultures 79. Moreover, we have recently demonstrated an intra-individual competition 
between S. aureus and S. pneumoniae in healthy children between 4 and 9 years of age 39. 
Similarly, competition between S. pneumoniae and species like H. influenzae, M. catarrhalis 
and N. meningitidis has also been shown in vitro. A possible solution for this problem might 
be to aim strictly for prevention of invasive disease and leave nasopharyngeal colonisation 
unhampered, although mucosal disease then remains unprevented. This is not possible with 
the currently available vaccines, but might be an option for future protein-based vaccines 
including disease-related proteins such as pneumococcal surface protein A, pneumolysin, 
the Pht family and autolysin 60,148,149. A second option might be to consider the different 
levels of protective antibodies necessary for systemic and mucosal protection. It has been 
suggested that for mucosal protection against S. pneumoniae colonisation and infection, 
higher levels of immune-protective antibodies are needed compared to antibody levels for 
systemic infection 90. Although highly speculative, one might consider adjusting the 
conjugate vaccines to such an extent that antibody levels are induced that are adequate 
enough to prevent invasive pneumococcal disease but insufficient to eradicate 
pneumococcal colonisation. However, such an approach would require individual monitoring 
and, hence, will not be achievable in case of large-scale vaccination. 
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In conclusion, although pneumococcal colonisation is mostly asymptomatic, it is the first step 
in the pathogenic route of pneumococci towards invasive disease. Moreover, it plays a 
crucial role in the prevention of pneumococcal infections and horizontal spread of virulent 
strains. Finally, a natural balance between pneumococci and co-colonising bacterial species 
exists, which may influence the outcome of vaccination strategies. These facts underline the 
key role for pneumococcal colonisation in pathogenesis and prevention of pneumococcal 
infections, which justifies extensive consideration in the decision-making regarding mass 
vaccination and future vaccine strategies. 
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ABSTRACT 
In 1999, Engelen and coworkers investigated colonization in Amsterdam among 259 
children attending 16 day-care centers (DCCs) and among 276 children who did not attend 
day-care centers (NDCCs). A 1.6- to 3.4-fold increased risk for nasopharyngeal colonization 
was observed in children attending DCCs compared with NDCC children, while no 
difference in antibiotic resistance was found between groups. The serotype and genotype 
distributions of 305 nasopharyngeal Streptococcus pneumoniae isolates of the latter study 
were investigated. The predominant serotypes in both the DCC and the NDCC groups 
included 19F (19 and 18%, respectively), 6B (14 and 16%, respectively), 6A (13 and 7%, 
respectively), 23F (9 and 7%, respectively), and 9V (7 and 7%, respectively). The theoretical 
vaccine coverage of the 7-valent conjugate vaccine was 59% for the DCC children and 56% 
for the NDCC group. Genetic analysis of the pneumococcal isolates revealed 75% clustering 
among pneumococci isolated from DCC attendees versus 50% among the NDCC children. 
The average pneumococcal cluster size in the DCC group was 3.8 and 4.6 isolates for two 
respective sample dates (range, 2 to 13 isolates per cluster), while the average cluster size 
for the NDCC group was 3.0 (range, 2 to 6 isolates per cluster). Similar to observations 
made in other countries, these results indicate a higher risk for horizontal spread of 
pneumococci in Dutch DCCs than in the general population. This study emphasizes the 
importance of molecular epidemiological monitoring before, during, and after implementation 
of pneumococcal conjugate vaccination in national vaccination programs for children. 
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INTRODUCTION  
Streptococcus pneumoniae is worldwide one of the major causes of severe infections such 
as meningitis, septicemia, and respiratory tract infections. In addition, S. pneumoniae is, 
together with Moraxella catarrhalis and Haemophilus influenzae, a dominant pathogen in 
middle ear infections and sinusitis. Risk groups for pneumococcal infections are young 
children under the age of 2 years, elderly people, and immunocompromised patients (1).  
Pneumococci are often part of the nasopharyngeal flora; probably all humans are colonized 
with this organism at least once early in life. The risk of pneumococcal colonization is high, 
especially under conditions with crowding, such as day-care centers (DCCs), nursing 
homes, hospitals, and jails (16, 22, 23). A strong relation between carriage and middle ear 
infections has been found, but the association between colonization and invasive disease 
has not been confirmed (11, 31).  
The emergence of penicillin- and multidrug-resistant pneumococci has been observed in 
various countries over the last decade. In some countries and populations, up to 60% of the 
pneumococcal isolates are resistant to one or more antibiotics (3, 12, 17). A significant 
proportion of pneumococcal resistance is the result of the worldwide spread of a limited 
number of multidrug-resistant clones (4, 14, 30, 35). Carriage of organisms with decreased 
antibiotic susceptibility is associated with young age, female sex, winter season, and 
exposure to antimicrobial drugs during the previous month (37).  
Children attending DCCs have several risk factors for carriage, i.e., young age, crowding, 
and frequent usage of antimicrobial agents. Furthermore, it is believed that DCCs may be a 
global reservoir for multidrug-resistant pneumococci (27). Therefore, prevention of carriage 
and infection with S. pneumoniae in these risk groups will become an important tool in the 
battle against (antibiotic-resistant) S. pneumoniae.  
Prevention of infections caused by S. pneumoniae and of spread of this pathogen is an 
important goal of an effective vaccine. Therefore, new vaccines have been developed that 
are also immunogenic in risk groups, such as young children, the elderly, and 
immunocompromised patients. Results with these conjugate vaccines, containing 
polysaccharides from up to 11 different serotypes conjugated to a protein carrier (tetanus-
diphtheria toxoid-Hib protein or meningococcal outer membrane protein), are promising (6, 
9, 21, 28, 29). Recently, one of these vaccines, the 7-valent pneumococcal conjugate 
vaccine from Wyett Lederle, has been approved by the Department of Health and Human 
Services in the United States and the European Agency for the Evaluation of Medicine for 
Europe.  
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The introduction of the conjugate vaccines underscores the need for detailed and long-term 
epidemiological surveillance of S. pneumoniae in the target groups in order to calculate the 
theoretical vaccine coverage and to evaluate the (long-term) effects of large-scale 
introduction of this vaccine in the general population by using serological and molecular 
techniques. So far, no data are available on the molecular epidemiology of S. pneumoniae 
carriage in young children in The Netherlands.  
In 1999, a study was performed in Amsterdam, The Netherlands, among 259 children 
attending 16 DCCs and 276 children who did not attend day-care centers (NDCC). We 
investigated nasopharyngeal carriage rates and susceptibility to antibiotics of the 
nasopharyngeal flora. Carriage rates for S. pneumoniae, M. catarrhalis, and H. influenzae of 
37, 48, and 11%, respectively, were observed in the NDCC group. Increased risks of 1.6, 
1.7, and 3.4 for carriage of S. pneumoniae, M. catarrhalis, and H. influenzae, respectively, 
were observed among DCC attendees. Finally, DCC attendees were ill more frequently and 
used more antibiotics than the controls. Similar to earlier surveillance data from The 
Netherlands (20), only 2% of the pneumococcal isolates showed reduced susceptibility to 
erythromycin and no penicillin resistance was found (P. Peerbooms, M. Engelen, A. van 
Belkum, and R. Coutinho, 11th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. 8, 2001). These 
results are in contrast to data from previous DCC studies in other countries, where antibiotic 
resistance among pneumococcal isolates was high, associated with previous antibiotic 
consumption, and correlated to increased spread of drug-resistant pneumococci among 
DCC attendees (2, 5, 24, 33, 37). Because drug resistance among pneumococci is 
negligible in our study group, we hypothesized that crowding, which is also a risk factor for 
nasopharyngeal carriage, is playing an important role in facilitating the transmission of 
bacteria among children in DCCs. To obtain insight in the transmission of pneumococci in 
children, the molecular epidemiology of the pneumococcal isolates collected from both the 
general population and DCCs was investigated by serotyping and genotyping.  
 
 
MATERIALS AND METHODS  
Bacterial sampling. S. pneumoniae strains were isolated from the nasopharynges of 259 
children, aged 3 to 36 months, attending 16 DCCs in Amsterdam, The Netherlands, from 
January to March 1999. All children were sampled twice, with a time interval of 4 weeks. In 
the same period, an additional 276 children from three well-baby clinics in Amsterdam, aged 
3 to 36 months, who did not attend DCCs were evaluated for S. pneumoniae carriage (P. 
Peerbooms et al., 11th Eur. Cong. Clin. Microbiol. Infect. Dis., 2001). Nasopharyngeal 
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samples were obtained with a dacron pernasal swab (Medical Wire & Equipment Co., 
Wiltshire, England). The swabs were transported in Amies transport medium to the 
Microbiology Laboratory of the Municipal Health Service (Amsterdam, The Netherlands), 
immediately plated on 5% sheep blood agar plates, and grown overnight at 36°C in a CO2-
enriched atmosphere. S. pneumoniae isolates were identified according to standard 
microbiological procedures (18). Molecular analyses were performed on all the 
pneumococcal isolates that were available for use, i.e., 115 and 129 strains collected from 
the 16 DCCs on the two occasions, respectively, and 61 strains collected from the NDCC 
children.  
Serotyping. Pneumococci were serotyped by the capsular quellung method (Quellung 
reaction) and observed microscopically using commercially available antisera (Statens 
Seruminstitut, Copenhagen, Denmark).  
RFEL. Typing of the 305 pneumococcal strains by restriction fragment end labeling (RFEL) 
analysis was performed as described by Van Steenbergen et al. (36) and as adapted by 
Hermans et al. (15). Briefly, purified pneumococcal DNA was digested by the restriction 
enzyme EcoRI. The DNA restriction fragments were end labeled at 72°C with [-32P]dATP 
using DNA polymerase (Goldstar; Eurogentec, Seraing, Belgium). The radiolabeled 
fragments were denatured and separated electrophoretically on a 6% polyacrylamide 
sequencing gel containing 8 M urea. Subsequently, the gel was transferred onto filter paper, 
vacuum dried (HBI, Saddlebrook, N.Y.), and exposed for variable lengths of time at room 
temperature to ECL Hyperfilms (Amersham, Little Chalfont, United Kingdom).  
Computer-assisted analysis of RFEL banding patterns. The RFEL types were analyzed 
using the Windows version of the Gelcompar software (version 4; Applied Maths, Kortrijk, 
Belgium) after imaging the RFEL autoradiograms using the Image Master DTS (Pharmacia 
Biotech, Uppsala, Sweden). For this purpose, DNA fragments in the molecular weight range 
of 160 to 400 bp were explored. The DNA banding patterns were normalized using 
pneumococcus-specific bands present in the RFEL banding patterns of all strains. 
Comparison of the banding patterns was performed by unweighted pair group method using 
arithmetic averages (25) and the Jaccard similarity coefficient applied to peaks (32). 
Computer-assisted analysis and methods and algorithms used in this study were carried out 
according to the instructions of the manufacturer of Gelcompar. A tolerance of 1.2% in band 
position was applied during comparison of the DNA patterns. For evaluation of the genetic 
relatedness of the isolates, we used the following definitions: score of 1, strains of the 
particular RFEL type are considered 100% identical by RFEL analysis; score of 2, the RFEL 
cluster represents a group of RFEL types that differs in only one band (>95% genetic 
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relatedness); score of 3, the RFEL lineage represents a group of RFEL types that differs in 
less than four bands (>85% genetic relatedness).  
The genotypes of the pneumococcal isolates were also compared with an international 
collection of pneumococcal strains representing about 320 distinct RFEL types originating 
from 17 different countries in America, Europe, Africa, and Asia (M. Sluijter, unpublished 
observations), including the 16 international clones described by the Pneumococcal 
Epidemiology Network (http://www.wits.ac.za/pmen/pmen.htm).  
Statistical analysis. For statistical analysis of the results, the Fisher exact test was used.  
 
   Table 1. Contribution of vaccine serotypes to carriage of S. pneumoniae in Dutch infants 
 
  
 
Serotype 
% of children with the 
serotype 
 DCC a NDCC 
   
19F 19 18 
6B 14 16 
9V 7 7 
23F 9 7 
14 7 5 
18 1 3 
4 0 0 
6A 13 7 
19A 4 2 
23A+23B 4 5 
7-valent conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) 59 57 
7-valent conjugate vaccine (including 6A) 72 64 
11-valent conjugate vaccine (7-valent + 1, 3,  5 and 7F) 62 62 
11-valent conjugate vaccine (including 6A) 75 70 
 
      a Average percentages were calculated from the two sampling dates. 
 
 
RESULTS  
We investigated the serotypes of 244 DCC isolates and 61 NDCC isolates (Table 1). The 
predominant serotypes in both the DCC and NDCC groups were the serotypes 19F (19 and 
18%, respectively), 6B (14 and 16%, respectively), 6A (13 and 7%, respectively), 23F (9 and 
7%, respectively), 9V (7 and 7%, respectively), and 14 (7 and 5%, respectively). The 
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serotypes 19F, 6B, 23F, 9V, and 14 are covered by the 7-valent pneumococcal conjugate 
vaccine. The other two serotypes covered by the 7-valent conjugate vaccine are serotypes 4 
and 18C. No children were colonized with vaccine type 4, and only 1 to 3% of the children 
were colonized with vaccine serotype 18. The theoretical vaccine coverages of the 7-valent 
conjugate vaccine are 59% for the DCC group and 57% for the NDCC group. The theoretical 
vaccine coverage of the 11-valent conjugate vaccine, in which the additional capsular types 
1, 3, 5, and 7F are included, is 62% for both the DCC and NDCC groups.  
Genotyping of the 305 pneumococcal isolates from this study was performed by RFEL 
analysis. The 61 isolates from the NDCC children showed 50 different genotypes; 50% of 
the strains represented 10 distinct genetic clusters. Cluster sizes in the NDCC group ranged 
from two to six strains per cluster with an average cluster size of 3.0. The DCC group 
displayed 66 and 75 different genotypes at the first and second sampling dates, 
respectively. Seventy-five percent of the strains from both the first and the second sampling 
dates represented 24 and 20 clusters, respectively. This percentage differed significantly 
from the 50% genetic clustering observed in the NDCC group (P < 0.01). Cluster sizes within 
the individual sampling data ranged from 2 to 13 strains, with an average cluster size of 3.8 
and 4.6 for the two sampling dates, respectively (Fig. 1). The majority of the clusters in both 
the DCC group (29 of 44 clusters) and the NDCC group (8 of 10 clusters) displayed a 
serotype covered by the 7-valent conjugate vaccine, including the cross-protective serotype 
6A (Fig. 1). We also investigated carriage turnover in the DCC group, defined as the 
percentage of children with positive pneumococcal samples at both sampling dates that 
changed genotypes within the 4-week interval between sampling dates. A total of 209 of 259 
children in the DCC group were carrying a pneumococcus on the nasopharynx at least once. 
Of the 259 children, 107 were carrying pneumococci on the nasopharynx at both sampling 
dates. The isolates from 69 children who were identified as being colonized by S. 
pneumoniae at both sampling dates were available for molecular analysis. Fourty-four of 
these 69 children had changed genotypes between the two sampling dates, i.e., a carriage 
turnover of 64%.  
Comparison of the RFEL data with the 16 international clones described by the 
Pneumococcal Epidemiology Network demonstrated that six isolates (10%) of the NDCC 
group were identical to the clones Taiwan19F-14 (1 isolate), France9V-3 (3 isolates), 
Slovakia14-10 (1 isolate), and Tennessee23F-4 (1 isolate), whereas 25 of the isolates from 
the DCC group (10%) belonged to the clones France9V-3 (15 isolates), Slovakia14-10 (6 
isolates), and Tennessee23F-4 (4 isolates). All but one of the isolates were susceptible to 
the antibiotics penicillin, tetracycline, erythromycin, and cotrimoxazole, in contrast to the 
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antibiotic resistance patterns of their genetically homologous clones. Only the isolate 
identical to clone Taiwan19F-14 was resistant to erythromycin (Peerbooms et al., 11th Eur. 
Cong. Clin. Microbiol. Infect. Dis., 2001).  
 
 
DISCUSSION  
 In The Netherlands, the prevalence of pneumococcal colonization in the pediatric 
population was found to be 58% in DCC attendees versus 37% in the NDCC group, i.e., a 
1.6-fold higher risk of pneumococcal colonization in DCC attendees compared to age-
matched NDCC children (Peerbooms et al., 11th Eur. Cong. Clin. Microbiol. Infect. Dis., 
2001). Known risk factors for carriage of S. pneumoniae are young age, crowding, and 
antibiotic usage. Since only 2% of the pneumococcal isolates were resistant to erythromycin 
and no resistance to the antibiotics penicillin, cotrimoxazole, or tetracycline was found, 
crowding is presumed to be the most important contributor to the difference in carriage seen 
in this study. We hypothesize that crowding facilitates horizontal transfer of bacteria from 
one child to another. Therefore, we investigated the molecular epidemiology of 305 
pneumococcal isolates from this study. Both the DCC group and the NDCC group showed a 
serotype distribution comparable to what is found in many other countries, such as Israel, 
Finland, Canada, and South Africa (6, 10, 16, 19, 34). The most predominant serotypes 
were 19F (19 and 18% in DCC and NDCC attendees, respectively), 6B (14 and 16%, 
respectively), 6A (13 and 7%, respectively), 23F (9 and 7%, respectively), and 9V (7 and 
7%, respectively). This serotype distribution implicates a theoretical coverage of 57 to 59% 
by the 7-valent conjugate vaccine. The additive value of an 11-valent conjugate vaccine is 
only 3 to 5% (62% total coverage for both study groups). An additive cross-protective effect 
is expected at least for serotype 6A (26), which increases the theoretical coverage of the 7-
valent conjugate vaccine to 64% for the NDCC group and to 72% for the DCC group. It is 
unknown whether a cross-protective effect can be expected for the serotypes 19A, 23A, and 
23B (13, 26, 38). With respect to the theoretical vaccine coverage, the long-term effect of 
large-scale implementation of the conjugate vaccine for the Dutch pediatric population 
remains unknown. Eskola et al. have found a similar serotype distribution before vaccination 
with the 7-valent pneumococcal conjugate vaccine and a shift towards nonvaccine serotypes 
causing middle ear infection after vaccination (10). Such a shift in distribution after conjugate 
vaccination was also observed among nasopharyngeal carriage isolates (7, 8, 19; S. K. 
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Obaro, R. A. Adegbola, W. A. Banya, and B. M. Greenwood, Letter, Lancet 348:271-272, 
1996). Therefore, it is concluded that a shift in distribution towards nonvaccine serotypes will 
reduce the efficacy of conjugate vaccination with respect to carriage and disease.  
In the DCC group, 75% of the pneumococci represented genetic clusters, in contrast to 50% 
in the NDCC group. These molecular epidemiological data suggest augmented spread of 
pneumococci among DCC attendees compared to the NDCC group. In addition, the average 
cluster size for the first and second sampling dates in the DCC group were 3.8 and 4.6, 
respectively, with a range of 2 to 13 isolates per cluster, compared to 3.0 for the control 
group with a range of 2 to 6 isolates per cluster (Fig. 1). These data show larger clusters in 
the DCC group, which supports the hypothesis that pneumococci are spread more 
frequently by horizontal transfer between DCC attendees than among NDCC attendees. A 
carriage turnover of 64% in the DCC children with two positive pneumococcal isolates at 
both sampling dates was observed. At present, no carriage turnover data are available for 
the NDCC population. Whether the genotype shift in the DCC population is due to 
recolonization of the nasopharyngeal niche by new genotypes or whether it is due to 
unmasking of genotypes which were already present but not detected as a result of the 
abundant presence of other genotypes needs to be further investigated.  
The RFEL patterns of both the DCC group and the NDCC group were compared with the 16 
international (multidrug-resistant) clones described by the Pneumococcal Epidemiology 
Network. Twenty-five isolates (10%) in the DCC group were homologous to 3 of the 
reference clones (100% identical), whereas 6 isolates (10%) in the NDCC group matched 
with 4 of these clones. In contrast to the multidrug-resistant reference clones, all isolates but 
one were fully susceptible to penicillin, erythromycin, and cotrimoxazole. The resistant 
isolate, identical to the clone Taiwan19F-14, had reduced susceptibility to erythromycin only, 
whereas the reference clone was resistant to erythromycin, penicillin, and tetracycline. 
These results suggest that these Dutch isolates represent members of the ancestor lineages 
of the resistant reference clones. The overall absence of resistant pneumococcal strains in 
The Netherlands may be explained by the restricted use of antibiotics in general compared 
to that in many other countries.  
In conclusion, an increased frequency of horizontal spread of S. pneumoniae strains was 
shown in DCCs. At least 56% of the nasopharyngeal pneumococcal isolates would be 
theoretically covered by a 7-valent conjugate vaccine. Furthermore, the majority of the 
horizontal spreading genotypes (70 to 80%) express capsular types that are covered by the 
conjugate vaccine. These data indicate that implementation of the pneumococcal conjugate 
vaccine in the near future in Dutch infants, and especially in risk groups like DCC attendees, 
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should be considered. Importantly, to investigate the long-term efficacy of the vaccine 
against pneumococcal infections, detailed molecular epidemiological monitoring of 
pneumococcal colonization and infection is required.  
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ABSTRACT 
A trial with a 7-valent pneumococcal-conjugate vaccine in children with recurrent acute otitis 
media showed a shift in pneumococcal colonisation towards non-vaccine serotypes and an 
increase in Staphylococcus aureus-related acute otitis media after vaccination.  
We investigated prevalence and determinants of nasopharyngeal carriage of S. pneumoniae 
and S. aureus in 3198 healthy children aged 1-19 years.  
Nasopharyngeal carriage of S. pneumoniae was detected in 598 children (19%), and was 
affected by age (peak incidence at 3 years) and day-care attendance (odds ratio [OR] 2.14, 
95% CI: 1.44-3.18). S. aureus carriage was affected by age (peak incidence at 10 years) 
and male sex (OR 1.46, 95% CI: 1.25-1.70), family size (≥ 5 members, OR: 1.17, 95% CI: 
1.00-1.37) and passive smoking (OR: 1.22, 95% CI: 1.04-1.42), whereas active smoking 
was inversely related to S. aureus carriage (OR: 0.75, 95% CI: 0.53-1.04). Serotyping 
showed 42% vaccine type and 58% non-vaccine type pneumococci. We noted a negative 
correlation for co-colonisation of S. aureus and vaccine-type pneumococci (OR 0.68, 95% 
CI: 0.48-0.94), but not for S. aureus and non-vaccine serotypes.  
These findings suggest the presence of a natural competition between vaccine-type 
pneumococci and S. aureus, which might explain the increase in S. aureus-related otitis 
media after vaccination. 
Bacterial interference and nasopharyngeal colonisation 57 
INTRODUCTION 
Streptococcus pneumoniae causes morbidity and mortality in young children, elderly people, 
and immunodeficient patients 1, but asymptomatic carriage of pneumococci is also common, 
especially in children. Children are thought to be an important vector for community-wide 
spread of this micro-organism, and prevention of pneumococcal carriage may therefore 
contribute to reduction in the prevalence of infections 2.   
Pneumococcal conjugate vaccination protects young children against invasive diseases with 
S. pneumoniae 3,4, but does not adequately prevent mucosal infections and colonisation, 
and, moreover, replacement with non-vaccine serotypes occurs 5. A study of pneumococcal 
vaccination in children with a history of recurrent acute otitis media showed an increased 
incidence of Staphylococcus aureus-related acute otitis media after vaccination 5. We 
postulated that the natural balance of microbial species in the nasopharynx might be altered 
by vaccination. To study age-related dynamics of pneumococcal and S. aureus carriage, we 
measured pneumococcal and staphylococcal colonisation in 3198 healthy children in The 
Netherlands. 
 
 
MATERIALS AND METHODS 
We enrolled 3198 children with no previous pneumococcal vaccination, aged between 12 
months and 19 years, who were participating in a national meningococcal vaccination 
campaign 6. We obtained signed informed consent from the parent, child or both, and 
recorded demographic data with a standardised questionnaire. The study was approved by 
the Medical Ethics Review Board of the Erasmus MC. 
A team of 10 specifically trained research nurses and medical doctors obtained one 
nasopharyngeal swab per child. The flexible swab (Copan Italia, Brescia, Italy) was inserted 
into the anterior nares, gently rubbed on the posterior nasopharyngeal wall, removed, and 
stored in Amies transport medium at room temperature. Swabs were transported to the 
medical microbiology laboratory and plated within 6 hours of sampling, first on a gentamicin 
blood agar plate, then submerged in phenyl mannitol broth, to isolate S. pneumoniae and S. 
aureus, respectively. We identified bacteria by use of standard methods 7, and serotyped 
pneumococci  by the capsular swelling method (Quellung reaction) with commercially 
available antisera (Statens Seruminstitut, Copenhagen, Denmark), according to the 
instructions of the manufacturer.  
We analysed data by SPSS version 11.0. We did a univariate regression analysis on the 
variables age, family size (0: < 5 persons, 1: ≥ 5 persons), passive and active smoking, 
antibiotic use within the last 7 days, and proxy measures of social contact (at least 3 hours 
per week of sport activities, youth club, sports club, discotheque visits; at least 3 days per 
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week day-care attendance). Colonisation with S. aureus or S. pneumoniae were dependent 
variables. We considered all variables with univariate associations as potential determinants 
of colonisation, and confirmed independence by multivariate logistic regression analysis by 
use of the stepwise backward Wald method for variables with a p-value of < 0.10. To assess 
co-colonisation we cross-tabulated S. aureus and S. pneumoniae carriage, and S. aureus 
and S. pneumoniae vaccine and non-vaccine serotype carriage. We did bivariate logistic 
regression analysis with S. aureus as dependent variable and S. pneumoniae vaccine 
serotype and non-vaccine serotype carriage as covariates. Because carriage of vaccine 
serotype pneumococci was negatively associated with S. aureus carriage with p<0.01, we 
did multivariate logistic regression analysis adjusting for the independent determinants of 
colonisation. We estimated reliability of the final analysis with the Hosmer & Lemeshow test 
8. 103 children had missing values, so we assessed data for 3085 out of 3198 children 
(97.4%).  
 
 
RESULTS AND DISCUSSION 
The 3198 children included in our study were a balanced representation of all age groups 
(Figure). 1670 (52%) were male, and the mean family size was 4.3 members with a mean of 
2.4 children per family. 45% of the households contained at least one smoker, and 275 
children above 12 years of age (21%) were active smokers. 1317 (42%) of all children above 
4 years of age practised a sporting activity, 909 (29%) attended a youth society or sports 
club, and 311(21%) of all children older than 10 years attended discotheques for more then 
3 hours per week. 262 children younger than 4 years (56%) were at a day-care centre for at 
least 3 days per week.  
We cultured 3198 swabs for S. pneumoniae; 3097 swabs were also cultured for S. aureus. 
We isolated S. pneumoniae from 598 children (19%) with a peak incidence during the first 
three years of life, followed by a gradual decline until reaching a stable colonisation rate 
after the age of 10 years (Figure). 250 of the pneumococcal isolates (41.6%) expressed 
capsular serotypes included in the 7-valent conjugate vaccine. The serotypes most 
frequently found were 6B (69, 11.5%), 19F (68, 11.3%), 23F (53, 8.8%), 6A (40, 6.7%), 3 
(36, 6.0%) and 11 (31, 5.2%). The conjugate vaccine serotypes showed a peak incidence at 
age 1 year followed by a steady decline till the age of 8 years. The non-vaccine type 
pneumococci showed initially a slight increase with a peak incidence of 27% at the age of 4 
years, followed by a decrease in incidence (Figure). S. aureus was isolated from 1117 
children (36%) showing an age-related parabolic distribution with a peak incidence at age 10 
years (Figure). 
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Figure 1. Age-related prevalence of S. aureus, S. pneumoniae and vaccine type (VT) and non-vaccine type (non-VT) 
pneumococci. Trend lines are shown [polynomial function with 5 degrees (quintic function)]. 
 
 
Age, passive smoking, active smoking, 3 days or more per week day-care attendance, 
family-size, 3 hours or more per week of sports, youth club visits, or discotheque attendance 
correlated with pneumococcal carriage. Age and day-care (odds ratio [OR] 2.14, 95% CI 
1.44-3.18) were found to be independent determinants of pneumococcal carriage by 
multivariate logistic regression analysis. The variables found to correlate with S. aureus 
colonisation by means of univariate analysis were age, number of children in the family, 
family-size, passive smoking, active smoking, sports, youth club and discotheque visits. 
Multivariate logistic regression identified age, male sex (OR 1.46, 95% CI 1.25-1.70), family-
size (OR 1.17, 95% CI 1.00-1.42), active smoking (OR 0.75, 95% CI 0.53-1.04) and passive 
smoking (OR 1.2, 95% CI 1.04-1.42) as independent determinants of S. aureus colonisation. 
Other variables that have previously been shown to be determinants of pneumococcal 
carriage 9, such as passive smoking at home, large households, and crowding among 
teenagers, did not correlate with pneumococcal carriage in our study.  
187 (6%) children had cultures positive for S. aureus and S. pneumoniae. We noted a 
negative correlation for co-colonisation of vaccine type pneumococci and S. aureus (23.2% 
co-colonisation), but not for non-vaccine serotypes (37.0%) compared with cultures negative 
for pneumococci (37.2%) (Table 1). This was supported by bivariate logistic regression 
analysis,  which  showed  an odds  ratio  of  0.51 (95% CI 0.38-0.70)  for  co-colonisation  of  
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Table 1. Cross-tabulation for colonisation with S. pneumoniae and S. aureus 
  S. pneumoniae colonisation  
  No 
 
Non-vaccine 
serotypes 
Vaccine 
serotypes 
Total 
No 1570 219 191 1980 S. aureus  
Colonisation Yes 930 129 58 1117 
 Total 2500 348 249 3097 
Chi-square: 19.63, df: 2, p-value: < 0.001  
 
 
Table 2. Odds Ratios of colonisation with Staphylococcus aureus for co-colonisation with Streptococcus pneumoniae 
and other independent risk factors (n = 3085) 
  
 Odds Ratio 95% CI p-value 
Age (years) 1.45 1.34-1.54 < 0.0001 
Age*Age‡ 0.98 0.98-0.99 <0.0001 
Gender (male versus female) 1.46 1.25-1.70 <0.0001 
Family size (<5 versus ≥5 members) 1.17 1.00-1.37 0.049 
Passive smoking (yes versus no) 1.22 1.04-1.42 0.013 
Active smoking (yes versus no) 0.75 0.53-1.04 0.083 
Pneumococcal vaccine serotypes (present versus absent) 0.68 0.48-0.94 0.020 
Pneumococcal non-vaccine serotypes (present versus absent) 1.04 0.81-1.34 0.741 
‡ Non-linear effect modification suggested by significance of the square of age 
 
 
vaccine serotype pneumococci and S. aureus. When adjusting for age, sex, family-size, and 
active and passive smoking in a multivariate logistic regression model, this difference was 
still significant for vaccine-type pneumococci but not for non-vaccine serotypes (Table 2). 
Because a non-linear effect modification of age was suggested by the significant correlation 
of S. aureus and the square of age, we did a subsidiary analysis for children younger than 
five years (data not shown). Again, we noted a negative correlation for co-colonisation of 
vaccine-type pneumococci and S. aureus (OR 0.61, 95% CI 0.38-0.98), and no correlation 
with non-vaccine serotypes. For the remaining determinants, the subsidiary analysis was too 
small to show significance.  
More research is needed to clarify the molecular basis of these serotype-related interactions 
between S. pneumoniae and S. aureus, and to ascertain the potential effect of 
pneumococcal conjugate vaccination on S. aureus carriage and S. aureus-related disease. 
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ABSTRACT 
Background. In Western countries Neisseria meningitidis is the most important cause of 
sepsis and meningitis in children. An increase in meningococcal sepsis and meningitis 
caused by group C meningococci in The Netherlands prompted a nation-wide campaign in 
the summer of 2002 to vaccinate all children between 12 months and 19 years of age 
against group C meningococcal disease.  
Methods. We investigated the prevalence and determinants of nasopharyngeal carriage of 
N. meningitidis in healthy children participating in the meningococcal vaccination campaign 
in Rotterdam, The Netherlands. A nasopharyngeal swab and a short questionnaire were 
obtained from 3,198 children between 12 months and 19 years of age. 
Results. We observed meningococcal carriage in 46 children (1.5%). Subtyping of the 
meningococcal strains showed 8 group B isolates, 9 group C isolates, 24 type xyzw 135 
isolates and 8 others. Peak incidences were seen in the first year of life (3.2% carriage) and 
after the age of 15 years (3.7% carriage). Independent determinants of N. meningitidis 
carriage included age, pneumococcal carriage (OR 4.1) and regular visits of youth clubs and 
dancings (OR 2.2 and 4.3, respectively).  
Conclusions. Nasopharyngeal carriage of N. meningitidis was low during the national 
meningococcal vaccination campaign in the summer of 2002 in The Netherlands. Age, 
crowding and pneumococcal carriage showed to be determinants of meningococcal 
colonization in healthy Dutch children. 
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INTRODUCTION 
Asymptomatic nasopharyngeal colonization with bacterial pathogens is common in children 
and in adults, and may predispose to the development of infections (1, 2). Furthermore, the 
upper respiratory tract is considered to be the primary reservoir from which community-wide 
spread of these microorganisms occurs (3-5). Detailed information about asymptomatic 
carriage of pathogenic bacteria in the population can provide insight into the nature of 
infections caused by these bacteria, which may ultimately help to prevent or control 
outbreaks. One of the pathogens of major interest is Neisseria meningitidis. This pathogen is 
an important cause of invasive diseases including meningitis and septicemia (6). N. 
meningitidis resides in the posterior nasopharynx. Morbidity and mortality is high despite the 
availability of antibiotic treatment. Known determinants for N. meningitidis colonization are 
winter season, large households, day-care visits, visits to discotheques, youth clubs and 
sport clubs and Streptococcus pneumoniae carriage (7-9). Unfortunately, most studies 
investigating nasopharyngeal carriage have limitations due to restricted age- and patient 
groups, small numbers of participants and the range of pathogens investigated. 
Because of a nation-wide increase in invasive meningococcal disease caused by group C 
meningococci in the first months of 2002 (10), all Dutch children between 12 months and 19 
years of age were offered immunization during a national vaccination campaign in the 
summer of 2002. The vaccination coverage nationwide was 80% (Municipal Health 
Services, personal communication). This opportunity was exploited to screen over 3,000 
healthy children in Rotterdam for nasopharyngeal carriage of N. meningitidis, S. 
pneumoniae and Staphylococcus aureus and to obtain information regarding age 
distribution, and social and environmental factors related to nasopharyngeal carriage of the 
three pathogens. Prevalences and determinants of S. pneumoniae and S. aureus 
colonization have been described previously (11). In the present paper, we will focus on the 
prevalence and determinants of N. meningitidis carriage in this Dutch cohort of healthy 
children. 
 
 
MATERIALS AND METHODS 
Study population. In total, 3198 children between 12 months and 19 years of age visiting 
the national meningococcal vaccination campaign in Rotterdam were enrolled in this study. 
All children were residents of Rotterdam who were vaccinated in July (age 12 months to 5 
years and 15 to 19 years) and September (age 6 to 15 years) of the year 2002. Signed 
informed consent was obtained from the parent accompanying the participating child under 
the age of 16 years and directly from the child above the age of 16 years.  
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Study design. When children and their parents agreed to participate in this study, 
demographic data were recorded for each child through a standardized questionnaire that 
was completed by the parent or the child under the supervision of an instructed interviewer. 
Questions addressed month and year of birth, zip code, family size, frequent sport activities 
(at least 3 hours per week), crowding (at least 3 hours per week attendance of youth and 
sport clubs, discotheques and at least 3 times per week day-care visits), active and passive 
smoking and recent antibiotic use (within last 7 days). Finally, a nasopharyngeal swab was 
obtained by a skilled research nurse or medical doctor. The study was approved by the 
Medical Ethics Review Board of the Erasmus MC, Rotterdam, The Netherlands. 
Cultures. The nasopharyngeal samples were obtained with rayon tipped dacron pernasal 
swabs (Copan Italia, Brescia, Italy) and transported in Amies transport medium to the 
medical microbiology laboratory of the Erasmus MC, samples were plated within 6 hours of 
sampling on Thayer-Martin medium for isolation of N. meningitidis. Bacteriological 
determination was performed according to standard procedures (12). In case 
morphologically different colonies were observed within one sample, multiple colonies were 
stored for further analysis.  
Data analysis. Statistical analysis was performed by SPSS version 11.0 for Windows. To 
evaluate determinants of colonization, we performed univariate regression analysis on the 
variables age, family size (0: < 5 persons, 1: ≥ 5 persons), a minimum of 3 hours per week 
sport activities, a minimum of 3 hours per week attendance of youth clubs, a minimum of 3 
hours per week attendance of sport clubs, a minimum of 3 hours per week discotheque 
visits, a minimum of 3 days per week day-care visits, passive and active smoking, recent 
antibiotic use (within the last 7 days) and co-colonization with S. pneumoniae and S. aureus. 
Colonization with N. meningitidis was used as dependent variable. The variables were 
coded 1 when present and 0 when absent. All variables with univariate associations (p-value 
< 0.10), were considered potential determinants of colonization. To identify independent 
markers, the variables were further analyzed by multivariate logistic regression analysis 
using the stepwise backward Wald method (including the variables with a p-value of <0.10). 
As cases with missing values were rejected from multivariate analyses, the analysis was 
based on the data of 2,850 out of 3,198 children (89.2%) participating in the study.  
 
 
RESULTS 
In total, 3,198 children participated in the study. We retrieved questionnaires and 
nasopharyngeal swabs of all 3,198 children, whereas 3,098 of the swabs were cultured for 
N. meningitidis. Full sets of data and clinical materials were obtained for 2850 children. 
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Demography. The 3,198 children formed a balanced representation of all age groups 
varying in size from 121 to 199 children per year of age. Fifty-two percent of all children 
were male. The average family size was 4.3 persons with on average 2.4 children per 
family. In 45% of the households at least one person smoked regularly. Twenty-one percent 
of all children above 12 years of age were active smokers. Overall, 42% of all children above 
4 years of age were actively involved in physical sports (≥ 3 hours per week), 29% attended 
a youth society or sports club for 3 hours or more per week and 21% of all children above 10 
years of age visited discotheques for more than 3 hours per week. Of all children under 4 
years of age, 56% visited a day-care center for at least 3 days a week.  
Bacterial carriage and susceptibility. Nasopharyngeal carriage of N. meningitidis was 
observed in 46 out of 3098 children (1.5%). Eight and nine children carried meningococci 
group B and group C, respectively. Twenty-four children were carriers of serotype xyzw 135 
meningococci. Eight children were carrier of other groups of meningococci. Two children 
were carriers of two types of meningococci; one child had a group B strain and a 
nontypeable strain and the second child had a group B and group C meningococcal strain. 
Meningococci were most frequently isolated during the second year of life with a peak 
incidence of 3.2%. Thereafter, the incidence dropped to 0% after the fifth year of life with a 
second peak incidence after the age of 14 years (Figure 1). Sixteen out of the seventeen 
group B and group C meningococcal strains were isolated in children older than 14 years of 
age. The remaining group C meningococcal isolate was retrieved from a one year old child. 
Determinants of meningococcal carriage. To evaluate potential determinants of 
nasopharyngeal carriage of N. meningitidis, we calculated the Odds Ratios by means of 
univariate logistic regression followed by multivariate logistic regression analysis. The initial 
correlation of active smoking and N. meningitidis carriage showed to be an indirect effect of 
age in the multivariate logistic regression model and was excluded from the model. Finally, 
we identified age, age*age, pneumococcal carriage (OR 4.1, 95% CI: 1.87-9.01), youth club 
visits for more than 3 hours a week (OR 2.3, 95% CI: 0.99-4.63) and discotheque visits for 
more than 3 hours a week (OR 4.4, 95% CI: 1.54-12.17) as significant determinants for N. 
meningitidis carriage (Table 1). Carriage of both vaccine serotype pneumococci (serotypes 
4, 6B, 9V, 14, 18C, 19F and 23F) and non-vaccine serotypes significantly correlated with 
meningococcal carriage with odds ratios of 3.5 (95% CI: 1.19-10.40) and 4.4 (95% CI: 1.90-
10.27), respectively. 
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Figure 1. Age-related prevalence of nasopharyngeal colonization with N. meningitidis. 
 
 
Table 1. Odds Ratios for the independent risk factors of colonization with Neisseria meningitidis (n = 2850) 
  
 Odds Ratio 95% CI p-value 
Age (years) 0.69 0.53-0.91 0.008 
Age*Age 1.02 1.01-1.03 0.007‡ 
Youth club visits (>3 hours/week versus < 3 hours/week) 2.32 0.99-4.63 0.054 
Discotheque visits (>3 hours/week versus < 3 hours/week) 4.36 1.54-12.17 0.005 
Pneumococcal vaccine serotype carriage (present versus 
absent) 
3.51 1.19-10.40 0.023 
Pneumococcal non-vaccine serotype carriage (present 
versus absent) 
4.42 1.90-10.27 0.001 
    ‡ Non-linear effect modification suggested by the significance of the square of age 
 
 
DISCUSSION 
In 2002, the Netherlands Reference Laboratory for Bacterial Meningitis noticed an increase 
in invasive diseases caused by meningococci group C (10). Therefore, a large-scale 
vaccination campaign was undertaken to prevent group C meningococcal disease in all 
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children up to the age of 19 years. This opportunity was used to evaluate asymptomatic 
colonization with N. meningitidis in this large open cohort of healthy children. 
Surprisingly, the incidence of N. meningitidis colonization was low, ranging between 0 and 
4% depending on the age. In the light of the recent increase in meningococcal disease, a 
higher incidence was expected, comparable to previously described incidences of up to 26% 
(8, 9). One might argue that this is caused by differences in the method of sampling, i.e. 
nasopharyngeal instead of oropharyngeal cultures. At present, there is still uncertainty about 
the most optimal method of meningococcal sampling (7, 13-16). Furthermore, high 
colonization rates of more than 20% have mostly been reported in certain risk groups 
including students and military recruits. These risk groups were not included in our study. 
However, our highest incidence in group B and group C meningococcal carriage was also 
observed in the children older then 15 years of age, which is in line with these findings (15, 
17). More importantly, the time of sampling, i.e. the summer, might explain the relatively low 
incidence in carriage. Most often, a peak in meningococcal colonization and infection is 
observed in autumn and winter when the crowding factor increases. For example, Neal et al. 
have shown a significant increase in pharyngeal colonization among university students 
during the first week of term starting with 6.9% on day 1 to 23.1% on day 4 (18). The 
seasonal variation also counts for invasive meningococcal diseases in Dutch children, where 
the highest incidence is found from January until April (10). With respect to the outbreak of 
meningococcal disease, also a rapid decline in meningococcal disease was observed after 
April of the year 2002. Also in line with the findings of the Netherlands Reference Laboratory 
for Bacterial Meningitis is the age-related distribution of colonization and infection. Both 
follow a similar pattern with peak incidences of colonization and infection during the second 
year of life, followed by a decrease with the lowest incidence at the age of 7 to 8 years, after 
which a small peak in incidence at the age of 11 years is observed and a major increase 
after the age of 14 years (according to the statistics of the Netherlands Reference 
Laboratory for Bacterial Meningitis: incidence of serogroup C meningococcal disease 2001).  
We investigated determinants of meningococcal colonization. After multivariate analysis we 
found colonization with pneumococci, age and crowding in case of teenagers (frequent 
youth club and discotheque visits) to correlate positively with meningococcal colonization. 
Although these determinants were described previously, other parameters such as smoking, 
large households and elementary school attendance showed no significant correlation with 
meningococcal carriage in our study. However, in contrast to our study these studies 
performed univariate regression. Our results are in agreement with Dominguez et al. who 
found the same determinants of meningococcal carriage after multivariate logistic regression 
analysis (16).  
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We also investigated co-colonization of S. pneumoniae and S. aureus as potential 
determinants of meningococcal colonization. Although we did not find a correlation between 
S. aureus and meningococcal carriage, we found a positive correlation between S. 
pneumoniae and N. meningitidis colonization. This finding is in accordance with a previous 
clinical study performed by Bakir et al. (7). Moreover, these data are supported by findings 
of Pericone et al. who have shown an enhanced growth of S. pneumoniae in co-culture with 
N. meningitidis mediated by catalase produced by the meningococcus. (19). In a previous 
analysis of nasopharyngeal carriage with S. pneumoniae and S. aureus in the same cohort 
of children, we observed a negative correlation between S. aureus and S. pneumoniae 
carriage, however, for vaccine serotype pneumococci only (11). Therefore, we re-analyzed 
the data for meningococcal and conjugate vaccine serotype and non-vaccine serotype 
carriage. A negative correlation was found with both groups of pneumococci, indicating that 
this correlation is independent from the pneumococcal serotype. 
Our data suggest a complex pattern of interactions between the different species colonizing 
the nasopharynx. Whether this interaction affects vaccination against one of these species is 
still unknown. For mass vaccination with the meningococcal C conjugate vaccine the first 
efficacy data are available. These data show a reduction in group C meningococcal disease 
of 66% after 12 months and no significant rise in other meningococcal serogroups yet (20). 
A possible effect on colonization with other species still has to be investigated. 
In conclusion, we performed a large meningococcal colonization study among children 
between 1 and 19 years of age at the time of the National meningococcal group C 
vaccination campaign in The Netherlands in the summer of 2002. We observed a relatively 
low incidence of meningococcal carriage with peak incidences in the first year of life and 
after the age of 15 years. Determinants of meningococcal carriage were age, crowding, 
especially in teenagers, and pneumococcal carriage.  
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ABSTRACT    
The aim of this study was to investigate the effect of bacterial colonization during stable 
disease on time to first exacerbation in patients who either discontinued or continued 
fluticasone propionate (FP).  
In a randomized controlled trial, 244 COPD patients either continued using FP or received 
placebo for 6 months, after 4 months of treatment with FP.  Sputum samples were collected 
at randomization and during exacerbations. We calculated the time to development of an 
exacerbation in colonized compared to non-colonized patients in relation to ICS use.  
At randomization, we collected sputum samples of 209 patients, of which 36% were 
colonized with potentially pathogenic microorganisms. We did not find effect modification by 
FP status (FP or placebo), but effect modification by FEV1 was present. The adjusted 
hazard ratio of a first exacerbation in colonized compared to non-colonized patients was 
1.29 (95% CI 0.76-2.20) and 1.01(95% CI 0.56; 1.81) in patients with a FEV1 ≥ 50%, and 
FEV1 <50% , respectively.  
Bacterial colonization in moderately severe COPD patients is not an independent risk factor 
for the development of acute exacerbations. There is no interaction between colonization 
and discontinuation of ICS on time to first exacerbation. 
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INTRODUCTION 
The clinical course of chronic obstructive pulmonary disease (COPD) is one of gradual 
progressive impairment, which despite optimal pharmacological treatment may lead to 
substantial functional limitations and eventually to respiratory failure (1,2). Morbidity and 
mortality among patients with COPD are for the most part related to acute exacerbations of 
COPD (3,4) which occur on average one to three times a year (5). The clinical effects of 
inhaled corticosteroids (ICS) on exacerbations in COPD observed in recent studies were a 
more rapid onset and higher recurrence-risk of exacerbations after discontinuation of ICS 
(6), and a decreased frequency (7) or severity (8) of exacerbations. ICS affect airway 
inflammation in COPD, which may explain the decrease in exacerbations (9). However, 
many issues related to exacerbations remain unclear or controversial including the role of 
microorganisms in the airways of the COPD patient. (10-12). A significant proportion of 
patients with COPD have lower airway bacterial colonization with a spectrum of pathogens 
including non- typeable Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella 
catarrhalis (13,14). Simple bronchial colonization or overgrowth of potentially pathogenic 
microorganisms (PPM) may promote bronchial inflammation (15) hence promoting bronchial 
injury and consequently, by higher sputum levels of inflammatory mediators, exacerbations 
(16,17). Recent longitudinal studies compared for the first time the role of bacterial 
colonization COPD exacerbations and in stable state (18-20). These have clearly 
demonstrated that especially the acquisition of a new bacterial strain promoted the 
development of a bacteriological proven exacerbation (19). Since ICS affect airway 
inflammation in COPD, discontinuation of these corticosteroids in colonized patients might 
have profound effects on the acquisition of new bacterial strains and so promoting 
exacerbations.  
The aim of this single center prospective study was to investigate the effect of bacterial 
colonization during stable disease on time to first exacerbation in patients who either 
discontinued or continued the inhaled steroid fluticasone propionate (FP) in a randomized 
double blind fashion. 
 
 
PATIENTS AND METHODS 
Patients. From May 1999 through March 2000, patients were recruited from the outpatient 
pulmonary clinic of the Medisch Spectrum Twente: an 1150 bed teaching hospital, in 
Enschede, The Netherlands. To be eligible for the study the patients had to meet the 
following criteria: 1) a clinical diagnosis of stable COPD, as defined by American Thoracic 
Society criteria (21); 2) no history of asthma; 3) no exacerbation in the month prior to 
enrollment; 4) current or former smoker; 5) age between 40-75 years; 6) baseline pre-
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bronchodilator FEV1 25- 80% of predicted; 7) pre-bronchodilator ratio FEV1 inspiratory vital 
capacity( IVC) value of  60% or less; 8) reversibility of FEV1 post inhalation of 80 µg of 
ipratropium bromide via metered dose inhalator with Aerochamber 12% of predicted value or 
less (22); 9) Total Lung Capacity (TLC) greater than the TLC predicted minus 1.64*SD; 10) 
no maintenance treatment of oral steroids or antibiotics; 11) no medical condition with low 
survival or serious psychiatric morbidity (e.g. cardiac insufficiency, alcoholism); 12) absence 
of any other active lung disease (e.g. sarcoidosis); and  13)  use of medication such as 
nasal corticosteroids, theophyllines, chronic use of acetylcysteine and all other 
bronchodilators was allowed. 
The hospital’s medical ethical committee approved this study. All patients provided written 
informed consent.  
Trial design. This study was designed as a randomized, double blind, parallel-group single 
center study that comprised of 4 months run-in, followed by 6 months of active treatment or 
placebo (6). In the run-in phase all patients were prescribed the inhaled corticosteroid, 
fluticasone propionate (FP) via Diskus/Accuhaler 500 µg twice daily, and bronchodilators to 
optimize lung function. After 4 months patients were randomly assigned to continue FP 500 
µg twice daily or to receive placebo for 6 months. Randomization was performed in blocks of 
6 by computer-generated allocation. Sputum samples were collected at randomization at 4 
month and at exacerbation. Only patients producing sputum at randomization were included 
in this analysis.  Follow-up visits were scheduled only when the patient was in a stable 
condition at 4, 7 and 10 months post baseline. At the regular follow-up visits data were 
collected, spirometry was performed post bronchodilation, and sputum was collected for 
analysis. At any time patients experienced any worsening of their respiratory symptoms they 
were instructed to contact the study personnel by telephone. They were subsequently 
invited to attend the outpatients department within 12 hours for spirometry measurements, 
sputum collection and consultation by one of the study physicians.  
Exacerbations were defined as worsening of respiratory symptoms that required treatment 
with a short course of oral corticosteroids or antibiotics as judged by the study physician. 
The type of an exacerbation was expressed by the Anthonisen scores type I, II, III (23). An 
exacerbation was scored Type 0 as the exacerbation was treated with a short course of oral 
corticosteroids or antibiotics, but did not fulfill the Anthonisen scores. A short course of oral 
corticosteroids was defined as 30 mg prednisolone for a period of 10 days. First choice of 
antibiotics was amoxicillin/clavulanic acid 625 mg four times daily for a period of 10 days. 
Second choice was doxycycline 100 mg daily for a period of 10 days. In order to differentiate 
between an ongoing and a new or recurrent exacerbations all patients’ clinical and 
pharmacy records were collected and analyzed. In order to avoid the impact of treatment 
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with antibiotics on lower airway colonization, we only analyzed the time to the first 
exacerbation of COPD. 
Sputum Samples. The laboratory technicians processing the sputum samples were 
unaware of the clinical condition of the patients. Spontaneously expectorated sputa were 
collected in sterile vials and processed in the laboratory within 4 hours. Sputa were 
homogenized by incubation at 37o C for 15 minutes with an equal volume of 0,1 percent 
dithiothreitol. Appropriate dilutions of homogenized sputum samples were placed on blood, 
chocolate, CLED and saboroud agar plates. Bacterial and mycological isolation and 
identification was performed with the use of standard techniques (24). Streptococcus 
pneumoniae, Haemophilus influenzae or Moraxella catarrhalis, Pseudomonas aeruginosa, 
Staphylococcus aureus, Aspergillus and Candida species and other gram-negative rods 
were considered to be potentially pathogenic microorganisms (PPM). Other bacterial 
species were classified as normal flora. 
Bacterial colonization was defined as the demonstration of bacteria in cultures of lower 
respiratory tract sample in a clinically stable COPD patient without symptoms attributable to 
infection (16). A bacterial infection was defined by the abundant presence of one or more 
potentially pathogenic microorganisms in relation to the normal microbiological flora in 
sputum in the presence of more than 105 per ml.  
Statistical Analysis. We calculated that 192 patients (96 per treatment group) were 
required to detect a hazard ratio of a first exacerbation of 1.50 (colonized compared to non 
colonized) with 80% power and a two-sided 0.05 α-level test (25). Baseline characteristics 
are reported as means ± SD or as percentages stratified by colonization at baseline yes or 
no. The effect of colonization on time to first exacerbation (the primary outcome) was 
assessed using multivariate Cox proportional hazard analyses. We adjusted for potential 
confounding variables, including age, sex, smoking status, number of exacerbations in 
preceding year and FEV1% predicted. We forced all of these variables in the final model(s) 
because they have been demonstrated to be associated with exacerbations or risk of 
bacterial colonization. The presence of effect modification by ICS (FP or placebo) and FEV1 
(continuous) was investigated by adding the product terms to the multivariate Cox 
proportional hazard model. If the p-value of the product term was lower than 0.1, further 
analyses were stratified by subgroups of the tested variable. For the stratified analysis, FEV1 
was dichotomized into patients with a relatively low (FEV1< 50%) and high FEV1 (FEV1 ≥ 
50%) according to the GOLD criteria (1). Furthermore, we analyzed time to a first 
Anthonisen type 0, I, II and III exacerbations for colonization (yes or no) in the parsimonious 
model. All statistical analyses were performed using SPSS version 10 (26). 
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RESULTS 
Of 509 eligible patients, 269 were enrolled as described in an earlier publication (6) (see 
Figure 1). After 4 months of treatment with fluticasone propionate (FP), 244 COPD patients 
were randomized to either continue using FP (FP-group) or to receive placebo for 6 months 
(placebo group). At randomization, sputum samples could be collected in 209 patients, 106 
in the FP and 103 in the placebo group. The mean age (± SD) of the participants was 64.0 ± 
7.2 years. During the double blind phase, two patients were withdrawn from the study; one 
in the FP group due to cancer and the other in the placebo group due to a cerebrovascular 
accident. Table 1 shows the baseline characteristics of the study population stratified by 
colonization (yes or no) in stable state.  
 
6CDNG$CUGNKPGEJCTCEVGTKUVKEUQHVJGRCVKGPVUYKVJURWVWOUCORNGUCVTCPFQOK\CVKQP
 Colonized Non colonized 
Number of patients  76  133  
Mean age in years (SD) 65 (7) 64 (8) 
Male (%)  86  87  
Mean number of exacerbations in preceding year (sd)  1.7 (1.8) 1.2 (1.6) 
Smoking status (%)   
 Ex-smokers 67   74  
 Current smokers 33  26  
Placebo (%) 54  47  
Lung function post bronchodilation (SD)   
 FEV1 in liters 1.6 (0.5) 1.8 (0.6) 
 FEV1 % predicted of normal 54 (15) 58  (15) 
 
 
The excluded patients without sputum sample at baseline (n=35) experienced slightly fewer 
exacerbations in the preceding year (0.9 ± 0.9), contained fewer current smokers (20%) and 
more women (30%) compared to the study population with a sputum sample at baseline. 
At randomization, 76 (36%) of the 209 patients were colonized. Haemophilus influenzae was 
observed in 50 patients, Streptococcus pneumoniae in 22 and Moraxella catarrhalis in 19 
patients. In the colonized group, 47 (62%) of the patients developed at least one 
exacerbation compared to 67 (50%) in the non-colonized group. At exacerbation 
predominantly new PPM were isolated compared to stable state COPD.  
The crude hazard ratio of a first exacerbation in colonized patients compared to non-
colonized was 1.30 (95% CI 0.89-1.89). Adding the product term (ICS* colonization) to the 
multivariate model, including age, sex, FEV1, number of exacerbations in preceding year and  
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Figure 1. Flow diagram of subject progress through the study.  
 
Baselinepopulation  
n = 615 
Excluded  
n= 106;  17.5% 
Transport/mobility problems: 19 
Refused to participate: 54 
Other reasons: 33 
 
Written informed consent 
n= 386 
Excluded  
n= 123;  24.2 % 
Problems with change in medication: 20 
Transport/ mobility problems: 10 
Refused to participate: 93 
 
Patients included 
n= 269 
Patients not meeting entry criteria at visit 1 
(lung function + general criteria) 
n= 117;  30.3 % 
Reversibility  : 49TLC: 8 
FEV1: 25  FEV1/VC: 19 
Other reasons: 16 
Open label study medication 
(visit 2) 
n= 263 
Withdrawn between visit 1 and 2. 
n=6;  2.2% 
Dead: 1 
Lobectomy: 1   Failure to return: 4 
 
Randomised (visit 3) n=244 
FP-group n=123 
Placebo group n=121 
Eligible patients 
n=509 
Patients without sputum sample 
at visit 3 
n=35 
Colonised patients 
n=76 (36%) 
Non-colonised patients 
n=133 (64%) 
Withdrawn between visit 2 and 3 
n=19;  7.2 % 
Reasons: 
Dead: 4    Failure to return: 7 
Intolerance FP: 6    Other: 2 
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smoking status, did not indicate effect modification by discontinuation of ICS (p=0.85). 
However, adding the product term (FEV1 * colonization) to this model, suggests effect 
modification by FEV1 (p=0.038). We therefore stratified the analysis by patients with a 
relatively low (FEV1< 50%) and high FEV1 (FEV1 ≥ 50%) according to the GOLD criteria (1). 
The adjusted hazard ratio of a first exacerbation in colonized compared to non-colonized 
patients was 1.01 (95% CI 0.56-1.81) in patients with a low FEV1 and 1.29 (95% CI 0.76-
2.20) in the patients with a high FEV1 (see Table 3).  
Analysis for the different types of exacerbation revealed that colonization increased the risk 
of a first Anthonisen type I exacerbation in the low FEV1 group: adjusted HR 4.42 (95% CI 
1.20-16.25) (see Table 4). No hazard ratio’s for the risk of a first type III could be calculated 
because of an insufficient number of cases. The type of the exacerbations differed 
significantly between colonized and non-colonized patients. Colonized patients experienced 
predominantly type I exacerbations: 53% (18/34) compared to 25% (13/52) in the non-
colonized patients. In the non-colonized patients, a type II exacerbation occurred most often 
(39% 20/52) (see Table 2).  
 
6CDNG&KUVTKDWVKQPQHGZCEGTDCVKQPV[RGUCEEQTFKPIVQ#PVJQPKUGPETKVGTKCKPVJGEQNQPKUGFCPFPQP
EQNQPKUGFRCVKGPVU
 Type 0 Type 1 Type 2 Type 3 
Colonized n(%) 1 (3%) 18 (53%) 8 (23%) 7 (21%) 
Non colonized n(%) 7 (13%) 13 (25%) 20 (39%) 12 (23%) 
 
 
6CDNG#FLWUVGFJC\CTFTCVKQUQHVJGHKTUVGZCEGTDCVKQPHQTEQNQPKUCVKQPCPFQVJGTTKUMHCEVQTUUVTCVKHKGF
D[('8
 
 FEV1 < 50% 
HR (95% CI) 
FEV1 ≥ 50% 
HR (95% CI) 
Colonization at randomization (yes versus no) 1.01 (0.56; 1.81) 1.29 (0.76; 2.20) 
Treatment (placebo versus FP)) 2.14 (1.14; 4.03) 1.35 (0.81; 2.26) 
Smoking status at baseline (yes versus no) 0.32 (0.15; 0.68) 0.70 (0.37; 1.29) 
FEV1% predicted  1.00 (0.96; 1.04) 0.98 (0.96; 1.01) 
Gender (male versus female) 1.61 (0.51; 5.08) 0.65 (0.36; 1.19) 
Age (years) 0.97 (0.93; 1.01) 0.99 (0.95; 1.02) 
Number of exacerbations in preceding year 1.30 (1.11; 1.52) 1.45 (1.25; 1.69) 
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6CDNG  #FLWUVGF JC\CTF TCVKQU HQT EQNQPKUCVKQP 
[GUPQ QH VJG HKTUV #PVJQPKUGP V[RG + CPF ++
GZCEGTDCVKQPUVTCVKHKGFD[('8
 
Outcome FEV1 < 50% 
HR (95% CI) 
FEV1 ≥ 50% 
HR (95% CI) 
Colonization and risk of type I exacerbation 4.42 (1.20-16.25) 1.23 (0.42-3.61) 
Colonization and risk of type II exacerbation 0.75 (0.13- 4.28) 0.89 (0.32-2.47) 
* No hazard ratio’s for the risk of a first type III could be calculated because of an insufficient number of cases 
 
 
DISCUSSION 
This study revealed three important new findings. First, in contrast to our hypothesis no 
interaction between colonization and discontinuation of ICS on the time to first exacerbation 
was found. Second, different from recent literature, bacterial colonization in moderately 
severe COPD patients was not shown to be an independent risk factor for the development 
of acute exacerbations. Third, as already indicated in an earlier publication (6) patients with 
a FEV1< 50% had a prominent increased risk of exacerbation following withdrawal of ICS, 
while such increased risk was not found in patients with a FEV1 of 50% or higher.  
This is the first study longitudinally investigating the effects of bacterial colonization on well-
documented exacerbations in moderately severe COPD in relation to discontinuation of ICS. 
The lack of effect of bacterial colonization on the development of exacerbations is in contrast 
to the findings of the Sethi study and a study of the East London Cohort (19,20), which both 
reported that bacterial colonization in stable state modulated frequency of COPD 
exacerbations. Both studies suggest that colonization is a risk factor for exacerbations, but 
they did not report the results corrected for potential confounders indicating the severity, like 
FEV1, smoking, and age. Since, we assumed FEV1 is not an intermediate between 
colonization and exacerbation, we considered FEV1 as a potential confounder or effect 
modifier. Although, in our study unadjusted Cox regression analysis showed a trend of 
increased risk in colonized patients, after correction for potential confounding factors no 
increased risk was found. The suggestion that an outgrow of colonizing bacteria, prompts an 
exacerbation (20) is disputed by the study of Sethi et al. (19) indicating that the increased 
exacerbations risk in colonized patients is caused by newly acquired bacteria. In the latter 
study, the relative risk of an exacerbation for colonized patients in stable state was 1.44, and 
rose to a maximum of 2.15 if a new strain of a bacterial pathogen was isolated. Similarly, we 
found in our study that most bacteria at exacerbations were different compared to those 
seen in stable state.  
Since, patients with bacterial colonization in the low FEV1 group experienced predominantly 
Anthonisen type I exacerbations and hence have a high chance to be treated with antibiotics 
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at exacerbation (23), new studies on the effects of frequent use of antibiotics in this 
subgroup of COPD patients are warranted.  
The increased risk of exacerbations following withdrawal of ICS was already reported in our 
recent publication (6) and is in accordance with other limited evidence available (27,28). 
There is still debate whether or not ICS are beneficial in airway inflammation in COPD 
(29,30)following reports of conflicting results on the effects of ICS on markers of 
inflammation (31-34). In a recent study, the inhaled corticosteroid FP (9) showed beneficial 
effects on airway inflammation in bronchial biopsies in COPD, which may explain the 
decrease in exacerbations seen in long-term studies with FP. We are not aware of a study 
investigating the interaction of ICS with lower airway bacterial colonization. We found that 
bacterial colonization is not a risk factor for a more rapid onset of exacerbations in patients 
who discontinue ICS.  
Although, we did not study colonization and infections with viruses and atypical bacteria, 
some non-differential sampling errors might have occurred and minimal oropharyngeal 
contamination of the sputum samples cannot be excluded, we feel confident about the 
following conclusions: Bacterial colonization in moderately severe COPD is not an 
independent risk factor for new bacterial exacerbations and colonized patients do not benefit 
more from the preventive effects of ICS in reducing the frequency and severity of 
exacerbations than non-colonized patients.  
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ABSTRACT  
A total of 145 penicillin-nonsusceptible Streptococcus pneumoniae strains were isolated 
from young carriers in Greece and analyzed by antibiotic susceptibility testing, serotyping, 
restriction fragment end labeling (RFEL), and penicillin-binding protein (PBP) genotyping. 
The serotypes 23A and 23F (54%), 19A and 19F (25%), 9V (5%), 15A, 15B, and 15C (4%), 
6A and 6B (4%), and 21 (4%) were most prevalent in this collection. Fifty-three distinct 
RFEL types were identified. Sixteen different RFEL clusters, harboring 2 to 32 strains each, 
accounted for 82% of all strains. Eight of these genetic clusters representing 60% of the 
strains were previously identified in other countries. A predominant lineage of 66 strains 
(46%) harboring five RFEL types and the serotypes 19F and 23F was closely related to the 
pandemic clone Spain23F-1 (genetic relatedness of 85%). Another lineage, representing 11 
strains, showed close genetic relatedness to the pandemic clone France9V-3. Another 
lineage of 8 serotype 21 strains was Greece specific since the RFEL types were not 
observed in an international collection of 193 genotypes from 16 different countries. 
Characterization of the PBP genes pbp1a, pbp2b, and pbp2x revealed 20 distinct PBP 
genotypes of which PBP type 1-1-1, initially observed in the pandemic clones 23F and 9V, 
was predominantly present in 11 RFEL types in this Greek collection of penicillin-
nonsusceptible strains (55%). Sixteen PBP types covering 52 strains (36%) were Greece 
specific. This study underlines the strong contribution of penicillin-resistant international 
clones to the prevalence and spread of penicillin-nonsusceptible pneumococci among young 
children in Greece.  
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INTRODUCTION  
Streptococcus pneumoniae is worldwide a common cause of invasive diseases such as 
meningitis, bacteremia, and pneumonia and of upper respiratory tract infections (1). 
Pneumococci are often part of the normal nasopharyngeal flora. Especially young children 
and elderly people are at risk of becoming colonized with S. pneumoniae. The colonization 
risk increases where crowding occurs, e.g., in day care centers, hospitals, and nursing 
homes (23, 30, 31). Although a positive correlation between colonization with pneumococci 
and acute otitis media has been found (12, 36), a relation between pneumococcal carriage 
and invasive disease has not yet been proven.  
Since the late 1970s and 1980s, antibiotic resistance among pneumococci has become an 
emerging problem. Several (multi)drug-resistant clones have rapidly spread throughout 
various European countries, North and Latin America, and Asia (2, 18, 20). Some of these 
clones were initially discovered in Spain, where so far the prevalence of penicillin resistance 
has reached levels of up to 60% (4). The most striking example is the spread of the 
pandemic multidrug-resistant clone 6B from Spain to Iceland in the late 1980s, where until 
1988 no drug resistance among S. pneumoniae isolates had been reported. From 1989 to 
1992 penicillin resistance rose steeply from 2.3 to 17% (39). In 1993, the resistance level 
among pneumococcal isolates in Iceland reached 20%, of which the vast majority was 
associated with the serogroups 6, 19, and 23 (25). In 1991, Munoz et al. have reported the 
intercontinental spread of a multidrug resistant S. pneumoniae clone of serotype 23F from 
Spain to the United States (29). Since then this clone, recently designated pandemic clone 
Spain23F-1 (http://www.wits.ac.za/pmen/pmen.htm) has rapidly spread throughout the 
United States (27). Finally, Gasc et al. have described in 1995 the spread of a penicillin-
resistant pneumococcal clone of serotype 9V (pandemic clone France9V-3) from Spain to 
France (14). Throughout the years these clones have been identified in many countries in 
different parts of the world (10, 20, 42). In addition, novel drug-resistant clones have been 
reported in France, former Czechoslovakia, Spain, Hungary, Japan, South Africa, the United 
States, Chile, England, etc. which tend to spread in a nationwide manner (6, 13, 16, 17, 19, 
35, 37, 45). The risk for colonization with and spread of antibiotic-resistant strains is related 
to younger-age children, occurrence of refractory middle ear infections, previous antibiotic 
consumption, and day care attendance (9, 28, 32).  
In Greece, the emergence of antibiotic resistance among pneumococcal isolates was 
recognized in the mid 1990s (41). During the period December 1995 through February 1996, 
53% of the pneumococci isolated from healthy carriers attending day care centers appeared 
to be resistant to one or more antibiotics, while 29% of these isolates were penicillin 
nonsusceptible (41). In a recent study in which 2,448 infants and toddlers were screened 
during a 2-year period (1997 to 1999) for pneumococcal carriage, 16% of the pneumococci 
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demonstrated reduced susceptibility to penicillin (40; G. Syrogiannopoulos, I. Grivea, G. 
Katopodis, and N. Beratis, unpublished data). The aim of the current study was to identify 
the molecular epidemiological nature of the penicillin-nonsusceptible pneumococci isolated 
in Greece. For this purpose, molecular analysis was performed on penicillin-nonsusceptible 
isolates of the two Greek studies. A total of 145 (multi)resistant pneumococcal isolates 
collected from both studies were characterized by drug susceptibility testing, serotyping, 
restriction fragment end labeling (RFEL), and penicillin-binding protein (PBP) genotyping.  
 
 
MATERIALS AND METHODS  
Bacteriology. Penicillin-nonsusceptible S. pneumoniae strains were isolated from the 
nasopharynx of 338 children attending seven day care centers in the city of Patras, 
Southwestern Greece, from December 1995 to February 1996 and from 2,448 children 
under the age of 2 years visiting health care centers in Southern and Central Greece from 
February 1997 to February 1999. Bacteriological diagnosis and susceptibility testing were 
carried out at the Laboratory of the Division of Pediatric Infectious Disease of the University 
of Patras, Patras, Greece. The bacteriological methods and serotyping have been described 
previously (40, 41). Molecular analysis was performed on 92% of the penicillin-
nonsusceptible isolates, i.e., 34 strains collected from seven day care centers in Patras and 
111 strains collected from 12 different provinces in Central and Southern Greece. In 
addition, the Greek isolates were compared with an international collection of pneumococcal 
strains representing 193 distinct RFEL types originating from 16 different countries in 
America, Europe, Africa, and Asia (M. Sluijter, unpublished observations), in which the 
international clones pandemic clone Spain23F-1, pandemic clone France9V-3, and 
pandemic clone Spain6B-2 are present (http://www.wits.ac.za/pmen/pmen.htm).  
RFEL analysis. Typing of the 145 pneumococcal strains by RFEL analysis was performed 
as described by van Steenbergen et al. (44) and as adapted by Hermans et al. (22). Briefly, 
purified pneumococcal DNA was digested by the restriction enzyme EcoRI. The DNA 
restriction fragments were end labeled at 72°C with [-32P]dATP using DNA polymerase 
(Goldstar; Eurogentec, Seraing, Belgium). The radiolabeled fragments were denatured and 
separated electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M urea. 
Subsequently, the gel was transferred onto filter paper, vacuum dried (HBI, Saddlebrook, 
N.Y.), and exposed for various times at room temperature to ECL Hyperfilms (Amersham, 
Bucks, United Kingdom).  
BOX PCR fingerprinting. Typing of the 145 pneumococcal strains by BOX PCR 
fingerprinting was performed as described by van Belkum et al. (43). Briefly, 50 ng of 
pneumococcal DNA was amplified by PCR (4 min at 94°C [predenaturation]; 40 cycles of 1 
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min at 94°C, 1 min at 60°C, and 2 min at 74°C; and 2 min at 74°C [extension]), using primer 
BOX-A (5'-ATACTCTTCGAAAATCTCTTCAAAC), which was designed from the primary 
structure of the pneumococcal BOX repeat motif. The amplified products were separated on 
a 1.5% agarose gel. Gels were stained with ethidium bromide, and the banding patterns 
were evaluated visually.  
PBP genotyping. Genetic polymorphism of the penicillin resistance genes pbp1a, pbp2b, 
and pbp2x of the penicillin-nonsusceptible isolates was investigated by restriction fragment 
length polymorphism (RFLP) analysis as described previously (20). Briefly, we amplified the 
genes by PCR. The primers used to amplify the genes pbp1a, pbp2b, and pbp2x were 
described previously (7, 11). The amplification products (5 µl) were digested by restriction 
endonuclease HinfI and separated by agarose gel electrophoresis. Gels were scanned and 
analyzed by the Geldoc 2000 system (Bio-Rad). The different PBP genotypes received a 
three-number code (e.g., 6-12-34) referring to the RFLP patterns of the genes pbp1a (6), 
pbp2b (11), and pbp2x (33), respectively.  
Computer-assisted analysis of the DNA banding patterns. The RFEL types were 
analyzed using the Windows version of the Gelcompar software version 4 (Applied Maths, 
Kortrijk, Belgium) after imaging of the RFEL autoradiograms using the Image master DTS 
(Pharmacia Biotech, Uppsala, Sweden). To this end, the DNA fragments in the molecular 
size range of 160 to 400 bp were explored. The DNA banding patterns were normalized 
using pneumococcus-specific bands present in the RFEL banding patterns of all strains. 
Comparison of the banding patterns was performed by unweighted-pair-group method using 
arithmetic averages (34) and using the Jaccard similarity coefficient applied to peaks (38). 
Computer-assisted analysis and methods and algorithms used in this study were carried out 
according to the instructions of the manufacturer of Gelcompar. A tolerance of 1.2% in band 
position was applied during comparison of the DNA patterns. For evaluation of the genetic 
relatedness of the isolates, we used the following definitions: (i) strains of particular RFEL 
type are 100% identical by RFEL analysis; (ii) a RFEL cluster represents a group of RFEL 
types that differs in only one band (ca. >95% genetic relatedness); and (iii) an RFEL lineage 
represents a group of RFEL types that differs in <4 bands (ca. >85% genetic relatedness).  
Statistical analysis. For statistical analysis of the results, we used the Fisher exact test.  
 
 
RESULTS  
A total of 145 penicillin-nonsusceptible pneumococcal strains were analyzed using 
serotyping, RFEL, and PBP genotyping. Serotyping revealed 12 different serotypes, namely, 
23F (52%); 23A (2%); 19F (15%); 19A (10%); 9V (5%); 15A, 15B, and 15C (4%); 6A (2%); 
6B (1%); 21 (4%); 14 (2%); 22 (1%); and 33F (1%) (40, 41; Syrogiannopoulos et al., 
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unpublished). RFEL analysis divided the strains into 53 distinct RFEL genotypes (Fig. 1). 
Sixteen genetic clusters were observed in this collection of strains, representing 82% of the 
strains and varying in size from 2 to 32 strains. The genetic relatedness within these clusters 
was confirmed by BOX PCR (43) (data not shown). Five of the sixteen clusters contained 
two serotypes, while one of the clusters harbored three different serotypes. We compared 
the 53 Greek RFEL types with our international library in which 193 RFEL genotypes of 
pneumococci from 16 different countries are present (M. Sluijter, unpublished observations). 
Six of the clusters representing 60% of the isolates were previously seen. To analyze the 
genetic heterogeneity in the penicillin resistance genes, we performed PBP genotyping. 
Twenty distinct PBP genotypes were observed (Table 1). PBP genotype 1-1-1, initially 
observed in the pandemic clones 23F and 9V, was most predominantly observed in this 
Greek collection; 81 strains representing 13 distinct RFEL types shared this penicillin 
resistance genotype.  
Clusters IX and X were the most predominantly observed clusters and consisted of 31 (21%) 
and 32 strains (22%), respectively (Fig. 1, Table 1). Both clusters belonged to one 
predominant lineage of 66 genetically related strains, representing five RFEL types and 
harboring the serotypes 23F and 19F. This lineage was closely related to the pandemic 
clone Spain23F-1 (genetic relatedness of 90%) which is widely spread all over the world (8, 
26, 42). All strains belonging to this lineage showed resistance to penicillin, 
chloramphenicol, tetracycline, and sulfamethoxazole-trimethoprim. In addition, cluster I was 
also resistant to erythromycin and clindamycin. Similar to the characteristics of the pandemic 
clone Spain23F-1, this lineage invariably demonstrated PBP genotype 1-1-1.  
The second lineage representing cluster VII contained 10 strains of serotypes 19F (Fig. 1, 
Table 1). Cluster VII was observed previously in The Netherlands, Thailand, and Vietnam 
and showed reduced susceptibility to penicillin, tetracycline, erythromycin and, in most 
cases, to sulfamethoxazole-trimethoprim. This cluster had another common feature since 
the genetic analysis of pbp1a by PBP genotyping of the vast majority of the strains was not 
applicable. Consequently, the PBP genotype of the majority of these strains was 0-3-30. 
Interestingly, this observation is in agreement with the genetically related strains present in 
the international data library.  
The third lineage representing 12 strains and the clusters III, IV, and V displayed serotype 
19A (Fig. 1, Table 1). These strains did not cluster with isolates from the international library 
and their PBP genotype did not match with any of the PBP genotypes present in the 
international library. All strains displayed the pbp1a and pbp2b genotype 2-2 that matched 
with the majority of the penicillin-susceptible pneumococci analyzed so far (Sluijter, 
unpublished).  We   observed   alterations  in  the  PBP  profile  of  pbp2x,  resulting  in   the 
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Figure 1. Dendrogram of the 53 RFEL types observed among 145 penicillin-nonsusceptible pneumococcal isolates 
from the nasopharynxes of Greek children. Molecular sizes of reference bands are indicated in bases (b). Serotypes, 
PBP types, RFEL types, bars representing the number of isolates per RFEL type, clusters and cluster codes are also 
shown. NT, nontypeable; D, RFEL types observed at least once in day care centers. Code "00" refers to untypeable 
PBP genotypes. Major serotypes (*) and PBP types (**) within RFEL types are indicated (for details, see Table 1).  
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genotypes 2-2-75 and 2-2-80. These PBP genotypes invariably corresponded to 
intermediate resistance to penicillin only.  
The fourth lineage represented the clusters XV (two strains) and XVI (nine strains) and 
harbored the serotypes 9V, 14, and 23A (Fig. 1, Table 1). These clusters corresponded to 
the pandemic clone France9V-3. All strains showed the PBP genotype 1-1-1 and were 
invariably resistant to penicillin, sulfamethoxazole-trimethoprim and, in some strains, to 
chloramphenicol and tetracycline.  
The fifth lineage represented the clusters XIII (serotype 21; six strains) and XII (serogroup 
23F; two strains) (Fig. 1, Table 1). These clusters were Greece specific since they were not 
present in the international library. Interestingly, these clusters consisted of strains that were 
isolated in day care centers only. Cluster XIII was mostly observed in a single day care 
center, whereas cluster XII was exclusively observed in another day care center (Fig. 1). 
Cluster XIII displayed PBP type 2-2-76 corresponding to low penicillin resistance. Cluster XII 
showed a different PBP genotype 2-5-10 with alterations in pbp2b and pbp2x. None of the 
latter two PBP genotypes were present in the international library.  
Both study groups were divided in day care center attendees and non-day care attendees to 
analyze the contribution of day care center attendance on clustering of pneumococcal 
strains. We observed that 86% of the strains from the day care center group containing 45 
pneumococcal isolates belonged to a cluster. Within the non-day care center group 
representing 100 pneumococcal isolates, 80% of the strains demonstrated genetic 
clustering. There was no statistical difference between the two groups. We reanalyzed our 
data for the largest day care center in Patras, where 21 strains were isolated. We observed 
that 19 of these 21 strains (90%) clustered within four clusters. Although this percentage 
demonstrated a higher degree of genetic clustering in children attending day care centers, 
this difference was statistically not significant. 
 
 
DISCUSSION  
Serotyping of the penicillin-nonsusceptible isolates revealed that 79% of the Greek strains 
belonged to serotypes 23F, 23A, 19F, and 19A (40, 41; Syrogiannopoulos et al., 
unpublished). These data correspond to earlier findings in other European countries and in 
the Americas in which these serogroups also significantly contributed to the prevalence of 
penicillin-resistant S. pneumoniae among young carriers (2, 3, 15, 23, 33, 42).  
RFEL genotyping of the 145 penicillin-nonsusceptible isolates showed that 82% of the 
strains matched within genetic clusters. These data suggest that penicillin-resistant 
pneumococci rapidly spread among children. This is in line with earlier findings by Hermans 
et al., who demonstrated that the degree of genetic clustering of penicillin-resistant strains in 
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the Netherlands and Thailand is 70 and 74%, respectively, whereas the degree of genetic 
clustering among Dutch penicillin-susceptible isolates is 32% (21). Similar data have been 
reported in various other parts of the world, including Europe, the United States, and South 
America (8, 20, 26, 42).  
The present study clearly demonstrates the significant contribution of the pandemic clone 
Spain23F-1 to the prevalence and spread of penicillin-nonsusceptible pneumococci among 
young children in Greece. This is in agreement with studies in other countries in which the 
predominance of this pandemic clone has also been observed (8, 26, 42). In addition, in the 
latter studies a second predominant clone, the pandemic clone France9V-3, was highly 
contributive to the penicillin-resistant pneumococcal population. This clone is also present in 
our Greek collection, but it does not play a predominant role. 
Serogroup 19 represented the major serotype among five lineages. The lineages of cluster 
VI and cluster VII represented mainly multidrug-resistant isolates and were closely related to 
isolates found in The Netherlands, Thailand, and Vietnam. Multilocus sequence typing 
(MLST) has demonstrated that cluster VII also matches with multidrug-resistant serotype 
19F isolates from Taiwan (B. Spratt, personal communication). The three other lineages, 
representing clusters I and II, clusters III, IV, and V, and cluster XI, respectively, showed 
intermediate resistance to penicillin only and displayed new PBP genotypes with alterations 
in pbp2x only. MLST has demonstrated that clusters III, IV, and V match with a drug-
susceptible serotype 19A invasive isolate from the United Kingdom. In general, this study 
showed a relation between accumulation of alterations in the three PBP genes and level of 
penicillin resistance; high resistance levels were often associated with changes in the DNA 
banding patterns of all three PBP genes (18). In addition, there was also a correlation 
between multidrug resistance and cumulative alterations in all three PBP genes. This 
phenomenon is in agreement with the previous observations of Hermans et al. and is 
hypothesized to be the effect of frequent horizontal cotransfer of resistance genes other than 
PBP genes in pneumococci with high-level penicillin resistance (20). 
Only one lineage, representing two RFEL clusters of serotype 21 and 23F, respectively, was 
found to be Greece specific since they were not present in the international data library. In 
addition, this lineage was found only in three day care centers. This is strongly suggestive 
for the dissemination of pneumococcal clones among day care center attendees within and 
between day care centers. MLST typing has recently demonstrated that this RFEL cluster of 
serotype 21 matches a drug-susceptible invasive isolate of serotype 21 in the United 
Kingdom (B. Spratt, personal communication).  
In conclusion, our observations demonstrate a high degree of genetic clustering among 
penicillin-nonsusceptible,   often   multidrug-resistant   pneumococci   in   young   children  in  
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Table 1. Clusters, serotypes, PBP genotypes and resistance patterns of the 145 penicillin- 
resistant pneumococci isolated from the nasopharynx of young infants in Greece. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Genetic clustering according to RFEL typing exclusively matched with BOX PCR fingerprinting.  
b Code “(0)” refers to untypeable PBP genotypes. 
b The antibiotic resistance pattern was evaluated for penicillin (P), erythromycin (E),  
chloramphenicol (C), tetracycline (T), clindamycin (CL) and sulfamethoxazole-trimethoprim (S). 
 
Cluster a 
 
No. of strains/no. 
of RFEL types 
 
Serotype(s) 
(no. of strains) 
 
PBP type b 
(nr. of strains)
 
Resistance 
Pattern c 
I 
II 
(2/2) 
(2/1) 
19F 
19F 
2-2-77 P 
III 
IV 
 
V 
(6/2) 
(3/1) 
 
(2/2) 
(1/1) 
19A/F 
19A        (2) 
9V          (1) 
19A 
23A 
2-2-75   
2-2-75   
1-1-1     
2-2-75 
2-5-61 
P 
P 
 
P 
PCTS 
VI (2/2) 
 
(1/1) 
(1/1) 
19A 
 
19A 
23A 
7-5-1 
2-1-23 
7-5-1 
2-5-27 
P(TE)S 
 
PCTS 
VII (10/2) 19F 1(0)-3-30(0) PTE(S) 
VIII (2/1) 23F 2-2-71 
25-3-1 
PCT 
PS 
IX 
X 
(32/2) 
(33/2) 
 
(1/1) 
23F 
23F         (32) 
19F         (1) 
23F 
1-1-1 PCTECLS 
PCTS 
 
PCTES 
XI (2/1) 
(2/2) 
19A 
19A 
2-2-75 PS 
XII 
XIII 
(6/1) 
(2/2) 
21           (5) 
23F 
2-2-76 
2-5-10 
P 
 (2/2) 23F 5-5-10 P 
XIV (4/2) 
 
15 
 
2-19-57    (2) 
20-19-57  (2) 
P 
 
XV 
XVI 
(8/2) 
(3/2) 
9V/ 14/ 23A 
23A/ 14 
1-1-1 P(CT)S 
PS 
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Greece, mainly caused by the spread of a restricted number of penicillin-resistant S. 
pneumoniae clones. Limiting antibiotic prescription and promoting compliance would 
probably contribute to the control of this problem. A better alternative to prevent the spread 
of multidrug-resistant clones in the near future, however, is large-scale vaccination using 
pneumococcal conjugate vaccines. Although the initial results of the conjugate vaccination 
trials look promising (5, 24; R. Dagan, N. Givon, P. Yagupsky, et al., Abstr. 38th Intersci. 
Conf. Antimicrob. Agents Chemother., abstr. G552, 1998), the epidemiological 
consequences of such strategies need to be monitored in detail. 
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ABSTRACT 
Since January 1996, and over a 3-year time span, a significant spread of serotype 6B 
multidrug-resistant (MDR) pneumococci, susceptible to penicillin and resistant to 
erythromycin, clindamycin, tetracycline, chloramphenicol, and trimethoprim-
sulfamethoxazole, was noted in young carriers living in central and southern Greece. Using 
restriction fragment end labeling and penicillin binding protein (PBP) genotyping, we studied 
41 serotype 6B penicillin-susceptible MDR pneumococci isolated during two independent 
studies in Greece. Forty (98%) of these 41 isolates were strongly related, representing a 
single lineage (genetic relatedness, 91%). The Greek isolates were closely related (genetic 
relatedness, ~91%) to the penicillin-resistant MDR clone of serotype 6B that spread from 
Spain to Iceland in the late 1980s. Moreover, the Greek group of isolates was genetically 
distinct (genetic relatedness < 83%) from other penicillin-susceptible or -resistant serotype 
6B strains from various parts of the world. All serotype 6B penicillin-susceptible MDR 
isolates displayed a penicillin-susceptible PBP 1A-2B-2X genotype. Our findings suggest 
that the penicillin-susceptible MDR 6B clone that was found in Greece between the years 
1996 and 1999 represents the ancestor of the pandemic penicillin-resistant MDR clone 6B.  
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INTRODUCTION 
Streptococcus pneumoniae is a common cause of invasive diseases, such as meningitis 
and bacteremia, and of respiratory tract infections (10, 15). S. pneumoniae isolates that are 
resistant to penicillin and/or to non-β-lactam agents have been reported with increasing 
frequency worldwide (15). This global increase in antibiotic-resistant and especially in 
multidrug-resistant (MDR) pneumococci appears, in part, to result from the spread of 
individual highly resistant pneumococcal clones (1, 4, 5, 12-14). A penicillin-resistant MDR 
clone of serotype 6B was initially isolated from Spain (14) and then spread to Iceland (20). 
This clone has been designated the Spain6B-2 clone (11). Additional clones of antibiotic-
resistant serotype 6B pneumococci have been found in Europe, North America, and South 
Africa (2, 4, 6, 7, 17, 19); it is not clear whether they share a common ancestor or emerged 
independently.  
Recently, penicillin-susceptible MDR serotype 6B pneumococci, resistant to 
chloramphenicol, tetracycline, erythromycin, clindamycin, and trimethoprim-
sulfamethoxazole (SXT) were isolated from young carriers in Greece. Specifically, this 
notable serotype 6B resistance pattern was described for the first time in the report of a 
study that was performed between December 1995 and February 1996 in the city of Patras, 
southwestern Greece (21). Following the initial isolation of pneumococci with this phenotype, 
between the years 1996 and 1999, isolates with the same characteristics were recovered 
from young carriers living in various Greek areas (21, 22). In addition, similar serotype 6B 
penicillin-susceptible MDR pneumococci were isolated from young carriers in Italy and Israel 
in 1997 to 1998 (23).  
The present study was undertaken to investigate, by using restriction fragment end labeling 
(RFEL) analysis and penicillin-binding protein (PBP) genotyping, the molecular 
characteristics of the Greek serotype 6B penicillin-susceptible MDR pneumococci and their 
genetic relatedness with other serotype 6B pneumococcal isolates, both penicillin-
susceptible and penicillin-resistant strains, isolated in various parts of the world.  
 
MATERIALS AND METHODS  
Study population. Penicillin-susceptible MDR pneumococci were isolated from 
nasopharyngeal cultures obtained from children during two independent studies in Greece 
(21, 22). The first study was performed with 338 children attending seven day-care centers 
in the city of Patras, southwestern Greece, during the 2-month period from 19 December 
1995 to 15 February 1996. In this study, 20 penicillin-susceptible MDR pneumococcal 
isolates were recovered from 132 carriers. The second study, the ‘Hellenic Antibiotic-
Resistant Respiratory Pathogens' (HARP) Study, was conducted from 10 February 1997 to 
10 February 1999. Nasopharyngeal cultures for S. pneumoniae from 2,448 children younger 
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than 24 months old living in central and southern Greece were performed. Ninety-five (3.9%) 
of the 2,448 children attended day-care centers. In the HARP Study, screening of the 
children revealed 46 penicillin-susceptible MDR pneumococci.  
Bacteriological procedures. Isolation, identification, and susceptibility testing of the Greek 
S. pneumoniae isolates were performed at the Laboratory of the Division of Pediatric 
Infectious Disease of the University of Patras as described previously (22). Penicillin and 
erythromycin MICs for the Greek isolates were determined by the E-test method (AB 
Biodisk, Solna, Sweden). Susceptibility to clindamycin, chloramphenicol, tetracycline, and 
SXT was determined by the disk-diffusion method (16). Multidrug resistance was defined as 
resistance to at least three classes of antimicrobial agents. Pneumococci were serotyped at 
the Centre National de Référence du Pneumocoque, Créteil, France, by latex agglutination 
using specific antisera prepared by the investigators at the Centre or at the Laboratory of the 
Division of Pediatric Infectious Disease of the University of Patras by the capsular swelling 
method using commercially available antisera (Statens Seruminstitut, Copenhagen, 
Denmark).  
International collection of serotype 6B S. pneumoniae strains. Twenty-five serotype 6B 
penicillin-susceptible or -resistant pneumococci, isolated from various parts of the world, 
were compared to 41 randomly selected Greek penicillin-susceptible MDR isolates of 
serotype 6B (Table 1). The international collection of serotype 6B pneumococci included 
strains from Thailand (n = 6), the United States (n = 5), The Netherlands (n = 4), Iceland (n = 
3), Poland (n = 3), Spain (n = 1), South Africa (n = 1), Finland (n = 1), and Cuba (n = 1) (7).  
RFEL typing. Pneumococcal strain typing by RFEL was done as described by van 
Steenbergen et al. (24) and adapted by Hermans et al. (8, 9). Briefly, purified pneumococcal 
DNA was digested by the restriction enzyme EcoRI. The DNA restriction fragments were 
end labeled at 72°C with [-32P]dATP using DNA polymerase (Goldstar; Eurogentec, 
Seraing, Belgium). After the radiolabeled fragments were denatured and separated 
electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M urea, the gel was 
transferred onto filter paper, vacuum dried (HBI, Saddlebrook, N.Y.), and exposed for 
various times at room temperature to ECL hyperfilm (Amersham Laboratories, Amersham, 
United Kingdom).  
PBP genotyping. Genetic polymorphism of the penicillin resistance genes pbp1a, pbp2b, 
and pbp2x of the penicillin-resistant isolates was investigated by restriction fragment length 
polymorphism (RFLP) analysis as described previously (9). The different PBP genotypes 
received a three-number code (i.e., 6-12-34), referring to the RFLP patterns of the genes 
pbp1a (6), pbp2b (12), and pbp2x (34), respectively (18).  
Computer-assisted analysis of DNA band patterns. RFEL autoradiographs were 
converted to images (Image Master DTS; Pharmacia Biotech, Uppsala, Sweden) and 
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analyzed by computer (Windows version Gelcompar software, version 4; Applied 
Mathematics, Kortrijk, Belgium). DNA fragments were analyzed as described previously (9). 
For evaluation of the genetic relatedness of the isolates, we used the following definitions: (i) 
strains of a particular RFEL type are 100% identical by RFEL analysis; (ii) an RFEL cluster 
represents a group of RFEL types that differ in only one band (>95% [approximate] genetic 
relatedness); and (iii) an RFEL lineage represents a group of RFEL types that differ in fewer 
than four bands (>85% [approximate] genetic relatedness).  
 
 
RESULTS  
Epidemiology of the Greek penicillin-susceptible MDR pneumococci. Of the 66 
penicillin-susceptible MDR pneumococci isolated during the two studies in Greece, 79% 
displayed capsular type 6B. These serotype 6B isolates were invariably susceptible to 
penicillin and resistant to erythromycin and clindamycin, while 98, 94, and 92% of them were 
resistant to tetracycline, chloramphenicol, and SXT, respectively.  
RFEL analysis. DNA fingerprinting of 41 penicillin-susceptible MDR 6B pneumococci from 
Greece and an international group of 25 serotype 6B pneumococcal strains revealed 34 
distinct types (Fig. 1 and Table 1). The 41 randomly selected Greek isolates represented a 
total of nine RFEL types. Forty (98%) of the 41 isolates were strongly related, representing a 
single lineage (genetic relatedness, 91%). RFEL analysis showed six clusters of strains.  
Only one strain had a unique type that was genetically unrelated to those of the other 
isolates (genetic relatedness, < 80%). There was no correlation between the slightly different 
resistance patterns and the distinct genotypes (Table 1). The group of Greek serotype 6B 
isolates was closely related (genetic relatedness, ~91%) to the penicillin-resistant MDR 
Spain6B-2 clone that spread from Spain to Iceland in the late 1980s, as represented by the 
isolates IC 08, IC 55, and IC 213. The group of Greek serotype 6B isolates was genetically 
distinct (genetic relatedness < 83%) from the other 22 serotype 6B pneumococci isolated 
from various parts of the world.  
PBP genotyping. All Greek serotype 6B isolates harbored PBP types which were clearly 
distinct from those of the penicillin-resistant isolates. They invariably displayed a penicillin-
susceptible PBP 1A-2B-2X genotype, namely, 2-2-71 (Table 1). 
       Chapter 4.2 104  
 
Figure 1. Dendrogram depicting genetic distances and overall relatedness of 6B pneumococcal isolates on the basis of 
RFLP data. Numbers of base pairs of the single-stranded DNA are indicated below the banding patterns. See Table 1 
for the characteristics of the isolates. 
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DISCUSSION 
The molecular and epidemiological factors that control the emergence of antibiotic 
resistance, increase in resistance levels, and the geographic spread of antibiotic-resistant 
pneumococci are not fully understood. The present study investigated the emergence and 
spread of antibiotic resistance in S. pneumoniae strains of serotype 6B.  
In Greece, serotype 6B is currently the leading capsular type among the penicillin-
susceptible, non-β-lactam-resistant pneumococci isolated from young carriers, representing 
46% of these isolates (references 21 and 22 and our unpublished data). Seventy-three 
percent of these serotype 6B pneumococci were resistant to four or five classes of non-β-
lactam agents. The penicillin-susceptible pneumococci of serotype 6B that are resistant to 
several non-β-lactams have to be considered potentially epidemic, since between the years 
1996 and 1999, they were recovered from a significant number of carriers living in various 
areas of Greece. These pneumococci were isolated from children both attending day-care 
centers and cared for at home.  
The relative importance of the clonal spread of strains and horizontal spread of resistance 
genes depends on the extent of recombination between chromosomal genes in nature. We 
used the combination of a method that indexes the overall genetic relatedness of isolates 
and one that can assess whether the isolates carry the same penicillin resistance 
determinants (altered PBP genes) to distinguish the clonal spread of strains from the 
horizontal spread of resistance genes.  
RFEL fingerprinting showed that the Greek serotype 6B penicillin-susceptible MDR 
pneumococcal isolates indicate the spread of a single clone. Another molecular technique, 
BOX PCR fingerprinting, was also tested (data not shown), but it did not increase the 
discriminatory power. All Greek isolates displayed an identical penicillin-susceptible PBP 1A-
2B-2X genotype, namely, 2-2-71. This PBP type has been previously described for 
penicillin-susceptible pneumococci after application of the same molecular analysis (18).  
A comparison of the RFEL patterns of the Greek serotype 6B isolates with those of serotype 
6B pneumococci recovered from diverse geographic locales has brought to light a notable 
finding: the close relatedness between the Greek and Icelandic serotype 6B isolates.  
Since the Greek penicillin-susceptible MDR serotype 6B isolates are closely related to the 
penicillin-resistant MDR serotype 6B pneumococci that spread from Spain to Iceland in the 
late 1980s, these results suggest that the penicillin-susceptible MDR 6B clone that was 
found throughout Greece represents the ancestor of one of the three most virulent, 
internationally disseminated, penicillin-resistant MDR clones, the Spain6B-2 clone (11, 14).  
Another molecular technique, multilocus sequence typing (3), has demonstrated that the 
Greek penicillin-susceptible MDR serotype 6B pneumococcal isolate GR 890, representative 
of the RFEL cluster of isolates that match their Spanish ancestor 6B, is genetically related to 
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Table 1.  Source as well as genotypic and phenotypic properties of serotype 6B penicillin-susceptible and  
penicillin-resistant pneumococcal isolates a 
Strain(s) Country 
Clinical 
origin 
RFEL 
type 
PBP 
genotype 
Penicillin 
MIC  
(µg/ml) 
Resistance pattern 
US 1761/91 United States MEF 102 16-01-01 1 PEN-ERY-STX 
US 1751/91 United States MEF 221 NA-3-30 1 PEN-ERY-STX 
FI 602r Finland NA 107 03-02-01 1 PEN-ERY-TET-STX 
US 2106/92 United States Sputum 3 02-01-04 1 PEN-ERY-STX 
CU 12/92 Cuba NP 256 02-02-40 0.03 STX 
PO 02 Poland NA 55 02-05-51 1 PEN 
TH BP304 Thailand NP 220 01-03-13 2 PEN-ERY-TET-STX 
TH PP409 Thailand NP 214 01-06-13 2 PEN-ERY-TET-STX 
GR 665, GR 558 Greece NP 253 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
GR B83, GR B78, GR B64, GR B44, GR B37,  
GR B26, GR B9, GR 728,  GR 890, GR 155, GR T8 
GR B36, GR B32,  GR T2A,  GR 157,  GR 163 
Greece NP 244 02-02-71 ≤ 0.016 ERY-CLI-TET-CHL-STX 
GR 217 Greece NP 244 02-02-71 0.016 ERY-CLI-TET-CHL 
GR 481 Greece NP 254 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
GR 686, GR 615, GR 464, GR 151 Greece NP 249 02-02-71 ≤ 0.016 ERY-CLI-TET-CHL-STX 
GR 279 Greece NP 249 02-02-71 0.016 ERY-CLI-TET-CHL 
GR B85, GR 216, GR 093, GR 174, GR 253, 
GR 254, GR 352, GR P83,  GR 115 
Greece NP 245 02-02-71 ≤ 0.016 ERY-CLI-TET-CHL-STX 
IC 213 Iceland NA 288 01-03-13 2 PEN-ERY-CLI-CHL-STX 
IC 08 Iceland NA 187 01-03-13 1 PEN-ERY-CLI-TET-CHL-STX 
IC 55 Iceland NA 188 01-03-13 0.75 PEN-ERY-CLI-TET-CHL-STX 
GR 406 Greece NP 251 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
GR P96, GR 62, GR P2 Greece NP 246 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
GR P3, GR 516 Greece NP 248 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
US 17.W-5/5 United States NP 218 01-16-47 0.5 PEN-STX 
NL 940195 The Netherlands Blood 255 02-02-02 NA NA 
NL 970047 The Netherlands Blood 51 04-26-01 0.5 PEN-STX 
TH C404 Thailand NP 203 01-10-13 2 PEN-ERY-TET-STX 
SP 3717 Spain Blood 199 01-03-13 1 PEN-STX 
NL 960587 The Netherlands NP 211 01-03-13 NA PEN-ERY-TET-STX 
PO 28 Poland NA 96 02-02-55 < 0.1 TET-ERY-STX 
TH BP458 Thailand NP 206 01-10-13 1 PEN-ERY-TET-STX 
TH P244 Thailand NP 215 01-06-13 2 PEN-ERY-TET-STX 
SA sa8 South Africa NA 138 NA-02-27 2 PEN-STX 
PO 15 Poland Blood 156 02-02-09 0.12 PEN-TET-STX 
US 15.K-2/5 United States NP 133 02-02-03 0.5 PEN-TET 
GR 141 Greece NP 247 02-02-71 0.016 ERY-CLI-TET-CHL-STX 
TH C034 Thailand NP 140 12-09-01 0.5 PEN-TET-STX 
NL 960644 The Netherlands NP 97 NA-29-70 2 PEN-ERY-STX 
 
a MEF, middle ear fluid; NA, not available; NP, nasopharyngeal culture; PEN, penicillin; ERY, erythromycin; TET, 
tetracycline; CLI, clindamycin; CHL: chloramphenicol; STX, trimethoprim-sulfamethoxazole.  
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the Spain6B-2 clone but is not identical (five of seven loci are identical). In addition, isolate 
GR 890 is closely related to a Finnish penicillin-resistant MDR serotype 6B strain (six of 
seven loci are identical). The Finnish strain is related to the Spain6B-2 clone, with five of 
seven loci being identical (B. G. Spratt, personal communication).  
Our findings suggest that the penicillin-susceptible MDR 6B clone that was found in Greece 
represents the ancestor of the penicillin-resistant MDR Spanish-Icelandic clone. An 
alternative hypothesis to explain these findings is that a Spanish-Icelandic strain restored 
penicillin susceptibility by mutations and that this genetic event gave rise to the Greek 
isolates. However, restoration of penicillin susceptibility through reacquisition of penicillin-
susceptible PBP genes is a process that, in a natural setting, has not been observed until 
now.  
The clinical implication of the significant spread of this penicillin-susceptible, MDR 6B clone 
in Greece is important, as it limits the available options for the therapy of pneumococcal 
infection, particularly in penicillin-allergic patients. In addition, caution should be directed to 
the fact that penicillin-susceptible MDR 6B strains are not identified when the susceptibility 
testing is performed by screening only for penicillin susceptibility status. Clinical 
microbiologists and infectious disease specialists have to be aware that, apart from widely 
spread penicillin-resistant pneumococci, other MDR, penicillin-susceptible pneumococcal 
strains circulate widely as well. 
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ABSTRACT 
A total of 128 Streptococcus pneumoniae isolates that were susceptible to penicillin but 
resistant to non-β-lactam agents were isolated from young carriers in Greece and analyzed 
by antibiotic susceptibility testing, serotyping, restriction fragment end labeling (RFEL), and 
antibiotic resistance genotyping. The serotypes 6A/B (49%), 14 (14%), 19A/F (11%), 11A 
(9%), 23A/F (4%), 15B/C (2%), and 21 (2%) were most prevalent in this collection. Of the 
isolates, 65% were erythromycin resistant, while the remaining isolates were tetracycline 
and/or trimethoprim-sulfamethoxazole resistant. Fifty-nine distinct RFEL types were 
identified. Twenty different RFEL clusters, harboring 2 to 19 strains each, accounted for 76% 
of all strains. Confirmatory multilocus sequence typing analysis of the genetic clusters 
showed the presence of three international clones (Tennessee23F-4, England14-9, and 
Greece6B-22) representing 30% of the isolates. The erm(B) gene was present in 70% of the 
erythromycin-resistant isolates, whereas 18 and 8% contained the mef(A) and mef(E) 
genes, respectively. The pneumococci representing erm(B), erm(A), and mef genes 
belonged to distinct genetic clusters. In total, 45% of all isolates were tetracycline resistant. 
Ninety-six percent of these isolates contained the tet(M) gene. In conclusion, penicillin-
susceptible pneumococci resistant to non-β-lactams are a genetically heterogeneous group 
displaying a variety of genotypes, resistance markers, and serotypes. This suggests that 
multiple genetic events lead to non-β-lactam-resistant pneumococci in Greece. Importantly, 
most of these genotypes are capable of disseminating within the community. 
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INTRODUCTION 
Streptococcus pneumoniae is a common cause of invasive diseases, such as meningitis 
and bacteremia, and of respiratory tract infections (5). S. pneumoniae isolates that are 
resistant to penicillin and/or non-β-lactam agents have been frequently reported (6, 12, 35). 
Resistance of S. pneumoniae to erythromycin and the other macrolides is increasing in 
many parts of the world (15, 17). Strains resistant to erythromycin are also resistant to 
azithromycin, clarithromycin, and roxithromycin (37). This global increase in antibiotic-
resistant and especially multidrug-resistant pneumococci is the result of the spread of 
various highly resistant pneumococcal clones (7, 25).  
In Greece, the emergence of antibiotic resistance among pneumococcal isolates was 
recognized in the mid-1990s (30). Recently, pneumococcal isolates susceptible to penicillin 
and resistant to chloramphenicol, tetracycline, erythromycin, clindamycin, and trimethoprim-
sulfamethoxazole (SXT) have been isolated from young Greek carriers. During the period 
from December 1995 to February 1996, 24% of the pneumococci isolated from healthy 
carriers attending day care centers were demonstrated to be penicillin-susceptible, non-β-
lactam-resistant isolates (29). In a recent study in which 2,448 children younger than 2 years 
old living in various areas in Greece were screened during a 2-year period (1997 to 1999) 
for pneumococcal carriage, 15% of the pneumococci appeared to have reduced 
susceptibility to non-β-lactam agents (31).  
The present study was undertaken to investigate the molecular epidemiological 
characteristics of the Greek pneumococci susceptible to penicillin but resistant to 
erythromycin and/or other non-β-lactam agents. Furthermore, penicillin, erythromycin, and 
tetracycline resistance determinants were studied at a molecular level.  
 
 
MATERIALS AND METHODS   
Bacterial isolates. We studied a collection of 128 S. pneumoniae isolates susceptible to 
penicillin but resistant to erythromycin and/or other non-β-lactam agents; the isolates were 
recovered from nasopharyngeal cultures obtained from children during two independent 
studies in Greece (3, 30, 31). The first study was performed in 338 children attending seven 
day care centers in the city of Patras in southwestern Greece during the 2-month period 
from December 1995 to February 1996. In this study, 30 penicillin-susceptible pneumococci 
resistant to one or more non-β-lactam agents were recovered from 132 carriers. Of these 30 
S. pneumoniae isolates, 26 were available for further analysis in the present investigation. 
The second study, the ‘Hellenic Antibiotic-Resistant Respiratory Pathogens’ (HARP) study, 
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was conducted from February 1997 to February 1999. Nasopharyngeal cultures for S. 
pneumoniae were performed in 2,448 children younger than 2 years old living in central and 
southern Greece. Ninety-five (3.9%) of the 2,448 children attended day care centers. In the 
HARP study, screening of the children revealed 119 pneumococci which were penicillin 
susceptible but resistant to non-β-lactam agents. Of these 119 pneumococci, 102 were 
available for further analysis. Thirteen of these pneumococci were isolated from children 
attending day care. Only two of these children attended the same day care center.  
Bacteriological procedures. Isolation, identification, and susceptibility testing of the Greek 
S. pneumoniae isolates were performed by applying standard methods as described 
previously (30, 31). Penicillin and erythromycin MICs for the Greek isolates were determined 
by the E-test method (AB Biodisk, Solna, Sweden). Susceptibility to clindamycin, 
chloramphenicol, tetracycline, and SXT was determined by the disk diffusion method 
according to the guidelines of the National Committee for Clinical Laboratory Standards 
(NCCLS) (21). Multidrug resistance was defined as resistance to three or more classes of 
antimicrobial agents. Pneumococci were serotyped by the capsular swelling method or the 
latex agglutination technique (30, 33).  
Penicillin-binding protein (PBP) genotyping. Genetic polymorphism of the penicillin 
resistance genes pbp1a, pbp2b, and pbp2x of the pneumococcal isolates was investigated 
by restriction fragment length polymorphism (RFLP) analysis of the PCR-amplified genes, as 
described previously (13).  
Detection and analysis of the erm(B) and mef genes. To detect the presence of erm(B) 
within the pneumococcal isolates, we used the protocol of Sutcliffe et al. (28). In summary, 
we amplified the genes by PCR and analyzed the amplified DNA products by agarose gel 
electrophoresis. The presence of the mef gene was also detected by PCR (28). In order to 
discriminate between mef(A) and mef(E), PCR-RFLP analysis was performed by the method 
of Del Grosso et al. (8). The amplicon was digested using BamHI and DraI. The mef(A) gene 
contains a single BamHI site, which is absent in the mef(E) gene. Digestion of mef(A) and 
mef(E) with DraI yields two and three fragments, respectively.  
Detection of the tet(M) and tet(O) genes. In order to discriminate between tet(M) and 
tet(O), a PCR-RFLP analysis was performed as described previously (2). In summary, a 
PCR mix was made of 25-µl reaction buffer containing 0.5 U of thermostable DNA 
polymerase, diluted in the buffer supplied by the manufacturer (Integro, Leuvenheim, The 
Netherlands), 0.2 mM (each) deoxynucleoside triphosphate, 1.5 mM MgCl2, 10 pmol of 
each primer, and 10 to 50 ng of pneumococcal DNA. Amplification cycling in a 
programmable thermal controller (PTC-100; MJ Research, Watertown, Mass.) consisted of 
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the following steps: predenaturation for 1 min at 94°C, followed by 30 cycles, with 1 cycle 
consisting of 1 min at 94°C, 1 min at 57°C, and 1 min at 72°C. Amplification was finished 
after 3 min at 72°C. A 1.5% agarose gel in 0.045 M Tris-borate buffer with 0.001 M EDTA 
(0.5x TBE buffer) containing 0.1 µg of ethidium bromide per ml was used to visualize the 
PCR products.  
RFEL typing. Pneumococcal strain typing by restriction fragment end labeling (RFEL) was 
performed by the method of van Steenbergen et al. (36) as adapted by Hermans et al. (13). 
Briefly, purified pneumococcal DNA was digested by the restriction enzyme EcoRI. The DNA 
restriction fragments were end labeled at 72°C with [α-32P]dATP using DNA polymerase 
(Goldstar; Eurogentec, Seraing, Belgium). After the radiolabeled fragments were denatured 
and separated electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M 
urea, the gel was transferred onto filter paper, vacuum dried (HBI, Saddlebrook, N.Y.), and 
exposed for variable times at room temperature to ECL hyperfilm (Amersham Laboratories, 
Amersham, United Kingdom).  
Computer-assisted analysis of DNA band patterns. RFEL autoradiographs were 
converted to images (Image Master DTS; Pharmacia Biotech, Uppsala, Sweden) and 
analyzed with a computer (Windows version Gelcompar software version 4; Applied Math, 
Kortrijk, Belgium). DNA fragments were analyzed as described previously (26). For 
evaluation of the genetic relatedness of the isolates, we used the following definitions: (i) 
isolates of a particular RFEL type are 100% identical by RFEL analysis; (ii) an RFEL cluster 
represents a group of RFEL types that differ in only one band (approximately >95% genetic 
relatedness); (iii) an RFEL lineage represents a group of RFEL types that differ in less than 
four bands (approximately >85% genetic relatedness).  
International comparison. The Greek genotypes were compared with an international 
collection of pneumococcal isolates representing 751 distinct RFEL types originating from 17 
different countries in America, Europe, Africa, and Asia (2, 12; M. Sluijter, unpublished 
observations). The international collection includes the first 16 international pandemic clones 
described by the Pneumococcal Molecular Epidemiological Network in 2000 
(http://www.pneumo.com/physician/pmen_clone_collection.asp) (18).  
MLST. The genotypes of all clusters were verified by multilocus sequence typing (MLST) 
analysis. For this purpose, a fully automated method for MLST was used as described 
previously (14), and one or two isolates per cluster were analyzed. The MLST types were 
compared with the global database at www.mlst.net.  
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RESULTS   
The serotypes 6A/B (49%), 14 (14%), 19A/F (11%), 11A (9%), 23A/F (4%), 15B/C (2%), and 
21 (2%) were most prevalent in the collection of 128 Greek pneumococcal isolates. All 
isolates were invariably susceptible to penicillin, while 84 (65%), 78 (60%), 69 (54%), 63 
(49%), and 62 (48%) isolates were resistant to erythromycin, SXT, tetracycline, 
chloramphenicol, and clindamycin, respectively.  
The isolates were classified as penicillin-susceptible erythromycin-resistant (65%) and 
penicillin-susceptible erythromycin-susceptible (35%) isolates. The latter group was 
represented by tetracycline- and/or SXT-resistant pneumococci. The 84 penicillin-
susceptible erythromycin-resistant pneumococci displayed capsular types 6B (56%), 14 
(18%), 19F (13%), 11A (11%), 10A (1.2%), and 15C (1.2%). Of these erythromycin-resistant 
isolates, 59 (70%), 15 (18%), and 7 (8.3%) isolates carried the erm(B), mef(A), and mef(E) 
erythromycin resistance determinants, respectively. In four erythromycin-resistant isolates 
belonging to a serotype 11A clone, an erm(A) gene was previously detected (32). 
Furthermore, 62 (74%), 57 (68%), 46 (55%), and 42 (50%) of the 84 penicillin-susceptible 
erythromycin-resistant pneumococci, were also resistant to clindamycin, tetracycline, SXT, 
and chloramphenicol, respectively. Clindamycin resistance was always identified in 
combination with erythromycin resistance. All 62 clindamycin- and erythromycin-resistant 
isolates carried an erm resistance gene. Of the 54 erythromycin-resistant isolates that were 
resistant to tetracycline, 51 carried the tet(M) resistance gene. The three remaining isolates 
were negative for both the tet(M) and tet(O) genes.  
The 44 penicillin-susceptible erythromycin-susceptible isolates belonged to serotypes 6B 
(29%), 23F (11%), 14 (6.7%), 21 (6.7%), 1 (4.4%), 6A (4.4%), 15B (4.4%), 18C (4.4%), 19A 
(4.4%), 8 (2.2%), 10A (2.2%), 11A (2.2%), 16F (2.2%), 19F (2.2%), 20 (2.2%), and 24F 
(2.2%) and nontypeable serotypes (4.4%).  
Sulfamethoxazole resistance was identified in 34 of the 44 penicillin-susceptible 
erythromycin-susceptible isolates (78%), whereas tetracycline resistance was identified in 
12 (27%) isolates. All but one carried the tet(M) resistance gene. All isolates were resistant 
to a single agent except for one isolate that was resistant to tetracycline and 
chloramphenicol and two isolates that were resistant to tetracycline and SXT.  
Fourteen distinct PBP genotypes were observed. Of the 128 isolates, 76 (59%), 24 (19%), 
and 4 (3.1%) displayed a known penicillin-susceptible PBP 1A-2B-2X genotype, being 2-2-
71, 2-2-3, and 2-2-2, respectively. The remaining isolates displayed alterations in pbp2x (11 
distinct types), pbp2b (2 types), and pbp1a (1 type).  
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Figure 1. Dendrogram of the 59 RFEL types observed among the 128 Greek S. pneumoniae nasopharyngeal isolates. 
The molecular sizes of reference bands (in bases [b]), serotypes, PBP types, RFEL types, MLST types, number of 
isolates per RFEL type, clusters, and cluster codes are depicted. One or two strains per RFEL clusters were analyzed 
by MLST. Day care center isolates from the 1995 to 1996 study (asterisks) and day care center isolates from the 1997 
to 1999 study (degree symbols) are indicated. If more than one day care center isolate belongs to a specific genotype, 
the total number is displayed in parentheses. Two new strains with new MLST types (new1 and new2) are indicated. 
These two strains have been submitted to the MLST database. nt, nontypeable. 
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RFEL analysis divided the 128 penicillin-susceptible isolates, which were resistant to one or 
more non-β-lactam agents into 59 distinct RFEL genotypes (Fig. 1). Ninety-nine isolates 
belonged to 20 genetic clusters, representing 77% of the isolates and varying in size from 2 
to 19 isolates (Table 1). The average cluster size was 5.0 isolates. Five of the 20 clusters 
contained two serotypes, while the remaining clusters contained only one serotype each. 
The 20 clusters belonged to 11 lineages. The three largest clusters were cluster III, XVI, and 
XVII. Cluster III consisted of 13 (10%) isolates and was identical to the pandemic clone 
England14-9 which was confirmed by MLST analysis (Fig. 1 and Table 1). This cluster 
belonged to a single predominant lineage of 14 genetically related isolates, representing 
three RFEL genotypes and harboring the serotypes 11A, 14, and 18C. The serotype 14 
pneumococci carried the mef(A) erythromycin resistance determinant and had a low to 
moderate level of resistance to erythromycin. The remaining pneumococci were resistant to 
SXT.  
Clusters XVI (19 isolates) and XVII (11 isolates) belonged, together with cluster XIV (6 
isolates) and XV (2 isolates), to one predominant lineage, representing 10 RFEL types and 
all harboring the serotype 6B. Most isolates were resistant to erythromycin, clindamycin, 
tetracycline, chloramphenicol, and SXT. These pneumococci carried the erm(B) 
erythromycin resistance determinant and had a high level of resistance to erythromycin. The 
latter clusters were identical to the pandemic clone Greece6B-22 and closely related to the 
penicillin-resistant MDR clone Spain6B-2 that has spread from Spain to Iceland in the late 
1980s (29).  
Clusters I (three isolates) and XIX (three isolates) represented genotypes identical to the 
pandemic clone Tennessee23F-4 and closely related to the pandemic clone Spain9V-3 (six of 
seven alleles) as described by the Pneumococcal Molecular Epidemiology Network. The 
genetic relatedness of the observed MLST profiles of the 20 RFEL clusters is depicted in 
Fig. 2.  
The 39 isolates recovered from children attending day care centers displayed 21 different 
genotypes; 10 isolates displayed unique genotypes, whereas the remaining 29 isolates 
displayed 13 genotypes belonging to 11 clusters. Cluster XVI contained nine isolates from 
one day care center, whereas cluster XVII contained three isolates from a second single day 
care center. The remaining clustering day care center isolates originated from different day 
care centers (Fig. 1).  
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Figure 2. Genetic relatedness of the 15 MLST sequence types (ST) observed within the 20 RFEL clusters. 
 
 
DISCUSSION   
We evaluated 128 S. pneumoniae isolates that were susceptible to penicillin but resistant to 
non-β-lactam agents from young carriers in Greece by antibiotic susceptibility testing, 
serotyping, RFEL, and antibiotic resistance genotyping. In general, the isolates could be 
divided into two groups: one group consisting of 84 erythromycin-resistant isolates, while the 
second group of 44 isolates were erythromycin-susceptible. Multidrug resistance, i.e., 
resistance to three or more different classes of antibiotics, was seen predominantly within 
the first group of isolates, whereas the erythromycin-susceptible isolates predominantly 
displayed monodrug resistance to tetracycline or sulfamethoxazole. Furthermore, clustering 
of isolates, which is the result of horizontal spread of the isolates within the community, was 
higher among multidrug-resistant genotypes. This is in line with previous findings where 
multidrug-resistant clones have shown to spread from country to country (3, 4, 7, 20, 22, 25, 
27, 35). This has led to the classification of pandemic clones by the Pneumococcal 
Molecular Epidemiological Network (18). Although the majority of these pandemic clones are 
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15 (1,5,4,5,5,3,8) 
9 (1,5,4,5,5,1,8) 
858 (2,16,19,28,6,5,26) 
507 (1,8,6,2,6,20,6) 
37 (1,8,6,2,6,4,6) 
273 (5,6,1,2,6,1,14) 
162 (7,11,10,1,6,8,14) 
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Table 1. Molecular and phenotypic characteristics of the 129 Greek pneumococcal isolates. Number (nr) of genotypes, 
size, serotypes, resistance patterns and genotypes are presented. 
RFEL 
cluster 
Number of 
isolates\ 
RFEL types 
Serotypes 
(nr of strains) 
Resistance pattern* 
(nr of strains) 
PBP type 
(nr of strains) 
E/T genotype 
(nr of strains) 
I 4\2 23F(4) S 2-2-3  
II 2\1 19F(2) TECLS 2-2-3 erm(B)/ tet(M) 
   ECLS  erm(B) 
III 13/2 14(13) E(13) 2-2-71 mef(A)  
IV 2\1 15B S 2-2-44  
  15C ECL 2-2-3 erm(B) 
V 7\2 11A(6) 
14(1) 
TECL(4) 
S(2) 
E(1) 
2-2-3(6) 
2-2-71(1) 
erm(B) (4),tet(M)(4) 
mef(E) (1) 
VI 4\1 11A (4) TECL 2-2-3 erm(A), tet(M) 
VII 7\2 6B(7) S(6) 2-2-71 erm(B) (1),tet(M)(1)  
   E(1)  mef(E) 
VIII 2\1 6B (2) S(2) 2-2-71  
IX 2\1 6B (2) CTECLS 2-2-71 unknown 
   S   
X 2\1 14(2) S(2) 2-2-71  
XI 3\1 21 S(3) 2-2-7  
    2-2-98  
XII 2\1 19F(2) TECL 2-2-98 erm(B) (2) 
     tet(M) (2) 
XIII 4\2 6B (2) T(3), TS(1) 2-5-22(2) tet(M) (4) 
  6A (2)  2-5-99(1)  
    2-2-71(1)  
XIV 6\2 6B (6) CTECLS(5) 2-2-71 erm(B) (6) 
   CTECL  tet(M) (6) 
XV 2\2 6B (2) CTECLS 2-2-71 erm(B) (2) 
   CTECL  tet(M) (2) 
XVI 19\2 6B (19) CTECLS (17) 2-2-71 (18) erm(B) (19) 
   CTECL (1) 0-0-0 (1) tet(M) (18) 
   TECLS (1)   
XVII 11\1 6B (11) CTECLS (11) 2-2-71 (10) erm(B) (11) 
    0-0-0 (1) tet(M) (11) 
XVIII 2/2 10A TECL(1) 
S 
2-2-71 
2-2-2  
erm(B)(1), tet(M)(1) 
XIX 4\2 19F (4) E 2-2-2 (4) mef(A) (1) 
     mef(E) (3) 
XX 2\1 19F (1) S 2-2-2 (1)  
  24F (1)  2-2-3 (1)  
* C, chloramphenicol; T, tetracyclin; E, erythromycin; C, clindamycin; S, trimethoprim-sulfamethoxazole 
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penicillin-resistant, our study as well as previous studies have shown that this is not a 
prerequisite for clonal spread.  
With emerging non-β-lactam resistance among pneumococci, the spread of penicillin-
susceptible non-β-lactam-resistant pneumococci has become apparent (1, 24, 29, 34). This 
is underlined by our observation that, in addition to one large lineage of serotype 6B isolates 
that were mostly susceptible to penicillin and resistant to erythromycin, tetracycline, 
chloramphenicol, and sulfamethoxazole, 16 smaller clusters were found. In total, 30% of the 
isolates displayed a genotype identical to those of the pandemic clones Tennessee23F-4, 
England14-9, and Greece6B-22 as reported by the Pneumococcal Molecular Epidemiological 
Network. These findings clearly indicate heterogeneity among the penicillin-susceptible, 
non-β-lactam-resistant isolates. Furthermore, these clusters represent not only the 
conjugate vaccine serotypes 6B, 14, 19F, and 23F, but also non-vaccine serotypes, such as 
11A, 15B/C, and 21. This observation implicates that non-vaccine serotypes are also able to 
spread among children; hence, vaccination with pneumococcal conjugate vaccines is not a 
solution for the emergence of multidrug resistance among pneumococcal isolates.  
In this study, 70% of the erythromycin-resistant isolates harbored the erm(B) gene, while 18 
and 8% of the isolates contained mef(A) and mef(E) genes, respectively. These data differ 
from previous findings made by Reinert and coworkers, who observed an almost equal 
distribution of erm(B) (43%) and mef(E) (56%) genes among erythromycin-resistant isolates 
in Germany (23). However, our data are in line with a recent study performed in Italy and 
Vietnam where the majority of the strains also displayed the erm(B) gene (2, 19). In the four 
low-level erythromycin-resistant isolates displaying an identical RFEL genotype and 
serotype 11A, the erm(A) gene was previously identified (32).  
Genetic analysis of tetracycline resistance genes tet(M) and tet(O) revealed that the tet(M) 
gene was exclusively observed in 91% of the Greek isolates. This is in line with the 
Vietnamese study where the tet(M) gene was also exclusively observed (2). In contrast to 
other studies, the remaining tetracycline-resistant isolates did not harbor the tet(O) gene 
(16). So far, no other tetracycline resistance determinants have been described; therefore, 
the underlying mechanism remains unclear. Also in line with the Vietnamese study is the 
isolation of tet(M)-containing but tetracycline-susceptible strains in Greece, suggesting the 
presence of a nonfunctional or unexpressed tetracycline resistance gene (2, 9). A similar 
phenomenon was seen for the PBP genes. Though the majority of the isolates displayed 
(known) susceptible genotypes, 10% of the isolates displayed alterations in one or two of the 
three major PBP genes, pbp1a, pbp2b, and pbp2x, which often implicates intermediate 
penicillin resistance (10). In our study, the observed alterations in pbp1a, pbp2b, and four of 
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the pbp2x alterations were identified previously in non-penicillin-susceptible pneumococci 
isolated in Thailand, the United States, and The Netherlands (11). Although these alterations 
have shown to be related to intermediate susceptibility, in all cases an additional alteration in 
one or two of the PBP genes was present (Sluijter, unpublished). These findings support the 
hypothesis that not all genetic alterations lead to amino acid substitutions or to substitutions 
which are relevant for penicillin resistance.  
We hypothesize that the ongoing antibiotic pressure will continue the process of alteration 
and spread of resistance genes among pneumococci. Our study underlines that antibiotic 
resistance in any form and irrespective of its serotype is of benefit for S. pneumoniae with 
respect to survival and spread in the community. This implies that despite the introduction of 
new and effective pneumococcal conjugate vaccines, restrictive use of antibiotics will be of 
major importance. 
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ABSTRACT 
Recently, a nation-wide molecular epidemiologic survey of penicillin-nonsusceptible 
Streptococcus pneumoniae has been performed in The Netherlands. In the current study, 
we analyzed the pbp genes from these clinical isolates in detail. The pneumococcal strains 
were selected on the basis of differences in restriction fragment length polymorphism 
(RFLP) patterns of the complete genes pbp1a, pbp2b and pbp2x, representing 8, 7 and 10 
distinct patterns, respectively. We characterized specific gene parts of pbp1a (nucleotide 
position 1741 to 2229), pbp2b (nucleotide position 1211 to 1714) and pbp2x (nucleotide 
position 1241 to 1786). Classification based upon sequence analysis of these pbp fragments 
correlated well with the classification according to RFLP analysis. Sequence analysis of 
pbp2b enables a refinement of the classification based on RFLP analysis. However, 
sequence analysis of pbp1a and pbp2x was less discriminatory compared to RFLP analysis. 
The mutations in the pbp sequences of the Dutch isolates invariably matched with the 
mutations described in pbp sequences of penicillin-nonsusceptible pneumococci isolated in 
other countries. This observation supports the hypothesis that multiple clones of penicillin-
resistant pneumococci have been imported and spread in The Netherlands. Interestingly, 
novel combinations of mosaic structures were also identified indicating horizontal exchange 
of pbp gene parts among penicillin-nonsusceptible pneumococci. 
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INTRODUCTION 
Streptococcus pneumoniae is a common cause of serious and life-threatening infections, 
such as pneumonia, bacteremia and of non-invasive infections such as otitis media and 
sinusitis. Ever since the beginning of the antibiotic era, penicillin has been the first choice 
drug against pneumococcal infections. However, in the last 20 years, increasing numbers of 
penicillin-nonsusceptible pneumococcal clinical isolates with rising MIC values have been 
isolated (11). 
Penicillin resistance in S. pneumoniae has emerged through the development of altered 
penicillin-binding proteins (PBPs), which show a decreased affinity for penicillin and other β-
lactam antibiotics. PBPs are membrane-bound D,D-peptidases, which catalyze the 
transpeptidation reaction that cross-links the peptidoglycan of the bacterial cell wall. The β-
lactam antibiotics interact with the PBPs and form a covalent penicilloyl complex via the 
active-site serine resulting in an inactivated enzyme. In penicillin-susceptible pneumococci, 
this interaction results in cellular lysis (4, 11). S. pneumoniae contains six PBPs: the high 
molecular weight proteins PBP1a, PBP1b, PBP2a, PBP2b and PBP2x, and the low 
molecular weight protein PBP3. In clinical isolates, altered PBP2b and PBP2x are the 
primary resistance determinants, i.e. they confer low-level resistance when introduced into 
sensitive strains, whereas alterations in PBP1a contribute to an increase in resistance levels 
(10, 13). The alterations in the PBPs are due to the formation of a mosaic structure of the 
genes, presumably as a result of horizontal gene transfer. The pbp genes of nonsusceptible 
isolates are composed of mosaic blocks that share identity with pbp genes from sensitive 
isolates and blocks that are identical to pbp genes from Streptococcus mitis, Streptococcus 
sanguis and Streptococcus oralis (23). It is therefore suggested that the mosaic pbp genes 
are the result of interspecies recombination. Some mosaic pbp genes are composed of a 
single block from viridans streptococci, whereas others are the result of complex multiple 
recombination events involving several donors (6). The presence of an enormous diversity 
of mosaic pbp genes suggests that resistance to penicillin has arisen on many independent 
occasions. These recombination events have resulted in multiple amino acid substitutions in 
the PBPs. Several amino acids are essential for the interaction of the PBPs with β-lactam 
antibiotics. Substitutions of these amino acids often result in a reduction of affinity and 
consequently in reduced penicillin susceptibility. Most mutations which confer resistance 
occur close to the motifs SXN or KT/SG, or close to the active-site serine which is part of the 
conserved STMK motif (11, 12). 
We have recently investigated the epidemiologic characteristics of penicillin-nonsusceptible 
pneumococci in The Netherlands in a nation-wide survey (16). The penicillin-nonsusceptible 
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clinical isolates have been analyzed by restriction fragment length polymorphism (RFLP) 
analysis of the genes pbp1a, pbp2b and pbp2x. In this study, we sequenced gene parts of 
pbp1a, pbp2b and pbp2x representing distinct RFLP patterns. These data were used to 
investigate the correlation between pbp RFLP analysis and pbp sequence analysis, and to 
identify the molecular nature of pneumococcal penicillin resistance in The Netherlands. 
 
 
MATERIALS AND METHODS 
Bacterial strains, growth conditions and growth medium. Penicillin-nonsusceptible 
pneumococcal strains were isolated from patients in The Netherlands between March 1995 
and March 1996. Their epidemiological characteristics have been described previously (16). 
The majority of the strains were isolates from patients with pneumococcal pneumonia. 
Clinical isolates representing distinct restriction fragment length polymorphism patterns of 
pbp1a, pbp2b and pbp2x, respectively, were used for nucleotide sequence analysis of their 
pbp genes. The pneumococcal strains reported in this study are listed in Fig. 1 to 3. The 
penicillin MICs of these strains ranged from 0.12 to 2 µg/ml. Bacteria were cultured at 37°C 
on Columbia agar supplemented with 5% sheep blood (Oxoid, Basingstoke, United 
Kingdom) in an atmosphere of increased CO2. Bacterial colonies were inoculated in Todd 
Hewitt broth (Difco laboratories, Detroit, USA) supplemented with 0.5% Yeast Extract (Difco 
laboratories; THY-broth) and grown at 37°C. 
PBP genotyping. Genetic polymorphisms of the penicillin resistance genes pbp1a, pbp2b, 
and pbp2x were investigated by restriction fragment length polymorphism (RFLP) analysis 
as described previously (16). Briefly, chromosomal DNA was extracted with cetyl 
trimethylammonium bromide (26). PCR amplification of the PBP-encoding genes was 
performed in 50 µl reactions containing 75 mM Tris-HCl (pH 9.0), 20 mM (NH4)2SO4, 0.01% 
(wt/vol) Tween 20, 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 10 pmol of the 
individual primers, 0.5 U of DNA polymerase (Eurogentec, Liège, Belgium), and 10 ng of 
purified chromosomal DNA. Cycling was performed in a PTC-100 Programmable Thermal 
Controller (MJ Research, Watertown, USA) and consisted of the following steps: 
predenaturation at 94°C for 1 min, 30 cycles of 1 min at 94°C, 1 min at 52°C, 2 min at 72°C, 
and a final extension at 72°C for 3 min. The primers used to amplify the genes pbp1a, 
pbp2b, and pbp2x were described previously (see Table 1). The amplification products (5 µl) 
were digested with the restriction endonuclease HinfI and separated by electrophoresis in 
2.5% agarose gels. Gels were scanned and printed with the Geldoc 2000 system (Biorad, 
Veenendaal, The Netherlands). The different PBP genotypes are represented by a three-
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number code (e.g., 06-14-43), referring to the RFLP patterns of the genes pbp1a (pattern 6), 
pbp2b (pattern 14), and pbp2x (pattern 43), respectively. The PBP RFLP codes used in this 
study refer to those described previously (16). 
Nucleotide sequence analysis. Nucleotide sequencing was performed on parts of the 
penicillin-binding domain of pbp1a, of pbp2b, and of pbp2x, respectively, from the 
pneumococcal strains mentioned in Fig. 1 to 3. The primer pairs Pbp1a.fw/Pbp1a.rev, 
Pbp2b.fw/Pbp2b.rev and Pbp2x.fw/Pbp2x.rev were used to amplify nucleotides 1723 to 
2350 of pbp1a, nucleotides 1199 to 1734 of pbp2b, and nucleotides 1217 to 1796 of pbp2x, 
respectively (Table 1). The numbering is based on published data for strain R6 [pbp1a (20), 
pbp2b (9), pbp2x (18)]. PCR-amplification was performed as described above in 100 µl 
reactions with 50 ng of purified pneumococcal chromosomal DNA. The PCR products were 
separated by electrophoresis in 1% agarose gels, cut from gel and purified with the 
QIAquick Gel Extraction kit (Qiagen, Westburg, Leusden, The Netherlands). Purified 
templates were sequenced with the Prism Ready Reaction Sequence Kit (Perkin Elmer, 
Roosendaal, The Netherlands) and 50 pmol of the primers M13.fw and M13.rev (Table 1). 
 
Table 1. Primers used in this study. The underlined sequence parts of the primers Pbp1a.fw, Pbp1a.rev, Pbp2b.fw, 
Pbp2b.rev, Pbp2x.fw, Pbp2x.rev represent M13-based sequences. 
 
primer name primer sequence reference 
Pn1Aup CGGCATTCGATTTGATTCGCTTCT (5) 
Pn1Adown CTGAGAAGATGTCTTCTCAGG (5) 
Pn2Bup GATCCTCTAAATGATTCTCAGGTGG (8) 
Pn2Bdown CAATTAGCTTAGCAATAGGTGTTGG (8) 
Pn2Xup CGTGGGACTATTTATGACCGAAATGG (22) 
Pn2Xdown AATTCCAGCACTGATGGAAATAAACATATTA (22) 
Pbp1a.fw TGTAAAACGACGGCCAGTCAAAGTCTCAAATCAGCAAG this study 
Pbp1a.rev CAGGAAACAGCTATGACCGTTGTGTTACTTGAAATGGC this study 
Pbp2b.fw TGTAAAACGACGGCCAGTCTGAAAAGTTATTTCAATTC this study 
Pbp2b.rev CAGGAAACAGCTATGACCAAWCCAGTWGAYTCATCTGG this study 
Pbp2x.fw TGTAAAACGACGGCCAGTAAAATGGGAGATGCTAC this study 
Pbp2x.rev CAGGAAACAGCTATGACCTGGATACCTGAATAATG this study 
M13.fw TGTAAAACGACGGCCAGT this study 
M13.rev CAGGAAACAGCTATGACC this study 
 
 
Sequencing was performed on an Applied Biosystems Prism 377 (PE Applied Biosystems, 
Nieuwerkerk, The Netherlands). The nucleotide and deduced amino acid sequences were 
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compared to the published sequence of pbp1a (20), pbp2b (9) and pbp2x (18) from the 
penicillin-susceptible strain R6 with BioEdit Sequence Alignment Editor (15). With the 
BLAST algorithm (1), the nucleotide sequences were analyzed for similarity to sequences 
deposited in the April 2000 version of the nucleotide database at the National Center for 
Biotechnology Information (Washinton D.C., USA).  
Nucleotide sequence accession numbers. The pbp1a sequence data for the following 
clinical isolates were submitted to the EMBL/GenBank databases under the indicated 
accession numbers (acc. nos.): isolate 950225, AJ403974; isolate 960036, AJ403975; 
isolate 950710, AJ403976; isolate 950421, AJ403977; isolate 950423, AJ403978; isolate 
950473, AJ403979; isolate 960027, AJ403980 and isolate 950035, AJ403981.  
The pbp2b sequence data for the following clinical isolates have been submitted to the 
EMBL/GenBank databases under the indicated acc. nos.: isolate 950279, AJ278222; isolate 
950961, AJ278223; isolate 950901, AJ278224; isolate 950138, AJ278225; isolate 960118, 
AJ278226; isolate 960035, AJ278227; isolate 960036, AJ278228; isolate 960030, 
AJ278229; isolate 954073, AJ278230 and isolate 960097, AJ278231.  
The pbp2x sequence data for the following clinical isolates have been submitted to the 
EMBL/GenBank databases under the indicated acc. nos.: isolate 950181, AJ278232; isolate 
950138, AJ278233; isolate 950423, AJ278234; isolate 960036, AJ278235; isolate 950454, 
AJ278236; isolate 950961, AJ278237; isolate 950637, AJ278238; isolate 950925, 
AJ278239, isolate 960097, AJ278240; and isolate 960165, AJ278241. 
 
 
RESULTS 
Sequence heterogeneity in pbp1a of penicillin-nonsusceptible pneumococcal 
isolates. We sequenced nucleotides 1741 to 2229 of pbp1a from 44 Dutch clinical 
pneumococcal isolates representing eight distinct pbp1a RFLP types. The pbp1a nucleotide 
sequences from strains representing identical pbp1a RFLP types were invariably identical 
(data not shown). A representative strain of each pbp1a RFLP type was chosen for 
sequence comparison. Fig. 1 provides a schematic illustration of the mosaic structures of 
pbp1a.  
The nucleotide sequences and deduced amino acid sequences of pbp1a obtained from the 
RFLP type 1 and 10 strains were identical (Fig. 1). Nucleotides 1741 to 1789 differed from 
the penicillin-susceptible strain R6 by one synonymous substitution, nucleotides 1790 to 
2039 were identical to pbp1a from S. mitis strain B6 (acc. no. AJ002290) (14), and 
nucleotides 2040 to  2229  differed  from  strain  R6  by 11 synonymous substitutions and 11  
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Figure 1. Schematic representation of pbp1a. The STMK-motif, SRN-motif and KTG-motif are depicted. The 
sequenced part is indicated by the open block. The mosaic structures in the deduced amino acid sequences of strains 
representing distinct RFLP types are shown below. Open blocks indicate DNA from susceptible pneumococcal strains 
and dotted blocks are homologous to S. mitis strain B6 DNA (14). Vertical lines indicate amino acid substitutions. 
Arrows indicate the identity between DNA sequences derived from genes representing distinct types. The 
pneumococcal strains, penicillin MICs, and pbp1a types are also listed. 
 
 
nonsynonymous substitutions resulting in eight amino acid changes (Thr371Ala, Leu382Ile, 
Glu388Asp, Ile393Met, His395Asn, Glu397Ile, Asn405Ser, Gly414Ala) (Fig. 1). The pbp1a 
sequences of RFLP types 1 and 10 matched with the pbp1a sequence of S. pneumoniae 
strain D isolated in Spain (21) and S. pneumoniae strains #5/H31 and #17/246 isolated in 
Japan (3). Part of pbp1a of the RFLP type 3 strain (nucleotides 1880 to 2229) and part of 
pbp1a of the RFLP type 6 strain [nucleotides 1920 to 2229 except for five synonymous 
substitutions and one nonsynonymous substitution (Ala371Thr)] were identical to pbp1a of 
RFLP type 1 and 10 strains (Fig. 1). The pbp1a regions of the RFLP type 2 and 5 strains 
were identical and differed from strain R6 by two synonymous substitutions and a single  
  Chapter 4.4 130 
 
Figure 2. Schematic representation of pbp2b. The SVV-motif, SSN-motif and KTG-motif are depicted. The sequenced 
part is indicated by the open block. The mosaic structures in the deduced amino acid sequence of strains representing 
distinct RFLP types are shown below. Open blocks indicate DNA from susceptible pneumococcal strains, dotted blocks 
are homologous to S. mitis strain B6 (acc. no. AJ 002289) and S. sanguis strain 1907 DNA (acc. no. M32226), and 
striped blocks are homologous to penicillin-resistant S. oralis strain 5296 DNA (acc. no. M32228). Vertical lines 
indicate amino acid substitutions. Arrows indicate the identity between DNA sequences derived from genes 
representing distinct types. The pneumococcal strains, penicillin MICs, and pbp2b type are also listed. 
 
 
nonsynonymous substitution (Glu388Asp) (Fig. 1). Interestingly, this substitution occurred in 
the deduced amino acid sequences from all isolates analyzed in this study. The pbp1a 
sequences of RFLP type 2 and 5 strains were identical to S. pneumoniae strain C, a 
penicillin-susceptible strain isolated in South Africa (21). The pbp1a sequence of the RFLP 
type 4 strain differed in seven additional synonymous substitutions and one additional 
nonsynonymous substitution (Asn405Asp) (Fig. 1). pbp1a of RFLP type 2, 4, and 5 strains 
were highly homologous to pbp1a of S. pneumoniae strain #23/HSB21 isolated in Japan (3). 
The pbp1a nucleotide and deduced amino acid sequence of the RFLP type 7 strain differed  
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Figure 3. Schematic representation of pbp2x. The STMK-motif, SSN-motif and KSG-motif are depicted. The 
sequenced part is indicated by open block. The mosaic structures in the deduced amino acid sequences of strains 
representing distinct RFLP types are shown below. Open blocks indicate DNA from susceptible pneumococcal strains, 
dotted blocks are homologous to S. mitis strain 10712 DNA (acc. no. X78216), and striped blocks are homologous to 
S. oralis strain U5 DNA (acc. no. Y10536), S. mitis strains 476 (acc no. Y10534) and 197 (acc. no. Y10533) DNA. 
Vertical lines indicate amino acid substitutions. Arrows indicate the identity between the DNA sequences derived from 
genes representing distinct types. The pneumococcal strains, penicillin MICs, and pbp2x type are also listed. 
 
 
significantly from the previous sequences, and differed from strain R6 by 52 synonymous 
substitutions and 13 nonsynonymous substitutions resulting in 12 amino acid changes 
(Ala347Ser, Thr371Ala, Gly385Asp, Val386Ile, Glu388Asp, Thr392Ser, Glu397Val, 
Asn405Asp, Val408Leu, Arg413Lys, Gly414Val, Leu421Ile) (Fig. 1). The partial pbp1a 
sequence of the RFLP type 7 was homologous to S. pneumoniae strain #14/Z42 isolated in 
Japan (3). Interestingly, the amino acid substitution Thr371Ala was found in all high-level 
penicillin-resistant strains. 
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Sequence heterogeneity in pbp2b of penicillin-nonsusceptible isolates. We sequenced 
nucleotides 1211 to 1714 of pbp2b from 57 Dutch clinical pneumococcal isolates 
representing seven distinct pbp2b RFLP types. The pbp2b sequences from strains 
representing identical pbp2b RFLP types were identical for RFLP types 2, 4 and 5, 
respectively (data not shown). In contrast, the pbp2b nucleotide sequences from strains 
representing RFLP type 1 could be divided into two sequence types designated type 1A and 
1B. In addition, the pbp2b nucleotide sequences from strains representing RFLP type 3 
could be divided into three sequence types designated type 3A, 3B and 3C. RFLP types 7 
and 8 were represented by one strain each. A representative strain of each RFLP type and 
sequence-type, respectively, was chosen for sequence comparison (Fig. 2). 
The pbp2b sequence of the RFLP type 1A strain was identical to pbp2b from the penicillin-
resistant S. sanguis strain 1907 (acc. no. M32226), except for one synonymous substitution 
(Fig. 2). In addition, this pbp2b fragment was identical to pbp2b of S. pneumoniae strains 
SP1470 isolated in France (acc. no. AF210766), M15 isolated in the United Kingdom (acc. 
no. AJ243054), 577 isolated in the United Kingdom (acc. no. AJ243053) and 56762 isolated 
in South Africa (acc. no. U20080). pbp2b of the RFLP type 1B strain was in part identical to 
the pbp2b sequence of the RFLP type 3A strain (nucleotides 1211 to 1402) and in part to 
the pbp2b sequence of the RFLP type 1A strain (nucleotides 1403 to 1714) (Fig. 2). The 
pbp2b fragment of the RFLP type 3A strain was identical to pbp2b of S. mitis strain B6 (acc. 
no. AJ002289), except for one nonsynonymous mutation (Ile382Val) (Fig. 2). In addition, this 
pbp2b fragment was identical to penicillin-resistant S. oralis strain 5296 (acc. no. M32228), 
except for one synonymous mutation and one nonsynonymous mutation (Ile382Val). The S. 
pneumoniae strain 52328 isolated in South Africa (acc. no. U20073) also contained the 
same pbp2b sequence, except for two synonymous mutations. The pbp2b fragment of the 
pneumococcal RFLP type 3B strain was identical to that of the RFLP type 3A strain, with the 
exception of the fragment formed by nucleotides 1227 to 1279, which was identical to that in 
the penicillin-susceptible strain R6 (Fig. 2). pbp2b of the RFLP type 3C strain was in part 
homologous to the R6 sequence (nucleotides 1211 to 1391) differing in 6 synonymous 
mutations and one nonsynonymous mutation (Glu368Asp), and in part identical to pbp2b of 
RFLP type 3A and 3B strains, except for one synonymous mutation (Fig. 2). pbp2b of the 
RFLP type 2 strain contained 26 synonymous substitutions and 9 nonsynonymous 
(Glu332Gly, Gln426Ala, Ala427Phe, Tyr428Ser, Gly429Arg, Ser430Pro, Phe431Met, 
Thr445Ala, Glu475Gly) substitutions compared to the R6 sequence. The pbp2b fragment of 
this strain was identical to S. pneumoniae strains DN87/669 isolated in the United Kingdom. 
(acc. no. M25521) and 8249 isolated in South Africa (acc. no. M25520), except for one 
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synonymous substitution (7). The pbp2b fragment of the RFLP type 4 strain contained 22 
synonymous substitutions and three nonsynonymous (Ser411Pro, Thr445Ala, Glu475Gly) 
substitutions compared to the R6 sequence and was not identical to any of the published 
sequences present in databases (Fig. 2). The pbp2b fragment of the RFLP type 5 strain 
differed in 49 synonymous mutations and 11 nonsynonymous mutations resulting in 10 
amino acid changes (Ser411Pro, Gln437Glu, Thr445Ala, Leu454Ile, Gly466Leu, Ser468Asn, 
Glu475Gly, Gly482Ala, Thr488Ala, Ala489Ser) from pbp2b of strain R6 and was identical to 
pbp2b of S. pneumoniae strain SP 1513 isolated in France (acc. no. AF210762) (Fig. 2). 
Part of the pbp2b fragment of the RFLP type 5 strain (nucleotides 1460 to 1714) was 
homologous to pbp2b of S. mitis strain NCTC 11189 (acc. no. Z22183). In this fragment, we 
observed 11 synonymous mutations and 4 amino acid substitutions (Thr445Ala, Gly466Leu, 
Ser468Asn, Ala480Ser) compared to the S. mitis sequence, while 40 synonymous mutations 
and the 11 nonsynonymous mutations (Ser411Pro, Gln437Glu, Thr445Ala, Leu454Ile, 
Gly466Leu, Ser468Asn, Glu475Gly, Gly482Ala, Thr488Ala, Ala489Ser) were observed 
compared to the R6 sequence (Fig. 2). pbp2b of the RFLP type 7 and 8 strains were in part 
identical to pbp2b from the RFLP type 5 strain (Fig. 2). The pbp2b sequence of the RFLP 
type 7 strain differed in nucleotides 1211 to 1455 from the R6 sequence by eight 
synonymous substitutions and two nonsynonymous substitutions (Glu332Gly, Ile360Leu), 
was identical to pbp2b of the RFLP type 8 strain for nucleotides 1456 to 1714, and, except 
for two synonymous mutations, was identical to pbp2b of the RFLP type 5 strain for 
nucleotides 1528 to 1714 (Fig. 2). pbp2b of the RFLP type 8 strain was identical to pbp2b of 
R6 for nucleotides 1211 to 1455 and to pbp2b of the RFLP type 7 strain for nucleotides 1456 
to 1714 (Fig. 2). The Thr445Ala substitution was found in all penicillin-nonsusceptible strains 
we investigated. In addition, the Glu475Gly substitution was found in all pbp2b sequence 
types of our strain collection. Six consecutive substitutions at residues 426 to 431 were 
found in pbp2b RFLP type 2 only. 
Sequence heterogeneity in pbp2x of penicillin-nonsusceptible strains. We sequenced 
nucleotides 1241 to 1786 of pbp2x from 53 Dutch clinical pneumococcal isolates 
representing 10 distinct RFLP types. The pbp2x nucleotide sequences from strains 
representing identical pbp2x RFLP types were identical as far as RFLP type 1, 4, 6, 8, and 
20 was concerned, except for two or less synonymous point mutations observed in RFLP 
type 1. The RFLP types 7, 13, 22, 25 and 31 were represented by single strains. A 
representative strain for each pbp2x RFLP type was chosen for sequence comparison (Fig. 
3).  
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The pbp2x DNA fragments of the RFLP type 1, 8 and 13 strains were identical in nucleotide 
and deduced amino acid sequence (Fig. 3). This sequence type shared identity with pbp2x 
of S. oralis strain U5 (acc. no. Y10536), and pbp2x of S. mitis strains 476 (acc. no. Y10534) 
and 197 (acc. no. Y10533). In addition, the pbp2x sequence of RFLP type 1, 8 and 13 
strains was identical to pbp2x of S. pneumoniae strain 577 isolated in the UNITED 
KINGDOM (19) and S. pneumoniae strains 34/H31 and 31/KU5 isolated in Japan (2). The 
pbp2x fragment from the RFLP type 4 strain was identical for the nucleotides 1319 to 1786 
with pbp2x from RFLP type 1, 8 and 13 strains. The 5' part of the sequence (nucleotides 
1211 to 1318) differed from pbp2x of strain R6 by 14 synonymous mutations and one 
nonsynonymous mutation (Ala434Ser) (Fig. 3). The pbp2x fragment of the RFLP type 6 
strain was highly homologous to pbp2x of S. mitis strain 10712 (acc. no. X78216), and 
differed in 10 synonymous substitutions and 5 nonsynonymous substitutions (Asp488Asn, 
Lys493Arg, Ser509Gly, Gln552Glu, Tyr568Asn) (Fig. 3). The pbp2x fragment of the RFLP 
type 6 strain was identical to pbp2x of S. pneumoniae strain F1 isolated in France (acc. no. 
AJ238581), except for two synonymous substitutions. pbp2x of the RFLP type 31 strain was 
identical to pbp2x RFLP type 6 sequences, except for five synonymous substitutions (Fig. 
3). The pbp2x sequence of the RFLP type 25 strain differed from pbp2x of the R6 sequence 
in 56 synonymous substitutions and 6 nonsynonymous substitutions (Val456Ala, 
Leu510Gln, Asn514His, Leu565Thr, Asp567Asn, Ser576Asn) (Fig. 3). The pbp2x sequence 
of the RFLP type 25 strain was identical to pbp2x of S. pneumoniae strain 53139/72 isolated 
in Papua New Guinea (19). pbp2x of the RFLP type 7 strain was in part homologous to 
pbp2x of the RFLP type 25 strain, in part to pbp2x of R6, and in part to pbp2x of the RFLP 
type 6 and 31 strains (Fig. 3): nucleotides 1241 to 1345 of pbp2x of the RFLP type 7 strain 
were identical to pbp2x of the RFLP type 25 strain except for two synonymous mutations, 
nucleotides 1346 to 1650 were identical to pbp2x of strain R6 except for two synonymous 
mutations, and nucleotides 1651 to 1786 were identical to pbp2x of strains representing 
RFLP types 6 except for two synonymous mutations. The pbp2x sequence of the RFLP type 
20 strain differed from R6 in 60 synonymous substitutions and 12 nonsynonymous 
substitutions (Gln447Met, Ser449Ala, Ile462Leu, Ile483Leu, Val516Ile, Gln552Glu, 
Leu565Ser, Asp567Asn, Tyr568Asn, Ala572Val, Ser574Ala, Ser576Asn) (Fig. 3). The pbp2x 
RFLP type 20 sequence was identical to pbp2x of S. pneumoniae strains SP1258 isolated in 
France (acc. no. AF210756) and 669 isolated in the UNITED KINGDOM (acc. no. X65133) 
(19). The sequenced pbp2x fragment of the RFLP type 22 strain was homologous to pbp2x 
of S. mitis strain 10712 (acc. no. X78216) although 32 synonymous and 5 nonsynonymous 
substitutions (Val423Ile, Asp488Asn, Thr490Ser, Gln552Glu, Tyr568Asn) were present. 
                                               Penicillin-binding protein genes of S. pneumoniae  135 
pbp2x of the RFLP type 22 strain was identical to pbp2x of S. pneumoniae strain SP1513 
isolated in France (acc. no. AF210754), except for one nonsynonymous substitution 
(Asn567His).  
 
DISCUSSION 
Pneumococcal isolates express six PBPs. Many penicillin-nonsusceptible isolates are 
modified in PBP1a, PBP2b and PBP2x only (12). If one or more amino acids change in the 
conserved amino acid motifs SXXK (with active site serine), SXN and K(H)T(S)G or adjacent 
amino acids, penicillin and other β-lactam antibiotics are often unable to bind efficiently to 
PBPs, which results in resistance.  
RFLP analysis has previously been performed to characterize pbp1a, pbp2b and pbp2x from 
penicillin-nonsusceptible strains isolated in The Netherlands that displayed a wide range of 
MIC levels (0.12 to 2 µg/ml) (16). In this study, we characterized parts of the DNA 
sequences of pbp1a, pbp2b and pbp2x of these clinical isolates. The classification based on 
sequence analysis of the pbp fragments correlated well with the classification according to 
pbp RFLP analysis. Sequence analysis of the pbp2b fragment (nucleotides 1211 to 1714) 
enables a refinement of the classification based on RFLP analysis of the complete pbp2b 
gene. The pbp2b RFLP types 1 and 3 were divided into sequence types 1A and 1B, and 3A, 
3B and 3C, respectively. However, the classification of the pbp2b RFLP types 2, 4, 5, 7 and 
8 was maintained after sequence analysis. We were unable to differentiate within the pbp1a 
RFLP types by pbp1a sequence analysis of nucleotides 1741 to 2229. Moreover, strains 
with pbp1a RFLP types 1 and 10, and strains with RFLP types 2 and 5 were classified to the 
same sequence type, respectively. In addition, we were not able to subdivide pbp2x RFLP 
types by sequence analysis of pbp2x nucleotides 1241 to 1786 and strains with pbp2x RFLP 
type 1, 8 and 13 were classified to the same sequence type. 
Most of the pbp sequences characterized in this study matched with pbp sequences from 
strains isolated in other countries. Martin et al. described pbp1a sequence parts of eight 
resistant isolates (21) and Asahi et al. classified pbp1a and pbp2x sequences from clinical 
isolates into five sequence types (I to V) each (2, 3). All pbp1a sequence types identified in 
this study could be matched with pbp1a sequences described by both research groups. The 
pbp2x sequences of RFLP type 1, 8 and 13 strains were identical to pbp2x sequence types 
IV and V (2). In addition, the pbp2x sequences of the RFLP type 20 and 25 strains matched 
with sequences described by Laible et al. (19). Dowson and colleagues have divided pbp2b 
from penicillin-resistant isolates in two classes, A and B (7). pbp2b RFLP type 1A was 
similar to class B pbp2b, and pbp2b RFLP type 2 belongs to class A pbp2b. All other pbp2b 
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RFLP types described in this study did not match any of the classes A or B, pointing to the 
limitations of Dowson's classification.  
Interestingly, penicillin-nonsusceptible strains with pbp sequences that were highly 
homologous to pbp1a sequences from susceptible strains were intermediately resistant. In 
contrast, penicillin-nonsusceptible strains with a high degree of heterogeneity in their pbp 
sequences compared to susceptible strains have often MIC levels of ≥1 µg/ml. The 
difference in penicillin susceptibility between strains belonging to the same sequence type 
may be due to amino acid alterations in non-sequenced parts of the penicillin-binding 
domain and in other pbp genes.  
All prominent PBP1a amino acid substitutions in penicillin-nonsusceptible isolates described 
by Smith et al. (24) were also observed in this study. The amino acid change Asn405Asp 
was previously identified as being one of the prominent amino acid substitutions in pbp1a of 
resistant isolates (24). In addition, we confirmed that the Thr371Ala substitution in PBP1a 
was important for high-level resistance (3), since all high-level penicillin-resistant strains 
contained this substitution. The PBP1a amino acid substitution Glu388Asp, which has been 
identified in all penicillin-nonsusceptible isolates in this study, also occurs in susceptible 
strains. This substitution is probably not able to confer penicillin resistance (24). The amino 
acid substitutions found in PBP2b in strains of our collection confirmed the previously 
described amino acid substitutions in penicillin-resistant isolates (8, 25, 27). The Thr445Ala 
substitution was found in all penicillin-nonsusceptible strains adjacent to the Ser443-Ser-Asn 
motif, and its importance has previously been noted by Dowson and coworkers (8). The Asn 
residue of this motif has been proposed to form a hydrogen bond with the carbonyl group of 
the R1 side chain of penicillin, and the Thr445Ala substitution presumably disrupts this 
hydrogen bond (8). The significance of Glu475Gly has been noted by Smith and Klugman 
(25), and was found in all pbp2b sequence types of our strain collection. In addition, the six 
consecutive residues at nucleotide position 426 to 431 found in pbp2b RFLP type 2 were 
previously described (25). Since these residues do not occur in other sequence types, they 
are presumably not critical to resistance development. Most of the PBP2x amino acid 
substitutions found in this study were also described previously (2, 17, 19). The amino acid 
substitution Leu546Val proceeding the KSG motif found in PBP2x of RFLP type 4 and RFLP 
types 1, 8 and 13 strains is presumed to be involved in cefotaxime resistance (2). All strains 
with this amino acid substitution had a reduced susceptibility for cefotaxime (MIC range 0.5 
to 1 µg/ml; unpublished observations), confirming the importance of the Leu546Val 
substitution for cefotaxime resistance. Although the amino acid substitution Gln552Glu has 
also been observed in cefotaxime resistant isolates, the impact on resistance is unknown 
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(17). Strains with the Gln552Glu substitution (RFLP types 6 and 31, RFLP type 7, RFLP 
type 20, and RFLP type 22) were all cefotaxime-susceptible (cefotaxime level: <0.016 to 
0.032 µg/ml; unpublished observations), suggesting that the Gln552Glu does not play a role 
in cefotaxime resistance. 
The pbp sequences identified in this study confirmed the acquisition of resistance by DNA 
transfer between non-pneumococcal species and pneumococci. Sequence blocks within 
pbp1a, pbp2b and pbp2x were identical to DNA from S. mitis, S. oralis and S. sanguis. Intra-
species horizontal transfer events among different genetic lineages of pneumococci have 
probably occurred as well, and this is especially suggested between strains with pbp1a 
RFLP types 1, 3, 6 and 10 and between strains with pbp2b RFLP types 5, 7 and 8. A 
recurrence of the recombination with viridans streptococci may have also taken place giving 
rise to a smaller section of the mosaic and is highly suggestive for pbp2b of the RFLP type 
1B and 3C strains and for pbp2x RFLP type 4 and 7. 
In conclusion, mutations in pbp sequences of most Dutch isolates were similar to those 
described in pbp sequences of strains isolated in other countries. This supports the 
hypothesis that multiple clones of penicillin-resistant pneumococci have been introduced 
and subsequently spread in The Netherlands as reported by Hermans et al. (16). However, 
novel combinations of sequence blocks in pbp1a, pbp2b and pbp2x were also identified, and 
suggests horizontal transfer of DNA between pbp genes of penicillin-resistant pneumococci 
previously described and pbp genes of susceptible strains.  
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ABSTRACT   
To investigate the molecular epidemiology of pneumococcal nasopharyngeal carriage in 
Hanoi, Vietnam, we studied 84 pneumococcal strains retrieved from children with upper 
respiratory tract infections. Serotypes 23F (32%), 19F (21%), 6B (13%), and 14 (10%) were 
found most often. A significant number of strains were antibiotic resistant. Fifty-two percent 
of the strains were (intermediate) resistant to penicillin, 87% were (intermediate) resistant to 
co-trimoxazole, 76% were resistant to tetracycline, 73% were resistant to erythromycin, and 
39% were (intermediate) resistant to cefotaxime. Seventy-five percent were resistant to 
three or more classes of antibiotics. A high degree of genetic heterogeneity among the 
penicillin resistance genes was observed. In addition, the tetracycline resistance gene tet(M) 
and the erythromycin resistance gene erm(B) were predominantly observed among the 
isolates. Molecular analysis of the 84 isolates by restriction fragment end labeling (RFEL) 
revealed 35 distinct genotypes. Twelve of these genotypes represented a total of eight 
genetic clusters with 61 isolates (73%). The two largest clusters contained 24 and 12 
isolates, and the isolates in those clusters were identical to the two internationally spreading 
multidrug-resistant clones Spain 23F-1 and Taiwan 19F-14, respectively. The remaining 
RFEL types were Vietnam specific, as they did not match the types in our reference 
collection of 193 distinct RFEL types from 16 countries. Furthermore, 57 of the 61 
horizontally spreading isolates (93%) in the eight genetic clusters were covered by the 
seven-valent conjugate vaccine, whereas this vaccine covered only 43% of the isolates with 
unique genotypes. According to the serotype distribution of the nasopharyngeal 
pneumococcal isolates, this study suggests a high potential benefit of the seven-valent 
pneumococcal conjugate vaccine for children in Hanoi.  
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INTRODUCTION 
Streptococcus pneumoniae is one of the major causes of respiratory tract infections and 
invasive diseases in children all over the world. At present, worldwide about 1 million 
children under 5 years of age annually die of pneumococcal disease (18). Pneumococci are 
often part of the nasopharyngeal flora; especially due to circumstances of crowding, as 
observed in day-care centers, nursing homes, and hospitals, the risk of being colonized with 
pneumococci is increased (3, 20, 27, 28). Usually, colonization is not followed by disease, 
as local barriers at the mucosal level of the respiratory tract and the human immune system 
are often protective. However, the balance between host and pathogen may be disturbed by 
highly pathogenic pneumococcal strains or by diminished host defense through viral 
infections, malnutrition, or immune deficiency (25).  
Another problem is the growing (multi)drug resistance among pneumococcal isolates. The 
emergence of penicillin- and multidrug-resistant pneumococci has been observed in various 
countries over the last decade. In some countries and populations, up to 60% of the 
pneumococcal isolates are resistant to one or more antibiotics (1, 12, 22). A significant 
proportion of pneumococcal resistance is the result of the worldwide spread of a limited 
number of multidrug-resistant clones (6, 15, 35, 39).  
Prevention of pneumococcal disease has become a major topic in the battle against 
pneumococcal disease. The prevailing 23-valent pneumococcal polysaccharide vaccines 
have been shown to be immunogenic in adults but not in the group most at risk of 
developing pneumococcal diseases, namely, young children (5). Recently, several 
conjugate vaccines have been developed which have proven to be effective in young 
children, especially against invasive diseases (2, 11). Unfortunately, these vaccines are 
protective against only a limited number of pneumococcal serotypes. Conjugate vaccines 
from up to 11 capsular serotypes have been developed, whereas over 90 serotypes exist. In 
order to evaluate the theoretical coverage of the vaccines and the effect of vaccination on 
future serotype distribution, we need to monitor in detail and on a large scale the molecular 
epidemiology of pneumococcal colonization and infection before and after the 
implementation of these vaccines.  
So far, the coverage of the conjugate vaccine has been investigated in several parts of the 
world. For instance, approximately 75% of all pneumococcal central nervous system 
infections in children in Europe, the United States, and Canada are covered by the seven-
valent conjugate vaccine. For China and Latin America, the rates are 50 and 48%, 
respectively (14). Several molecular epidemiological studies have been performed in Asian 
countries such as Thailand and Taiwan; however, in most studies the serotype distribution 
has not been investigated (8, 34). In South Korea the seven-valent conjugate vaccine 
covered 65% of the isolates retrieved in the period from 1991 to 1993 (22). Recently, the 
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Asian Network for Surveillance of Resistant Pathogens has studied nasal carriage of 
pneumococci in healthy children in Taiwan, South Korea, Sri Lanka, and Vietnam. The most 
common serogroups were 6, 23, 19, 14, and 15. Because no subtypes were determined, the 
exact vaccine coverage could not be calculated (23).  
In this study, we investigated the molecular epidemiology of 84 pneumococcal carriage 
isolates of children attending several outpatient departments in Hanoi, Vietnam, with acute 
respiratory tract infections. The serotype distribution, vaccine coverage rates, resistance 
patterns, and genetic properties of these isolates will be discussed.  
 
 
MATERIALS AND METHODS 
Serotyping. Eighty-four S. pneumoniae strains were isolated from the nasopharynges of 
410 children with upper respiratory tract infections visiting the outpatient departments of the 
Vietnam-Cuba Clinic and the Children's and Bach Mai Hospitals in Hanoi from September 
1997 to December 1999. Bacteriological diagnosis was performed according to procedures 
published in the Manual of Clinical Microbiology (11a), and pneumococci were serotyped by 
the capsular swelling method (Quellung reaction) with capsular antisera (Statens 
Seruminstitut, Copenhagen, Denmark).  
Susceptibility testing. The susceptibilities of the Vietnam strains to penicillin, co-
trimoxazole, tetracycline, erythromycin, rifampin, vancomycin, ciprofloxacin, and cefotaxime 
were determined by the agar dilution method as described previously (13). To discriminate 
between susceptible and nonsusceptible strains, we used the antibiotic breakpoints 
according to the NCCLS guidelines (26).  
Penicillin-binding protein (PBP) genotyping. The genetic polymorphisms of penicillin 
resistance genes pbp1a, pbp2b, and pbp2x of the pneumococcal isolates were investigated 
by restriction fragment length polymorphism (RFLP) analysis of the amplified genes, as 
described previously (4).  
Detection and analysis of erm(B) and mef genes. To detect the presence of erm(B) in the 
pneumococcal isolates, we used the protocol described by Sutcliffe et al. (38). In summary, 
we amplified the genes by PCR and analyzed the amplified DNA products by agarose gel 
electrophoresis. The presence of the mef gene was also detected by PCR (38). In order to 
discriminate between mef(A) and mef(E), PCR-RFLP analysis was performed as described 
by Del Grosso et al. (9). The amplicon was restricted with BamHI and DraI. The mef(A) gene 
contains a single BamHI site, which is absent in the mef(E) gene. Restriction of mef(A) and 
mef(E) with DraI yields two and three fragments, respectively.  
Detection of tet(M) and tet(O) genes. In order to discriminate between tet(M) and tet(O), 
PCR-RFLP analysis was performed. Primers tetOfw (5'-TGTCGGGTTGTCCATAGAG-3') 
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and tetOrev (5'-AAATTTACCAATAGCTGGC-3') were used to amplify tet(O). The primer 
sequences were based on the tet(O) gene (GenBank accession number Y07780; positions 
1455 to 1474 and positions 1957 to 1976, respectively). Primers tetM-fw (5'-
CCATTGGTTTATCTGTATCA-3') and tetM-rev (5'-CAGGTTCACCGGTAGTAACA-3') were 
used to amplify tet(M). The primer sequences were based on the tet(M) gene (GenBank 
accession number X90939; positions 3428 to 3447 and 3930 to 3949, respectively). The 
PCR mixture consisted of 25 µl of reaction buffer containing 0.5 U of thermostable DNA 
polymerase diluted in the buffer supplied by the manufacturer (Integro, Leuvenheim, The 
Netherlands), 0.2 mM each deoxynucleoside triphosphate, 1.5 mM MgCl2, 10 pmol of each 
primer, and 10 to 50 ng of pneumococcal DNA. Amplification cycling in a programmable 
thermal controller (PTC-100; MJ Research, Watertown, Mass.) consisted of the following 
steps: predenaturation for 1 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 
57°C, and 1 min at 72°C. Amplification was finished after 3 min at 72°C. A 1.5% agarose gel 
in 0.5x TBE (Tris-borate-EDTA) containing 0.1 µg of ethidium bromide per ml was used to 
visualize the PCR products.  
RFEL analysis. The 84 pneumococcal isolates were subjected to DNA fingerprinting 
analysis. Genotyping of the pneumococcal strains by restriction fragment end labeling 
(RFEL) analysis was performed as described by Van Steenbergen et al. (40) and adapted 
by Hermans et al. (16). Briefly, purified pneumococcal DNA was digested with restriction 
enzyme EcoRI. The DNA restriction fragments were end labeled at 72°C with [-32P]dATP by 
using DNA polymerase (Goldstar; Eurogentec, Seraing, Belgium). The radiolabeled 
fragments were denatured and separated electrophoretically on a 6% polyacrylamide 
sequencing gel containing 8 M urea. Subsequently, the gel was transferred onto filter paper, 
vacuum dried (HBI, Saddlebrook, N.Y.), and exposed for various lengths of time at room 
temperature to ECL Hyperfilms (Amersham, Little Chalfont, United Kingdom).  
Computer-assisted analysis of RFEL banding patterns. The RFEL types were analyzed 
by using the Windows version of GelCompar software (version 4; Applied Maths, Kortrijk, 
Belgium) after the RFEL autoradiograms were imaged with an Image Master desk top 
scanner (Pharmacia Biotech, Uppsala, Sweden). To this end, the DNA fragments in the 
molecular size range of 160 to 400 bp were explored. The DNA banding patterns were 
normalized with the pneumococcus-specific bands present in the RFEL banding patterns of 
all strains. Comparison of the banding patterns was performed by the unweighted pair group 
method with arithmetic averages (30) and by using the Jaccard similarity coefficient applied 
to peaks (37). Computer-assisted analysis was carried out, and the methods were 
performed and the algorithms were used according to the instructions of the manufacturer of 
GelCompar. A tolerance of 1.2% in band position was applied during comparison of the DNA 
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patterns. For evaluation of the genetic relatedness of the isolates, we used the following 
definitions: (i) strains of a particular RFEL type are 100% identical by RFEL analysis, (ii) an 
RFEL cluster represents a group of strains with RFEL types that differ by only one band 
(>95% genetic relatedness), and (iii) an RFEL lineage represents a group of strains with 
RFEL types that differ by less than four bands (>85% genetic relatedness).  
International comparison. The Vietnamese genotypes were compared with the genotypes 
of an international collection of pneumococcal strains representing 193 distinct RFEL types 
originating from 15 different countries in Europe, Africa, and Asia and from the United States 
(M. Sluijter, unpublished observations, 2002), in which all international pandemic clones 
described by the pneumococcal epidemiological network are present 
(http://www.wits.ac.za/pmen/pmen.htm).  
 
 
RESULTS  
Eighty-four isolates retrieved from the nasopharynges of children under 5 years of age with 
acute respiratory tract infections were investigated by serotyping, susceptibility testing, and 
RFEL analysis. The most frequently observed serotypes were 23F (32% of strains), 19F 
(21%), 6B (13%), and 14 (10%). The rate of coverage of the seven-valent conjugate vaccine 
(covering serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) was 80%. The additive rate of 
coverage of the 11-valent conjugate vaccine (covering the additional serotypes 1, 3, 5, and 
7F) was negligible: only one serotype 3 isolate was found, and isolates of the other three 
serotypes were absent. The most common serotypes not covered by the conjugate vaccine 
were 23A (2%), 6A (4%), and 15 (4%); one isolate could not be serotyped.  
The rate of resistance to one or more antibiotics was 96%. The three isolates susceptible to 
all antibiotics were nonvaccine capsular types. The proportions of strains resistant to 
penicillin, co-trimoxazole, tetracycline, and erythromycin were 39, 71, 76, and 73%, 
respectively. None of the strains were resistant to rifampin, vancomycin, or ciprofloxacin. 
Intermediate resistance to penicillin, co-trimoxazole, and cefotaxime was found in 13, 16, 
and 39% of the strains, respectively. In total, 78% of the strains were multidrug resistant.  
These multidrug-resistant strains were of serotypes 23F (24 strains), 19F (17 strains), 6B 
(12 strains), 14 (6 strains), 9V and 16 (2 strains each), and 15, 23A, and untypeable (1 strain 
each).  
Molecular analysis of the 84 isolates revealed 35 different genotypes. Twelve of these 
genotypes represented eight genetic clusters with 61 isolates (72%) (Fig. 1). The largest 
cluster, cluster VIII, consisted of 24 isolates of serotype 23F and RFEL type 015. The 
second largest cluster was cluster VI, which consisted of 12 isolates of serotype 19F and 
RFEL type 006. The third and fourth largest clusters had 10 and 7 isolates, respectively, and 
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each cluster had two different genotypes. In contrast to all other clusters, cluster III, with 10 
isolates, harbored isolates with two distinct capsular types, namely, serotypes 19F and 14. 
Cluster I, with seven isolates, consisted of serotype 6B strains only (Fig. 1).  
We compared all Vietnamese RFEL types with the types in our international database 
representing 193 isolates from 16 different countries as well as those of all international 
pandemic clones described by the Pneumococcal Epidemiology Network 
(http://www.wits.ac.za/pmen/pmen.htm). Two of the genotypes, comprising the two largest 
clusters, clusters VIII and VI, were identical to international clones Spain 23F-1 and Taiwan 
19F-14, respectively. The remaining 33 RFEL types were Vietnam specific, as these 
genotypes were not found in our present database.  
PBP genotyping of the 84 pneumococcal isolates revealed 19 distinct types, and the cluster 
sizes ranged from 1 to 24 strains. Despite the observation that 61% of the strains were 
penicillin susceptible, only 15 isolates displayed wild-type PBP genotype 2-2-2, 2-2-3, or 2-
2-71. Isolates in the major RFEL clusters, clusters VIII and VI, displayed PBP genotypes 1-
1-1 and (26)-3-30, respectively. The pbp1a gene of the last PBP cluster could not be 
amplified from 5 of 12 strains. In addition, genetic analysis of tetracycline resistance genes 
tet(M) and tet(O) revealed that the tet(M) gene was exclusively observed in 77 of the 84 
pneumococcal isolates (91%). Interestingly, 13 tet(M)-containing strains were fully 
susceptible to tetracycline. Finally, the erythromycin resistance gene erm(B) was present in 
70 of the 84 pneumococcal isolates (83%). Seven of the erm(B)-containing strains also 
harbored the mef(E) gene. In the remaining 14 strains, erm(B), mef(A), and mef(E) were 
absent. Ten erm(B)-containing isolates and one erm(B)- and mef(E)-containing isolate were 
erythromycin susceptible (data not shown).  
 
 
DISCUSSION 
To determine the serotype distribution and theoretical rate of coverage of the new 
pneumococcal conjugate vaccines in Vietnam, we investigated 84 pneumococcal strains 
isolated from children under 5 years of age who visited several outpatient clinics in Hanoi 
with acute respiratory tract infections during the period from September 1997 to November 
1999. Serotypes 23F (32%), 19F (21%), 6B (13%), and 14 (10%) were predominantly 
observed. The theoretical rate of coverage of the seven-valent conjugate vaccine was 80%. 
Since several studies have demonstrated a cross-reactive effect against serotype 6A, we 
assume a cumulative rate of coverage of the conjugate vaccine of 83% (7, 32). These data 
are comparable to those found in studies conducted in Europe and the United States, where 
rates of coverage of 60 to 80% are expected (17, 19, 21, 31, 33, 39).  
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A high rate of drug resistance was observed among the pneumococcal isolates. Ninety-six 
percent of the isolates were (intermediate) resistant to penicillin, co-trimoxazole, tetracycline, 
erythromycin, or cefotaxime. Seventy-eight percent of the isolates were resistant to three or 
more classes of antibiotics. This suggests a major problem with respect to treatment of 
pneumococcal infections with these antibiotics.  
The epidemiological behavior of the pneumococcal strains isolated from the Vietnamese 
children was investigated by RFEL analysis. Among the 84 strains, 35 different genotypes 
were observed, of which 12 genotypes represented eight clusters with 61 strains. This 
indicates that 73% of the strains were recently transmitted. Ninety-three percent of the 
clustered isolates displayed capsular serotypes, which are covered by the seven-valent 
conjugate vaccine. The two largest clusters, clusters VI and VIII, containing 12 and 24 
isolates, respectively, were identical to international clones Taiwan 19F-14 and Spain 23F-1, 
respectively. The remaining clusters, with 42% of the recently transmitted strains, and all 
strains with unique genotypes were considered to be Vietnam specific, as they were not 
previously observed for isolates from the 16 countries present in our database. These data 
indicate that strains of nationally and internationally spreading genotypes make a significant 
contribution to nasopharyngeal carriage and, consequently, respiratory tract infections 
among children in Hanoi. The four largest clusters, with 53 strains, i.e., 87% of the 
disseminating isolates, were multidrug-resistant. This indicates a significant transmission of 
multidrug-resistant pneumococci among children in Hanoi.  
Because of the high percentage of resistance to penicillin, erythromycin, and tetracycline 
among the collection of isolates, we analyzed the corresponding resistance genes in detail. 
Since the degree of genetic heterogeneity of pbp genes in both penicillin-susceptible and 
penicillin-nonsusceptible isolates is high, a high degree of genetic plasticity irrespective of 
the penicillin resistance phenotype is suggested. This observation, which is in contrast to 
previous data, which showed that penicillin-susceptible pneumococci display a limited 
number of PBP genotypes (36), is in line with recent findings for pneumococcal isolates from 
Greece (4; Sluijter, unpublished). PBP genotype 1-1-1, which has been predominantly 
observed in various pneumococcal clones, including pandemic clones Spain 23F-1 and 
France 9V-3 (4), was also observed in Vietnamese cluster VIII, which represents clone 
Spain 23F-1. The second largest, Vietnam-specific cluster, cluster VI, primarily displayed 
PBP genotype 26-3-30.  
Genetic analysis of tetracycline resistance genes tet(M) and tet(O) revealed the tet(M) gene 
in 91% of the Vietnamese isolates. This is in line with observations made by Luna and 
Roberts (24), who have demonstrated the presence of the tet(M) gene in 90% of the 
tetracycline-resistant strains. However, in the latter study, an additional 10% of the strains 
contained the tet(O) gene. Thirteen tet(M)-containing strains were fully susceptible to 
 Chapter 5.1 150 
tetracycline, suggesting the presence of a nonfunctional tetracycline resistance gene. A 
similar observation has previously been reported by Doherty et al. (10).  
The erythromycin resistance gene erm(B) was present in 82% of the pneumococcal isolates, 
and 10% of the erm(B)-containing strains also harbored the mef(E) gene. This is in contrast 
to recent observations made by Reinert and coworkers (29), who have observed almost 
equal distributions of erm(B) (43%) and mef(E) (56%) genes among erythromycin-resistant 
isolates. Ten erm(B)-containing isolates and one erm(B)- and mef(E)-containing isolate were 
erythromycin susceptible. To our knowledge, this is the first study to describe the occurrence 
of nonfunctional erythromycin resistance genes in pneumococci.  
 
 
Figure 2. RFEL genotypes and theoretical coverage of the 7-valent conjugate vaccine. Vaccine serotypes are depicted 
in grey. Cluster codes and number of isolates per cluster (in brackets) are depicted. 
 
When our data are compared with those from a recent study of Lee et al. (23), who have 
investigated pneumococcal carriage in healthy children in South Korea, we noticed slight 
differences in the serotype  distributions. In both studies the three most common serogroups 
were 6, 23, and 19. However, the rate of carriage of serotype 23F was twice as high in the 
Vietnamese children with upper respiratory tract infections (30%) as in healthy carriers in 
South Korea (15%), whereas the rate of carriage of serogroup 6 was significantly higher in 
the healthy children in South Korea. In both studies, serogroup 23 isolates represented 
international clone Taiwan 23F. Assuming that the serotype distributions among children in 
Vietnam and South Korea are comparable, we hypothesize that clone Taiwan 23F is more 
often correlated with respiratory disease, whereas serogroup 6 is more frequently correlated 
with carriage. To strengthen this hypothesis, comparative epidemiological studies 
             Pneumococcal carriage in Hanoi 151 
demonstrating a significant correlation between pneumococcal carriage and respiratory 
disease are required.  
In conclusion, our study demonstrated a high theoretical rate of coverage of the seven-
valent conjugate vaccine against pneumococcal carriage strains isolated from children with 
acute respiratory tract infections in Hanoi. Moreover, the genotypes transmitted the most 
frequently were covered by the conjugate vaccine. Finally, 78% of the pneumococcal 
isolates are multidrug-resistant, and 92% of these multidrug-resistant isolates are 
theoretically covered by the seven-valent conjugate vaccine. Our data suggest that the 
children in Vietnam will benefit from implementation of vaccination with the pneumococcal 
conjugate vaccine.  
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ABSTRACT 
A multidrug-resistant strain of Streptococcus pneumoniae was isolated in The Netherlands 
during a nosocomial outbreak among 36 patients who mainly had chronic obstructive 
pulmonary disease. After the commencement of barrier nursing and short-term ceftriaxone-
rifampin eradication therapy, the epidemic ceased. However, eradication therapy failed in 3 
patients, and follow-up investigation of these patients showed the emergence of rifampin-
resistant isolates. 
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INTRODUCTION 
Streptococcus pneumoniae (pneumococcus) continues to be a common cause of serious 
and life-threatening infections, such as pneumonia, bacteremia, and meningitis, and of 
noninvasive infections, such as otitis media and sinusitis. Serious pneumococcal bacteremia 
is most prevalent in the extreme ages of life, resulting in illness in children in the first 2 years 
of life and in older patients (>70 years of age) [13]. An important risk factor for the 
acquisition and spread of drug-resistant pneumococci is chronic obstructive pulmonary 
disease (COPD) [3, 4]. Many studies have reported an increase in the prevalence of 
pneumococcal strains that are resistant to β-lactam antibiotics [5]. In addition, multidrug-
resistant (MDR) strains have also been reported with increasing frequency. As a 
consequence, penicillin may no longer be the first-choice drug for treatment of 
pneumococcal infections in regions with a high prevalence of MDR strains. A variety of other 
antimicrobial agents can be used that have appropriate activity against penicillin-resistant 
pneumococci [5]. This includes rifampin, a semisynthetic derivative of the rifamycins that is 
primarily prescribed for the treatment of tuberculosis. Although not routinely used, it may be 
included in the treatment of penicillin-resistant pneumococcal infections in combination with 
the third-generation cephalosporins because of broad-spectrum activity, efficient (mucosal) 
tissue penetration, and a low side-effect profile [5-8]. Because of the possibility for rapid 
emergence of resistance, rifampin should never be prescribed as single-agent therapy [5, 7].  
Rifampin resistance has arisen in several different species of bacteria because of alterations 
in the target of the antibiotic, the β-subunit of RNA polymerase encoded by rpoB. Rifampin 
acts by binding to the β-subunit of RNA polymerase, causing premature termination during 
DNA transcription, and point mutations, most of which map to 2 regions in the center of the 
rpoB gene and can lead to resistance to rifampin [8, 9]. Nucleotide sequence analysis of 
rpoB from rifampin-resistant and rifampin-susceptible isolates of S. pneumoniae has 
revealed that a defined set of point mutations within rpoB confers resistance to rifampin in S. 
pneumoniae in a similar manner as described elsewhere in resistant isolates of 
Mycobacterium tuberculosis, S. mitis, and Escherichia coli [8, 9]. In addition to the 
resistance to rifampin in S. pneumoniae caused by point mutation, interspecies gene 
transfer may also play a role in the evolution of rifampin resistance in S. pneumoniae [8]. 
Alternatives previously hinted at for organisms other than S. pneumoniae may also 
contribute to rifampin resistance. These include the modification in rifampin alteration in drug 
uptake or efflux mechanisms and changes in antibiotic permeability or metabolism [9].  
In The Netherlands, a country with a low prevalence of pneumococcal resistance to 
antibiotics, several pneumococcal outbreaks have been reported in populations of patients 
with COPD [3, 4]. This study describes the emergence of primary rifampin resistance in 3 (of 
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which 2 were inadequately treated with rifampin monotherapy) patients with COPD in a 
Dutch hospital during therapeutic management of an outbreak of MDR pneumococci.  
 
 
SETTING AND TREATMENT 
In March 1997, isolates of restriction fragment end labeling (RFEL) type 19 pneumococci 
with reduced sensitivity to penicillin and other antibiotics were isolated from 36 patients 
admitted to the pulmonology ward of a 500-bed teaching hospital in Veldhoven, The 
Netherlands. This pneumococcal clone was unique for the current patient population, 
because it was not observed during the national survey of penicillin-resistant pneumococci 
in The Netherlands over the last 5 years. Retrospective research revealed nosocomial 
transmission among 36 COPD patients who had been hospitalized between July 1995 and 
August 1997. This outbreak was the continuation of the clonal spread of an MDR strain after 
interhospital transmission. In recognition of this outbreak, described elsewhere, an infection 
control team was set up in the hospital [3, 4].  
Intervention therapy consisted of barrier nursing with separate rooms and cohort nursing. 
Antibiotic treatment before initiation of the treatment protocol followed susceptibility test 
results and always included a β-lactam antibiotic. After initiation of the protocol, a 7-day 
course of iv ceftriaxone 2 g once daily was prescribed. The treatment protocol was 
continued until 2 consecutive cultures were negative or until the patient was discharged from 
the hospital. The intervention therapy always included eradication therapy. Because 
colonization had been shown to contribute to further dissemination with drug-resistant 
pneumococci, eradication of carriage was sought. For this purpose, a 5-day course of 
rifampin (600 mg once daily) was added in the final stage of the patients' original antibiotic 
regimen as duotherapy. Rifampin was chosen as eradication therapy, because high levels 
can be obtained in respiratory secretions. In subsequent follow-up visits, nasopharyngeal 
swabs were taken for at least 1 year. Three patients did not respond to treatment, as 
described above.  
Microbiology. The DNA profiles of the isolates were examined by computerized analysis, 
after being confirmed as S. pneumoniae [4, 10]. A 617-bp internal region of the rpoB gene 
was amplified by PCR with primers RpoB2fw (5-GTACGTTTGGGACTTTCTCG-3, 
nucleotide position 10871106) and RpoB1rev (5-CATGCTGTTCGCAACGGCAAC-3, 
nucleotide position 16841703). Positioning of the primers is based on the rpoB gene 
sequence from the S. pneumoniae genome database of The Institute for Genomic Research 
(TIGR). Amplification was carried out in 100-mL volumes containing 75 mM Tris-HCl (pH 
9.0), 20 mM (NH4)2SO4, 0.01% (w/v) Tween 20, 1.5 mM MgCl2, 0.2 mM deoxynucleoside 
triphosphates, 50 pM of the individual primers, 0.5 U of Taq DNA polymerase (Goldstar, 
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Eurogentec), and 10 ng of purified chromosomal DNA. Cycling was performed in a PTC-100 
Programmable Thermal Controller (MJ Research) and consisted of the following steps: 
predenaturation at 94°C for 1 min; 30 cycles of 1 min at 94°C, 1 min at 52°C, and 1 min at 
72°C; and a final extension at 72°C for 3 min. Before nucleotide sequence analysis, the 617-
bp amplicons were purified by sodium acetate precipitation. Each amplicon was sequenced 
by using 50 pM of the following primers: RpoB2fw, RpoB2rev (5-
TTGTTCAAGTGTCCATAAG-3, position 14271446), RpoB1fw (5-
ACTCACTATGGTCGTTATGTG-3, position 13541373), and RpoB1rev. DNA sequencing 
reactions were carried out with 300500 ng of DNA with the Thermo Sequenase dye 
terminator cycle sequencing premix kit (Pharmacia Amersham). The DNA sequencing 
procedure was performed according to the manufacturer's recommendations. Samples were 
analyzed with the Applied Biosystems Prism 377 (Pharmacia Amersham).  
Transformation experiments were performed with S. pneumoniae Rx1 cells, as described by 
Lacks [11]. The cells were incubated for 2.5 h at 37°C with 0.5 mg of amplified rpoB DNA 
(617 bp) from rifampin-resistant pneumococcal isolates and 300 ng of synthetic competence 
stimulating factor 1 (CSP-1; kindly provided by D. Morrisson) before plating on Todd-Hewitt 
agar plates (Difco) containing 0.5% yeast extract (Difco) and 2 g/L rifampin (Yamanouchi 
Pharma). The susceptibility of the pneumococcal transformants for rifampin was determined 
by the agar dilution method according to the guidelines of the National Committee for 
Clinical Laboratory Standards [12].  
Patient 1. Patient 1 was admitted to the pulmonary department in November 1997 for 
exacerbation of COPD. Screening had revealed MDR rifampin-susceptible strains of S. 
pneumoniae, the first of which was isolated in March 1997. This patient received an 
antibiotic treatment followed by administrations of rifampin 600 mg for 5 days. In contrast to 
the protocol, rifampin was given in monotherapy. In December 1997, an MDR strain of S. 
pneumoniae with a rifampin resistance (MIC, 8 mg/L) was isolated from the nasopharynx of 
this patient. Although amoxicillin and rifamycin were given in duotherapy, rifampin-resistant 
isolates were collected on 5 different occasions.  
Patient 2. Patient 2 was admitted to the hospital in September 1997 with exacerbation of 
COPD and constitutional eczema. MDR S. pneumoniae was isolated. She received a course 
of penicillin, followed by cotrimoxazole and rifampin for 5 days. During follow-up in the 
outpatient clinic in October 1997, an MDR pneumococcal isolate with an additional 
resistance for rifampin (MIC, >32 mg/L) was detected. A new rifampin eradication course for 
5 days was prescribed in monotherapy. In December 1997, a rifampin-resistant strain of 
MDR S. pneumoniae (MIC, 8 mg/L) was detected. A combination course of an increased 
dose of penicillin and ceftriaxone iv was prescribed, resulting in the eradication of the 
rifampin-resistant strain in January 1998.  
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Figure 1. Partial amino acid sequence of Streptococcus pneumoniae rpoB from rifampin-susceptible control strain Rx1 
and the strains isolated from patients 1, 2, and 3 before (A) and after (B) eradication therapy. Amino acid residues are 
numbered according to their position in the rpoB protein. The striped bar indicates the PCR-amplified and PCR-
sequenced gene part. Rifampin MIC values of the strains are also depicted. 
  
 
Patient 3. Patient 3 had dehydration and obstipation. Microbiologic screening revealed an 
MDR, but rifampin-susceptible, strain of S. pneumoniae in both April and September 1997, 
without signs of COPD exacerbation. In contrast to the protocol, rifampin monotherapy was 
prescribed in an attempt to eradicate the pneumococcus. A subsequent specimen in 
November 1997 was negative for S. pneumoniae. In March 1998, a rifampin-resistant (MIC, 
4 mg/L) MDR strain of S. pneumoniae, also highly resistant for tetracycline (MIC, >256 
mg/L), emerged in the patient's sputum. In April 1998, the patient was readmitted for 
exacerbation of COPD. Antibiotic treatment was given without a second eradication 
regimen. After hospital discharge in May 1998, the MDR pneumococcus was isolated that 
year on several occasions.  
Susceptibility testing of the rifampin-resistant pneumococcal MDR strains demonstrated a 
MIC for rifampin of 8, >32, and 4 mg/L for patients 1, 2, and 3, respectively (figure 1). 
Microbiologic analysis showed that all rifampin-resistant isolates belong to chromosomal 
genotype RFEL type 19 and serogroup 15. The penicillin-resistance genotype was PBP type 
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3-3-4. These findings match with the observations made during the initial outbreak [3], 
implying primary resistance of these S. pneumoniae isolates.  
Mutations within rpoB showed a switch at position 526 from histidine to asparagine in patient 
1, and in patient 2, from histidine to aspartic acid. Patient 3 had a point mutation at position 
511 resulting in an amino acid substitution from serine to proline (figure 1). The amplified 
gene parts derived from the rifampin-resistant isolates were used to transform rifampin-
susceptible pneumococcal strain Rx1. DNA transfer conferred rifampin resistance in the Rx1 
transformants to MIC levels equal to the donor strains (data not shown). These observations 
indicate that the single point mutations in the rpoB genes of the COPD isolates were 
responsible for the rifampin-resistant phenotype.  
 
 
DISCUSSION 
COPD is a disease associated with frequent exacerbations, which are often accompanied by 
infections caused by Haemophilus influenzae or S. pneumoniae. As a consequence, 
antibiotic therapy is used widely in the treatment of exacerbations of COPD [3, 13]. 
Antimicrobial use is generally considered to be the driving force of bacterial resistance, 
resulting in the homing of MDR bacteria in this antibiotic "niche." Therefore, the prevalence 
of infections with MDR strains of pneumococci in this group of patients is often increased.  
The combination of barrier nursing, a course of β-lactam antibiotics, and rifampin eradication 
therapy in the treatment protocol in Veldhoven was evidently effective. However, the MDR 
pneumococcus could not be eradicated in 3 patients. Microbiologic analysis confirmed that 
the studied isolates were of clonal origin and were identical to the initial outbreak strain. The 
mutations occurred in 2 different regions in the rpoB gene and displayed 3 distinct amino 
acid substitutions. We conclude that inadequate therapy caused by inaccurate prescription 
resulted in a primary rpoB-mediated rifampin resistance on 2 occasions. Obviously, the use 
of rifampin monotherapy in patients 1 and 3 contributed to the acquisition of rifampin 
resistance, and these patients did not respond to treatment [5, 7]. Patient 2 manifested 
primary resistance despite accurate therapy. We hypothesize that the pathological lung 
structure of these COPD patients has contributed to inadequacy of treatment by the 
treatment protocol. This study indicates the importance of accurate bacteriologic monitoring 
of patients with COPD who are colonized or infected with MDR pneumococci and suggests 
extension of the current eradication regimen with an additional (β-lactam) antibiotic.  
 
 
 
 
Chapter 5.2 160 
REFERENCES  
1. Caputo GM, Appelbaum PC, Liu HH. Infections due to penicillin-resistant pneumococci. Arch Intern Med 1993; 
153:130110.  
2. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and 
treatment. Clin Infect Dis 1992; 14:8019.  
3. De Galan BE, van Tilburg PMB, Sluijter M, et al. Hospital-related outbreak of infection with multidrug-resistant 
Streptococcus pneumoniae in The Netherlands. J Hosp Infect 1999; 42:18592.  
4. Hermans PWM, Sluijter M, Elzenaar K, et al. Penicillin-resistant Streptococcus pneumoniae in The Netherlands: 
results of a 1-year molecular epidemiologic survey. J Infect Dis 1997; 175:141322.  
5. Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current 
antibiotic therapy in the 1990s. Clin Infect Dis 1997; 24(Suppl 2):S21321. First citation in article | PubMed   
6. Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998; 
18:34557.  
7. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus 
pneumoniae. N Engl J Med 1994; 331:37782.  
8. Enright M, Zawadski P, Pickerill P, Dowson CG. Molecular evolution of rifampicin resistance in Streptococcus 
pneumoniae. Microb Drug Resist 1998; 4:6570.  
9. Padayachee T, Klugman KP. Molecular basis of rifampicin resistance in Streptococcus pneumoniae. Antimicrob 
Agents Chemother 1999; 43:23615.  
10. Hermans PWM, Sluijter M, Hoogenboezem T, Heersma H, van Belkum A, de Groot R. Comparative study of five 
different DNA fingerprint techniques for molecular typing of Streptococcus pneumoniae strains. J Clin Microbiol 
1995; 33:160612.  
11. Lacks S. Integration efficiency and genetic recombination in pneumococcal transformation. Genetics 1966; 
53:20735.  
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for 
bacteria that grow aerobically. 4th ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 
1997:M7A4.  
13. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by 
multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for 
antibiotic therapy. J Infect Dis 1999; 180:4049.  
 
 
 
Chapter 5.3 
 
 
Molecular dynamics of pneumococcal colonization 
in healthy dutch children 
 
 
 
D. Bogaert, M. Sluijter, N. Lemmens-den Toom, T.J. Mitchell, W.H.F. Goessens,  
S.C. Clarke, R. de Groot and P.W.M. Hermans 
 
 
Submitted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5.3 162 
ABSTRACT 
Introduction. Streptococcus pneumoniae is a common cause of invasive diseases, such as 
sepsis and meningitis. Treatment is often complicated by multidrug resistance of this 
pathogen. Colonization with this species is common, particularly in young children. Recently, 
we have studied pneumococcal colonization among 3198 healthy children 1-19 years of age 
in The Netherlands. Overall, pneumococcal colonization was 19% with a peak-incidence of 
55% at the age of 2 years. In addition, we have found an age-related serotype distribution 
among children, with a shift from vaccine to non-vaccine serotypes after the age of three 
years (Bogaert et al. Lancet: accepted). 
Methods. In this study, we characterized the genetic background and resistance profiles of 
the 578 pneumococcal isolates from the latter study by means of chromosomal genotyping 
and susceptibility testing.  
Results. In total, we observed 153 unique genotypes and 92 genetic clusters representing 
425 isolates. In contrast to the observed age-related serotype distribution, the genetic 
background of the strains was not age-related. Comparison of the pneumococcal population 
to the international PMEN database of drug-resistant clones (PMEN) revealed close 
homology (>95%) with the international clones Spain9V-3 (10 isolates), England 14-9 (4 
isolates), Tennessee23F-4 (2 isolates), CSR14-10 (1 isolate) and Sweden15A-25 (1 isolate). In 
total 19% of all strains showed resistance to one or more antibiotics. Resistance to 
cotrimoxazole, tetracycline, erythromycin and penicillin was found in 12.9%, 5.6%, 5.0% and 
2.7%, respectively. Multidrug resistance was found in 1.9% of all strains.  
Conclusion. Pneumococcal colonization isolates from healthy Dutch children represent a 
heterogeneous, mostly susceptible genetic population with a high degree of genetic 
clustering, which suggests a high tendency to spread within the community. 
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INTRODUCTION 
Streptococcus pneumoniae is worldwide one of the major pathogens causing invasive 
disease and respiratory tract infections. Risk groups for pneumococcal infections are young 
children, elderly and immunodeficient patients. Despite adequate antibiotic treatment, 
morbidity and mortality due to pneumococcal disease remains high (8). The increasing 
(multi) drug resistance among pneumococcal isolates hampers adequate treatment (1, 9, 
19, 32). 
Nasopharyngeal colonization with pneumococci is common; in general humans get 
colonized at least once early in life. Although colonization with pneumococci is mostly 
asymptomatic, it can progress to respiratory or even systemic disease as a result of a 
(temporary) defect in the mucosal barrier function, for example by a viral infection. 
Importantly, pneumococcal disease has to be preceded by nasopharyngeal colonization with 
the homologous strain (13, 14). Moreover, pneumococcal colonization causes horizontal 
spread of this pathogen within the community. For example crowding, which occurs in 
hospitals, day-care centers and jails, enhances horizontal spread of pneumococcal strains 
(17, 20, 23, 26, 29). Because the highest incidence in pneumococcal colonization and the 
highest crowding index is found in young children, this risk group is considered to be the 
most important vector for horizontal dissemination of pneumococcal strains within the 
community (21). New pneumococcal conjugate vaccines are highly effective against 
invasive diseases in young children (2). Furthermore, a protective effect against mucosal 
infections, such as (recurrent) otitis media, albeit limited, has been observed (2, 12). At 
nasopharyngeal level, however, replacement of vaccine-type pneumococci with non-vaccine 
serotypes as a result of vaccination has also been observed (10, 24, 35). In addition, 
replacement of mucosal disease, i.e. (recurrent) acute otitis media, has been found (12, 35). 
What effect this serotype replacement has on invasive diseases remains unclear, although it 
has clearly been demonstrated that several non-vaccine serotypes have high potential for 
causing invasive disease (7). Because few data are available on the age-related incidence 
and serotype distribution of S. pneumoniae among healthy children, a cross-sectional study 
has been performed in the summer of 2002 among 3200 healthy children aged 1-19 years in 
which the prevalence and determinants of pneumococcal carriage were studied (5). This 
study has shown a significant age-related colonization rate with a peak incidence at 3 years 
of age of 55% followed by a gradual decline till a stable colonization rate of 10% was 
reached after the age of 10 years. Moreover, a significant age-related serotype distribution 
was noticed with a primary peak of vaccine serotypes early in life, followed by a secondary 
peak with non-vaccine serotypes (5).  
In this study, we investigated the molecular epidemiological dynamics and resistance 
profiles of  the  pneumococcal  strains  collected  during  the latter  study  in  order  to  obtain  
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detailed insight in the occurrence and age-related distribution of pneumococcal genotypes 
and resistance profiles. 
 
 
MATERIAL AND METHODS 
Bacterial isolates. In total, 3198 healthy children, aged 1-19 years, participating in a 
national meningococcal vaccination campaign in Rotterdam were enrolled. All children were 
residents of Rotterdam and were vaccinated either in July (age 12 months to 5 years plus 15 
to 19 years) or in September (age 6 to 15 years) of the year 2002. Signed informed consent 
was obtained from the parent accompanying the participating children under the age of 16 
and directly from the children above the age of 16. Demographic data were collected as 
described previously (5). The study was approved by the Medical Ethics Review Board of 
Erasmus MC, Rotterdam, The Netherlands. 
Cultures. Nasopharyngeal samples were obtained with rayon tipped dacron pernasal swabs 
(Copan Italia, Brescia, Italy) and transported in Amies transport medium to the medical 
microbiology laboratory and plated within 6 hours of sampling. The swabs were plated on 
gentamicin blood agar for the isolation of S. pneumoniae. Identification of S. pneumoniae 
isolates was performed by standard methods as described previously (22). Susceptibility 
testing was performed by the disc diffusion method. Resistance was defined by measuring 
the zone diameters for the respective antibiotics as defined by the NCCLS (27). Strains 
showing reduced susceptibility to oxacillin were additionally tested for penicillin and 
cefotaxime resistance by the E-test. Multidrug resistance was defined as resistance to ≥3 
classes of antimicrobial agents.  
Restriction fragment end labeling (RFEL) typing. Pneumococcal strain typing by RFEL 
was done as described by van Steenbergen et al. (33) and adapted by Hermans et al. (16). 
Briefly, purified pneumococcal DNA was digested by the restriction enzyme EcoRI. The DNA 
restriction fragments were end labeled at 72oC with [α-32P]dATP using DNA polymerase 
(Goldstar; Eurogentec, Seraing, Belgium). After the radiolabeled fragments were denatured 
and separated electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M 
urea, the gel was transferred onto filter paper, vacuum dried (HBI, Saddlebrook, NY), and 
exposed for variable times at room temperature to ECL hyperfilm (Amersham Laboratories, 
Amersham, UK).  
Computer-assisted analysis of DNA band patterns. RFEL autoradiographs were 
converted to images (Agfa Arcus II, Agfa Gevaert, Rijswijk, The Netherlands) and analyzed 
by computer (Windows version Bionumerics; Applied Maths, Sint-Martens-Latem, Belgium). 
DNA fragments were analyzed as described previously (31). For evaluation of the genetic 
relatedness of the isolates we used the following definitions: (1) isolates of a particular RFEL  
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type are 100% identical by RFEL analysis; (2) an RFEL cluster represents a group of RFEL 
types that differ in only one band (approximately >95% genetic relatedness).  
International comparison. The  genotypes were compared with an international collection 
of pneumococcal isolates representing 751 distinct RFEL types originating from 17 different 
countries in America, Europe, Africa and Asia (4, 15, 30), in which the first 26 international 
pandemic clones as described by the pneumococcal molecular epidemiological network 
(PMEN) in 2002 are present (25).  
Multi locus sequence typing (MLST). The genotypes of the 24 largest clusters (n>4)were 
verified by MLST analysis, and one, two or three isolates per cluster were analyzed. For this 
purpose, a fully automated method for MLST was used as described previously (18). The 
MLST types were compared with the global PMEN database (http://www.pneumo.com/ 
physician/pmen/pmen_history.asp). 
Data-analysis. P-values for differences were calculated with the Chi-square test using 
GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, USA). 
 
 
 
Table 1. Serotype distribution of the pneumococcal isolates. 
 
 Total number of pneumococci (%)  
S. pneumoniae  601 (100 %) 
Vaccine types  250 (41.6%) 
Non-vaccine types 351 (58.4%) 
   
Vaccine types   
Serotype 6B 69 (11.5%) 
Serotype 19F 68 (11.3%) 
Serotype 23F 53 (8.8%) 
Serotype 14 23 (3.8%) 
Serotype 18C 17 (2.8%) 
Serotype 9V 14 (2.3%) 
Serotype 4 6 (1.0%) 
   
Non-vaccine types   
Serotype 6A 40 (6.7%) 
Serotype 3 36 (6.0%) 
Serotype 11 31 (5.2%) 
Serotype 8 21 (3.5%) 
Serotype 15 19 (3.2%) 
Serotype 19A 19 (3.2%) 
Serotype 10 18 (3.0%) 
Serotype 23A 16 (2.5%) 
Serotype 16 12 (2.0%) 
Serotype 38 12 (2.0%) 
Serotype 7 10 (1.7%) 
   
Other serotypes 93 (15.4%) 
Untypeable 31 (5.2%) 
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RESULTS 
In total, 601 pneumococci were isolated from 3198 healthy children aged 1-19 years visiting 
the meningococcal vaccination campaign in the summer of 2002 in the city of Rotterdam, 
The Netherlands. The most prevalent serotypes found were the serotypes 6B, 19F, 23F, 6A, 
3, 11 and 14 (Table 1). The age-related distribution of the most prevalent serotypes is 
depicted in Figure 1. The vaccine serotypes as well as the cross-protective serotypes 
invariably showed peak incidences at the age of 1-2 years, whereas the majority of the non-
vaccine serotypes peaked at older age. 
578 of the pneumococci were available for genetic analysis by means of RFEL genotyping 
(96%). We observed 337 genetically distinct genotypes of which 153 types were unique 
(found only once). The remaining 425 pneumococcal isolates (74%) comprised 92 genetic 
clusters.  Of the RFEL clusters observed in this collection 5 showed close homology with 
RFEL profiles of the international PMEN clones. The PMEN genotype Spain9V-3 was 
observed 10 times, England 14-9 4 times, Tennessee23F-4 2 times, CSR14-10 1 time and 
Sweden15A-25 1 time. In Figure 2 all genetic clusters are represented in a genetic 
dendrogram, including the serotype distribution, age distribution and number of isolates 
representing each cluster. In contrast to the age-related serotype distribution, no additional 
correlation between age and genetic profile was noted, except for Cluster I which showed an 
average age of 11 years compared to 6 years for the entire pneumococcal population.  
We also investigated the clustering rate for the most common serotypes. In total, 55%, 72%, 
56%, 48%, 67%, 67%, and 60% of the isolates representing the serotypes 6A, 6B, 14, 19F, 
23F, 3 and 11 isolates, respectively, were part of one of the clusters. The remaining isolates 
represented unique genotypes. Statistical analysis of these data showed a significantly 
lower clustering rate for the serotypes 6A and 19F. 
In Table 2 we depicted the 9 largest genetic clusters, representing more then 10 isolates 
each. The largest cluster, Cluster V, consisted of 45 serotype 6B (35), 6A (8) and 19F (2) 
strains, representing 5 genotypes. No homology was observed with any of the PMEN 
clones. The second and third largest clusters, i.e. Cluster VIII (18 strains) and Cluster I (17 
strains) represented 2 and 3 genotypes, respectively and harbored mainly serotype 3. Only 
one major cluster, Cluster IX representing serotype 9V and 19F (13 strains), showed close 
homology (>95%) with an international clone, Spain9V-3. MLST analysis showed that Cluster 
IX and Spain9V-3 had 5 out of 7 alleles in common. In contrast to the original PMEN clone all 
Dutch isolates were fully susceptible to penicillin, tetracycline, erythromycin and 
cotrimoxazole. The remaining clusters, i.e. Cluster II (13 strains), Cluster III (10 strains), 
Cluster IV (13 strains), Cluster VI (10 strains) and Cluster VII (13 strains) represented 
predominantly the serotypes 14, 15, 23F, 23F, and 23F, respectively. Six of the 9 major 
clusters consisted of conjugate vaccine serotypes, whereas only three clusters
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              Serotypes                                 Age (years)                Strains(n)           Cluster 
 
8(1),11(1),NT(2) 
19F(6),NT(1) 
23A(5) 
23A(3),9V(1),19A(1) 
22(1),23A(1) 
9V(1),9N(1) 
19F(2) 
6B(2),19F(1) 
19F(5),6B(1) 
19F(1),16(1) 
6B(1),19A(1),23F(1) 
14(3),6B(1),12(1) 
11(1),17(1) 
3(3),8(6),NT(3),38(1),47(1),19(1),unk(2) 
14(8),19(1),19A(1),23A(1),23F(1),35(1) 
15(6),6A(1),8(1)19F(1),31(1) 
6A(2) 
19A(1),19F(1) 
18C(1),20(1),33(1) 
18C(1),18(1),18a(1) 
4(4),37(1) 
9V(3),16(4),19F(1),NT(1) 
4(1),19F(1),22(1) 
31(3),19A(1) 
18C(6),35/42(1) 
21(1),19A(1) 
19F(2) 
19F,21 
19F(2) 
19F(2),19A(1) 
7(1),14(1) 
19F(1),19(A) 
16(3) 
23F(1),14(1) 
23F(13) 
23F(2),23B(2) 
19F(2) 
6B(35),6A(8),19F(2) 
6B(3),6A(2),8(1),29/35(1),unk(1) 
6A(1),16(1) 
6A(2) 
6A(2),36(1) 
34(2) 
14(1),34/35(1),42(1) 
35(2) 
35(2) 
6B(5),6A(1) 
19F(1),19B(1) 
6B(2) 
8(2) 
3(3) 
11(2) 
11(4) 
11(2),7(1) 
11(5) 
11(4) 
11(1),17(1) 
8(2),19F(1),33(1) 
15(2) 
19F(1),33(1) 
38(7),18C(1),NT(1) 
8(3) 
23F(4),15(1) 
23F(8),17(1),23A(1) 
23F(8),17(2),19A(1),23B(1) 
23F(2),15(1) 
18C(2) 
19F(2),1(1) 
3(17),23B(1) 
19A(1),23F(1) 
19A(2),21(1) 
19A(3) 
15(1),21(1) 
14(3) 
19F(3) 
6A(4),19A(1) 
18C(1), unk(1) 
6A(1),NT(1) 
6A(4) 
7(2),11(1) 
7(2),23A(1) 
31(3) 
31(2) 
9V(5),19F(6),14(1),23A(1) 
10(2) 
10(4) 
10(3) 
9V(1),23F(1),NT(2) 
17(1),19A(1),29(1) 
NT(6),4(1),7(1),23A(1) 
19F(1),21(1) 
22(1),NT(1) 
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Table 2. Properties of the most predominant genetic clusters. 
 
Cluster 
 
Number of 
isolates 
Serotypes Number of 
genotypes 
Average age 
(years) 
     
I 17 3(3), 8(6), NT(3), others (6) 3 11 
II 13 14(8), others (5) 4 4 
III 10 15(6), others (4) 2 6 
IV 13 23F(13) 4 3 
V 45 6B(35), 6A(8), 19F(2) 5 4 
VI 10 23F(8), others (2) 3 5 
VII 12 23F(8), 17(2), others (2) 3 4 
VIII 18 3(17), others (1) 2 7 
IX 13 9V(5), 19F(6), others(2) 4 5 
 
 
represented the non-vaccine serotypes 3 and 15.  
We characterized the 24 largest clusters by MLST (Figure 3). This method confirmed the 
presence of an additional PMEN clone, namely England 14-9. The remaining clusters 
showed ST types differing from the international multidrug-resitant clones, however most 
clusters matched ST types present in the international database.  
Susceptibility testing was performed on 587 pneumococcal isolates for the following 
antimicrobial drugs: penicillin, erythromycin, tetracycline, cotrimoxazole, chloramphenicol, 
cefotaxime, ciprofloxacin and vancomycin. In total, 18.1% of the isolates showed resistance 
to one or more of the antimicrobial drugs investigated. Resistance to cotrimoxazole, 
erythromycin, and tetracycline was found in 12.9%, 5.0% and 5.6%, respectively. No 
resistance to vancomycin and ciprofloxacin was observed. In 13.6% of the isolates, 
resistance to a single drug was observed. In 2.6% of the isolates dual resistance was found 
and in 1.9% multidrug resistance.  The resistance patterns observed are depicted in Table 3. 
High-level penicillin resistance was not observed. However, 2.7% of the pneumococcal 
isolates was intermediate susceptible to penicillin. In addition, the majority of these strains 
(11 out of 15 isolates) showed dual or multidrug resistance. In Table 4, the number of 
strains, resistance level and the average age of the children carrying these isolates is 
shown. No significant difference could be observed for the average age of the children 
carrying resistant isolates (5.4 years) versus children carrying susceptible isolates (5.9 
years), nor for the individual resistance profiles.  
 
 
 
Figure 2 (left). Dendrogram of the 92 genetic clusters observed by RFEL genotyping among the Dutch S. pneumoniae 
nasopharyngeal isolates. Serotypes with number of strains per  serotype in brackets, bars representing average age of 
children carrying these isolates, number of isolates per RFEL cluster and cluster codes are depicted.  
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Figure 3.  Dendrogram of 35 representative pneumococcal strains belonging to the 24 largest clusters. The MLST 
profiles of these strains are depicted.  
a100% homology with England 14-9.  
b 5/7 alleles homology with Spain9V-3. 
 
 
We also determined the contribution of vaccine serotypes to the total number of resistant 
strains. 60 out of 104 resistant strains depicted serotypes, which are covered by the 7-valent 
conjugate vaccine (58%) and 74 out of 104 resistant isolates (71%) were vaccine serotype 
isolates when the cross-protective serotypes 6A, 9N/L, 19A/B and 23A/B were included. In 
both cases, the contribution of vaccine serotypes to resistance is significantly higher 
compared to the contribution of vaccine serotypes to the total group of pneumococci. In case 
of dual resistance 10 out of 15 (67%) displayed vaccine serotypes and 11 out of 15 isolates 
(73%) when cross-protective serotypes were included. With respect to multidrug resistance 
6 out of 11 (55%) strains represented vaccine serotypes and 7 out of 11 (64%) when cross-
reactive serotypes were included. However, numbers were too small to show significant 
50           60           70           80            90        100% Cluster Serotype  ST  aroE gdh gki recP spi xpt ddl 
 
II 14  124 7 5 1 8 14 11 14 
X 14  9a 1 5 4 5 5 1 8 
III 15  199 8 13 14 4 17 4 14 
III 15  199 8 13 14 4 17 4 14 
XII 16  414 1 5 27 5 1 28 1 
XI 4  205 10 5 4 5 13 10 18 
XIII 18C  113 7 2 1 1 10 1 21 
IV 23F  36 1 8 4 1 1 4 6 
I 8  447 29 33 19 1 36 22 31 
I 8  447 29 33 19 1 36 22 31 
I 3  447 29 33 19 1 36 22 31 
XIV 11  408 2 5 6 12 16 3 14 
XIV 11  62 2 5 29 12 16 3 14 
XV 23A  42 1 8 9 9 6 4 6 
XVI 23A  1040 1 8 9 9 6 26 6 
XVII 6A   1141 2 13 9 6 6 19 14 
V 6B   176 7 13 8 6 10 6 14 
V 6A   1143 7 25 4 1 15 1 28 
XVIII 6B   176 7 13 8 6 10 6 14 
XIX 6B   176 7 13 8 6 10 6 14 
V 6B   176 7 13 8 6 10 6 14 
XX 19F  177 7 14 4 12 1 1 14 
XX 19F  1045 7 14 4 12 1 14 14 
XXI 19F  236 15 16 19 15 6 20 26 
XXI 19F  236 15 16 19 15 6 20 26 
VII 23F  440 7 5 1 1 13 31 14 
VII 17  392 7 5 1 1 6 31 14 
XXII 23F  440 7 5 1 1 13 31 14 
VI 23F  440 7 5 1 1 13 31 14 
XXIII 38  1140 7 43 41 18 13 49 6 
XXIII 38  393 10 43 41 18 13 49 6 
XXIII 38  393 10 43 41 18 13 49 6 
VIII 3  180 7 15 2 10 6 1 22 
IXb 9V   1142 29 11 10 1 6 8 14 
XXIV 4  449 8 37 9 29 2 47 5 
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differences compared to the contribution of vaccine serotypes to the susceptible 
pneumococcal population.   
 
 
Table 3. Resistance profiles of the drug-resistant pneumococcal strains 
 
Antibiotic* Number of strains Resistance rate   
P  4 0.5%   
T  13 2.2%   
E  6 0.9%   
S 57 9.7% Mono resistance:  13.6% 
PT 0 0.0%   
PS 3 0.5%   
TE 5 0.9%   
TS 4 0.5%   
SE 3 0.5% Dual resistance: 2.6% 
PTS 1 0.2%   
PTE 2 0.3%   
PES 0 0.0%   
TSE 2 0.3%   
PTSE 5 0.9%   
PSEC 1 0.2% Multi resistance  1.9% 
     
Total 106 18.1%   
* P, penicillin; T, tetracyclin; E, erythromycin; C; cotrimoxazole 
 
 
 Table 4. Susceptibility profiles of the pneumococcal isolates 
 Percentage of  
Resistant strains 
Percentage of 
intermediate  
Resistant strains 
Total Average age 
(years) 
Penicillin  2.7% 2.7% 7.1 
Tetracyclin 3.9% 1.7% 5.6% 5.9 
Erythromycin 4.5% 0.6% 5.0% 5.1 
Cotrimoxazole 7.5% 5.5% 12.9% 5.7 
Chloramphenicol 0.2%  0.2% 18.0 
 
 
DISCUSSION 
We studied the molecular epidemiology of 578 pneumococcal isolates retrieved from healthy 
children varying from 12 months to 19 years of age in Rotterdam, The Netherlands. Genetic 
clustering was observed in 74% of the strains, which comprised 92 distinct genetic clusters. 
These data implicate that most pneumococci observed in this study have a high tendency to 
spread within the community. Moreover, because the majority of the strains is fully 
susceptible to the most common antibiotics, these data suggest that a high tendency to 
spread is per definition not related to (multi)drug resistance. Since the prevalence of 
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resistant pneumococci is very low (18.1%), we are unable to compare the tendency to 
spread within the community between resistant and fully susceptible strains. 
In our cohort the largest genetic cluster comprised mainly serotype 6A and 6B isolates. 
These isolates were all fully susceptible to penicillin, tetracycline, erythromycin and 
cotrimoxazole. In addition, comparison of the genotypes of this cluster showed no close 
homology to any of the known serotype 6B clones from the PMEN database (25). Of the 
genotypes observed in this collection only 5 showed close homology with 5 distinct PMEN 
clones (25). These data indicate that the international drug-resistant clones do not 
significantly contribute to colonization and spread of pneumococci among children in The 
Netherlands. The data confirmed the observations of recent studies performed in The 
Netherlands among day-care center attendees and children suffering from recurrent acute 
otitis media (3, 6). 
Recently, we have observed an age-related pneumococcal serotype distribution within our 
study population (5). Pneumococcal conjugate vaccine serotypes showed an initial peak 
incidence of 30% at the age of 1 years after which a decline is observed to an incidence of 
2-3% after the age of 8 years. For non-vaccine serotypes an initial increase in incidence was 
observed to 27% at the age of 4 years, followed by a decline,  which stabilizes after the age 
of 15 years at 4% (5). This was mainly caused by predominance of a limited number of 
predominant non-vaccine serotypes after the age of 3 years, i.e. serotype 3, 8, 10, and 11. 
Because children under 2 years of age who show the highest risk for pneumococcal 
infections carry mainly vaccine serotype strains, a difference in virulence between vaccine 
and non-vaccine serotypes might exist. We, therefore, investigated the age-related 
distribution of genotypes. In contrast to the predominant serotype 3 Cluster I with an 
average age of 11 years, no age-related genetic clustering was observed. This observation 
suggests that despite the observed shift in serotype with age, the chromosomal make-up 
and, corollarily, virulence of pneumococcal strains does not shift with increasing age. 
 The most frequently found serotypes in this study were 6A, 6B, 19F, 23F, 3 and 11. We 
questioned whether specific serotypes show a higher tendency to spread horizontally. The 
clustering rate of these serotype-specific isolates was on average 60-70%, whereas the total 
pneumococcal population showed 74% clustering. Surprisingly, the serotypes 6A and 19F 
showed a decreased tendency to spread in the community (55% and 48%, respectively), 
harboring more isolates representing unique genotypes. This is in line with previous findings 
among penicillin-susceptible isolates in The Netherlands (28). For the serotype 14 isolates a 
similar degree of clustering was found being 56%, although this was not significantly 
different because of the limited number of isolates.  
When evaluating the 9 largest clusters each harboring 10 or more isolates, we observed that 
6 of these clusters represented the conjugate vaccine serotypes 6B, 14 and 23F, whereas 
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the remaining three clusters consisted of the non-vaccine serotypes 3, 8 and 15. These data 
suggest that besides vaccine serotype pneumococci, also non-vaccine pneumococcal 
serotypes are able to spread at high frequency within the community. These findings are in 
accordance with several vaccination studies, where replacement of vaccine serotypes with 
non-vaccine pneumococcal serotype carriage was found at the nasopharynx after 
pneumococcal conjugate vaccination (10, 24, 35). The question remains, whether these 
non-vaccine serotype strains are as pathogenic as their vaccine-serotype counterparts. 
Several studies have already shown replacement from vaccine serotypes to non-vaccine 
serotype pneumococci causing mucosal disease (12, 34). With respect to invasive disease, 
replacement has not been observed yet. However, Brueggemann et al. have demonstrated 
epidemiological evidence for the high invasive capacity of certain non-vaccine serotypes (7).  
Susceptibility testing showed in 18.1% of the strains resistance to at least one of the most 
commonly used antimicrobial drugs. Resistance to a single drug was observed most often 
(13.6%). Multidrug resistance was found in only 1.9% of the isolates. Most commonly, we 
observed resistance to cotrimoxazole (12.9%), which is a first line antibiotic used commonly 
among children in The Netherlands. Finally, we found antibiotic resistance to be associated 
with vaccine serotype pneumococci, which is in line with previous studies (4, 11, 36). 
We conclude that drug resistance, with respect to pneumococcal carriage and disease, is 
still of minor concern in The Netherlands. However, a strict policy with respect to antibiotic 
prescription is still required. 
In conclusion, pneumococcal colonization isolates from healthy Dutch children represent a 
heterogeneous, genetic population of mostly susceptible strains, which display a high 
tendency to spread horizontally irrespective of age of the colonized children.  
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ABSTRACT  
The molecular epidemiological characteristics of all Streptococcus pneumoniae strains 
isolated in a nationwide manner from patients with meningitis in The Netherlands in 1994 
were investigated. Restriction fragment end labeling analysis demonstrated 52% genetic 
clustering among these penicillin-susceptible strains, a value substantially lower than the 
percentage of clustering among Dutch penicillin-nonsusceptible strains. Different serotypes 
were found within 8 of the 28 genetic clusters, suggesting that horizontal transfer of capsular 
genes is common among penicillin-susceptible strains. The degree of genetic clustering was 
much higher among serotype 3, 7F, 9V, and 14 isolates than among isolates of other 
serotypes, i.e., 6A, 6B, 18C, 19F, and 23F. We further studied the molecular epidemiological 
characteristics of pneumococci of serotype 3, which is considered the most virulent serotype 
and which is commonly associated with invasive disease in adults. Fifty epidemiologically 
unrelated penicillin-susceptible serotype 3 invasive isolates originating from the United 
States (n = 27), Thailand (n = 9), The Netherlands (n = 8), and Denmark (n = 6) were 
analyzed. The vast majority of the serotype 3 isolates (74%) belonged to two genetically 
distinct clades that were observed in the United States, Denmark, and The Netherlands. 
These data indicate that two serotype 3 clones have been independently disseminated in an 
international manner. Seven serotype 3 isolates were less than 85% genetically related to 
the other serotype 3 isolates. Our observations suggest that the latter isolates originated 
from horizontal transfer of the capsular type 3 gene locus to other pneumococcal genotypes. 
In conclusion, epidemiologically unrelated serotype 3 isolates were genetically more related 
than those of other serotypes. This observation suggests that serotype 3 has evolved only 
recently or has remained unchanged over long periods.  
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INTRODUCTION  
Streptococcus pneumoniae continues to be a common cause of serious and life-threatening 
infections, such as pneumonia, bacteremia, and meningitis, in both adults and children (1). 
Pneumococci can be classified according to differences in capsular polysaccharide 
structure. As many as 90 different capsular types can be distinguished by serotyping (10). 
The distribution of serotypes varies in different populations and different geographic areas, 
and certain pneumococcal serotypes are known to be more virulent than others (24, 28). 
Pneumococcal serotype 3 isolates are considered to represent the most virulent serotype. 
These isolates are often responsible for invasive disease (17, 20), particularly in adults (15, 
19). Bacteremia caused by this organism is considered to have the highest mortality rate 
compared to that caused by other serotypes (15, 20). To date, the frequency of penicillin 
resistance among serotype 3 isolates has remained low (16).  
Serotyping as a tool for epidemiological studies has several disadvantages. S. pneumoniae 
is a naturally transformable species, and frequent exchange of capsular genes occurs (2-4, 
13, 23). In addition, serotyping determines the variation in a single genetic locus, i.e., the 
cps locus. Therefore, several other typing methods have been developed to assist with the 
identification of relatedness between strains and their cellular structures. These methods 
include multilocus enzyme electrophoresis (9), penicillin-binding protein (PBP) profile 
analysis (21, 22), pneumococcal surface protein A typing (22), and DNA fingerprint methods, 
such as pulsed-field gel electrophoresis, multilocus sequence typing (MLST) (7), ribotyping, 
restriction fragment end labeling (RFEL) analysis, BOX PCR fingerprinting, and DNA 
fingerprinting of the PBP genes (14, 32). RFEL analysis provides a high degree of 
discriminatory power, and RFEL profiles are reproducible and suitable for computerized 
comparisons (14). In addition, RFEL analysis provides a DNA fingerprint that represents 
multiple loci in the pneumococcal genome. This technique is routinely used in our laboratory 
to generate a data library of pneumococcal DNA fingerprints. In this study, we investigated 
the molecular epidemiological characteristics of S. pneumoniae strains isolated in a 
nationwide manner from patients with meningitis in The Netherlands in 1994. The genetic 
relatedness within pneumococcal serotypes was determined. In addition, we studied the 
molecular epidemiological characteristics of epidemiologically unrelated serotype 3 
pneumococci from four distinct countries. The isolates were characterized by serotyping, 
RFEL analysis, and PBP genotyping.  
 
 
MATERIALS AND METHODS  
Bacterial isolates. We studied a collection of S. pneumoniae strains (n = 153) isolated from 
Dutch patients suffering from meningitis in The Netherlands in 1994. These strains were 
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collected by the National Reference Center for Bacterial Meningitis in a nationwide manner 
and represent all pneumococcal meningitis isolates collected in a 1-year period. In addition, 
these strains were penicillin-susceptible and were presumed to be epidemiologically 
unrelated. In addition, 42 penicillin-susceptible invasive serotype 3 pneumococci were 
isolated from patients in the United States (n = 27), Thailand (n = 9), and Denmark (n = 6). 
The latter strains were also presumed to be epidemiologically unrelated, since they were 
isolated from various geographic regions within these countries and at different times 
ranging from 1960 to 1962 and from 1992 to 1998 (Table 1).  
Serotyping. Pneumococci were serotyped on the basis of capsular swelling (Quellung 
reaction) observed microscopically after suspension in antisera prepared at Statens 
Seruminstitut, Copenhagen, Denmark (8).  
 
 
Table 1. Geographic origins of and isolation dates for 50 penicillin-susceptible serotype 3 pneumococcal isolates. 
  
Strain designation State or country Isolation date RFEL type (pbpla-pbp2b-pbp2x) 
    
DK001 Denmark 1961 294 2-2-1971 
DK002 Denmark 1961 294 2-2-1971 
DK003 Denmark 1960 292 2-2-1971 
DK004 Denmark 1991 167 2-2-1971 
DK005 Denmark 1992 299 2-2-1971 
DK006 Denmark 1962 289 2-2-1971 
NL100 The Netherlands 1994 167 2-2-1971 
NL101 The Netherlands 1994 167 2-2-1971 
NL102 The Netherlands 1994 167 2-2-1971 
NL103 The Netherlands 1994 393 2-2-1971 
NL104 The Netherlands 1994 300 2-2-1971 
NL106 The Netherlands 1994 291 2-2-1971 
NL107 The Netherlands 1994 290 2-2-1971 
NL108 The Netherlands 1994 294 2-2-1971 
TH001 Thailand 1998 93 2-2-1971 
TH002 Thailand 1998 96 9-2-1971 
TH003 Thailand 1998 122 2-2-2003 
TH004 Thailand 1998 122 2-2-2003 
TH005 Thailand 1998 121 2-2-2003 
TH006 Thailand 1998 123 2-2-2003 
TH007 Thailand 1998 165 2-2-1971 
TH008 Thailand 1998 105 2-2-2003 
TH009 Thailand 1998 242 2-2-1971 
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US001 United States 1960 294 2-2-1971 
US002 United States 1960 294 2-2-1971 
US003 Alaska 1995 295 2-2-1971 
US004 Colorado 1993 167 2-2-1971 
US005 California 1992 167 2-2-1971 
US006 Alaska 1993 167 2-2-1971 
US007 Alaska 1993 167 2-2-1971 
US008 Alaska 1993 167 2-2-1971 
US009 Wisconsin 1992 167 2-2-1971 
US010 Pennsylvania 1995 167 2-2-1971 
US011 Pennsylvania 1995 167 2-2-1971 
US012 Maryland 1995 167 2-2-1971 
US013 Alaska 1993 167 2-2-1971 
US014 Oklahoma 1996 167 2-2-1971 
US015 Washington 1993 167 2-2-1971 
US016 Washington 1995 167 2-2-1971 
US017 Ohio 1993 167 2-2-1971 
US018 United States 1990s 167 2-2-1971 
US019 United States 1990s 167 2-2-1971 
US020 United States 1990s 167 2-2-1971 
US021 United States 1990s 167 2-2-1971 
US022 United States 1990s 167 2-2-1971 
US023 Maryland 1994 297 2-2-1971 
US024 United States 1990s 297 2-2-1971 
US025 California 1994 298 2-2-1971 
US026 Wisconsin 1992 296 2-2-1971 
US027 Oklahoma 1996 76 2-2-1971 
  
 
RFEL analysis. Typing of pneumococcal strains by RFEL analysis was performed as 
described by van Steenbergen et al. (33) and adapted by Hermans et al. (14). Briefly, 
purified pneumococcal DNA was digested with restriction enzyme EcoRI. The DNA 
restriction fragments were end labeled at 72°C with [-32P]dATP by using Taq DNA 
polymerase (Goldstar; Eurogentec, Seraing, Belgium). The radiolabeled fragments were 
denatured and separated electrophoretically on a 6% polyacrylamide sequencing gel 
containing 8 M urea. The gel was transferred to filter paper, vacuum dried (HBI, Saddle 
Brook, N.Y.), and exposed to ECL Hyperfilms (Amersham, Little Chalfont, Bucks, United 
Kingdom).  
PBP genotyping. Genetic polymorphisms of the penicillin resistance genes pbpla, pbp2b, 
and pbp2x were investigated by restriction fragment length polymorphism analysis. PCR 
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amplification of the PBP-encoding genes was performed with a 50-µl PCR buffer system 
containing 75 mM Tris-HCl (pH 9.0), 20 mM (NH4)2SO4, 0.01% (wt/vol) Tween 20, 1.5 mM 
MgCl2, 0.2 mM each deoxynucleoside triphosphate, 10 pmol of each primer, 0.5 U of Taq 
DNA polymerase (Goldstar), and 10 ng of purified chromosomal DNA. Cycling was 
performed with a PTC-100 programmable thermal controller (MJ Research, Watertown, 
Mass.) and consisted of the following steps: predenaturation at 94°C for 1 min; 30 cycles of 
1 min at 94°C, 1 min at 52°C, and 2 min at 72°C; and final extension at 72°C for 3 min. The 
primers used to amplify the genes pbp1a, pbp2b, and pbp2x were described previously (3, 
6, 21). The amplification products (5 µl) were digested with restriction endonuclease HinfI 
and separated by electrophoresis in 2.5% agarose gels (27). Gels were scanned and printed 
with a Geldoc 2000 system (Biorad, Veenendaal, The Netherlands). The different PBP 
genotypes are represented by a three-number code (e.g., 06-14-43), referring to the 
restriction fragment length polymorphism patterns of the genes pbp1a (pattern 6), pbp2b 
(pattern 14), and pbp2x (pattern 43), respectively.  
Computer-assisted analysis of the DNA banding patterns. The RFEL types were 
analyzed with the Windows version of Gelcompar software, version 4 (Applied Maths, 
Kortrijk, Belgium), after imaging of the RFEL autoradiograms with Image Master DTS 
(Pharmacia Biotech, Uppsala, Sweden). DNA fragments in the molecular size range of 160 
to 400 bp were documented. The DNA banding patterns were normalized with 
pneumococcus-specific bands present in the RFEL banding patterns of all strains. 
Comparison of the banding patterns was performed by the unweighted pair-group method 
with arithmetic averages (26) and with the Jaccard similarity coefficient applied to peaks 
(31). Computer-assisted analysis and the methods and algorithms used in this study were in  
 
 
Table 2. PBP genotypes of the 153 S. pneumoniae  
strains isolated from patients with meningitis in 1994  
in The Netherlands 
 
PBP 
genotype 
 
No. of 
strains 
 
Serotype(s) of  
the strains 
   
02-02-03 67 21 distinct serotypes 
02-02-71 54 14 distinct serotypes 
02-02-02 22 10 distinct serotypes 
02-02-14 4 Serotype 8 
02-02-05 3 Serotype 19F 
02-02-15 2 Serotype 5 
02-02-16 1 Serotype 32A 
 
Table 3. RFEL clusters consisting of strains with  
different stereotypes 
 
 
  
RFEL cluster a 
(RFEL types) 
Serotypes  
(no. of strains) 
A(28) 14 (4), 15C (1), 19F (1), 
24F (3) 
B(101) 4(1), 18B (1), 18C (7) 
C(23) 9V (3), 19F (1) 
D(328,330) 23F (2), 23B (1) 
E(119,342) 8 (2), 33F (1) 
F(56,341) 14 (1), 19F (1) 
G(321) 14 (1), 19F (1) 
H(377) 18F (1), 18C (1) 
a For definition of RFEL clusters and RFEL types, 
see Materials and Methods 
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accordance with the instructions of the manufacturer of Gelcompar. A tolerance of 1.2% in 
band positions was applied during comparison of the DNA patterns.  
For evaluation of the genetic relatedness of the strains, we used the following definitions: (i) 
strains of a particular RFEL type are 100% identical on the basis of RFEL analysis, (ii) an 
RFEL cluster represents a group of RFEL types that differs by only one band (approximately 
95% genetic relatedness), and (iii) an RFEL clade represents a group of RFEL types that 
differs by less than four bands (approximately 85% genetic relatedness). The genetic 
heterogeneity is defined as the number of RFEL clades representing one or more strains 
divided by the total number of strains.  
 
 
RESULTS  
Epidemiology of invasive pneumococcal isolates in The Netherlands. The epidemiology of S. 
pneumoniae strains isolated in a nationwide manner from patients with meningitis in 1994 in 
The Netherlands was investigated. These strains (n = 153) were all found to be penicillin 
susceptible and were analyzed by serotyping, PBP typing, and RFEL typing. The results are 
shown in Fig. 1 and Table 2. The invasive isolates represented 31 serotypes: 1 (n = 3), 3 (n 
= 8), 4 (n = 3), 5 (n = 2), 6A (n = 7), 6B (n = 15), 7F (n = 7), 8 (n = 4), 9N (n = 4), 9V (n = 7), 
10F (n = 2), 10A (n = 4), 11A (n = 2), 14 (n = 12), 15A (n = 1), 15C (n = 2), 16F (n = 2), 18F 
(n = 1), 18B (n = 2), 18C (n= 12), 19F (n = 18), 19A (n = 2), 22F (n = 1), 23F (n = 16), 23A (n 
= 1), 23B (n = 2), 24F (n = 3), 32A (n = 1), 33F (n = 5), 34 (n = 1), and 38 (n = 3).  
Seven distinct PBP genotypes displaying variations in the RFLP patterns of pbp2x only were 
observed. The PBP types 02-02-03, 02-02-71, and 02-02-02 occurred most frequently. In 
addition, all serotype 8 strains displayed PBP genotype 02-02-14, both serotype 5 strains 
displayed PBP genotype 02-02-15, and the single serotype 32A strain displayed PBP 
genotype 02-02-16. Finally, 3 of the 18 19F strains displayed PBP genotype 02-02-05 (Table 
2).  
RFEL analysis divided the 153 strains into 116 distinct RFEL types. These RFEL types 
represented 28 genetic clusters, i.e., strains showing over 95% genetic relatedness, and 73 
RFEL types that were less than 95% related to other strains. RFEL clusters were 
represented by 80 strains (52%). The cluster size varied from two (19 clusters) to nine (2 
clusters) strains. In addition, four clusters of three strains and three clusters of four strains 
were observed. RFEL types 28 (genetic clade II) and 101 (genetic clade III) were the most 
predominant types. They were each represented by nine isolates. Within genetic clusters, 
different serotypes were observed. Eight of the 28 RFEL clusters displayed two or more 
serotypes (Table 3). The strain collection could be divided into 25 genetic clades, i.e., strains  
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with more than 85% RFEL homology. The genetic clades varied in size from 2 to 23 strains 
(Fig. 1).  
Comparison of penicillin-susceptible invasive strains with penicillin-nonsusceptible strains 
representing 193 distinct RFEL types present in the international data library and 
representing 16 countries (13) revealed no overlap in RFEL types between penicillin-
susceptible strains and penicillin-non-susceptible strains.  
Genetic relatedness within serotypes in The Netherlands. The genetic relatedness of strains 
within the nine most predominant serotypes present in the collection was investigated. All 
strains of serotype 7F (n = 7) belonged to clade IX, and all strains of serotype 9V (n = 7) 
belonged to clade VII. Strains of serotype 3 (n = 8) belonged to two distinct genetic clades, I 
and VIII. Strains of serotype 14 (n = 12) represented three distinct genetic clades, III, X, and 
XI. Strains of serotypes 6B, 18C, and 23F were genetically more heterogeneous. However, 
most strains of serotypes 6B, 18C, and 23F belonged to one clade. Eight of the 15 serotype 
6B strains belonged to clade V, 9 of the 12 serotype 18C strains belonged to clade III, and 7 
of the 16 serotype 23F strains belonged to clade IV. Strains with serotypes 6A and 19F 
displayed the most heterogeneity in this collection of S. pneumoniae strains, as 7 serotype 
6A strains were represented by 4 genetic clades and 18 serotype 19F strains were 
represented by 11 genetic clades (Fig. 1).  
Genetic relatedness within serotype 3 isolates of distinct geographic origins. We 
investigated the molecular epidemiology of serotype 3 strains from The Netherlands (n = 8) 
and three additional countries: the United States (n = 27), Thailand (n = 9), and Denmark (n 
= 6). These 50 epidemiologically unrelated serotype 3 strains were characterized by RFEL 
analysis. Four distinct RFEL clades and seven RFEL types that were less than 85% related 
to other serotype 3 strains were observed among these strains (Fig. 2). The most 
predominant RFEL clade, I, represented 29 serotype 3 strains (58%). This RFEL clade was 
represented by 22 isolates from the United States, 2 isolates from Denmark, and 5 isolates 
from The Netherlands. RFEL cluster VIII was represented by eight strains (16%)two 
American, three Danish, and three Dutch strains. RFEL clade XII was represented by four 
Thai isolates. In addition, two Thai isolates formed a Thai-specific clade. Thus, 43 strains 
shared RFEL types with at least one other strain (86%). Seven serotype 3 strains with RFEL 
types 296, 295, 165, 105, 289, 76, and 242 did not match the four genetic clades, and six of 
them did not match any of the 153 Dutch invasive strains representing 116 RFEL types and  
 
 
Figure 1 (left). Genetic relatedness of 153 penicillin-susceptible invasive pneumococcal isolates, based on the RFEL 
banding patterns of the isolates. The country code (NL, The Netherlands), strain codes, RFEL types, and serotypes are 
depicted. Codes I to XI refer to genetic clades of pneumococcal strains; genetic clusters are indicated by a grey box in 
the dendrogram (for definitions, see Materials and Methods).  
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31 serotypes. In contrast, the serotype 3 strain with RFEL type 105 was genetically related 
(90.9%) to a serotype 19F strain representing RFEL type 352.   
The serotype 3 collection was also analyzed by PBP typing. PBP genotype 02-02-71 was 
invariably observed in the strains from the United States, Denmark, and The Netherlands. 
The Thai strains displayed three distinct PBP genotypes: 02-02-03 (n = 5), 02-02-71 (n = 3), 
and 09-02-71 (n = 1) (Table 1).  
 
 
DISCUSSION  
Few studies have documented genotype analyses of penicillin-susceptible strains (12, 29) 
and of serotype-specific strains (9, 18). We investigated the epidemiological characteristics 
of 153 penicillin-susceptible S. pneumoniae strains isolated from patients with meningitis in 
The Netherlands in 1994. The isolates represented 31 serotypes. The most predominant 
serotypes were 19F, 23F, 6B, 18C, 14, 3, 6A, 7F, and 9V. Various investigators have 
reported the occurrence of horizontal transfer of capsular genes (2, 11-13). In Dutch 
penicillin-susceptible isolates, horizontal transfer of capsular genes has occurred frequently. 
A high frequency of capsular exchange has been reported in molecular epidemiological 
studies of penicillin-resistant isolates from many countries (12, 13). This is the first study 
suggesting the frequent occurrence of horizontal transfer of capsular genes among 
penicillin-susceptible isolates.  
RFEL analysis revealed that 52% of the strains belonged to genetic clusters. The amount of 
genetic clustering was substantially lower among the penicillin-susceptible isolates than 
among the penicillin-nonsusceptible isolates in other studies (2, 5, 11-13, 25). A comparison 
of the penicillin-susceptible invasive isolates studied here with 193 penicillin-nonsusceptible 
strains representing 193 distinct RFEL types in the international data library and 
representing 16 countries revealed no overlap (12, 13).  
The PBP genotypes 02-02-03, 02-02-71, and 02-02-02 were found most frequently. This 
observation corresponds with the PBP typing results for penicillin-susceptible pediatric 
carriage isolates in the U.S. population (30). Interestingly, four additional PBP genotypes 
(02-02-14, 02-02-15, 02-02-16, and 02-02-05) were identified for serotypes 8, 5, 32A, and 
19F, respectively. The serotype specificity of the latter PBP genotypes suggests a 
divergence of the PBP genotypes before the origin of the capsular types 8, 5, 32A, and 19F.  
The genetic relatedness within the specific pneumococcal serotypes was highly variable. 
RFEL genotypes of serotype 6A and 19F strains displayed high levels of heterogeneity; i.e., 
strains of these serotypes represented many RFEL types that belonged to many genetic 
clusters and genetic clades. In contrast, the RFEL genotypes of serotype 7F, 9V, 14, and 3 
strains were found to be genetically related. Interestingly and consistent with our  
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Figure. 2.   Genetic relatedness of 50 penicillin-susceptible pneumococcal serotype 3 isolates, based on the RFEL 
banding patterns of the isolates. RFEL types are depicted. Codes I, VIII, XII, and XXVII refer to genetic clades of 
pneumococcal strains; genetic clusters are indicated by a grey box in the dendrogram (for definitions, see Materials 
and Methods). Bars represent the number of isolates per RFEL type.  
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observations, Canadian penicillin-susceptible isolates of serotypes 3 and 7F were also more 
genetically related than isolates of other serotypes (18). Moreover, invasive penicillin-
susceptible serotype 3 isolates from the United Kingdom also tended to be more closely 
related to each other than to isolates of other serotypes (9).  
We focused on the molecular epidemiological characteristics of epidemiologically unrelated 
serotype 3 pneumococci and extended our serotype 3 collection with isolates from theUnited 
States, Thailand, and Denmark. RFEL analysis demonstrated that serotype 3 strains 
isolated in these countries displayed a strong degree of genetic relatedness: the vast 
majority of the strains represented two distinct RFEL clades. Furthermore, both genetic 
clades harbored isolates from three countries: the United States, Denmark, and The 
Netherlands. These observations indicate that two serotype 3 clones have been 
disseminated internationally. In addition, six Thai serotype 3 isolates belonged to two RFEL 
clades (clades XII and XXVII). The data suggest strong genetic homogeneity within the 
serotype 3 pneumococci and support the observations for Canada and the United Kingdom 
(9, 18). Interestingly, the Canadian serotype 3 strains displayed two distinct genotypes, and 
the majority of the epidemiologically nonrelated serotype 3 strains from the United Kingdom 
displayed two genotypes. Moreover, MLST analysis of serotype 3 strains isolated in six 
countries identified two major genetic clusters (M. C. Enright and B. G. Spratt, 
http://mlst.zoo.ox.ac.uk). Since the strains have been characterized by distinct typing 
methods, i.e., pulsed-field gel electrophoresis, multilocus enzyme electrophoresis, MLST, 
and RFEL analysis, and since there is no overlap in the characterized strains, the genetic 
relatedness between the latter serotype 3 strains and the strains characterized in this study 
is currently unknown. The remaining six serotype 3 RFEL types each occurred once in our 
collection. Our observations suggest that these latter strains have been derived from 
horizontal transfer of the capsular type 3 gene locus to other pneumococcal genotypes.  
PBP genotyping of the serotype 3 strains demonstrated limited variation in the pbp1a, 
pbp2b, and pbp2x genes. All serotype 3 strains from the United States, Denmark, and The 
Netherlands displayed PBP genotype 02-02-71. However, variation was demonstrated in the 
Thai serotype 3 isolates. PBP type 09-02-71 was represented by a single Thai isolate. This 
PBP type was also specific for the penicillin-susceptible phenotype, as there was no overlap 
with penicillin-nonsusceptible isolates from 16 countries (13).  
In conclusion, pneumococcal strains belonging to serotype 3 display limited genetic 
heterogeneity despite the lack of epidemiological relatedness. We hypothesize that this 
serotype has recently evolved or has remained unchanged for a prolonged period. The few 
serotype 3 isolates not belonging to the main clusters are presumably derived from 
horizontal transfer of capsular genes.  
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ABSTRACT 
Streptococcus pneumoniae is a major cause of morbidity and mortality in infants, children 
and the elderly. Despite the availability of excellent antimicrobial therapy and adequate 
health care systems, respiratory diseases and invasive infections caused by pneumococci 
still comprise a major health problem. The emerging resistance to penicillin and other 
commonly used antibiotics underscores the importance of the development of novel vaccine 
strategies to combat pneumococcal disease. Although the 23-valent polysaccharide (PS) 
vaccine is immunogenic and protective in most adults and children over 5 years of age, they 
fail to protect children under two years of age. Fortunately, the recent conjugate vaccines 
have shown to be highly efficacious in preventing invasive diseases in this risk group. 
Moreover, promising results regarding prevention of pneumonia and acute otitis media have 
been published. Unfortunately, protection is raised against a limited number of 
pneumococcal serotypes, and serotype replacement and subsequent vaccine failure have 
become a serious concern. Currently, several pneumococcal surface proteins are 
considered as alternative vaccine candidates because of their serotype-independence. Thus 
far, PsaA has proven to be highly protective against colonization in animal models. 
Moreover, PspA and pneumolysin have shown to elicit protection against invasive diseases. 
Future research will elucidate their true potential in protecting humans. In this paper we 
discuss the present knowledge on pneumococcal vaccines and the current status of novel 
vaccine strategies. 
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INTRODUCTION 
Streptococcus pneumoniae is a major cause of invasive diseases such as meningitis, 
septicaemia and pneumonia. Approximately, 1 million children under 5 years of age die of 
pneumococcal disease annually [1]. In countries where the incidence of Neisseria 
meningitidis and Haemophilus influenzae infections has drastically decreased through the 
introduction of vaccines against meningococci group C and H. influenzae type B, S. 
pneumoniae has become the major cause of meningitis and septicemia in children. In 
addition, the morbidity by S. pneumoniae through respiratory tract infections such as otitis 
media and sinusitis is enormous.  30-50% of all patients with otitis media and a substantial 
percentage of cases of sinusitis and pneumonia are caused by pneumococci. Risk groups 
for serious pneumococcal disease include children under the age of 2 years, elderly and 
patients with immunodeficiencies [2]. 
Nasopharyngeal colonization by S. pneumoniae is common: probably all humans are 
colonized with this organism at least once early in life. Especially in circumstances of 
crowding, as in day-care centers, nursing homes, hospitals and jails, the risk of colonization 
with pneumococci is high [3-5]. Colonization is not usually followed by disease, since this is 
prevented by the innate and adaptive immune system. However, disturbance of 
homeostasis between host and pathogen, for example through viral infections, malnutrition 
or local damage of the mucosa, is associated with the development of (invasive) diseases 
[6-8].  
Since the discovery of the antibacterial properties of penicillin by Fleming in 1929, many 
antibiotics have been used for treatment of pneumococcal infections. Recently, antibiotic 
resistance has become a worldwide problem, which limits the choice of antimicrobial agents. 
Therefore, prevention of pneumococcal disease has become of great interest. Up till now, 
many research groups have focused on the development of new effective vaccines to be 
used in particular risk groups including immunocompromised patients and children. In this 
article we will discuss the history of pneumococcal vaccination, and we will evaluate the 
different vaccine strategies, which are currrently undertaken. Furthermore, we will discuss 
the recent developments in novel vaccine strategies.  
 
 
HISTORY 
Sternberg and Pasteur were the first to identify S. pneumoniae, initially described as the 
pneumococcus [9]. Effective therapy against pneumococcal disease was reported only a few 
years later by Klemperer and Klemperer, who discovered the protective potential of patient 
serum against homologous organisms [10]. The first preventive strategy was introduced by 
Sir Almroth E. Wright in 1911, who suggested that inoculation of killed, whole pneumococci 
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might induce a protective effect against pneumococcal infections [11]. Unfortunately this 
pioneering vaccine failed because only one of the two serotypes discovered t that time was 
included, and the maximum applicable vaccine dosage was insufficient because of the 
relatively large inocula required. In 1926 Felton and Bailey for the first time isolated 
pneumococcal capsular polysaccharides [12]. This directly led to the first capsular PS 
vaccine, which proved its effectiveness by successfully aborting an outbreak of pneumonia 
at a state hospital in Worcester, Massachusetts in 1931 [13]. Because of the subsequent 
development of successful antibiotic therapy that could more effectively deal with 
pneumococcal disease, the vaccine’s popularity decreased and finally the PS vaccine was 
withdrawn from the market [14,15]. However, despite the development of new classes of 
antibiotics, morbidity and mortality stopped declining [16]. An additional problem was the 
rapidly emerging penicillin and multidrug resistance. The first reports on resistance to 
penicillin were reported in the 1930s in Australia and New Guinea [17]. It took until 1977 
before highly resistant pneumococci were reported in South Africa (MIC >1,0 mg/L). In 
addition, these strains were also resistant to other penicillins and cephalosporins [18]. In the 
years following, penicillin resistant pneumococci rapidly spread throughout the world. The 
cause of this international spread was mostly due to a few multidrug-resistant clones with 
serotypes 6B, 9V, 14, 19A, 19F and 23F [19]. These problems have lead to renewed interest 
in vaccine strategies, resulting in 1977 in the production of a 14-valent pneumococcal PS 
vaccine by Robert Austrian and coworkers [16]. This vaccine was expanded in 1983 to a 23-
valent vaccine and had a theoretical coverage of ≥ 80% of the pneumococci causing 
infections in adults. Unfortunately, the vaccine was less immunogenic in small children and 
immunocompromised patients [20]. This finding has accelerated the current search for new 
and promising vaccine candidates. In order to gain insight into the mechanisms of vaccine 
response we will first discuss the natural host defense mechanisms against pneumococcal 
disease.  
 
 
HOST DEFENSE AGAINST PNEUMOCOCCAL DISEASE 
The pneumococcal outer surface consists of a cell wall covered by a polysaccharide 
capsule. Capsule polysaccharides are highly heterogeneous and, thus far, almost 100 
different capsular serotypes have been described. The polysaccharide capsule is the most 
important virulence factor of the pneumococcus as it protects the bacteria from 
phagocytosis. Capsular polysaccharides are highly immunogenic and antibodies against 
these polysaccharides protect against infection with the homologous serotype. The 
antigenicity of the capsule is type-specific, but cross-reactions occur because of shared 
polysaccharides [21]. The next layer, the cell wall, consists of polysaccharides, teichoic acid 
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and several cell wall associated surface proteins. The cell wall is responsible for the intense 
inflammatory reaction that accompanies pneumococcal infection since it stimulates the influx 
of inflammatory cells. In addition, it activates the alternative complement cascade and 
induces cytokine production [21]. The cell-surface associated proteins are believed to 
specifically contribute to virulence as well.  The most immunogenic part of the cell wall is the 
phosphocholine part of the teichoic acid, which is also playing a major role in the 
inflammatory process. The cell wall is shielded from the host response by the capsule, which 
is completely covered.  
Pneumococcal clearance from the lung mainly results from phagocytosis and intracellular 
killing of the bacteria by neutrophils and alveolar macrophages. This process can only occur 
in the presence of type-specific immunoglobulins (IgG1 and IgG2, IgM and IgA) and active 
complement. This antibody-initiated complement-dependent opsonization, which activates 
the classical complement pathway, is believed to be the major immune mechanism 
protecting the host against infections with pneumococci. Pneumococci may escape this 
mechanism in the absence of serotype-specific antibodies, and consequently, may enter the 
host through the interstitial tissue of the lung resulting in lymphatic spread and subsequent 
blood stream invasion causing bacteremia [22].  
The mechanism of clearance from the blood appears to depend on the interaction of type-
specific antibodies (IgG) complement and phagocytic cells in the liver and spleen. The 
absence of the spleen or cirrhosis of the liver predisposes for severe pneumococal infection. 
Congenital deficiencies in immunoglobulin or complement are also associated with 
predisposition to pneumococcal infection [21]. 
Non-capsular antibodies, for example immunoglobulins directed against cell wall 
components, may play a role in the host response to pneumococcal infection as well. 
Although most cell wall components are protected from opsonization and phagocytosis by 
the capsule, certain proteins may penetrate the capsule and may therefore be recognized by 
the immune system. So far, several animal studies have shown a protective effect of 
immunoglobulins directed against selected cell surface-associated proteins including PspA, 
PsaA, and pneumolysin [22]. This T-cell dependent (TD) immune response, which is present 
from birth, mainly induces IgG1 subclass immunoglobulins. Type-specific immunoglobulins 
may be more effective if from the IgG2 subclass. The adult antibody response against 
capsular polysaccharides mainly generates these IgG2 subclass antibodies. However, the 
antibody response to (pneumococcal) polysaccharides is relatively immature in young 
children and generates predominantly IgG1 antibodies, which may result in an enhanced 
susceptibility to pneumococcal infections [23]. Thus, with the type of vaccination, the type of 
immune response may differ, and so may the level of protection. One has to take this into 
account when evaluating different (future) preventive strategies. 
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POLYSACCHARIDE VACCINES 
At present one pneumococcal PS vaccine is still licensed and marketed, i.e. Pneumovax 23 
produced by Merck Research Laboratories, USA. These vaccines contain 23 purified 
capsular polysaccharide antigens (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) accounting for 85-90% of pneumococcal 
diseases [20]. These vaccines are effective in adults and children above 2 years of age. 
Several studies have also shown a protective effect in risk groups such as patients with 
sickle cell disease or asplenia, and elderly with underlying conditions including chronic 
obstructive pulmonary disease [20,21,24]. Unfortunately, children under two years of age, 
who suffer the highest rates of pneumococcal carriage and disease, and 
immunocompromised patients show a severely impaired antibody response upon this 
vaccination [25, 27-28]. Furthermore, the PS vaccine is not effective against acute otitis 
media caused by S. pneumoniae [29]. In addition, the PS vaccines do not induce a T-cell 
dependent immune response. This implicates the absence of memory B-cells and limits the 
period of protection. Finally, several capsule polysaccharides are poorly immunogenic. 
These include several serotypes associated with penicillin resistance [30]. These factors 
have induced to the development of new pneumococcal vaccines, although this has not yet 
resulted in the complete replacement of the PS vaccines. The PS vaccines do have an 
efficacy of 61-75% in children over 2 years of age as well as in adults, and, thus, are still 
useful for various purposes [31,32]. Therefore, the Advisory Committee on Immunization 
Practices (ACIP) recommends this vaccine in a) persons aged ≥ 65 years, b) 
immunocompetent children ≥ 5 years who are at increased risk for illness and death 
associated with pneumococcal disease because of chronic illness, c) persons aged ≥ 5 
years with functional or anatomic asplenia and d) immunocompromised patients aged ≥ 5 
years who are at high risk for infection. They also recommend vaccination for people living in 
high-risk environments with emphasis on American Indians and Alaska natives [20,33]. 
Several studies have shown an additional effect of the PS vaccine when used as a booster 
after a primary conjugate vaccination [34,35]. For example, Breukels et al. (1999) showed a 
poor IgG2 response in otitis prone children when vaccinated with a conjugate vaccine only, 
but boosting with a PS vaccine could overcome this problem [36]. It has been suggested 
that administration of conjugate vaccines in infancy followed by the administration of a PS 
vaccine after the age of 10 years would offer the prospect of reducing the total burden of 
pneumococcal morbidity and mortality throughout life [9,37]. At this moment, the ACIP 
recommends to use the PS vaccine as a booster 2 months after conjugate vaccination in 
children 2-5 years of age [33]. 
An emerging risk group for pneumococcal infections is that of HIV positive patients. The 
pneumococcal attack rate is 40 times higher in these patients than in seronegative 
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individuals [38,39]. Therefore, the use of the PS vaccine is considered to be an important 
preventive strategy. However, due to a low peak concentration of protective Ig antibodies 
after vaccination, the protected period is significantly shorter (<3 years compared to 5 years 
in HIV negative adults) [19,40]. The impaired antibody response does not account for all 
serotypes. This is probably caused by the phenomenon that some anti-polysaccharide 
responses are T-cell dependent (TD), which is impaired in HIV infected patients, while 
others are T-cell independent (TI) [19]. Vaccination with conjugate vaccine, therefore, offers 
no solution either. This is because of the effectiveness of this vaccine, which depends 
mainly on the impaired T-cell dependent immune response in this patient group. So until 
new, more promising alternatives are found, the best strategy for this risk group appears to 
be revaccination with polysaccharides every three years. Recently though, in sub-Saharan 
Africa this strategy has proven to be inefficient. French et al. (2000) did not only show a lack 
of efficacy of the 23-valent PS vaccine in HIV-1-infected Ugandan adults, but they also 
described evidence of deleterious vaccine-associated side-effects. Significantly more cases 
of pneumonia were seen in the vaccine recipients compared to controls. This phenomenon 
may be explained by transient stimulation of HIV-1 transcription after pneumococcal 
vaccination, but also destruction of polysaccharide-responsive B-cell clones by 
pneumococcal polysaccharides has been suggested [41].  
 
 
CONJUGATE VACCINES 
Already in 1929, Avery and coworkers showed that covalent binding of capsular 
polysaccharides to proteins increases the immunogenicity of the polysaccharides [30]. This 
comprises linkage of capsular polysaccharides to a protein carrier, either by covalent binding 
or through reactive groups [30,42]. The proteins that have proven to be good 
immunocompetent carriers in the case of H. influenzae type b vaccines are tetanus toxoid, 
diphtheria toxoid and outer membrane protein from meningococcus group B [30,43]. The 
difference in the immune response towards pure PS vaccines is the observed switch to a TD 
response promoted by the protein. This leads to the induction of memory B-cells and an 
improved B-cell response. In addition, it leads to a better immune response early in 
childhood. This is explained by the stepwise maturation of the human immune system with 
the earlier maturation of the TD response compared to anti- (poly) saccharide antibodies (TI-
2 response). Unfortunately, linkage of polysaccharides to proteins is restricted: too much 
carrier antigen may impair the antibody response to the polysaccharides by antigen 
competition or carrier-mediated epitope suppression [44,45]. Thus, protection is restricted to 
a certain number of serotypes. Conjugate vaccine variants with 4 to 11 serotypes linked to 
variable protein carriers have been designed, and all showed to be safe and immunogenic in 
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infants and toddlers (Table 1) [35,46-48]. The most prevalent serotypes, correlated with 
invasive diseases and antibiotic resistance, were chosen as vaccine candidates. Thus far, 
the 7-valent pneumococcal conjugate vaccine Prevnar (Wyeth, USA) or Prevenar (Wyeth, 
Europe), containing polysaccharides of serotype 4, 6B, 9V, 14, 18C, 19F and 23F, has been 
approved by the Food and Drug Administration (USA), and the Committee on Proprietary 
Medicinal Products (Europe) for the prevention of invasive diseases in children. These 
vaccines have a potential coverage of over 85% of the pneumococcal isolates for the USA, 
60-70% for Europe and around 55% for Asia [49]. Clinical efficacy of the 7-valent conjugate 
vaccine against invasive diseases has been convincingly shown by Black and coworkers in 
the northern California Kaiser Permanente trial. Besides an efficacy of 97.4% against 
invasive diseases caused by vaccine serotypes, they also showed a significant impact on 
pneumonia and otitis media (Table 1) [50-52]. This was supported by data of a Finnish 
vaccination trial [53]. Moreover, several investigators have shown a significant reduction in 
nasopharyngeal carriage of vaccine type pneumococci in infants as a result of different 
conjugate vaccinations (Table 1) [47,54-56]. Mucosal immunity in addition to systemic 
immunity would explain this decline in nasopharyngeal colonization. This is supported by the 
results of a second Finnish study, showing that a tetravalent pneumococcal conjugate 
vaccine induces both mucosal and systemic antibody responses in toddlers [57]. It was 
suggested that diminished nasopharyngeal carriage could lead to reduced person to person 
spread of the pneumococcal serotypes most often associated with disease and antibiotic 
resistance, and even to herd immunity [47,58,59]. Because of these promising data, the 
ACIP recommended pneumococcal conjugate vaccination for all children under the age of 
24 months, and children 24-59 months of age when at risk of pneumococcal disease [20,33]. 
Unfortunately, the Dutch OMAVAX study investigating the efficacy of the 7-valent conjugate 
vaccine against recurrent otitis media in children 12 months to 7 years of age, showed no 
effect on the number of otitis media events despite good antibody responses [60]. The 
authors suggested that interference in an existing balance between host and pathogen by 
means of vaccination may induce pneumococcal strain replacement. The appearance of a 
new pathogen, in turn, increases the risk of acute otitis media [61,62]. This might explain the 
different results of the two landmark studies in California and Finland investigating the effect 
of conjugate vaccination on otitis media in infants: at infant age the conjugate vaccination 
may prohibit or delay nasopharyngeal acquisition of the most prevalent pneumococcal 
serotypes, thus preventing or delaying early pneumococcal AOM until a later age. 
Replacement is therefore not possible in young children whereas the OMAVAX colonization 
data showed full replacement of vaccine type pneumococci by non-vaccine type strains [63]. 
With ongoing follow-up, more studies have reported this phenomenon [53,55 ,64]. The effect 
of  replacement  to  the  burden  of  invasive  diseases  still remains  unknown, although one 
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conjugate vaccination trial in the US recently reported 25% increase in invasive diseases 
caused by non-vaccine serotypes. Though this was not yet statistically significant, in the 
future it may become clinically relevant [65].  
Meanwhile, the conjugate vaccine has been implemented nation wide in the United States 
[66]. For the European union, only Austria is currently (January 2003) recommending 
country-wide childhood vaccination [67]. However, most other countries, including Belgium, 
The Netherlands, Denmark, Finland, France, Germany, Ireland, Italy, Spain and the UK limit 
vaccine application to high-risk groups including patients with functional asplenia, 
immunodeficiencies, diabetes and chronic diseases like kidney, liver, lung, and heart 
diseases and children with cochlear implants [67]. The Achilles heel as presented by the 
Finnish national expert group appears to be the less favourable cost-effectiveness of the 
recommended 4-dose vaccination schedule [66].  
 
 
IMMUNOGENIC PROTEINS 
Though conjugate vaccines are highly protective against pneumococcal diseases, long-term 
vaccine failure due to the limited serotype coverage, and consequently, induction of  
replacement disease is realistic. Moreover, the vaccine is rather expensive, prohibiting 
implementation in most developing countries. [53,55,60,64,65,68,69]. In the last decade, 
several groups have investigated the use of pneumococcal proteins as potential vaccine 
candidates and promising results have been reported. Although many proteins including 
pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A 
(PsaA), Choline binding protein A (CbpA), neuraminidase, and autolysin have been 
suggested as potential candidates, the proteins PspA, PsaA and pneumolysin are currently 
the leading vaccine candidates (Table 2) [70].  
Pneumococcal surface protein A (PspA) is a member of a family of structurally related 
choline-binding surface proteins, which are able to interfere with complement fixation. They 
block the initiation of the alternative pathway through reduction of the amount of C3b 
deposited on the pneumococci. These proteins reduce the effectiveness of the complement 
receptor mediated pathways of clearance [71-74]. Although PspA shows considerable 
antigenic heterogeneity between different strains, Nabors at al. (2000) found broadly cross-
reactive antibodies to heterologous PspA molecules after immunization with a single 
recombinant PspA preparation [75,76]. This is supported by findings of Kolberg et al. who 
showed that a combination of two monoclonals identify 94% of clinical isolates [77]. 
Moreover, active immunization with PspA in animal models has proven protective against 
invasive infections and nasopharyngeal carriage [78-82]. In addition, Nabors and coworkers 
have performed the first phase I vaccination trial with a single  recombinant  PspA variant  in 
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humans. This vaccine showed to elicit broadly cross-reactive antibodies to heterologous 
PspA molecules [76]. Furthermore, these antibodies were found to protect mice challenged 
intraperitoneally with pneumococci [83,84]. 
Another inportant candidate is pneumococcal surface adhesin A (PsaA), a member of the 
family of metal binding lipoproteins. This protein is part of an ABC transporter complex 
thought to be involved in the transport of manganese into pneumococci [85,86]. The first 
immunization studies with PsaA showed significant protection against colonization but little 
to modest protection against invasive infections [70,87-89]. Recently though, Seo et al. 
showed that oral vaccination with PsaA encapsulated in microalginate microspheres elicits 
significant protection against colonization, pneumonia as well as septicemia in mice [90]. 
Because PsaA and PspA have different functions in virulence, an additive role for these 
proteins in vaccination was suggested.  Indeed, promising results have been found for the 
combination of PsaA and PspA in prevention of colonization and otitis media in animal 
models [79,85].  
Pneumolysin, also containing a choline-binding domain, is suggested to interfere with host 
immunity and inflammatory responses by a variety of functions, including complement 
fixation and inhibition of phagocyte function. It also inhibits ciliary activity in the bronchus 
and is therefore important in pathogenesis of pulmonary infection [3,91]. Knock-out 
mutagenesis of pneumolysin has proven its role in virulence in case of colonization as well 
as infection [92-94]. Several investigators have described the protective properties of 
pneumolysin against challenge with pneumococci in mice, be it against invasive diseases 
only [95,96]. PspA has shown complementary protection to invasive diseases in animals 
when used in combination with pneumolysin [70,79].  
Other pneumococcal proteins that have shown potential as vaccine candidates are PspC 
(CbpA), the Pht family, PpmA, autolysin and neuraminidase. PspC either contains a choline-
binding domain like PspA and pneumolysin or a LPXTG motif like other Gram-positive 
bacteria [97]. This protein is supposed to bind secretory IgA and to interact with human 
epithelial and endothelial cells [97,98]. Vaccination with PspC has shown to be protective 
against sepsis in mice. Moreover, antibodies directed against this protein have shown cross-
reactivity against PspA [99]. It is not yet clear though whether vaccination with PspC elicits 
protection against heterologous PspC type strains. The Pht family is one of cell surface-
exposed homologous proteins representing histidine triad motifs of which several members 
have shown to elicit protection against different pneumococcal serotypes in a mouse sepsis 
model [100]. Importantly, these proteins appear to be highly conserved among pneumococal 
strains, implicating a potential broad coverage. The putative proteinase maturation protein A 
(PpmA) is a highly conserved surface-associated protein which shows homology to 
members of the family of peptidyl-prolyl cis/trans isomerases. Mutagenesis of PpmA 
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reduced virulence of pneumococci in a mouse pneumonia model. However, further in vivo 
studies are necessary to investigate the potential protective properties of this protein [101]. 
Pneumococci also produce two neuroaminidases, NanA and NanB. These pneumococcal 
enzymes cleave N-acetylneuraminic acid from mucin, glycolipids, glycoproteins and 
oligosaccharides on host cell surfaces. Although the precise role in the pathogenesis of S. 
pneumoniae has not yet been identified, neuraminidase is presumed to contribute to 
adherence to mucosal surfaces through decreasing the viscosity of the mucuslayer or 
through exposing cell surface receptors for pneumococci [102]. However, mutagenesis of 
neuraminidaseA did not affect virulence of pneumococci after intraperitoneal challenge 
[103], which suggests a limited role in invasive disease. Pneumococcal autolysin (LytA) is, 
like PspA, CbpA and pneumolysin, a choline-binding protein, which contributes to virulence 
by mediating the release of pneumolysin and possibly inflammatory cell wall degradation 
products [94,104]. The exact role of autolysin in pathogenesis is still unclear, and 
controversial data have been reported regarding the protective properties of this protein 
[105]. 
So far, none of the proteins are considered to elicit species-wide pneumococcal protection. 
This can be explained by the occurence of allelic variation within most individual proteins 
[75,97,105]. Antibodies raised against a single protein may not recognize allelic variants. 
Therefore, immunological interference using multiple variants of a single protein or using 
multiple proteins will limit immunological escape by the pneumococcus. Therefore, a 
combination of proteins should be considered in future protein vaccine strategies. Which 
combination of proteins should be chosen remains open for discussion. Although a 
combination of pneumolysin and PspA is suggested because of their protective effect 
against invasive diseases in animal models, the route of infection investigated in these 
models is either directly intravascular or via intraperitoneal challenge, and therefore not 
physiological. The natural route of infection with S. pneumoniae is believed to start with 
colonization, which progresses to (invasive) disease, by crossing of the natural physical and 
immunological barriers. Therefore, it seems rational to aim for prevention of colonization. By 
preventing nasopharyngeal colonization of S. pneumoniae, horizontal spread of 
pneumococcal strains will be diminished as well, thereby enhancing herd-immunity. This 
theory supports the usage of PsaA as vaccine candidate as this protein has shown to elicit 
significant protection against pneumococcal colonization. In combination with PspA full 
protection may even become reality.  
Several recent studies suggest that administrating the protein vaccine via the oral or nasal 
route is as effective as systemic application [78,81,82,90]. One of these routes is strongly 
preferable because of the high number of vaccines already administered intramuscularly or 
subcutaneously to children as part of community vaccination programs. Moreover, in 
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contrast to pneumococcal conjugate vaccines and PS vaccines, protection is also expected 
in children with HIV/AIDS, even in a later stadium, because of the intact mucosal immune 
response in these patients [90].  
The addition of an adjuvant will be inevitable when full protection is pursued; recent studies 
have all shown a significant increase in protection when adjuvants are used [81,82,85,88-
90]. Which adjuvant elicits the best protection should be further investigated. Finally, 
encapsulating the proteins should be considered because this may elicit additional 
systemical protection due to prevention of degradation in the stomach [90].  
Care should be taken that the vaccine elicits a high level of cross-reactivity against the 
heterogeneous spectrum of subtypes to avoid escape by recombination events. Several of 
the potential proteins display complex mosaic structure as a result of horizontal (inter-
species) exchange of gene parts [97,105,106, 107]. However, for the PspA molecules, 
cross-reactivity between the different variants is present because they share cross-reactive 
epitopes [76,77].  
On the other hand, cross-reactivity with species other than S. pneumoniae should be closely 
monitored; for example, Jado et al. have shown close homology between the PsaA 
molecules of S. pneumoniae and PsaA molecules in three different viridans streptococci 
[108].  The eradication of these species is undesirable because they may protect humans 
from respiratory tract infections by other streptococci and species [109-111]. All in all, 
thorough investigation of these proteins still is necessary before large-scale immunization 
studies in humans will become within reach.  
  
 
CONCLUSION 
At the moment, prevention of pneumococcal diseases is possible through 23-valent PS 
vaccines and a 7-valent conjugate vaccine. Although the PS vaccine has several 
disadvantages, of which the most important one is its minimal efficacy in children < 2 years 
and immunodeficient patients, they are still useful for immunocompetent individuals ≥ 5 
years of age who are at risk of pneumococcal infections [20 ,33]. The more recently 
approved conjugate vaccine, which contains the capsule polysaccharides of the 7 most 
prevalent serotypes conjugated to a carrier protein, is highly immunogenic in children < 2 
years of age, showing better immune responses and immunological memory. Unfortunately, 
the efficacy is limited due to the restricted number of serotypes included, and in the long run 
the efficacy will be threatened by serotype replacement. Therefore pneumococcal proteins 
have been studied thoroughly to evaluate their possible role in future pneumococcal 
vaccination. First of all, it is suggested that these proteins can be used as carrier protein in a 
conjugate vaccine, eliciting protection against the remaining serotypes thus preventing 
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serotype replacement. In this respect, the results from Kuo et al., showing significant 
protection in mice by a conjugate vaccine containing polysaccharides of serotype 18C 
conjugated to pneumolysin, look promising [26]. Secondly, if the proteins turn out to elicit 
sufficient protection by themselves or in combination, a pure protein vaccine could also be 
optional. Because of the additive roles in virulence and protection of pneumolysin, PspA and 
most importantly PsaA, a combination of these proteins is most promising. A major 
advantage of this combination is serotype-independent protection. In addition, this concept 
will limit the costs due to the relatively simple production of these recombinant proteins [22]. 
Distribution of this vaccine to the third world countries would become possible, thus reaching 
a broader target group then ever before. Importantly, if the vaccine can be administered via 
the oral or intranasal route a major risk group, the HIV/AIDS patients, will also benefit of the 
protection elicited by the mucosal immune-system which is unimpaired in these patients 
[90]. On the other hand, escape mechanisms of the pathogen in response to the 
immunological pressure is not unlikely if full eradication cannot be achieved. Moreover, 
cross-responsiveness to commensal species is realistic.  
The effect of vaccination on the bacterial dynamics depends the kind of protection that is 
elicited. When vaccination leads to the prevention of pneumococcal carriage, the horizontal 
spread of pneumococcal strains will also be diminished. This may lead to herd immunity 
resulting in protection of unvaccinated individuals against pneumococcal diseases. In 
addition, the prevention of nasopharyngeal colonization indicates the presence of mucosal 
immunity, which may also reduce mucosal diseases caused by S. pneumoniae. On one 
hand, when eradication of pneumococcal carriage at the nasopharynx occurs, replacement 
of colonization and infection with non-vaccine serotype pneumococci and competitive 
species might easily happen. On the other hand, this may also lead to herd susceptibility 
towards non-vaccine sero- or genotypes and even alternative pathogenic species, and 
hence, disease burden. In contrast, when aiming for the prevention of invasive diseases 
without disturbing the nasopharyngeal niche, the risk for replacement disease is minimal. 
Systemic antibodies against proteins involved in invasion but not adherence may 
accomplish this. Unfortunately, positive ‘side-effects’ such as prevention of mucosal disease 
and the induction of herd immunity will not occur with this strategy.  
In conclusion, thorough investigation of the efficacy and safety of these vaccine candidates 
and monitoring of side-effects have to be performed before human use is optimized. Until 
then, the available vaccines can be used in the prevention of invasive diseases in infants but 
close monitoring of escape mechanisms and vaccine failures remains necessary. 
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ABSTRACT 
Background. Pneumococcal conjugate vaccine prevents recurrent acute otitis media (AOM) 
in infants immunised at 2, 4, 6, and 12–15 months of age. We aimed to find out whether this 
vaccine also prevents AOM in older children who have had previous episodes of AOM.  
Methods. In this double-blind, randomised study, we enrolled 383 patients aged 1–7 years 
who had had two or more episodes of AOM in the year before entry. Randomisation was 
stratified in four groups according to age (12–24 months vs 25–84 months) and the number 
of previous AOM episodes (two or three episodes vs four or more episodes). Children 
received either 7-valent pneumococcal conjugate vaccine followed by 23-valent 
pneumococcal polysaccharide vaccine, or hepatitis A or B vaccines. They were followed up 
for 18 months for recurrence of AOM. We also cultured samples of middle-ear fluid and 
nasopharyngeal swabs to assess association of pneumococcal serotypes with AOM after 
vaccination.  
Findings. We noted no reduction of AOM episodes in the pneumococcal vaccine group 
compared with controls (intention-to-treat analysis: rate ratio 1·25, 95% CI 0·99–1·57). 
Although nasopharyngeal carriage of pneumococci of serotypes included in the conjugate-
vaccine was greatly reduced after pneumococcal vaccinations, immediate and complete 
replacement by non-vaccine pneumococcal serotypes took place.  
Interpretation. These data do not lend support to the use of pneumococcal conjugate 
vaccine to prevent otitis media in previously unvaccinated toddlers and children with a 
history of recurrent AOM.  
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INTRODUCTION 
The American Academy of Pediatrics has recommended immunisation with 7-valent 
pneumococcal conjugate vaccine (PCV7) for children with recurrent or severe acute otitis 
media (AOM) and children who have tympanostomy tubes because of recurrent AOM. [1] 
This advice was based on the results of two clinical trials with PCV7. The trials included 
almost 40000 healthy infants, who were immunised at 2, 4, and 6 months of age, and had 
booster vaccinations at 12–15 months of age. [2 and 3] These children were followed up for 
the occurrence of AOM up to their second birthday. The pneumococcal vaccine reduced the 
number of infants with recurrent episodes of AOM by 9%. The largest effect was a reduction 
of 23% in the number of children developing a severely otitis-prone condition (five episodes 
in 6 months or six episodes per year). [2] Furthermore, the number of children receiving 
tympanostomy tubes was reduced by 20%. [2]  
However, the benefits of pneumococcal conjugate vaccine have not been investigated in 
previously unvaccinated toddlers and older children who have documented episodes of 
AOM before vaccination. Assessment of the vaccine's effectiveness is especially important 
in this group, since children with recurrent AOM can have subtle immunodeficiencies that 
alter the vaccine's immunogenicity. [4, 5 and 6] Genetically determined factors in innate and 
adaptive immunity may also affect the effectiveness of the vaccine. [7 and 8] Furthermore, 
vaccine effectiveness in older children might differ from that in infants due to differences in 
pneumococcal serotype coverage and environmental factors. [9] Therefore, the efficacy of 
pneumococcal conjugate vaccine needs to be assessed in randomised trials to support 
recommendations that these children should also be immunised.  
We investigated whether combined vaccination with PCV7 followed by 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) could prevent AOM in children aged 1–7 
years, with two or more documented episodes of AOM before vaccination. This combination 
was chosen because of the booster effect of the polysaccharide vaccine after priming with 
conjugate vaccine both in infants and in children prone to otitis. [10 and 11] Furthermore, the 
broad pneumococcal serotype coverage by the 23-valent vaccine could benefit children 
older than 2 years of age. We assessed the protective efficacy of pneumococcal vaccination 
against recurrent AOM, and the effect of vaccination on culture-confirmed pneumococcal 
AOM and nasopharyngeal carriage.  
 
 
METHODS 
We did a randomised, double-blind trial between April, 1998, and January, 2002, at a 
general hospital (Spaarne Hospital, Haarlem) and a tertiary care hospital (Wilhelmina 
Children's Hospital of the University Medical Center Utrecht) in the Netherlands. Parents 
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were informed about the study by primary care physicians, paediatricians, and 
otolaryngologists from across the Netherlands. Parents who were willing to participate 
signed a consent form to enrol their child in the study.  
Inclusion criteria for the study were two or more episodes of AOM in the year before study 
entry, and age 1–7 years. The number of previous AOM episodes was based both on 
parental report––with AOM defined as having one or more of the symptoms: acute earache, 
new-onset otorrhea, irritability, and fever––and on clinical confirmation of the diagnosis by a 
physician. Exclusion criteria were primary or secondary immunodeficiency, cystic fibrosis, 
immotile cilia syndrome, craniofacial abnormalities such as cleft palate, chromosomal 
abnormalities such as Down's syndrome, and severe adverse events during previous 
vaccinations.  
 
 
 
 
 
Figure 1. Trial profile 
*One child discontinued treatment because of gastroenteritis directly after first vaccination (link with vaccination 
questionable); three discontinued because parents were not motivated. † The patient moved and we did not know their 
new address. ‡Four discontinued because of fears about vaccination and venous sampling; two because of 
disappointment of parents about efficacy of vaccine; two because parents were not motivated; one because the 
patient's mother was disappointed about communication with study physicians; one because common variable immune 
deficiency was diagnosed immedately after first vaccination; one for unknown reasons.  
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The children were randomised to receive either PCV7 followed by PPSV23, or hepatitis A or 
B vaccines. PCV7 (Prevnar®, Wyeth, Rochester, NY, USA) consisted of 2 µg each of 
capsular polysaccharides of pneumococcal serotypes 4, 9V, 14, 19F, and 23F, 4 µg of 
serotype 6B polysaccharide, and µ2 g of serotype 18C oligosaccharide, each conjugated 
individually to the CRM197 protein. PPSV23 (Pneumune®, Wyeth) consisted of 25 µg of 
capsular polysaccharides of each of the pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. Control vaccines 
were recombinant hepatitis B vaccine (Engerix-B = AE Junior®, GlaxoSmithkline, Rixenart, 
Belgium) and hepatitis A vaccine (Havrix = AE Junior®, GlaxoSmithkline).  
Since we expected that age at baseline and the number of episodes of AOM in the year 
before study entry would be important prognostic indicators for AOM, we randomised the 
children within four groups according to age (12–24 months vs 25–84 months) and number 
of previous AOM episodes per year (two or three episodes vs four or more episodes). The 
children were assigned a number from a table of random numbers that identified the vaccine 
scheme. The vaccine was administered to the child by a study nurse, so that parents and 
physicians were unaware of treatment. Children aged 12–24 months in the pneumococcal 
vaccine group were immunised with PCV7 twice (with a 1-month interval between 
immunisations) followed 6 months later by PPSV23. The control vaccine group aged 12–24 
months received three hepatitis B vaccinations according to a similar time schedule. 
Children aged 25–84 months in the pneumococcal vaccine group received one dose of 
PCV7, followed 7 months later by PPSV23. The control group aged 25–84 months received 
hepatitis A vaccine twice.  
The primary endpoint was the efficacy of pneumococcal vaccination against clinical 
episodes of AOM during a follow-up period of 18 months, starting 1 month after completion 
of the vaccination scheme. AOM episodes occurring during the 6–7 month period beginning 
1 month after PCV7 or control vaccinations and ending 1 month after the last vaccination 
were also recorded. We instructed parents to visit the study clinics or their family physician, 
otolaryngologist, or paediatrician to assess symptoms suggesting AOM. Physicians 
registered signs and symptoms of every AOM episode on standard registration forms. 
Guidelines issued by the Dutch College of General Practitioners define AOM as the 
presence of an abnormal tympanic membrane on otoscopy (red, dull, or bulging), or 
otorrhoea and at least one of these signs or symptoms of acute infection: acute earache, 
new-onset otorrhoea, irritability, or fever greater than 38·5°C rectally or 38·0°C axillary. [12] 
New episodes of AOM were recorded after a minimum 7-day interval free of AOM-related 
symptoms and treatment.  
Additional outcomes in our study included number of AOM episodes due to the seven 
pneumococcal serotypes included in the conjugate vaccine and nasopharyngeal carriage of 
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conjugate vaccine serotypes. Bacterial cultures from middle-ear fluid were obtained only 
once in every child, at the time of the first AOM episode arising at least 1 month after the last 
vaccination. Parents had been asked to bring their child to the study clinic within 24 h after 
the onset of symptoms suggesting AOM. After clinical confirmation of the diagnosis of AOM, 
middle-ear fluid was collected by myringotomy or by spontaneous drainage near the 
perforation site with an aspirator (Juhn Tym-Tap collector, Xomed, Jacksonville, USA) or 
sterile dry cotton-wool swab (Copan Italia, Transwab, Medical Wire and Equipment 
Company, Corsham, England). At study entry and follow-up visits, we took nasopharyngeal 
samples transnasally with a flexible, sterile, dry cotton-wool swab. After sampling, we 
immediately placed swabs in Stuart's transport medium. Samples of middle-ear fluid and 
nasopharyngeal swabs were plated within 6 h onto two 5% sheep blood agar plates, a 5% 
sheep blood agar plate with 5 mg/L gentamicin, and a chocolate agar plate. Agar plates 
were incubated at 37°C for 48 h; the blood agar plates aerobically and anaerobically, the 
blood agar plate with gentamicin and the chocolate agar plate with raised CO2. Identification 
of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis was 
based on colony morphology and conventional methods of determination. When S 
pneumoniae was isolated, we undertook serotyping with the capsular swelling method 
(Quellung reaction) by microscopy with commercially available antisera (Statens 
Seruminstitut, Copenhagen, Denmark).  
All baseline and follow-up visits took place at the study clinics. At entry into the study, 
parents filled out a standard questionnaire on the medical history of their child and risk 
factors for AOM. For every episode of AOM diagnosed by a physician during follow-up, 
parents were asked to record all AOM-related symptoms and treatment in a diary for as long 
as symptoms persisted. At follow-up visits scheduled at 7, 14, 20, and 26 months after 
randomisation, AOM registration forms filled in by the physicians and diaries were brought in 
and checked with the parents. We recorded information on ear, nose, and throat operations. 
Between these scheduled visits, study physicians contacted the parents by telephone every 
3 months. Previous to and 1 month after each vaccination, a blood sample was taken for 
immunological assessment.  
Concentrations of IgG to the seven pneumococcal serotypes in the conjugate vaccine were 
measured in serum by ELISA. [13] All laboratory work was done by individuals who were 
unaware of treatment allocation.  
The study was undertaken in accordance with the European statements for good clinical 
practice, which includes the provisions of the Declaration of Helsinki of 1989. The medical 
ethics committees of both participating hospitals approved the study protocol.  
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Statistical analysis. On the basis of data from previous studies in the Netherlands, we 
estimated that 55% of our high-risk patients in the control group would have at least one 
episode of AOM during the 18 months of follow-up after completion of vaccinations. In view 
of the multifactorial causes of AOM and comparison of the expected benefit of vaccinations 
to that of antibiotic prophylaxis and tympanostomy tubes, we judged a reduction of at least 
25% to a recurrence rate of 40% of one or more AOM episodes in the pneumococcal 
vaccine group to be clinically relevant. In  order  to detect such a  reduction, with a  (2-sided)  
0-05 and power 80%, 176 patients would have to be included in each group. To compensate 
for an estimated dropout of about 10%, 388 patients would have to be randomised.  
Vaccine efficacy was assessed with Cox-type proportional hazards regression models, 
including a frailty term allowing for differences between individuals in numbers of recurrent 
AOM episodes. We undertook this analysis in S-plus, version 2000; all other analyses were 
done with SPSS 10·1. Results are presented as rate ratios with 95% CI; we judged 
significance to be reached when CI did not include 1. We did both intention-to-treat and per-
protocol analyses.  
The differences in conjugate and non-conjugate nasopharyngeal pneumococcal carriage 
between the treatment groups were assessed as follows: children were classified as having 
had a positive culture for any pneumococcal serotype included in PCV7 or any 
pneumococcal serotype not included in PCV7 if they had such a positive culture at any of 
the scheduled follow-up visits after complete vaccination. Proportional differences in 
pneumococcal carriage and pathogens causing AOM were analysed with Chi2 tests or 
Fisher's exact tests when appropriate. We judged p<0·05 to be significant. Differences in 
diary data between groups were assessed with the Mann-Whitney U test.  
All values are medians (range) or means (SD) unless otherwise indicated. * Atopy is defined 
as suffering from eczema, hay fever, or recurrent wheezing/asthma. 
 
 
RESULTS 
We enrolled 383 children between April, 1998, and January, 2001; 190 children were 
randomised to receive pneumococcal vaccinations and 193 to receive control hepatitis 
vaccinations (figure 1). Age, sex, number of previous AOM episodes, and other risk factors 
for AOM did not differ between the groups (table 1). In the pneumococcal vaccine group, 
186 of 190 children (98%) completed the vaccination scheme, as did 181 of 193 controls 
(94%). The median follow-up after complete vaccination was similar in the pneumococcal 
vaccine group (18·1 months, range 2·4–23·0) and control group (18·0 months, range 0·5–
23·0). One patient was lost to follow-up immediately after the first vaccination. No serious 
adverse events were noted after pneumococcal or hepatitis vaccinations. 
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Table 1.  Baseline characteristics, ear, nose, and throat history, and risk factors for AOM. 
 
 
*Atopy defined as having eczema, hay fever, or recurrent wheezing or asthma. 
 
Variable Pneumococcal vaccine group (n=190) 
Control vaccine group 
(n=193) 
Male sex   118 (62%) 119 (62%) 
Median age, years (range) 2·09  (1-6·86) 2·36  (1-6·99) 
Age      
    12-24 months 83 (44%) 79 (41%) 
    25-84 months 107 (56%) 114 (59%) 
Number of AOM episodes in      
preceding year (%)     
    2-3 72 (38%) 69 (36%) 
    4-5 55 (29%) 63 (33%) 
    6 or more 63 (33%) 61 (32%) 
Ventilation tube placement      
    None    90 (47%) 96 (50%) 
    Once 63 (33%) 63 (33%) 
    Twice or more 37 (20%) 34 (18%) 
Adenoidectomy  90 (48%) 89 (46%) 
Mean gestational age in weeks 39·3   (SD 2·1) 39·4  (SD 2·1) 
Mean birthweight (g)   3358·4 (SD 603·5) 3334·8  (SD 637·1) 
Day care  (%)     
   At age 12-24 months 38 of 83  (46%) 35 of 79  (44%) 
   At age 25-48 months 53 of 66  (80%) 55 of 65  (85%) 
Mean number of siblings 1.05       (SD 0·81)   1.11    (SD 0·93)  
Median age at first AOM   8.0     (1-54)   9.0    (1-48) 
episode, months (range)     
Breastfeeding > 3 months 83 (44%) 85 (44%) 
Atopy*      
    Patient history  94 (50%) 100 (52%) 
    Family history  110 (58%) 115 (60%) 
Family history of recurrent AOM     
    Parents 107 (56%) 117 (61%) 
    Siblings 83 (44%) 72 (37%) 
Tobacco smoke exposure indoors  58 (31%) 63 (33%) 
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Of the 475 AOM episodes diagnosed during follow-up after the final vaccination, 275 
episodes were recorded in 107 of 186 children (58%) in the pneumococcal vaccine group 
who completed all vaccinations (recurrence rate 1·1 episodes per person-year) and 200 
episodes in 101 of 181 controls (56%; recurrence rate 0·83 episodes per person-year). In 
this per-protocol analysis after complete vaccination, the rate ratio of recurrence of AOM for 
the pneumococcal vaccine group versus controls was 1·29 (95% CI 1·02–1·62). The results 
of the intention-to-treat analysis did not differ from those of the per-protocol analysis over the 
same period (rate ratio 1·25, 95% CI 0·99–1·57). The cumulative hazard function for AOM of 
the fully vaccinated pneumococcal vaccine group and controls is shown in figure 2. 
Subgroup analysis suggested a slightly higher rate ratio of recurrence of AOM in the 
pneumococcal vaccine group than in controls in children older than 2 years at the time of 
first vaccination (rate ratio 1·45, 95% CI 1·09–1·94), compared with the group aged 1–2 
years (1·07, 0·72–1·60). The rate ratio also seemed higher in children who had two or three 
episodes of AOM in the year preceding the study (1·66, 1·11–2·49) compared with those 
who had four or more episodes (1·20, 0·92–1·56). However, since neither of the interactions 
between age and treatment effect (1·37, 0·87–2·14) and between previous AOM episodes 
and treatment effect (0·74, 0·45–1·22) was significant, we were not able to conclude that 
rate ratios differed across subgroups. Excluding the severely otitis-prone children with six or 
more AOM episodes in the year before study entry from the analyses did not change the 
outcome of the study (1·30, 0·83–2·06).  
We recorded a total of 840 episodes of AOM during the investigation, including those that 
arose in the period of 6–7 months between first study vaccinations and 1 month after the last 
vaccination. 445 episodes were in 135 of the 190 children (71%) in the pneumococcal 
vaccine group (recurrence rate 1·23 episodes per person-year), and 395 episodes in 139 of 
the 192 controls (72%; recurrence rate 1·08 episodes per person-year). During this whole 
period, the intention-to-treat analysis also showed no decrease of AOM in the pneumococcal 
vaccine group compared with controls (rate ratio 1·11, 95% CI 0·92–1·33).  
We used data from the diaries to assess the severity and duration of the AOM episodes. 
Parents of 179 of 208 children with AOM during follow-up completed diaries for 399 of the 
475 episodes. We noted no differences between pneumococcal vaccine group and controls 
in median days per episode for ear-related symptoms such as earache, otorrhea, irritability, 
and fever, and ear-related treatment such as use of analgesics, antibiotics, and ototopical 
medications. The number of children treated with tympanostomy tubes during follow-up was 
similar in the pneumococcal vaccine and control groups (33 and 39, respectively; P = 0·36).  
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Figure 2. Cumulative hazard function for risk of AOM  
 
Nasopharyngeal swabs were taken at baseline, just before the last vaccination, and at 7, 13, 
and 19 months after complete vaccinations in 375, 358, 346, 282, and 240 of the children, 
respectively. At baseline, nasopharyngeal carriage of S pneumoniae was found in 49% of all 
children, regardless of age. Of these nasopharyngeal pneumococcal serotypes, 53% had 
been included in PCV7; these were serotypes 19F (13%), 6B (12%), 23F (11%), 14 (9%), 
9V (5%), 18C (1%), and 4 (1%). In the pneumococcal vaccine group the nasopharyngeal 
carriage of the conjugate vaccine serotypes fell substantially after complete vaccination 
compared with the control group (p<0·001). However, overall nasopharyngeal carriage of 
pneumococci was not affected by pneumococcal vaccination, because of a concurrent 
significant increase in non-conjugate-vaccine serotypes (p=0·04; figure 3). Booster 
vaccination with PPSV23 did not seem to prevent carriage of serotypes not included in the 
conjugate vaccine. The largest reduction in carriage of conjugate vaccine serotypes (69%) 
was noted for serotype 18C (p=0·03); the lowest reduction (30%) was found for serotype 6B 
(p=0·29). Replacement by non-conjugate vaccine serotypes was mainly caused by 
serotypes 11 (p=0·01) and 15 (p=0·02), even though these serotypes were included in 
PPSV23, and by serotype 16 (p=0·03), which was not included in PPVS23. Carriage rate of 
cross-reacting pneumococcal serotype 6A did not differ between the pneumococcal vaccine 
and control groups (p=0·47).  
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Figure 3. Nasopharyngeal carriage of pneumococci  
*Differences in nasopharyngeal carriage of conjugate vaccine and non-conjugate-vaccine pneumococcal serotypes 
were significant between the two treatment groups (p<0·05, see results section).  
 
We took no more than one sample of middle-ear fluid during an episode of AOM from any 
child. Middle-ear fluid was obtained from 92 of 107 children (86%) with AOM in the 
pneumococcal vaccine group and 89 of 101 controls (88%; table 2). S pneumoniae was 
isolated more often in middle-ear fluid samples in controls (21%) than in the pneumococcal 
vaccine group (14%). 4% of middle-ear fluid samples from the pneumococcal vaccine group 
were positive for pneumococcal serotypes included in PCV7, compared with 9% of controls. 
These numbers were too small for meaningful statistical analysis. 30% of our bacterial 
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cultures were negative. Numbers of middle-ear fluid cultures of untypable H influenzae, M 
catarrhalis, group A streptococci, and P aeruginosa did not differ between the groups. 
However, we isolated S aureus more often in the pneumococcal vaccine group than in the 
control group (26 vs nine children, P=0·002). All S aureus cultures and P aeruginosa 
cultures were derived from spontaneous drainage of ears; 75% of the children had 
ventilation tubes.  
 
Table 2. Pathogens cultured at the first AOM episode after completion of the vaccination scheme 
 
 Pneumococcal vaccination 
Control 
vaccination p-value 
No. of children with at least one AOM episode 107 101  
No. of AOM episodes MEF obtained 92 89  
MEF obtained by:    
  - spontaneously draining ear 71 66  
  - myringotomy  21 23  
Culture confirmed S. pneumoniae 13 19 0·22 
PCV7 pneumococcal serotypes 4 8 0·21 
Other pneumococcal serotypes 9 11 0·44 
H. influenzae 21 23 0·64 
M. catarrhalis 8 6 0·62 
Group A streptococcus 6 4 0·75 
    
Negative cultures 32 35 0.53 
    
Others (all from spontaneously draining ears)    
P. aerigunosa 9 6 0·46 
S. aureus 26 9 0·002* 
 
* p-value was considered statistically significantly different at p<0·05. MEF= middle ear fluid.  
 
 
IgG anti-pneumococcal antibody concentrations were measured for 126 randomly selected 
children, 24 from each of the four randomisation groups who received pneumococcal 
vaccines and 30 controls. Geometric mean concentrations of these antibodies were 
consistently higher in the pneumococcal vaccine group than in controls, and reached values 
far above 1·5 mg/L, apart from concentrations of serotype 6B, which remained below 0·2 
mg/L (table 3).  
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Table 3. Geometric mean concentrations (mg/L) of IgG anti-pneumococcal antibodies against conjugate vaccine 
pneumococcal serotypes 
 
Pneumococcal 
Serotype Pre-vaccination 
1 month  
after PCV7 
1 month  
after PPSV23 
 PV CV PV CV PV CV 
4 0·04 0·05 0·38 0·11 2·48 0·11 
6B 0·04 0·04 0·06 0·02 0·19 0·05 
9V 0·16 0·16 0·51 0·32 4·94 0·30 
14 1·44 1·85 6·24 4·02 30·44 8·01 
18C 0·17 0·16 6·61 0·29 10·62 0·27 
19F 0·25 0·27 1·25 0·37 8·49 0·40 
23F 0·47 0·45 5·67 0·50 24·32 0·65 
 
Pneumococcal vaccine group (PV), control vaccine group (CV), 7-valent pneumococcal conjugate vaccine (PCV7), 23-
valent pneumococcal polysaccharide vaccine (PPSV23). 
 
 
DISCUSSION 
Our results show that combined pneumococcal conjugate and polysaccharide vaccination is 
not effective in prevention of AOM in children older than 1 year of age with recurrent AOM. 
Exclusion of children who were severely prone to otitis from the analysis did not change the 
outcome of the investigation.  
During the trial we saw a marked reduction in AOM episodes both in the pneumococcal 
vaccine and control groups to an average of one episode per child per year. This decrease 
could be the result of overestimation of the number of AOM episodes by parents before 
study entry; such overestimation has been reported previously in studies of children with 
recurrent AOM.[14] Furthermore, spontaneous recovery of recurrent AOM with increasing 
age would have had a role in our investigation, [15] since the recurrence rate of AOM 
episodes per person-year decreased in the total group of patients from 1·63 in the interval 
between first and last vaccination to 0·97 between the last vaccination and the end of the 
study. Finally, evidence suggests that medical outcomes can improve substantially due to 
trial participation itself, which is assumed to be related to expectation of future benefit, 
improved clinical follow-up, and other aspects of management of the condition. [16 and 17]  
In accord with our assumptions, 101 of 181 (56%) children in the control group had at least 
one episode of AOM during follow-up. On the basis of results from previous trials with PCV7 
in healthy infants,[2 and 3] we assumed the efficacy of the vaccine to be higher in children 
with increased baseline risk of AOM. The children in our study had already had recurrent 
episodes of AOM and were followed up for a sufficiently long period to detect the reduction 
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of AOM episodes by PCV7 that we intended. Our results do not show any beneficial effect of 
this vaccination scheme in terms of reduction of AOM. Since randomisation was successful, 
loss to follow-up was very low, and AOM episodes were meticulously recorded, we believe 
that this outcome is valid and that a further increase of precision (more included children) 
would be unlikely to change these estimates.  
We noted very good IgG antibody responses to pneumococcal vaccination in our group of 
children with recurrent otitis. These responses were significantly higher than those reported 
in the California and Finnish infant studies,[2 and 3] except for those to serotype 6B. Recent 
data from the Finnish otitis media study group also show higher concentrations of antibody 
in infants after booster vaccination with the polysaccharide vaccine at 14 months of age, 
compared with PCV7 booster vaccination, which was associated with a better clinical 
protection against AOM caused by serotype 19F. [18] The deficient response to serotype 6B 
in our study might be due to a subtle immune deficiency, which is characteristic of children 
who are prone to otitis. [19] Results of other studies have shown that when healthy infants 
and toddlers were vaccinated with PCV, they were less likely to carry serotype 6B and 
cross-reactive serotype 6A or have AOM caused by these pathogens. [3 and 20] By 
contrast, we found a low effect of pneumococcal vaccination against carriage of serotype 6B 
and no effect against 6A. This finding is probably the result of the low titres of antibody 
against serotype 6B, and might have influenced the outcome of our study, since serotypes 
6B and 6A are among the most common AOM serotypes. [3]  
Our findings of no beneficial effect of pneumococcal vaccinations contrast with those of the 
two landmark studies on prevention of AOM by PCV7 in infants.[2 and 3] These 
investigations both showed a small but beneficial effect on AOM and improved results in 
prevention of frequent recurrent AOM. Apart from the booster vaccination with PPSV23, the 
most important difference between these two studies and ours is that the former studies 
include healthy infants, who were vaccinated as early as 2 months of age. At this age the 
child has not yet developed AOM and does not have fully established nasopharyngeal 
pneumococcal carriage. [21] S pneumoniae is a frequent pathogen in early AOM.[9] 
Because of inflammation and subsequent damage to the middle-ear mucosa and eustachian 
tube, early pneumococcal AOM could predispose infants to recurrent AOM caused by other 
pathogens such as H influenzae, which was shown to become increasingly important in 
recurrent AOM episodes.[9] Arguably, conjugate vaccination at infant age might prohibit or 
delay nasopharyngeal acquisition of the most frequent pneumococcal serotypes, preventing 
or delaying pneumococcal AOM until a later age, at which time the child is immunologically 
and anatomically more mature and more capable of handling an AOM infection than in 
infancy. Thus, prevention of early pneumococcal AOM could be especially important for the 
prevention of the otitis-prone condition.  
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In our study, pneumococcal carriage was noted in 50% of children at study entry. This 
proportion remained constant throughout follow-up, both in the pneumococcal vaccine group 
and in controls. Although pneumococcal vaccinations did reduce nasopharyngeal carriage of 
the seven conjugate vaccine serotypes, including serotype 6B, this reduction was 
accompanied by an increase in pneumococcal serotypes not included in the conjugate 
vaccine. This shift in nasopharyngeal pneumococcal carriage after conjugate vaccination is 
consistent with observations in other studies[22 and 23] and is most probably the result of 
replacement. [24 and 25] The finding that replacement by serotypes 11 and 15 cannot be 
prevented by PPSV23, which includes these serotypes, lends support to previous results 
showing that polysaccharide vaccine did not affect nasopharyngeal carriage. [26 and 27] 
Although children aged 2–7 years showed better responses to the polysaccharides 11 and 
15 compared with the younger group, nasopharyngeal carriage was still unaffected by 
vaccination (data not shown). By induction of nasopharyngeal replacement with non-
conjugate pneumococcal serotypes, PCV could even induce recurrence of AOM, because 
newly acquired carriage is associated with an increased risk for AOM compared with the risk 
associated with established carriage. [28] This risk might account for the increased number 
of AOM episodes in the pneumococcal vaccine group in our study. The potentially 
pathogenic capacity of non-conjugate-vaccine pneumococcal serotypes was previously 
shown in the Finnish infant study on AOM; [3] the conjugate vaccine reduced AOM caused 
by conjugate-vaccine-type pneumococci by 57%, but AOM caused by non-conjugate-
vaccine pneumococcal serotypes was increased by 34%.  
We were not able to confirm that replacement took place in middle-ear fluid. For ethics 
reasons, we obtained middle-ear fluid only in the first episode of AOM after vaccination. 
Therefore, the number of middle-ear fluid cultures investigated was small. We noted a 51% 
reduction in AOM caused by conjugate-vaccine-serotype pneumococci, and overall 
pneumococcal AOM was reduced by 34%; this finding was similar to that of the Finnish 
study.[3] We noted no difference between the groups in presence of other middle ear 
pathogens, apart from S aureus. This species was noted more often in middle-ear fluid 
cultures from the pneumococcal vaccine group, although only in samples taken from 
spontaneously draining ears. Whether S aureus is a true AOM pathogen or is the result of 
contamination from the external ear canal is uncertain,[29 and 30] but the double-blind 
nature of our study suggests that pneumococcal vaccination has an effect on the isolation of 
S aureus in samples from spontaneously draining ears.  
To summarise, we found that pneumococcal conjugate vaccination combined with 
pneumococcal polysaccharide vaccination does not prevent AOM in children older than 1 
year who have had recurrent episodes of AOM before vaccination. Therefore, 
pneumococcal vaccinations are not indicated in the management of recurrent AOM in 
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toddlers and older children. In view of the results of other studies, we might conclude that to 
prevent pneumococcal AOM in general, and to protect children from developing the otitis-
prone condition, pneumococcal vaccinations should be given early in life, at least before 12 
months of age and preferably before two or more episodes of AOM have occurred.  
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ABSTRACT 
The impact of 7-valent pneumococcal conjugate followed by 23-valent polysaccharide 
vaccination on pneumococcal nasopharyngeal carriage was studied in a prospective, 
randomized trial, including 383 children with previous acute otitis media, aged 1-7 years. 
Nasopharyngeal swabs were collected at baseline and at 6-7 months intervals during 26 
months follow-up. Overall pneumococcal carriage rates did not diminish, remaining around 
50%. A significant shift from conjugate vaccine to non-conjugate vaccine type pneumococci 
was observed in children aged 1-2 years, who received twice the conjugate vaccine before 
polysaccharide vaccination. Conjugate vaccine serotype carriage was not influenced in older 
children, who received the conjugate vaccine once before the polysaccharide booster. 
Vaccination with the conjugate vaccine at least twice also after 2 years of age may be 
mandatory for carriage reduction of conjugate vaccine serotypes in children with recurrent 
otitis media. Polysaccharide booster vaccination did not affect nasopharyngeal colonization 
of serotypes not included in the conjugate vaccine.  
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INTRODUCTION 
Streptococcus pneumoniae is one of the leading causes of bacterial infections worldwide, 
mucosal disease like acute otitis media (AOM) being a thousand times more frequent as life-
threatening invasive disease like meningitis. S. pneumoniae commonly colonizes the 
nasopharynx with carriage being highest in infants and toddlers [1-3]. From ages 3 to 5 
years carriage rates decrease, coinciding with a natural increase of antibodies against the 
capsular polysaccharide antigens of pneumococci and natural decrease of pneumococcal 
diseases [4].  
Pneumococcal conjugate vaccines have been shown to reduce nasopharyngeal (NP) 
carriage of conjugate vaccine type (CVT) S. pneumoniae in healthy infants and toddlers [5-
8]. This may partly explain the observed reduction of upper and lower respiratory tract 
infections and AOM [9-12]. In several studies, however, decreased carriage of CVT S. 
pneumoniae after vaccination coincided with an increase of non-conjugate vaccine 
serotypes (NCVT) [5,6,8]. Most likely, this shift from CVT to NCVT S. pneumoniae is due to 
replacement [13,14]. So far, no significant increase in NVCT S. pneumoniae in invasive 
disease has been reported [15]. For mucosal infections like acute otitis media however, 
infants vaccinated with heptavalent pneumococcal conjugate vaccine showed a 27-33% 
higher rate of AOM caused by NCVT S. pneumoniae than controls, alongside a significant 
decrease of AOM caused by CVT S. pneumoniae [10,16]. Serotype replacement at the NP 
level therefore may have a larger impact on mucosal infections as compared to invasive 
disease [17].  
So far, reported clinical efficacy on AOM and carriage studies of pneumococcal conjugate 
vaccines mainly focused on healthy infants and toddlers [9-11,16]. One study published data 
of the clinical efficacy of a 7-valent pneumococcal conjugate vaccine (PCV7, Prevnar®, 
Wyeth) in children with recurrent AOM [18]. In this study combined vaccination with PCV7 
and 23-valent pneumococcal polysaccharide vaccine (PPSV23) had no effect on the clinical 
recurrence rate of AOM. Possibly, particularly in children prone to recurrent respiratory tract 
infections, phenomena like pneumococcal replacement at the NP level after pneumococcal 
vaccination strongly influence the clinical outcome in the prevention of mucosal infections. 
We now describe in detail the impact of vaccination with PCV7 followed by a booster 
PPSV23 on NP carriage of S. pneumoniae in children aged 1 to 7 years with a history of 
recurrent AOM with respect to the different pneumococcal vaccination schemes used in the 
study. 
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SUBJECT, MATERIALS, METHODS 
Nasopharyngeal carriage of S. pneumoniae was studied in a double blind, randomized, 
controlled trial, conducted between April 1998 and January 2002. This study was part of a 
larger study on the clinical efficacy of pneumococcal vaccination on AOM in children with 
recurrent AOM. Overall results of this study have recently been published [18]. Subjects, 
materials and methods of the current study were also described.  
Inclusion criteria for the study were two or more AOM episodes in the year before study 
entry, and age 1-7 years [18]. Exclusion criteria for the study were primary or secondary 
immunodeficiency, cystic fibrosis, immotile cilia syndrome, craniofacial malformation such as 
cleft palate, chromosomal abnormalities such as Down syndrome, and severe adverse 
events during previous vaccinations. Vaccination schemes and timing of NP sampling and 
antipneumococcal antibody evaluation  are shown in figure 1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Vaccination scheme and time points at which nasopharyngeal sampling and immunological evaluation 
(antipneumococcal antibodies against PCV7 serotypes) were performed. Children aged 12-24 months received PCV7 
twice and children aged 25-84 months once before the booster PPSV23. The controls received hepatitis vaccines in a 
similar time-schedule.  
 
 
Vaccinations. The children were randomized to receive either PCV7 followed by PPSV23, 
or hepatitis A or B vaccines. PCV7 (Prevnar®, Wyeth) contained 2 µg each of saccharides 
of pneumococcal serotypes 4, 9V, 14, 18C, 19F and 23F and 4 µg of 6B, coupled to the 
protein carrier CRM197. PPSV23 (Pneumune®, Wyeth) consisted of 25 µg each of 
Intervention group: 7-valent pneumococcal conjugate vaccine 
[Prevnar®]
23-valent polysaccharide vaccine 
[Pneumune®]
Control vaccination:
- Hepatitis B vaccine (<2 years)
- Hepatitis A vaccine (>2 years)
Nasopharyngeal sample
Immunological evaluation
0 1 7 8 14 20 26 months
(< 2 yrs)
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polysaccharides of pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. Control vaccines were recombinant 
hepatitis B vaccine (Engerix®,-B=AE Junior, GlaxoSmithkline) and hepatitis A vaccine 
(Havrix®,=AE Junior, GlaxoSmithkline).    
Nasopharyngeal swabs. NP samples were cultured for S. pneumoniae, H. influenzae, and 
M. catarrhalis. NP samples were obtained by the study physicians by using a flexible sterile 
dry cotton-wool swab (Copan Italia, Transwab, Medical Wire & Equipment Co. Ltd., 
Corsham, England) induced into the nostrils and advanced until resistance was found. The 
swabs were inoculated directly in Stuart’s transport medium and plated within 6 h onto two 
5% sheep blood agar plates, a 5% sheep blood agar plate with 5 mg/L gentamicin, and a 
chocolate agar plate. Agar plates were incubated at 370C for 48 h; the blood agar plates 
aerobically and anaerobically, the blood agar plate with gentamicin and the chocolate agar 
plate with raised CO2. Identification of S. pneumoniae, H. influenzae, and M. catarrhalis was 
based on colony morphology and conventional methods of determination. Initially, 4 S. 
pneumoniae colonies of each plate were serotyped. Since the 4 colonies were found to be 
identical in the first 20 patients, we later serotyped one colony of each plate. Serotyping was 
performed with the capsular swelling method (Quellung reaction) by microscopy with 
commercially available antisera (Statens Seruminstitut, Copenhagen, Denmark).  
Vaccine immunogenicity. Blood samples for serum IgG to the seven pneumococcal 
serotypes in the conjugate vaccine were analyzed by ELISA in randomly selected patients in 
the pneumococcal vaccine group [19].  
Statistical Analysis. In children with a positive culture for S. pneumoniae, carriage of CVT 
and NCVT S. pneumoniae and individual serotypes were analyzed both at 7 months after 
conjugate/control vaccination(s) and after booster polysaccharide/control vaccination. After 
this last vaccination, for each individual only the first pneumococcal culture occurring at 14, 
20 or 26 months was included in the analysis. 
Proportional differences in carriage of S. pneumoniae, H. influenzae, and M. catarrhalis at 
enrolment, after conjugate vaccination alone and after booster with the polysaccharide 
vaccine were analyzed using Chi-square tests or Fisher’s exact tests when appropriate. 
Differences between IgG anti-pneumococcal antibodies between children aged 12-24 
months and children aged 25-84 months were analyzed with Mann-Whitney U test. We 
judged P<0.05 to be significant.  
The study was undertaken in accordance with the ethical standards of the responsible 
committees of both participating hospitals and with the Helsinki Declaration of 1975, as 
revised in 1983.   
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RESULTS 
A total of 383 children were enrolled; 190 children received pneumococcal vaccinations and 
193 control hepatitis vaccinations. Both groups were comparable for age, sex, number of 
previous AOM episodes and environmental risk factors for AOM, like out-of home care (table 
1). More than 95% of all children completed the vaccination scheme and the median follow-
up in both groups was similar [18]. 
Nasopharyngeal swabs were obtained in a similar number of children of the pneumococcal 
vaccine and control group (respectively 185, 182, 175, 141, and 121 children vs. 190, 174, 
169, 140, and 118 children) at study entry and 7, 14, 20, and 26 months after the first 
vaccine dose.  
Pneumococcal carriage at baseline. At enrolment 185 (49%) of the 375 NP swabs of 
children were positive for S. pneumoniae. Of all pneumococcal cultures obtained, 53% 
 
 
Table 1.  Baseline data and clinical characteristics  
Variable Pneumococcal vaccine group (n=190) 
Control vaccine group 
(n=193) 
Male sex  (%) 
 
118 (62%) 119 (62%) 
Median age in years (range) 
 
2.1 (1-6.9) 2.4 (1-7.0) 
Age (%)     
   12-24 months 83 (44%) 79 (41%) 
   25-36 months 42 (22%) 35 (18%) 
   37-84 months 
 
65 (34%) 79 (41%) 
No. of AOM episodes in  
preceding year (%) 
    
   2-3 72 (38%) 69 (36%) 
   4 or more 
 
118 (62%) 124 (64%) 
Day care  (%)     
   At age 12-24months 38/83 (46%) 35/79 (44%) 
   At age 25-48 months 
 
53/66 (80%) 55/65 (85%) 
Mean no. of siblings (SD) 
 
1.1 (0.8) 1.1 (0.9) 
Tobacco smoke exposure indoors (%) 
 
58 (31%) 63 (33%) 
No. of children who completed 
the vaccination scheme (%)  
 
186 (98%) 181 (94%) 
Median months of follow-up 
after completion of vaccination  
scheme (range) 
18.1 (2.4-23.0) 18.0 (0.5-23.0) 
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belonged to CVT: serotype 19F 13%; serotype 6B 12%; serotype 23F 11%; serotype 14 9%; 
serotype 9V 6%; serotypes 18C and 4 both 1%. Of the remaining isolates, 45% were found 
to be NCVT, most frequently cross-reactive serotypes 6A (11%) and 19A (3%) and non-
cross-reactive serotypes 11 (4%) and 3 (3%). Furthermore, 2% of all pneumococcal isolates 
were not typable. Pneumococcal carriage rate at baseline was not influenced by age (12-24 
months vs. 25-84 months) or the number of previous AOM episodes (2-3 AOM vs. 4 or 
more) in the year prior to first vaccination (results not shown). However, the relative 
contribution of CVT pneumococci tended to be less in children 25 months and older (49/102 
pneumococcal isolates; 48%) compared with the younger group aged 1-2 years (49/83 
pneumococcal isolates; 59%, P=0.14).  Even after the age of 36 months still 25 of the 60 
isolated pneumococci (42%) belonged to the CVT. Regardless of age the relative 
contribution of CVT and NCVT S. pneumoniae was not influenced by the number of previous 
AOM episodes (results not shown). 
Impact of vaccination on pneumococcal carriage. Seven months after the first PCV7, the 
number of children carrying S. pneumoniae (85 of 182 children; 47%) was found to be 
decreased compared with controls (101 of 174 children; 58%, P=0.04). With respect to age, 
this difference was found to be significant only in children older than 2 years of age at the 
time of the first vaccination (47% vs. 57%; P=0.04). After PPSV23 overall pneumococcal 
carriage was not reduced compared with controls, remaining around 50% in both age 
groups during follow-up (figure 2).  
The relative contribution of CVT S. pneumoniae to all pneumococcal isolates 7 months after 
the first vaccination was lower in pneumococcal vaccinees (33/85 pneumococcal isolates; 
39%) compared with controls (49/101; 49%). This difference was not significant (P=0.19) 
and not influenced by age (table 2). After PPSV23 however, the contribution CVT S. 
pneumoniae to all pneumococcal cultures was now markedly decreased (35/141 
pneumococcal isolates; 25%) compared with control vaccinees (64/144; 44%, P=0.001). 
This difference was most pronounced in those children first vaccinated at age 12-24 months 
(25% vs. 52%; P=0.002) (table 2). Among children enrolled between 2-7 years, CVT 
carriage rates fell over time among both treatment groups and less difference in CVT 
contribution was observed between pneumococcal vaccinees and controls (25% vs. 38%; 
P=0.06).  
Both after PCV7 vaccination(s) alone at 7 months as well as after PPSV23, the decrease in 
carriage rates of CVT S. pneumoniae occurred in parallel with an increase of carriage of 
NCVT S. pneumoniae (table 2). Seven months after PCV7, 45 of 85 pneumococcal isolates 
(53%) proved to be NVCT compared with 46 of 101 pneumococcal isolates (46%) in controls 
(P=0.31). After PPSV23, 103 of 141 pneumococcal isolates (73%) were NCVT compared 
with 78 of 144  pneumococcal  isolates (54%) in controls (P=0.001). The difference  in NCVT  
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carriage between most treatment groups was more pronounced in children aged 12-24 
months (73% vs. 48%; P=0.004) than in older children (73% vs. 59%; P=0.07).  
Figure 3 shows the relative contributions of CVT and NCVT S. pneumoniae to overall 
pneumococcal carriage during total follow-up according to age at the time of first  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overall pneumococcal carriage percentages at study entry and at 7, 14, 20 and 26 months after thefirst 
vaccination in children according to age 12-24 months (A) and 25-84 months (B) at the time of first vaccination. For the 
number of vaccinees at various time points see results section. Differences in carriage of S. pneumoniae were 
analyzed using Chi-square tests.  
* Statistical significance was considered reached at P<0.05.  
 
 
vaccination; the lower impact of pneumococcal vaccination on pneumococcal NP carriage 
among children enrolled between 2-7 years of age held true when this group was stratified 
further into those 25 to 36 months and those 37 to 84 months at the time of first vaccination  
With respect to the impact of pneumococcal vaccinations on the individual CVT 
pneumococci in children carrying S. pneumoniae 7 months after the first dose of PCV7, only 
the reduction of the conjugate vaccine serotype 14 was found to be significant (P=0.04) in 
children aged 25-84 months at the time of first vaccination (table 2). After PPSV23 the 
reduction of serotype 14 and other individual CVT serotypes did not reach significance. The 
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Table 2. Relative contribution of CVT and NCVT S. pneumoniae  
 
    7 months after first vaccination 
 
     Follow-up after last vaccination 
                 
               Age first vaccination 
                
                   Age first vaccination 
      12-24 months      25-84 months       12-24 months      25-84 months 
      PV 
PI, n=41 
    CV 
PI, n= 41 
     PV 
PI, n=44 
    CV 
PI, n=60 
    PV 
PI, n=60 
    CV 
PI, n=63 
    PV 
PI, n=81 
    CV 
PI, n=81 
 
All PCV7 
serotypes 
 
18 (44%) 
 
21 (51%) 
 
15 (34%)
 
28 (47%)
 
15 (25%)
 
33 (52%)* 
 
20 (25%) 
 
31 (38%) 
4 0 0 1 0 0 1 1 0 
6B 5 7 2 6 4 9 5 5 
9V 0 2 2 2 1 3 0 2 
14 0 4 0 6 * 1 3 3 6 
18C 0 1 1 1 0 5 1 3 
19F 8 3 3 7 3 4 6 9 
23F 5 4 6 6 6 8 4 6 
 
Other 
serotypes 
 
19 (46%) 
 
17 (41%) 
 
26 (59%)
 
29 (48%)
 
44 (73%)*
 
30 (48%) 
 
59 (73%) 
 
48 (59%) 
6A   ** 4    8   5    3    10  10   10  7    
19A ** 0    1   1    2    0    2    2   3    
23A ** 1    1   3    0    1    2    2   1    
23B ** 1    0   2    1   3   0    4   4    
3 1    0   1    1   1    2    3   4   
10 1    0   1    1   1    4    2   3    
11 3    1   3   4  10 *  1   10  6    
15 3    2   3   4  9    4    5   3   
16 0    1   0    1  2    2    6   3   
21 3    0   0    0  1    0    2   2   
Various 2    3   7    12  6    3   13  12  
 
Non- 
Typeable 
 
4 (10%) 
 
3 (8%) 
 
3 (7%) 
 
3 (5%) 
 
1 (2%) 
 
0 (0%) 
 
2 (2%) 
 
2 (3%) 
  
Note. In children positive for pneumococcal isolates (PI, n) the number of children with a conjugate vaccine serotype 
(CVT) or non-conjugate vaccine serotype (NCVT) are shown for pneumococcal vaccinees (PV) and control vaccinees 
(CV). Children are stratified according to age at the time of the first vaccination. Results are shown for time points 7 
months after the first PCV7/control vaccinations and pooled after booster PPSV23/control vaccination. Data of results 
at 14, 20 and 26 months are pooled, including only the first pneumococcal isolate in a child analysis. Differences in 
carriage of the individual CVT and NCVT S. pneumoniae between both vaccine groups were analyzed using Chi-
square tests or Fisher’s exact tests when appropriate. * P<0.05 was considered significant. ** Cross-reactive serotypes 
with PCV7. 
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Figure 3. Carriage of CVT and NCVT S. pneumoniae in pneumococcal and control vaccinees.   
Note. Relative contribution of CVT and NCVT S. pneumoniae to overall pneumococcal carriage according to age at 
first vaccination. Percentages of CVT and NCVT at study entry and at 7, 14, 20 and 26 months after the first vaccine 
dose are shown for pneumococcal vaccinees (solid squares) and control vaccinees (open squares). 
 
 
increase of NCVT S. pneumoniae was significant for serotype 11 (P=0.007) only after 
PPSV23 in the youngest children (table 2). With respect to possible cross-protection 
between different serotypes of the same serogroup, no protective effect of pneumococcal 
vaccination for serotype 6A was observed. Serotypes 19A, 23A and 23B were only rarely 
cultured.  
Vaccine immunogenicity. After complete vaccination, geometric mean IgG concentrations 
reached values far above 1.0 mg/L and were roughly similar in children first vaccinated at 
age 12-24 months and older children for all CVT serotypes with the exception of 6B, which 
remained below 1.0 mg/L in the youngest group (table 3).  
Nasopharyngeal carriage of H. influenzae and M. catarrhalis. At study entry H. influenzae 
and M. catarrhalis were found in the nasopharynx of 58% and 50% of children, respectively. 
With respect to age and history of AOM, only carriage of M. catarrhalis was influenced by 
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age; 12-24 months 57% and 25-84 months 44% (P=0.02). Pneumococcal vaccinations did 
not affect carriage of H. influenzae or M. catarrhalis during follow-up as compared to control 
vaccinations (data not shown). 
 
Table 3. Antipneumococcal antibodies  
 
PCV7 
serotypes 
Pre vaccination p-value After last vaccination p-value 
 
 
Age first vaccine dose  Age first vaccine dose  
  
12-24  
months 
 
>25  
months 
  
12-24  
months 
 
> 25  
months  
 
       
4 0.05 0.04     0.02  * 5.85 3.33      0.02   * 
6B 0.04 0.04 0.70 0.56 1.52      0.01   * 
9V 0.18 0.20 0.61 28.40 24.94 0.64 
14 1.03 2.01 0.09 78.06 75.89 0.86     
18C 0.15 0.29      0.003 * 9.63 9.01 0.97 
19F 0.22 0.36      0.04   * 12.34 13.05 0.98 
23F 0.42 0.60      0.02   * 1.71 3.69 0.05 
       
 
Note. Geometric mean concentrations (mg/L) of IgG antibodies against the 7 conjugate vaccine pneumococcal 
serotypes at baseline and one month after booster PPSV23 are shown separately for children first vaccinated at age 
12-24 months (n=42) and age 25-84 months (n=51) Statistical differences between the youngest and older children 
were analyzed with Mann-Whitney U test. * We judged P<0.05 to be significant. 
 
 
DISCUSSION 
We describe for the first time the impact of 7-valent pneumococcal conjugate followed by 23-
valent polysaccharide vaccination on NP carriage of S. pneumoniae in a group of toddlers 
and children aged 1-7 years with a history of recurrent AOM. Overall pneumococcal NP 
carriage rates in these children did not diminish after pneumococcal vaccinations during 2 
years of follow-up. However, in particular in children first vaccinated at age 1-2 years who 
received PCV7 twice before PPSV23, a shift was induced from CVT to NCVT S. 
pneumoniae. In older children, who received PCV7 only once before PPSV23, the impact of 
pneumococcal vaccinations on pneumococcal carriage was far less pronounced. Since both 
age groups showed a similar contribution of CVT S. pneumoniae to NP carriage at start of 
the study, this does not explain the lower vaccine influence after 2 years of age. Also both 
age groups achieved roughly similar IgG serum levels against pneumococcal serotypes by 
pneumococcal vaccinations except for IgG titers against serotype 6B, which remained below  
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1 mg/L in the youngest group. We therefore assume that the greater shift from CVT to NCVT 
in children aged 1-2 years is primarily explained by the difference in vaccine schemes; the 
younger patients receiving two and the older patients one PCV7. This is underlined by the 
fact that vaccination influence was already nearly absent in pneumococcal vaccinees aged 
25 to 36 months.  
The T-cell dependent characteristics of a conjugate vaccine result in recruitment of new 
memory B-cells, which increase after each vaccination whereas a polysaccharide vaccine 
may only trigger pre-existing memory cells [20]. At the mucosal level, the extra B-cell 
recruitment may result in better opportunity to boost mucosal immunity by transient natural 
contacts with conjugate vaccine serotypes. Nurkka et al. previously described an increase in 
salivary IgG several months after a last vaccination with PCV7 in several children whereas 
only one child showed a late increase in salivary IgG after a booster polysaccharide vaccine 
[21]. Thus, although both PCV7 and PPSV23 booster vaccinations significantly increase 
serum quantitative IgG responses, the conjugate vaccine may be superior in inducing 
mucosal memory for the conjugate vaccine serotypes. Also other qualities like antibody 
affinity may be superior after extra conjugate vaccinations as compared to the 
polysaccharide booster, which may also lead to better mucosal immunity [22]. 
Pneumococcal polysaccharide vaccine is known to have little influence on NP 
pneumococcal colonization [23,24]. Our study shows it also fails to prevent the increase of 
nasopharyngeal carriage of NCVT pneumococci such as serotype 11, despite induction of 
good serum IgG levels [18] and apparently does not affect the NP flora of those serotypes 
included in the PPSV23 but not in PCV7. Hypothetically, a polysaccharide booster might 
even frustrate future antibody responses at the mucosal site on subsequent natural 
challenge with polysaccharides [25]. After the conjugate vaccinations, we saw an initial 
decrease of pneumococcal carriage just before booster vaccination with the 23-valent 
polysaccharide vaccine, particularly in children over 2 years of age. After the polysaccharide 
booster however, pneumococcal carriage rates subsequently increased again to levels 
similar to before vaccinations and identical to controls. We do not think however, that this 
failure to bring down pneumococcal carriage is due to the polysaccharide booster because 
after pneumococcal vaccination in healthy infants and toddlers overall pneumococcal 
carriage also was not affected [6-8]. 
In our risk group for AOM, baseline NP pneumococcal carriage rate was around 50%, which 
is in line with average carriage rates for similar age groups worldwide [1]. PCV7 serotypes 
comprised 53% of the pneumococcal strains isolated from the nasopharynx, which is similar 
to recent Finnish data on NP pneumococcal carriage in children [26]. Whether otitis-prone 
children do have higher pneumococcal carriage rates during health as compared to non 
otitis-prone children is still a matter of debate [27]. However, in contrast to a recent report in 
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the Netherlands [28], in our study older children aged 3-7 years did not show decreasing 
overall pneumococcal colonization rates even after 2 years of follow-up. It may be 
speculated that older children suffering from recurrent otitis still have high pneumococcal 
carriage rates because they are unable to eradicate pneumococci from their nasopharynx or 
prevent new acquisition due to minor immunodeficiency [18,29-33]. 
Despite low mean serum IgG concentrations for serotype 6B (< 1 mg/L), a significant  
decrease in carriage of serotype 6B by 50% was noted in the youngest age group. We found 
a lack of influence of pneumococcal vaccinations on carriage of the cross-reactive serotype 
6A, most probably related to the low anti-6B antibody response. Väkeväinen et al. showed 
that on average, 2-6 times more anti-6B antibodies were needed for 50% opsonophagocytic 
killing of the type 6A than the type 6B strain [34]. A low IgG response against serotype 6B 
upon PCV7 as in both younger and older patients of our study group was also reported in 
other small groups of infection–prone patients [35,36]. A third study in otitis-prone children 
could not confirm this observation [37]. 
The observed nasopharyngeal replacement from CVT to NCVT pneumococci after 
pneumococcal vaccination in our study population seems to be due largely to replacement 
[Bogaert et al. submitted]. Apart from replacement by NVCT pneumococci, pneumococcal 
vaccinations did not influence carriage of other in potential AOM pathogens, like H. 
influenzae and M. Catarrhalis. 
Clinically, we previously reported that no protective effect of combined pneumococcal 
conjugate and polysaccharide vaccination was found for the prevention of AOM after 1 year 
of age in children with a history of AOM [18]. Particularly in the youngest children this may 
be due to the replacement of CVT by NCVT S. pneumoniae. After two years of age, 
pneumococcal carriage was less influenced by vaccination and therefore may not have 
affected the incidence of AOM.  
The results of our study show that in high risk groups not only vaccine immunogenicity 
studies should be performed but also clinical efficacy studies combined with the evaluation 
of the bacterial changes in nasopharyngeal colonization to provide insight in the impact of 
vaccinations. Despite adequate quantitative serum IgG levels, at least two doses of 
conjugate vaccinations seem to be mandatory for reduction of nasopharyngeal carriage of 
CVT serotypes. To obtain higher serum IgG levels for serotype 6B, a third or perhaps fourth 
conjugate vaccination may be required at all ages, which may only than result in reduction of 
carriage of serotype 6A. Booster vaccination with a polysaccharide vaccine does not seem 
to enhance mucosal immunity. The results of this study should be kept in mind when 
recommending pneumococcal vaccinations for mucosal disease like AOM but also for lower 
respiratory tract infections like pneumonia in children after 1 year of age, particularly for risk 
groups. 
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ABSTRACT 
Introduction. A randomized double-blind trial with a 7-valent pneumococcal conjugate 
vaccine was conducted in The Netherlands among 383 children, aged 1-7 years, with a 
history of recurrent acute otitis media. No effect of vaccination was found on the 
pneumococcal colonization rate. However, a shift in serotype distribution was clearly 
observed (Veenhoven, 2003. Lancet: 361:2189-95).  
Methods. We investigated the molecular epidemiology of 921 pneumococcal isolates 
retrieved from both the pneumococcal vaccine (PV) and control vaccine (CV) group during 
the vaccination study.  
Results. Within individuals a high turnover rate of pneumococcal genotypes was observed, 
which was unaffected by vaccination. Comparison of the genetic structure before and after 
completion of the vaccination scheme revealed, despite a shift in serotypes, clustering 
between 70% of the pneumococcal populations. The remaining isolates (30%) were equally 
observed in the PV and the CV group. In addition, the degree of genetic clustering was 
unaffected by vaccination. However, within the population genetic structure, non-vaccine 
serotype clusters with the serotypes 11, 15 and 23B became predominant over vaccine-type 
clusters after vaccination. Finally, overall pneumococcal resistance was low (14%), and, 
albeit not significant, a reduction in pneumococcal resistance as a result of pneumococcal 
vaccination was observed. 
Conclusion. Molecular surveillance of colonization in Dutch children shows no effect of 
pneumococcal conjugate vaccination on the degree of genetic clustering, and the genetic 
structure of the pneumococcal population. However, within the genetic pneumococcal 
population structure, a clear shift was observed towards non-vaccine serotype clusters. 
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INTRODUCTION 
Streptococcus pneumoniae is worldwide one of the major bacterial causes of invasive 
disease and respiratory tract infections in children. Risk groups for pneumococcal infections 
are young children, elderly and immune-deficient patients. Despite adequate antibiotic 
treatment, morbidity and mortality due to pneumococcal disease remains high (6). Moreover, 
the increasing (multi) drug resistance among pneumococcal isolates hampers adequate 
treatment (1, 11, 21, 30). New pneumococcal conjugate vaccines, have shown to be 
effective against invasive diseases in young children (4). Furthermore, a protective effect 
against respiratory tract infections such as (recurrent) otitis media has been observed (4, 
15). Thus far, the 7-valent pneumococcal conjugate vaccine Prevnar (Wyeth, USA) has 
been approved by the Food and Drug Administration (USA), and the Committee on 
Proprietary Medicinal Products (Europe), and is recommended by the Advisory Committee 
on Immunization Practices (USA) for the prevention of invasive diseases in children under 2 
years of age. Recommendations are also made for older children at increased risk for 
invasive disease, like those with HIV and asplenia, and those with increased risk for 
pneumococcal mucosal disease, such as children with recurrent acute otitis media (2). We 
recently studied the effect of a 7-valent pneumococcal conjugate vaccine followed by a 23-
valent polysaccharide vaccine in children aged 1-7 years with a history of recurrent acute 
otitis media (32). Clinically, no protective effect of the pneumococcal vaccines on recurrence 
of acute otitis media was found. At the nasopharyngeal level, however, a significant 
reduction of colonization with vaccine-type pneumococci was found after vaccination, 
whereas a simultaneous increase in colonization with non-vaccine serotypes was observed 
(32). 
In this study, we investigated the molecular epidemiological dynamics and resistance 
profiles of the pneumococcal isolates collected from both children in the pneumococcal 
vaccine (PV) and the hepatitis control vaccine group (CV) in order to obtain insight in the 
effect of conjugate vaccination on the genetic pneumococcal population structure. 
 
 
MATERIAL AND METHODS 
Bacterial isolates. In total, 383 children, aged 1-7 years, suffering from recurrent acute 
otitis media, were enrolled in this double-blind randomized vaccination trial in the period 
April 1998 to December 2001 (32). Hundred-ninety children received once a 7-valent 
pneumococcal conjugate vaccine when 24 months of age and older (Prevenar®, Wyeth 
Lederle), or twice in children 12-24 months of age, followed by a 23-valent pneumococcal 
polysaccharide vaccine after 6 months for all children (Pneumune®, Wyeth Lederle). The 
193 control children received, depending on the age, three times Hepatitis B (Engerix-B®, 
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Smithkline Beecham) or twice Hepatitis A vaccine (Havrix junior®, Smithkline Beecham). 
Nasopharyngeal cultures were performed at study entry, just before booster vaccination at 7 
months and at 14, 20 and 26 months. An additional nasopharyngeal sample was obtained at 
the first acute otitis media event after full vaccination. Pneumococcal carriage was observed 
in around 50% of all children. This carriage rate was maintained in both study groups in the 
26 months follow-up period. Thus, no influence on overall colonization was observed during 
the study. Instead a decline in vaccine serotype carriage was observed in the PV group 
whereas the non-vaccine serotype carriage increased (32). Nine hundred twenty-one 
isolates (95%) from 353 out of 383 patients participating in this study were available for 
further analysis by genotyping and susceptibility testing. 
Bacteriological procedures. Isolation and identification of the S. pneumoniae isolates were 
performed by standard methods as described previously (32). Susceptibility testing was 
performed by the agar-dilution method (25). Resistance was defined by the breakpoint 
concentrations for the respective antibiotics as defined by the NCCLS (26). Multidrug 
resistance was defined as resistance to ≥3 classes of antimicrobial agents.  
Serotyping. Pneumococci were serotyped by the capsular swelling method (Quellung 
reaction) observed microscopically using commercially available antisera (Statens Serum 
institute, Copenhagen, Denmark).  
Restriction fragment end labeling (RFEL) typing. Pneumococcal strain typing by RFEL 
was done as described by van Steenbergen et al. (31) and adapted by Hermans et al. (19). 
Briefly, purified pneumococcal DNA was digested by the restriction enzyme EcoRI. The DNA 
restriction fragments were end labeled at 72oC with [α-32P]dATP using DNA polymerase 
(Goldstar; Eurogentec, Seraing, Belgium). After the radiolabeled fragments were denatured 
and separated electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M 
urea, the gel was transferred onto filter paper, vacuum dried (HBI, Saddlebrook, NY), and 
exposed for variable times at room temperature to ECL hyperfilm (Amersham Laboratories, 
Amersham, UK).  
Computer-assisted analysis of DNA band patterns. RFEL autoradiographs were 
converted to images (Image Master DTS; Pharmacia Biotech, Uppsala Sweden) and 
analyzed by computer (Windows version Gelcompar software version 4; Applied Math. 
Kortrijk, Belgium). DNA fragments were analyzed as described previously (27). For 
evaluation of the genetic relatedness of the isolates we used the following definitions: (1) 
isolates of a particular RFEL type are 100% identical by RFEL analysis; (2) an RFEL cluster 
represents a group of RFEL types that differ in only one band (approximately >95% genetic 
relatedness).  
Multi locus sequence type (MLST) analysis. The genotypes of 38 isolates representing 
different serotypes were investigated by MLST analysis. Within the 23 largest clusters 
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representing 29 RFEL genotypes, the most prevalent serotypes were analyzed. For this 
purpose, a fully automated method for MLST was used as described previously (20). The 
MLST types were compared with the global PMEN database (http://www.pneumo.com/ 
physician/pmen/pmen_history.asp). 
Data-analysis. P-values for differences were calculated with the Chi-square test using 
GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, USA).  
 
 
RESULTS 
Nine hundred twenty-one pneumococcal isolates from nasopharyngeal samples of 351 
children participating in the study were available for molecular analysis by RFEL. In total, 
450 of these 921 pneumococcal isolates were isolated from children in the pneumococcal 
vaccine group, whereas 471 isolates were isolated in the control group. Of the 921 isolates, 
180 isolates were isolated at the start of the study (T=0 months; day of (first) conjugate 
vaccination), 176 isolates were retrieved at 7 months (day of booster vaccination) and 186, 
163 and 119 isolates were isolated after completion of the vaccination scheme at 14, 20 and 
26 months of study duration, respectively (Table 1). The remaining 97 isolates were 
retrieved at the first AOM events after full vaccination (>7 months). The serotype distribution 
of all pneumococcal isolates collected during this study was discussed previously (32). In 
summary, the contribution of vaccine serotype pneumococci to colonization gradually 
declined from 46% at study entry to 26% at the end of the study compared to the control 
group in which the contribution of the conjugate-vaccine serotypes remained approximately 
50%, whereas the total pneumococcal carriage rate remained unaffected.   
 
Table 1. Pneumococcal isolates with regard to study group and study phase. 
 
 Total Vaccine 
group 
% vaccine-type strains Control group % vaccine-type 
strains 
All phases 921 451  470  
      
0 months 180 96 46% 84 58% 
7 months 176 81 41% 95 46% 
14 months 186 84 26% 102 40% 
20 months 163 81 25% 82 49% 
26 months 119 64 26% 55 54% 
First AOM 97 45 24% 52 44% 
 
 
All 921 isolates were characterized by RFEL. We identified 275 different genotypes 
representing one to 49 isolates per genotype with an average of 3.35 isolates per genotype. 
Analysis of the per-patient follow-up revealed a high turnover rate of pneumococcal 
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genotypes; only in 54 out of the 351 children persistent carriage was found for at most 3 
consecutive samples (recurrence twice after a 6-7 months interval) (Table 2). No statistical 
difference in the rate of persistent carriage was found between the pneumococcal vaccine 
group and the control group children (15% versus 16%; p = 0.67). In both groups, the 
majority of the persistent isolates (60%) were non-vaccine serotypes. On three occasions, 
persistence of a specific genotype was accompanied by a switch in serotype. In one case, 
colonization with one particular genotype which is closely related to MLST type displaying 
serotype 15 was 6 months later followed by colonization with a second genotype of serotype 
19A. Another 6 months later the initial genotype with a capsular switch to serotype 19A was 
identified. In the second case a switch was observed from serotype 14 to serotype 8 within 
the same genotype after a 6 months interval. The third case represented a capsular switch 
from serotype 6A to serotype 19F observed after a 6 months interval.  
We analyzed the genetic relatedness of the pneumococcal isolates retrieved at start of the 
study and 14 months after the initial vaccination from both study groups. The 180 
pneumococci isolated at start of the study displayed 93 genotypes, representing 52 unique 
genotypes and 30 clusters (128 isolates) with an average cluster size of 4.3. The 186 
isolates isolated 14 months after start of the study displayed 105 genotypes, representing 54 
unique genotypes and 29 clusters (132 isolates) with an average cluster size of 4.6. Close 
homology (≥ 95% genetic relatedness) was found between 70% of the isolates at both time 
points (T=0 and T=14 months). The remaining genotypes equally represented strains from 
either PV or CV children (49% and 51%, respectively). The 4 most predominant clusters at 
start of the study were cluster I (7.8% of all isolates; serotypes 6A and 6B), cluster II (7.3%; 
serotype 14), cluster III (4.5%; serotype 23F) and cluster IV (4.5%; serotype 9V). These 
clusters were still predominant 14 months after vaccination, though slightly reduced in size 
(4.8%, 4.3%, 4.3% and 2.2%, respectively) and mainly observed in control group children 
(Figure 1). In addition, five minor clusters observed in the initial phase of the study, cluster A 
(2.8% of all isolates; serotype 11), cluster B (1.1%; serotype 11), cluster C (2.8%; serotype 
15), cluster D (2.8%; serotype 16) and cluster E (1.7%; serotype 23B), became predominant 
clusters 14 months after vaccination with a prevalence of 4.8%, 4.3%, 4.3%, 5.4% and 
3.8%, respectively. The first 2 clusters, which resembled 85% homology, were 
predominantly present in PV children (89% and 63%, respectively) (Figure 1).  
 
Figure 1 (right). Population genetic structure of the 180 and 186 pneumococcal isolates retrieved before vaccination 
(T=0 months) and after pneumococcal conjugate vaccination (T=14 months), respectively. Genetic relatedness is 
depicted in percentages. The serotypes and number of isolates per genotype are shown in bars for the two periods 
separately. The contribution of vaccinated children and control children is shown in grey and black, respectively. The 
numbers I-IV represent predominant clusters at the initial phase of the study. The letters A-E represent emerging 
clusters after conjugate vaccination. Clusters consisting of two or more genotypes are shown in brackets. Clusters of 
one genotype are depicted with x.  
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Figure 2. Genetic relatedness of the 38 MLST sequence types observed within the 23 largest RFEL clusters. 
 
We investigated 38 isolates representing different serotypes by MLST analysis. Within the 
23 largest clusters representing 29 RFEL genotypes, the most prevalent serotypes were 
analyzed. (Figure 2). We found no PMEN clones in our collection of pneumococci. In 
addition, we observed 4 new MLST genotypes. In general, the observed homology by RFEL 
genotyping was confirmed by MLST, except for RFEL genotype 028 for which RFEL 
genotyping showed to be less discriminatory than MLST analysis (Figure 2).  
We determined the MICs for penicillin, cotrimoxazole, tetracycline, erythromycin, rifampicin, 
vancomycin and ciprofloxacin of 919 isolates. Resistance to at least one antibiotic was found 
in  128  pneumococcal  isolates (14%).    High  level  resistance  to  penicillin, cotrimoxazole,  
241 9V 941 8 10 15 27 2 28 71 
241 NT 941 8 10 15 27 2 28 71 
23 15 162 7 11 10 1 6 8 14 
23 9V 162 7 11 10 1 6 8 14 
599 10 097 5 7 4 2 10 1 27 
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426 NT NEW 2 5 2 NEW 2 19 14 
422 11 062 2 5 29 12 16 3 14 
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490 11 NEW 2 5 29 12 9 NEW 14 
420 19F 395 1 5 7 12 17 1 35 
420 6A 395 1 5 7 12 17 1 14 
167 3 180 7 15 2 10 6 1 22 
RFEL  sero  MLST  aroE  gdh   gki   recP  spi   xpt   ddl 
      type   
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tetracycline, erythromycin and ciprofloxacin was found in 2 (0.2%), 37 (4.0%), 28 (3.0%), 29 
(3.2%), and 2 (0.2%) isolates, respectively. Furthermore, intermediate resistance to penicillin 
and cotrimoxazole was found in 8 (0.9%) and 61 (6.6%) isolates, respectively. Intermediate 
resistance to tetracycline, erythromycin and cefotaxime was seen only occasionally (Table 
3).  
 
 
Table 3. Antibiotic resistance rates for the S. pneumoniae collection 
 
 Nr. of resistant  
strains 
Percentage 
of total 
Nr. of intermediate 
resistant strains 
Percentage of total 
Penicilline 2 0.2% 8 0.9% 
Cotrimoxazole 37 4.0% 61 6.6% 
Tetracycline 28 3.0% 5 0.5% 
Erythromycin 29 3.2% 1 0.1% 
Ciprofloxacin 2 0.2% 0  
Cefotaxim 0  2 0.2% 
 
 
Table 4. S. pneumoniae antibiotic resistance profiles, profile rates, number of genotypes and their serotype distribution. 
 
Resistance  
Profile* 
Nr. of 
strains 
 
(%) 
Nr. of 
genotypes 
Serotypes 
     
Co(I) 53  (5.7) 29 3/ 7/ 8/ 10/ 11/ 12/ 14/ 18C/ 18F/ 6A/ 
6B/ 9A/ 9V/ 19A/ 19F/ 23F/ 31/ 33D 
/NT 
 
Co 25  (2.7) 16  6A/ 6B/ 9V/ 18C/ 21/ 23F/ NT/ 34 
  
T 7    (0.8) 6 3/ 19C/ 19F 
T(I) 4    (0.4) 4 23F/18C/ 11/ 38 
T(I)E 1    (0.1) 1 33 
Tci 1    (0.1) 1 19F 
TE 7    (0.8) 6 9N/ 19F 
E 8    (0.9) 6 11/ 14/ 15/ 33 
E(I) 1    (0.1) 1 23B 
Co(I)E 2    (0.2) 2 6A/ 8 
Co(I)T 1    (0.1) 1 6B 
Co(I)TE 1    (0.1) 1 6B 
CoT 2    (0.2) 2 23A/ 19F 
CoTE 5    (0.5) 4 6A/6B 
P(I) 1    (0.1) 1 11 
P(I)CoCf(I) 1    (0.1) 1 14 
P(I)Co(I)ECf(I) 1    (0.1) 1 6B 
P(I)CoTE 3    (0.3) 3 19F/ 6B/ 14 
PCo(I) 1    (0.1) 1 15 
P(I)Co(I) 2    (0.2) 2 14/ 23F 
PcoTE 1    (0.1) 1 6B 
PE 1    (0.1) 1 6A 
                       
Total 
 
128  
 
(13.8) 
  
*Co: cotrimoxazole; P: penicilline; T: tetracyclin; E: erythromycin; Cf: cefotaxim; Ci: ciprofloxacin.  
(I): intermediate resistance 
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No cases of resistance to rifampicin and vancomycin were identified. In Table 4, the 
resistance profiles and their rates, serotypes and number of genotypes are depicted. In total, 
21 different resistance profiles were observed. We observed (intermediate) resistance to a 
single drug in 99 isolates (10.7% of all isolates), dual resistance in 17 isolates (1.8%) and 
multidrug resistance (resistance to 3 or more antibiotics) in 12 isolates (1.3%).  
To evaluate the effect of vaccination on pneumococcal resistance, we compared resistance 
rates before full vaccination (samples at study entry plus at 7 months study duration) and 
after full vaccination (samples at 14, 20 and 26 months). In the PV children resistance 
declined from 17.5% before full vaccination to 11.8% after full vaccination, whereas in the 
CV children resistance was stable (14.5% and 14.3% before and after full vaccination, 
respectively). This difference did not reach statistical significance. We also evaluated the 
serotype distribution among the resistant isolates. 57% of all resistant isolates displayed 
vaccine serotypes. In addition, 10 out of the 12 multidrug-resistant isolates (83%) were 
vaccine serotype isolates, whereas the remaining two isolates displayed the cross-reactive 
serotype 6A.  
 
 
DISCUSSION 
Between 1998 and 2002 a large randomized, double blind vaccination trial with a 7-valent 
pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine was 
performed among 383 children, aged 1-7 years, with a history of recurrent acute otitis 
media. Surprisingly, no beneficial effect was observed on the frequency of acute otitis media 
after pneumococcal vaccination nor on the overall colonization rate of S. pneumoniae. 
However, a shift of vaccine type pneumococci to non-vaccine type pneumococci was 
observed among nasopharyngeal colonization isolates. Emerging non-conjugate vaccine 
serotypes were serotypes 11, 15 and 16 (32). We questioned whether this shift occurred 
within specific genotypes or whether replacement took place with genetically different 
strains. If the latter was true, we wondered if these different genotypes were equally capable 
of horizontal dissemination and whether they represented comparable antibiotic resistance 
profiles. 
Therefore, we analyzed the 921 pneumococcal isolates retrieved from 351 of the 383 
participating children. We observed 275 different genotypes, representing 106 genetic 
clusters and 75 unique genotypes. Analyzing the per-patient follow-up revealed few 
episodes of persistent carriage. This implicates that pneumococcal colonization is a dynamic 
process with a high turnover rate of colonizing strains. No effect of vaccination was found on 
the limited rate of persistent strains. This was to be expected, because the majority of the 
persistent strains in both PV and CV group were non-vaccine serotypes.  
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Remarkably, in three cases of persistent carriage, a serotype switch was observed. 
However, one could argue whether the consecutive colonization with the serotype 15 and 
serotype 19A variant of a strain closely related to MLST 199 suggests the recruitment of a 
second isolate with identical genotype rather than a capsular switch. Importantly, in contrast 
to many countries including the US, this genotype is not very common in The Netherlands 
(3%) and a 19A serotype variant has not been previously observed. Therefore, our findings 
strongly suggest a capsular switch. So far, this phenomenon was only reported in vivo twice 
by Barnes et al. (3) and Sluijter et al. (27). Indirect proof for capsular switch was previously 
shown by other investigators who demonstrated the true recombinational exchanges at the 
capsular locus (7-9, 24). One might argue that our observations are events enhanced by 
conjugate vaccination due to the induction of a selective immunological pressure. Indeed, 
the serotype 15/19A switch was observed in a PV child but no conjugate vaccine type 
pneumococci were involved. The two additional cases (serotype 6A/19F and 14/8 switch) 
were observed in CV children. Although our data support the theory that serotype switch is a 
natural process which can be observed occasionally within an individual, a large quantity of 
data will be required to study the impact of conjugate vaccination on this process.  
Comparison of the genetic structure of the pneumococci isolated at study entry and at 14 
months after pneumococcal conjugate vaccination showed 70% homology between the 
pneumococcal isolates at the two time points. The non-overlapping isolates were equally 
distributed among PV and CV children. Furthermore, initially predominant clusters displaying 
vaccine serotypes had been partially replaced by non-vaccine serotype clusters after 
vaccination, which displayed a similar capability to spread horizontally. Though replacement 
of vaccine types by non-vaccine serotypes has has been described as a result of growing 
age (12), we observed this shift significantly more often in children who received the 
pneumococcal vaccines, indicating this process is enhanced by vaccination.  
Our most predominant clusters represented multiple vaccine and non-vaccine serotypes. 
Since the observed genetic homology was confirmed by MLST analysis, our data suggest 
that a large number of recombinational events at the capsular loci have occurred within 
these clusters. This is in line with previous data from the USA and Latin America where the 
major (resistant) clones also show multiple serotypes as a result of capsular serotype switch 
(9, 10, 16, 22, 29). Wolf et al. (33) have shown that these events occur even more often in 
susceptible pneumococcal clones, which is in line with our findings.  
Our data support the hypothesis that serotype replacement observed after conjugate 
vaccination does not directly indicate a shift in the genetic structure of the pneumococcal 
population. Shifts towards and predominance of non-vaccine serotype variants are likely to 
occur within genetic clusters displaying both vaccine and non-vaccine serotypes. However, 
MLST  analysis  of  the most  predominant clusters of our collection of pneumococcal strains 
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showed the presence of new genotypes and the absence of PMEN homologous clones. 
Therefore, this collection of strains might not be representative for countries where multidrug 
resistant clones are predominantly present.  
To evaluate whether vaccination will have an effect on the presence of antibiotic resistance, 
we determined the antibiotic resistance profiles of all 921 isolates. Susceptibility testing of 
919 of the 921 pneumococcal isolates was performed for penicillin, cotrimoxazole, 
tetracycline, erythromycin, rifampicin, vancomycin, cefotaxime and ciprofloxacin. In 
agreement with previous studies performed in The Netherlands, the overall resistance is low 
(14% of the isolates) compared to other European countries (5, 13, 14, 17, 18). Penicillin 
resistance was found rarely in our study. In contrast, we most frequently observed 
resistance to cotrimoxazole, tetracyclin and erythromycin. We compared our data with a 
previous study performed in The Netherlands, where 10,489 clinical pneumococcal isolates 
have been tested for drug susceptibility (14). Compared to this study (reference year 1999), 
we noted a higher incidence in cotrimoxazole resistance (4.4 versus 10.6) and a lower 
incidence in tetracyclin resistance (3.5% versus 6.6%). Both observations can be explained 
by the age difference between the study groups; our study was performed in children under 
7 years of age, whereas the surveillance study represented all age groups including adults. 
In contrast to adults, tetracyclines are contraindicated in children whereas cotrimoxazole is 
often first choice treatment.  
We found an equal percentage of (intermediate) resistance to a single drug in our study 
population compared to the surveillance study (77% of the resistant isolates), comparable 
dual resistance (13% an 19%, respectively) and significantly higher multidrug resistance (9% 
and 4%, respectively; p < 0.01). We hypothesize that our children might select for multidrug 
resistant strains because of higher antibiotic consumption which is in accordance with 
previous findings (23, 28).  
In addition, we analyzed changes in the incidence of pneumococcal resistance. To this end, 
we compared resistance among the pneumococcal isolates between the initial phases of the 
study (before full vaccination) and the post-vaccination phases. Although a trend was seen 
with a decline in resistance from 17.5% to 11.8%, this was not statistically significant. 
Because of the low resistance rates, no subsidiary analysis could be performed for the 
separate sample dates. Therefore, we analyzed the serotype distribution among the 
resistant isolates, which showed that 57% of the resistant isolates depict a vaccine serotype, 
which is comparable to the overall serotype distribution. However, all multidrug-resistant 
isolates were vaccine types or cross-reactive serotypes. Although resistance is low among 
S. pneumoniae in The Netherlands, these data suggest that vaccination with the 7-valent 
conjugate vaccine may reduce pneumococcal resistance in the population, particularly 
multidrug resistance. 
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In conclusion, pneumococcal conjugate vaccination did not induce a shift in the population-
based structure of the pneumococci, nor decreased their tendency to spread horizontally. 
Our observations combined with the vaccine efficacy data of Veenhoven et al. (32) suggest 
that pneumococcal conjugate vaccination is not very useful for prevention of pneumococcal 
colonization in children above 1 year of age. Moreover, we strongly advice continuous and 
close monitoring of the pneumococcal genetic structure in areas with a conjugate 
vaccination policy. 
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ABSTRACT 
The efficacy of pneumococal conjugate vaccines in young children may be complicated by 
serotype replacement. We developed a colony blot assay which enables the identification of 
re-colonization with novel serotypes (replacement), overgrowth by minor co-colonizing 
serotypes or suppression of previously predominant vaccine serotype strains as a result of 
vaccination. This method allows the identification of multiple serotypes in a single specimen 
in a ratio of 1:1000. In order to demonstrate the potential of our method, we investigated the 
consecutive nasopharyngeal samples of 26 children who had shown a shift in pneumococcal 
colonization after conjugate vaccination. Mixed colonization was found once in 15 pre-
vaccination samples and 4 times in 26 post-vaccination samples. In the remaining children 
‘true replacement’ had presumably occurred. Hence, we conclude that the colony blot assay 
is an easy to apply method, which allows the identification of different pneumococcal 
serotypes within single clinical specimens. 
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INTRODUCTION 
Current pneumococcal conjugate vaccines are protective against invasive diseases in 
children [1]. However, the impact of vaccination on otitis media and nasopharyngeal 
colonization is limited [2,3]. Several studies demonstrated a shift in carriage from vaccine-
type pneumococci towards non-vaccine types after conjugate vaccination [4]. Whether this is 
caused by unmasking of pneumococcal serotypes which are already present at the 
nasopharynx or by replacement, i.e. the acquisition of other serotypes, remains unknown [5]. 
We therefore developed a colony blot assay, which allows the detection of multiple 
serotypes, i.e. mixed colonization, within clinical specimens. Such a method is a useful tool 
to investigate the pneumococcal serotype dynamics, e.g. changes in pneumococcal 
population structure during colonization. Furthermore, this method has important 
applications with respect to the monitoring of pneumococcal vaccination. 
 
 
MATERIALS AND METHODS 
Clinical specimens. We studied the nasopharyngeal cultures from 26 children participating 
in a pneumococcal conjugate vaccine trial in The Netherlands [2]. Inclusion criteria for this 
study were (1) two or more AOM episodes prior to study entry, and (2) age of 1 to 7 years. 
The number of previous AOM episodes was based on parental report. Children aged 12-24 
months were immunized with PCV7 (Prevnar®, Wyeth) twice at a one-month interval 
followed 6 months later by PPSV23 (Pneumune®, Wyeth). Children aged 25-84 months 
received one dose of PCV7 followed 7 months later by PPSV23.  
Nasopharyngeal swabs. At study entry, at 7 months (just before booster PPSV23 
vaccination) and at 7, 14, 20 and 26 months after the last vaccination a nasopharyngeal 
sample was obtained for culture of S. pneumoniae, H. influenzae, and M. catarrhalis. The 
nasopharyngeal samples were taken transnasally by the study physicians using a flexible 
sterile dry cotton-wool swab (Copan Italia, Transwab, Medical Wire & Equipment Co. Ltd., 
Corsham, England). After sampling, swabs were placed directly in Stuart’s transport 
medium. Samples of nasopharyngeal swabs were plated within 6 hours. Isolation and 
identification of the isolates was performed by standard methods [2]. In addition, in case of 
positive cultures for S. pneumoniae the gentamycin plates were rinsed with 1.0 ml THY 
broth containing 18.5% glycerol and stored at -80ºC (primary culture). Pneumococci were 
microscopically serotyped by the capsular swelling method (Quellung reaction) using 
commercially available antisera (Statens Seruminstitut, Copenhagen, Denmark).  
Colony blot assay. The colony blot assay is based on the dot blot method of Fenoll et al. 
[6]. This method, used for serotyping of pneumococcal isolates, was adjusted to determine 
single colonies of a second serotype among predominant serotypes. In summary, serial 
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dilutions of primary cultures in 0.9% phosphate buffered saline (PBS) were plated onto 
blood-agar plates and grown overnight in 5-10% CO2 at 37ºC to obtain colony densities of 
approximately 1000 individual colonies per plate. The colonies were blotted onto a 
nitrocellulose membrane (Optitran, Schleicher & Schuell, ‘s-Hertogenbosch, Netherlands) by 
applying the membrane on top of the plate for 20 minutes. After careful colony lifting, the 
membranes were dried for 30 minutes at room temperature (RT). The membrane was 
incubated in PBS for 30 minutes at 56ºC to inhibit pneumococcal phosphatase activity. After 
incubation in blocking buffer (5% skim milk in PBS) for 1 hour at RT, the membranes were 
washed 3 times for 10 minutes in PBS containing 0.05% Tween 20 (PBST). To detect 
serotype-specific colonies the membranes were incubated with anti-capsule-specific rabbit 
sera (Statens Seruminstitut, Copenhagen, Denmark) diluted 1: 10,000 in PBS for 1 hour at 
RT. For the detection of serotype 6B pneumococci, we used a 1: 4,000 dilution of 
monoclonal mouse antibodies (14A2), which were kindly provided by PG van der 
Dobbelsteen, Netherlands Vaccine Institute, Bilthoven, The Netherlands. Prior to this 
incubation, these sera were preadsorbed with R6 pneumococci to remove aspecific non-
capsular antibodies. The plates were washed 3 times with PBST after which antibody 
binding was detected by alkaline-phospatase-conjugated anti-rabbit IgG (Sigma, USA) or 
anti-mouse IgG (Serotec, UK) for 1 hour at RT. Conjugate binding was identified by the 
substrate p-nitrophenyl phosphate (Sigma). A colony blot using a pneumococcal strain with 
an identical serotype as searched for served as a positive control. After the membranes 
were dried at room temperature, positive colonies were identified and compared to the 
colonies on the original plate. The corresponding colonies were picked from the plate and 
re-grown overnight. Subsequently, the strains were serotyped and characterized by RFEL 
genotype analysis.  
Cross-reactivity of the capsule-specific antisera of the Statens Seruminstitut was tested by 
means of colony blot analysis of at least two pneumococcal strains of each of the 7 
conjugate vaccine serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, the cross-reactive serotypes 6A 
and 23B, and the serotypes 3, 10, 11, 15, and 16. Pre-incubation of the sera with cell wall 
polysaccharides of strain R6 eliminated cross-reactivity for most sera. Only the serotype 6B 
anti-serum showed cross-reactivity with all remaining serotypes. Therefore, this antiserum 
was replaced by monoclonal mouse antibodies raised against serotype 6B capsule 
polysaccharides (14A2). Cross-reactivity remained for 19F antiserum and the pneumococcal 
serotypes 6A and 16 (data not shown).  
In order to test the sensitivity of the colony blot method, we mixed cultures of different 
pneumococcal serotypes in various ratios. We were able to identify minor pneumoccocal 
serotypes representing 0.1% of the bacterial population.  
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The colony blot analysis was performed in a group of children who had shown a shift in 
colonization from a vaccine serotype A to a (non-) vaccine serotype B strain during 2 
consecutive nasopharyngeal samples. Mixed colonization was defined as the presence of 
serotype A colonies among primarily serotype B colonies, or as the presence of serotype B 
colonies among primarily serotype A colonies. Replacement was defined as the absence of 
serotype A in the serotype B culture or the absence of serotype B in the serotype A culture.  
For the 26 children included in this analysis at least two primary cultures from consecutive 
specimens following pneumococcal vaccination were present. Only from 15 children a 
primary culture was available at study entry. Children displaying a shift in colonization but 
with less than two primary cultures available for analysis were excluded from analysis (n=5). 
RFEL analysis. Pneumococcal strain typing by RFEL was performed as described 
previously [7]. Briefly, purified pneumococcal DNA was digested by the restriction enzyme 
EcoRI. The DNA restriction fragments were end labeled at 72oC with [α-32P]dATP using 
DNA polymerase (Goldstar; Eurogentec, Seraing, Belgium). After the radiolabeled fragments 
were denatured and separated electrophoretically on a 6% polyacrylamide sequencing gel 
containing 8 M urea, the gel was transferred onto filter paper, vacuum dried (HBI, 
Saddlebrook, NY), and exposed for variable times at room temperature to ECL hyperfilm 
(Amersham Laboratories, Amersham, UK). RFEL autoradiographs were converted to 
images (Image Master DTS; Pharmacia Biotech, Uppsala Sweden) and analyzed by 
computer (Windows version Gelcompar software version 4; Applied Math. Kortrijk, Belgium). 
DNA fragments were analyzed as described previously [8]. The genetic relatedness of the 
isolates was evaluated by computerized comparison of the individual banding patterns.  
 
 
RESULTS  
We developed a colony blot assay which enables the identification of re-colonization with 
novel serotypes (replacement), overgrowth by or suppresion of minor co-colonizing 
serotypes as a result of vaccination. This method allows the identification of multiple 
serotypes in a single specimen in a ratio of 1:1000 (Figure 1). 
To validate the colony blot assay, we applied the technology to clinical specimens from 
children vaccinated with a 7-valent pneumococcal conjugate vaccine, who were colonized 
with pneumococci before and after vaccination. Samples were only included when a shift in 
pneumococcal serotype and genotype from a vaccine-type strain before vaccination to a 
non-vaccine  type  strain  after  vaccination had occurred.  We re-grew  the primary  cultures  
using serial dilutions to obtain densely grown bacterial plates but with individual bacterial 
colonies (approximately 1000 colonies per plate). Initial cultures were tested for the 
presence     of     the    post-vaccination     serotype     strain,     whereas     post-vaccination 
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Figure 1. Culture containing multiple pneumococcal serotypes. The colonies were blotted onto a nitrocellulose 
membrane. The two colored colonies marked by arrows represent a minor serotype 6A colony among predominant 
serotype 38 colonies. 
 
 
cultures were tested for the presence of pre-vaccination serotype strains. In case the 
intended serotype was found, we confirmed the genetic similarity with the original strain by 
RFEL genotyping (figure 2). Post-vaccination cultures were available for all 26 children and 
were tested for the presence of the pre-vaccination serotype (Table 1). In 4 instances 
representing 3 children the pre-vaccination serotype strain was observed as a minor strain in 
the post-vaccination culture. For only 15 children pre-vaccination cultures were available 
and could be tested for the presence of the post-vaccination serotype as a minor strain 
(Table 1). This phenomenon was observed in 1 child only (patient 20). The latter child 
showed an initial carriage of a serotype 19F strain followed 7 months later by colonization 
with a serotype 11 strain. Another 6 months later a serotype 19F strain with identical 
genotype was cultured as predominant strain again. With the colony blot assay we were 
able to detect the presence of the serotype 19F strain as minor strain among the serotype  
11 pneumococci. The suppression of serotype 19F in specimen 14 with the subsequent 
predominance one culture later in specimen 20 is depicted in Table 1. In the remaining 14 
children re-colonization (replacement) of the vaccine serotype strains by the newly acquired 
non-vaccine type pneumococci had most likely occurred. 
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Figure 2. RFEL patterns of the consecutive isolates of the children who displayed mixed colonization by colony blot 
screening. Patient numbers, moment of sampling (months) and serotypes of the pneumococcal isolates are depicted.  
*predominant strain. 
 
 
DISCUSSION 
In 2000 the Advisory Committee on Immunization Practices (ACIP) in the US has advised 
the 7-valent pneumococcal conjugate vaccine Prevnar (Wyeth, USA) to prevent invasive 
diseases in children under 2 years of age [9]. Moreover, they recommend conjugate 
vaccination for children 2-5 years of age at risk of developing pneumococcal diseases. 
However, as a result of vaccination, replacement of vaccine serotype pneumococci with 
non-vaccine serotype strains colonizing the nasopharynx occurs [10-12]. It has initially been 
suggested that replacement may be an innocent phenomenon: instead of true replacement 
outgrowth and thus detection of an already present strain may occur. In other words, by 
eradicating the predominant vaccine type strain due to vaccination a second minor strain is 
‘unmasked’. The latter strain might not be as harmful as a newly acquired strain [13]. It has 
also been suggested that replacement strains are less virulent and  that the vaccine  actually  
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protects the host from serious pneumococcal disease by replacing virulent strains with 
weaker variants [13]. However, recent reports have shown the emergence of replacement 
disease caused by non-vaccine serotype strains [2,3].  
In order to test whether re-colonization (replacement) occurs, we developed a colony blot 
assay that can detect multiple and minor serotypes within a single specimen in a 1:1000 
ratio. Alternative screening of individual colonies using the quellung method, is unsuitable 
because it is time and labor consuming. Moreover, it is inappropriate for high throughput 
screening of thousands of colonies.  
To demonstrate the potential of the colony blot technique to answer this question, we 
selected a test cohort of 26 children who had shown a shift in pneumococcal carriage from 
vaccine to non-vaccine serotypes after pneumococcal conjugate vaccination. Among the 26 
children who were investigated by this method, four events of persistence of vaccine type 
pneumococci as minor strains after vaccination were observed in the presence of a 
predominant non-vaccine serotype strain. In one child, predominance of an initially 
suppressed serotype strain was observed after vaccination. These data may implicate that 
in the majority of these cases replacement of serotypes occurs. However, the persistence of 
vaccine type strains accompanied by immunological pressure due to vaccination and the 
availability of non-vaccine serotype strains for replacement might create ideal circumstances 
for recombinational exchange of capsular genes [4]. Assuming that this phenomenon occurs 
as a result of vaccination, future vaccine failures with respect to prevention of disease and 
elimination of multidrug-resistant clones may take place. To study the true effect of 
conjugate vaccination on replacement, obviously a larger study should be performed. For 
such study, the colony blot assay will be a useful additional tool. 
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Table 1 (left). Colony blot results of 26 patients vaccinated with the 7-valent pneumococcal conjugate vaccine (CV) 
followed by the 23-valent pneumococcal polysaccharide vaccine (PV) who displayed a serotype shift in 
nasopharyngeal colonization. The initial cultures (0, 7 and 14 months) were tested for the presence of the post-
vaccination strain(s), and the post-vaccination cultures (14, 20 and 26 months) were tested for the presence of the 
initial strain(s) 
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ABSTRACT 
Aim. In a prospective controlled study in young children with a history of recurrent acute 
otitis media, we analyzed the salivary IgA and IgG antibody titers upon vaccination with a 7-
valent pneumococcal conjugate vaccine (PCV) given once or twice, followed by a 23-valent 
polysaccharide booster vaccination. 
Methods. Salivary IgA and IgG antibody concentrations to vaccine serotype 6B, 14, 18C and 
19F were measured by enzyme immunoassay in 38 samples of children vaccinated with 
PCV and 45 control samples. In the PCV group, 12 samples were taken prior to vaccination, 
12 samples 4 weeks after the polysaccharide booster (8 months after the first conjugate 
vaccination) and 14 samples 7 months after the last vaccination (14 months after the first 
conjugate vaccination). In the control group 15 children were sampled at each of these 3 
time points.  
Results. We observed increased salivary IgG antibody concentrations against serotype 6B, 
14, and 18C 14 months after the primary vaccination in the vaccinated children but not the 
controls, although this was significant for serotype 14 only. This increase was restricted to 
children vaccinated with PCV twice but not observed in children vaccinated once with PCV. 
IgA antibody titers increased significantly after 8 and after 14 months in both the 
pneumococcal vaccine recipients and the controls, however the observed increase in mean 
antibody titers was significantly higher in control children compared to the PCV group.  
Conclusion. We suggest that repeated pneumococcal conjugate vaccination is necessary to 
induce an increase in salivary IgG antibodies and effectuate clearance of S. pneumoniae 
from the nasopharyngeal mucosa of children with recurrent acute otitis media. We 
hypothesize that the increase in salivary IgA is caused by the local boosting of the mucosal 
immune response by carriage and recurrent infections, which occurs less often in the PCV 
group compared to the control children. 
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INTRODUCTION 
Clinical efficacy of the 7-valent conjugate vaccine (PCV7) against invasive pneumococcal 
diseases was recently demonstrated by Black and coworkers [1]. These and other 
investigators also showed that PCV7 has a significant impact on pneumonia and otitis media 
[1-3]. In a Finnish trial with PCV7, a 57% reduction in acute otitis media episodes caused by 
conjugate-vaccine serotypes was observed in children under the age of one year [4]. 
However, this study did not investigate whether pneumococcal vaccination also prevents 
AOM in older children with recurrent episodes of AOM. We therefore questioned whether 
combined vaccination with PCV7 followed by 23-valent pneumococcal polysaccharide 
vaccine  (PPSV23) could prevent AOM in children 1 to 7 years of age, with two or more 
documented AOM episodes in the year prior to vaccination [5]. In this double blind 
randomized study, 383 patients aged 1 to 7 years received either once (> 24 months of age) 
or twice (< 24 months of age) a 7-valent pneumococcal conjugate vaccination followed by 
PPSV23 or hepatitis A or B vaccines. We observed a significant systemic IgG response as a 
result of pneumococcal vaccination. However, we found no reduction in AOM episodes in 
the pneumococcal vaccine group as compared to the control group. In addition, overall 
pneumococcal carriage rates did not diminish, although we observed a significant shift from 
conjugate vaccine to non-conjugate vaccine type pneumococci in the PCV group [5]. 
 Because pneumococcal vaccine recipients showed decreased colonization with vaccine 
serotype strains but no effect on the occurrence of otitis media, we questioned whether 
pneumococcal vaccination had provoked a mucosal immune response. Therefore, we 
compared the IgG and IgA antibody concentration in saliva of children of the pneumococcal 
vaccine group with that in children of the control vaccine group. 
 
 
MATERIAL AND METHODS 
The study population of the OMAVAX study has previously been described in detail [5]. 
Shortly, a randomized double blind trial was conducted between April 1998 and January 
2002. A signed informed consent was obtained from all participants. Inclusion criteria for the 
study were two or more AOM episodes in the year prior to entry, and age between 1 and 7 
years. The children were randomized to receive either PCV7 (Prevnar®, Wyeth) followed by 
PPSV23 (Pneumune®, Wyeth), or hepatitis A (Havrix=AE Junior®, GlaxoSmithkline) or B 
(Engerix-B=AE Junior®, GlaxoSmithkline) control vaccines. Children aged 12-24 months of 
the pneumococcal vaccine group were immunized with PCV7 twice at a one-month interval 
followed 6 months later by PPSV23; the control vaccine group aged 12-24 months received 
3 hepatitis B vaccinations according to a similar time schedule. Children aged 25-84 months 
  Chapter 8.1 276 
of the PCV group received one dose of PCV7 followed 7 months later by PPSV23. The CV 
group aged 25-84 months received hepatitis A vaccine twice.  
From September 2000, saliva samples were obtained from children at enrollment, and one 
month and 7 months after the pneumococal booster or control vaccination. Unstimulated 
saliva samples were collected by placing a sponge swab (Saliva Swab, Malvern, Medical 
Development, Worcester, UK) in the cheek area to allow uptake of saliva until saturation 
was reached. The  saliva  samples  were  immediately  put  on ice, transported and stored at  
-70°C until analysis. Samples were thawed and centrifuged at 19,000 g for 10 min prior to 
the immunological analysis. The supernatants were used for antibody measurement.  
In the PCV group we had saliva samples available for analysis  from 12 children at 0 
months, 12 children at 8 months and 14 children at 14 months after the primary conjugate 
vaccination. For the CV group saliva samples from 15 children at each of these time points 
were available. Serotype specific IgG and IgA antibodies were measured by enzyme 
immuno assay (EIA) as described previously [6]. Briefly, microtiter plates (high binding 
polystyrene EIA plates; Costar, New York, USA) were coated overnight with 100 µl/well 
coating solution containing capsule polysaccharides at a concentration of 10 µg/ml (ATCC, 
LGC Promochem, Teddington, UK). The saliva samples were diluted 1:10 in PBS containing 
5% cell wall polysaccharides (CPS; Statens Serum Institute, Copenhagen, Denmark) and 
incubated for 30 minutes at 4°C. A 3-fold serial dilution of the sputum sample was incubated 
for 2 hours at 37°C in duplicate. After washing, antibody binding was detected by addition of 
alkaline-phosphatase-conjugated anti-human IgG or anti-human IgA (Sigma, St Louis, USA). 
The color was developed by the substrate p-nitrophenyl phosphate (Sigma). Optical density 
(OD) was measured at 405 nm on an EIA reader (Molecular Devices SpectraMAX, 
Sunnyvale, USA). Phosphate-buffered saline (PBS)- treated plates were used to assess the 
unspecific binding of antibodies to the polystyrene wells. Optical density (OD) readings from 
the PBS wells were subtracted from the values of the antigen wells before calculation of 
antibody concentrations. The cut-off for positivity was set at 2 SD above the average OD of 
the blank wells. The antibody titers for saliva were calculated as µg IgA or IgG per mg of 
albumin (µg IgA/mg albumin or µg IgG/mg albumin calculated from the officially assigned 
IgG and IgA values of the 89-SF reference serum [7] and corrected for the excretory dilution 
component [8,9]. The albumin concentration in saliva was measured using the Human 
Albumin ELISA Core Kit (Koma Biotech, Seoul, Korea). 
All statistical analyses were performed using the statistical software SPSS 11. Antibody 
concentrations are depicted as geometric mean concentrations (GMCs). Group differences 
between pneumococcal vaccinees and controls were analyzed with the independent sample 
t-test. Time-related differences within groups were analyzed with the one-way ANOVA test. 
Significance was set at a p-value of <0.05.  
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RESULTS 
We measured IgG and IgA antibodies in serum as well as in saliva of 38 children of the PCV 
group and compared these to the data of 45 children in the CV group. The children were 
comparable with respect to age at study entry and frequency of AOM in the previous year. 
Their characteristics are depicted in Table 1.  
We determined the GMC of IgG and IgA against the serotypes 6B, 14, 18C and 19F in 
saliva at 0, 8 and 14 months. An increase in IgG antibodies directed against the serotypes 
6B, 14 and 18C was found 14 months after the first conjugate vaccination, although this was 
only significant for serotype 14 which showed an increase from 3.8 to 29.6 µg per mg of 
albumin (Table 2). The GMC for IgG directed against serotype 6B increased from 19.6 µg 
per mg of albumin to 31.2 µg per mg of albumin. For the IgG antibodies against serotype 
18C an increase from 10.1 to 26.3 µg per mg of albumin was found. A baseline titer of 19.6 
µg per mg of albumin was observed for IgG antibodies directed against capsular 
polysaccharides of serotype 19F. The GMC of anti-serotype 19F antibodies did not increase 
after conjugate and booster vaccination.  
 
Table 1. Characteristics of the children of whom saliva samples were investigated. Number of samples, age of children, 
and history of AOM per study group are depicted. 
 
 0 months  
(pre-vaccination) 
7 months  
(1 months post booster) 
14 months  
(7 months post booster) 
 PV CV PV CV PV CV 
Number of samples 12 15 12 15 14 15 
Median age(years)† 2.3 2.7 1.9 2.0 2.0 2.0 
Range (years) 1.3-6.9 1.2-6.7 1.1-3.6 1.0-6.2 1.0-4.2 1.0-6.2 
> 4 AOM events‡ 
in previous year 
9/12 11/15 6/13 8/15 8/14 9/15 
No significant differences were observed with respect to age † and history of AOM ‡ between the pneumococcal 
vaccine and control vaccine group.  
 
 
Because the vaccination regime differed between children under two years of age, who 
received pneumococcal conjugate vaccination twice, and children older than two years of 
age, who received pneumococcal conjugate vaccination once, we performed separate 
analysis for both groups (Figure 1). We found that the observed increase in IgG antibodies 
directed against the serotypes 6B, 14 and 18C occurred only in children under two years, 
whereas no increase in salivary IgG was observed in the older children.  
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Table 2. GMC ( in µg per mg of albumin) of IgG and IgA antibodies against the serotypes 6B, 14, 18C and 19F at 0, 8 
and 14 months. 
Serotype 6B Serotype 14 
        PV group CV group PV group CV group 
  
IgG (SD) IgG (SD) IgG (SD) IgG (SD)
  
0 mths       19,63 (19,17) 23,64 (45,28) 3,85 (2,53) 4,43 (6,01)
8 mths       15,89 (20,66) 23,57 (34,25) 5,54 (8,91) 5,93 (5,00)
14 mths     31,23 (44,12) 15,12 (14,30) 29,55 (45,86) 14,16 (15,53)
  
IgA  IgA IgA IgA 
 0 mths        5,03 (5,27) 4,29 (3,863) 16,50 (19,63) 10,21 (11,84)
8 mths        5,25 (11,66) 12,87 (15,80) 10,88 (16,37) 14,01 (24,71)
14 mths     20,84 (24,36) 52,20* (33,44) 36,20 (54,93) 54,61 (35,28)
  
Serotype 18C Serotype 19F 
PV group CV group PV group CV group 
  
IgG (SD) IgG (SD) IgG (SD) IgG (SD)
  
0 mths       10,11 (11,05) 13,39 (12,56) 19,59 (30,05) 9,68 (9,12)
8 mths         4,73 (4,83) 7,96 (7,12) 7,51 (6,89) 6,95 (8,15)
14 mths     26,26 (66,75) 12,21 (8,58) 18,84 (17,36) 17,86 (13,87)
  
IgA  IgA IgA IgA 
0 mths        3,15 (3,23) 2,52 (2,78) 12,79 (16,23) 12,35 (7,69)
8 mths        3,56 (3,71) 13,05 (7,45) 10,74 (10,78) 27,36 (30,77)
14 mths     17,47 (21,93) 42,79* (33,91) 37,09 (46,17) 80,46* (67,96)
 
Significant difference (p-value < 0.05) between PV and CV group are marked by asteriks (independent samples t-test). 
A significant increase (p-value < 0.05) in antibodies over time is underlined (one-way ANOVA). 
 
 
IgA titers increased significantly over time in both the PCV group as well as the control 
vaccine group (Table 2). For IgA antibodies against capsular polysaccharides of serotype 6B 
an increase of 5.0 to 20.8 µg per mg of albumin was observed, whereas for IgA against  
serotype 14 an increase from 16.5 to 36.2 µg per mg of albumin was found. The GMC for 
IgA directed against serotype 18C increased from 3.1 to 17.5 µg per mg of albumin, 
whereas for antibodies against serotype 19F an increase from 12.8 to 37.1µg per mg of 
albumin was observed. However, the IgA titer increased significantly more in the CV children  
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compared to the PCV group. The average increase in antibodies directed against serotype 
6B was almost 3 times higher in control vaccinees compared to pneumococcal vaccinees 
(12.2- versus 4.2-fold increase, respectively). The IgA antibody titer against serotype 14 
showed an over 2-fold higher increase in IgA antibodies in the control vaccinees compared 
to the pneumococcal vaccinees (5.1- and 2.2- fold increase, respectively), albeit not 
statistically significant. For the serotypes 18C and 19F the increase in IgA antibodies were 
5.7 (pneumococcal vaccinees) and 17.5 (controls), and 2.9 (pneumococcal vaccinees) and 
6.6 (controls), respectively. Again, we performed separate analyses for the children younger 
and older than two years of age. The observed increase in IgA antibodies directed against 
the four serotypes investigated as well as the larger increase in IgA antibodies in the CV 
group compared to the PCV group was found in both age groups (Figure 1). 
 
 
DISCUSSION 
We studied serotype-specific mucosal IgG and IgA antibody levels in a subgroup of children 
who participated in our pneumococcal vaccination study. All children showed detectable 
levels of IgA and IgG against the serotypes 6B, 14, 18C and 19F in saliva. We also 
observed a rise in IgG antibody levels against the serotype 6B, 14 and 18C after 
vaccination. However, this increase was only significant for serotype 14. This might be due 
to the small number of children investigated and the large variability in initial antibody titers 
observed. Because the salivary IgG titers resembled the previous serological findings, they 
suggest that salivary IgG is a reflection of the serum IgG concentrations, thus supporting the 
hypothesis that salivary IgG is transudated from serum rather then being produced locally. 
Our study findings are in agreement with the results of previous trials, where similar low 
levels of anti-pneumococcal IgG in saliva corresponding to serum IgG concentrations were 
found [12,13]. Unfortunately, serum samples were not available from the children in our 
study. Therefore, we were unable to calculate the serum-mucosal IgG ratio. 
In contrast to the mucosal IgG response, we observed a significant increase in salivary IgA 
levels 7 months after booster vaccination. Surprisingly, this increase was found both in the 
pneumococcal vaccine group and the control vaccine group. Furthermore, the IgA titers in 
the control vaccine group were significantly higher then in the pneumococcal vaccine group. 
These data suggest that a natural IgA response has occurred, rather then a vaccine-induced 
response. We previously showed a decrease in vaccine serotype carriage in the PCV group 
as compared to the controls, possibly explaining the more pronounced increase in the 
controls compared to the vaccinated children. Previous studies, however, have indicated the 
presence of a vaccine-induced mucosal IgA response upon pneumococcal conjugate 
vaccination [12-15]. The  differences  between these  studies and our study are i)  the age of 
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Figure 1. GMC of IgG and IgA anti-pneumococcal antibodies for the pneumococcal capsular polysaccharides 6B, 14, 
18C and 19F at 0, 8 and 14 months in children vaccinated twice with pneumococal conjugate vaccine (< 24 months of 
age) or once (> 24 months of age). Concentrations of IgG and IgA are depicted in µg per mg of albumin.  
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the vaccinees, ii) the vaccination scheme, iii) the medical history, and iv) the control group. 
The age of our children at study entry is on average 24 months compared to 0-12 months in 
the other studies. This age difference might result in differences in systemic IgG responses 
between the study groups, but less likely reflect differences in mucosal IgA responses, 
because the mucosal response has shown to mature early in life, i.e. from the age of 6 
months [16,17].  
Our vaccination scheme differs from previous studies, since we used one conjugate 
vaccination instead of a series of two, or three conjugate vaccinations in the children older 
then 24 months. Indeed, separate analysis of the two vaccination regimes, i.e. one or two 
conjugate vaccinations followed by a polysaccharide booster, showed a trend towards an 
increase in IgG antibodies in saliva after two conjugate vaccinations, but not after one 
conjugate vaccination. This is in agreement with data of Nurkka et al. who observed 
significantly more often salivary IgG antibodies after a booster with the pneumococcal 
conjugate vaccine but not with the polysaccharide vaccine [12]. In addition, these data 
support the observed shift from conjugate vaccine type to non-conjugate vaccine type 
pneumococci at the nasopharynx of children who received twice the PCV7 followed by 
PPS23, but not in the children who received PCV7 once (Veenhoven et al. submitted). 
These findings suggest that vaccination with at least twice the conjugate vaccine also after 2 
years of age may be mandatory for carriage reduction of conjugate vaccine serotypes in 
children with recurrent otitis media. However, IgG serum titers do not explain this difference 
because similar serum IgG levels were found after one or two conjugate vaccinations, 
respectively. We hypothesize, that as a result of repeated conjugate vaccination additional 
B-cell recruitment occurs, which results in enhanced boosting of the mucosal immunity by 
natural contacts with conjugate vaccine serotype pneumococci, and consequently, in 
increased mucosal IgG antibody levels. 
Furthermore, in our study a PPS23 booster was given after 6 months, whereas in most 
studies a booster with PCV7 was used. Several investigators however have compared both 
types of booster vaccination and have found no significant difference in immune response 
between these two regimens [6,13].  
The children in our study have a history of recurrent acute otitis media. Therefore, they 
might differ immunologically from the healthy children participating in previous studies. 
However, the mucosal antibody response in our children prior to vaccination seemed 
adequate as is demontrated by the presence of detectable IgG and IgA levels in saliva. 
Importantly, none of the previous studies included a control group that did not receive a 
pneumococcal (booster) vaccination. Only one study used a control group without 
pneumococcal vaccination, however they sampled only at study entry and before booster 
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vaccination [15]. Without the results of the control group, the significant increase in secretory 
IgA in our study population could have been wrongly interpreted as vaccine-induced.  
The follow-up period also varied between our study and previous studies. Whereas all 
previous studies evaluated the mucosal response of the booster vaccination one months 
after administration, we evaluated this response both one month and 7 months after the 
polysaccharide vaccination. The observed increase in antibodies occurred 7 months after 
the first vaccination, which has been missed by the other studies [6,12,13,15]. 
The main question remains why the CV group shows higher salivary IgA titers compared to 
the PCV group. As described previously, we found a decrease in vaccine serotype carriage 
in the pneumococcal vaccine group after vaccination [5]. This can be explained by 
elimination of the vaccine serotype strains by the passive transudation of serum IgG at the 
mucosa or by boosting of memory B-cells resulting in the local production of IgG. Though we 
were not able to show a significant increase in serotype-specific IgG in saliva presumably 
due to the low numbers of specimens, a trend was observed in increased GMCs for the 
serotypes 6B, 14 and 18C. Because pneumococcal carriage has been shown to induce a 
type-specific IgA response in saliva [17], the immediate drop in vaccine serotype carriage as 
a result of vaccination may explain the absence of an IgA response against the vaccine 
serotypes in these children. However, this cannot be the full explanation, since a difference 
in IgA titers between pneumococcal vaccine and control group was also observed for the 
children who were vaccinated once with pneumococcal conjugate vaccine, whereas these 
children did not show a significant decrease in vaccine serotype carriage as compared to 
controls.  
In conclusion, our study suggests that pneumococcal conjugate vaccination followed by a 
polysaccharide booster does not elicit a persistent mucosal IgA antibody response and only 
a mucosal IgG response after repeated conjugate vaccinations. We hypothesize that 
mucosal vaccination, i.e. intranasally or orally, might sufficiently elicit a mucosal immune 
response that could protect against carriage as well as respiratory infection. This is 
supported by recent findings of Lynch et al. who have shown that intranasal vaccination with 
pneumococcal polysaccharides in the presence of IL-12 enhances systemic and mucosal 
immune responses to pneumococci and protects against pneumococcal carriage and 
invasive infection in a mouse model [20]. Further studies are needed to evaluate the effect 
of these mucosal vaccines against mucosal diseases in humans. 
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ABSTRACT   
Acute exacerbation is a frequent complication of chronic obstructive pulmonary disease 
(COPD). Recent studies suggested a role for bacteria such as Streptococcus pneumoniae in 
the development of acute exacerbation. For this study, we investigated the following in 
COPD patients: (i) the epidemiology of pneumococcal colonization and infection, (ii) the 
effect of pneumococcal colonization on the development of exacerbation, and (iii) the 
immunological response against S. pneumoniae. We cultured sputa of 269 COPD patients 
during a stable state and during exacerbation of COPD and characterized 115 
pneumococcal isolates by use of serotyping. Moreover, we studied serum immunoglobulin G 
(IgG) antibody titers, antibody avidities, and functional antibody titers against the seven 
conjugate vaccine serotypes in these patients. Colonization with only pneumococci 
(monocultures) increased the risk of exacerbation, with a hazard ratio of 2.93 (95% 
confidence interval, 1.41 to 6.07). The most prevalent pneumococcal serotypes found were 
serotypes 19F, 3, 14, 9L/N/V, 23A/B, and 11. We calculated the theoretical coverage for the 
7- and 11-valent pneumococcal vaccines to be 60 and 73%, respectively. All patients had 
detectable IgG levels against the seven conjugate vaccine serotypes. These antibody titers 
were significantly lower than those in vaccinated healthy adults. Finally, on average, a 2.5-
fold rise in serotype-specific and functional antibodies in S. pneumoniae-positive sputum 
cultures was observed during exacerbation. Our data indicate that pneumococcal 
colonization in COPD patients is frequently caused by vaccine serotype strains. Moreover, 
pneumococcal colonization is a risk factor for exacerbation of COPD. Finally, our findings 
demonstrate that COPD patients are able to mount a significant immune response to 
pneumococcal infection. COPD patients may therefore benefit from pneumococcal 
vaccination.  
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INTRODUCTION   
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality 
in adults. According to the Global Burden of Disease Study, COPD is the fifth most common 
disease and fourth leading cause of death in the world. Both the prevalence and mortality 
rate are still expected to increase in the coming decades (11). The chronic course of this 
disease is frequently interrupted by acute exacerbation, which has a major impact on the 
morbidity and mortality of COPD patients (17). Acute exacerbation of COPD is characterized 
by an acute sustained worsening of the patient's condition from a stable state, beyond 
normal day-to-day variations, which occurs one to three times a year and may warrant 
additional treatment (3, 18). Bacterial infections are thought to contribute to the 
pathogenesis and clinical course of COPD (20). Several recent studies have shown a clear 
association between the isolation of bacterial species such as Streptococcus pneumoniae, 
Moraxella catarrhalis, and Haemophilus influenzae and acute exacerbation (18). Patel et al. 
were the first investigators who observed a significant relation between lower airway 
colonization in the stable state and exacerbation frequency. However, their study population 
was too small to investigate the correlation for individual bacterial species (12). In contrast, 
Sethi et al. showed a significant increase in the occurrence of exacerbation when S. 
pneumoniae and M. catarrhalis were isolated (18).  
We hypothesize that the prevention of bacterial growth in the airways of COPD patients will 
significantly decrease the occurrence of exacerbation and thus improve the quality of life for 
COPD patients. One of the pathogens that is frequently involved in colonization and 
infection of COPD patients is S. pneumoniae. For this pathogen, a 23-valent polysaccharide 
vaccine and a 7-valent conjugate vaccine are available. The 23-valent vaccine is protective 
against pneumococcal invasive disease in adults and elderly patients, but not in children 
under the age of two or immunocompromised patients (14). In addition, the 23-valent 
polysaccharide vaccine has not shown a significant reduction in cases of pneumonia in 
elderly patients (7). Moreover, the polysaccharide vaccine induces no immunological 
memory, which necessitates revaccination (2). In contrast, the conjugate vaccine is effective 
in young children against invasive as well as mucosal diseases and elicits immunological 
memory, but it covers fewer (7) serotypes. To investigate the relevance of pneumococcal 
colonization and infection in COPD patients, we determined the effect of pneumococcal 
colonization on the development of exacerbation. In addition, to assess the theoretical role 
of pneumococcal vaccination in COPD patients, we determined the serotype distribution 
among pneumococcal sputum isolates found during colonization and infection. Finally, we 
investigated the presence of immunoglobulin G (IgG) antibodies against pneumococcal 
capsular polysaccharides in COPD patients and the development of capsule-specific 
antibodies as a result of pneumococcal infection during exacerbation.  
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MATERIALS AND METHODS   
Study population. Two hundred sixty-nine patients, aged 40 to 75 years, in the outpatient 
department of Medisch Spectrum Twente Hospital, Enschede, The Netherlands, 
participating in the COPE study and with a history of COPD, were recruited from May 1999 
through March 2000 (19). The patients had to meet the following criteria: (i) a clinical 
diagnosis of stable COPD, as defined by American Thoracic Society criteria; (ii) no history of 
asthma; (iii) no exacerbation in the month prior to enrollment; (iv) current or former smoker; 
(v) age between 40 and 75 years; (vi) a baseline prebronchodilator forced expiratory volume 
in 1 s (FEV1) of 25 to 80% that predicted; (vii) a prebronchodilator ratio of FEV1 to 
inspiratory vital capacity value of 60% or less; (viii) reversibility value of FEV1 postinhalation 
of 80 µg of ipratropium bromide via a metered dose inhalator with Aerochamber of 12% the 
predicted value or less; (ix) a total lung capacity that was higher than the predicted total lung 
capacity minus 1.64 x the standard deviation; (x) no maintenance treatment with oral 
steroids or antibiotics; (xi) no medical condition with a low survival rate or serious psychiatric 
morbidity (e.g., cardiac insufficiency or alcoholism); (xii) absence of any other active lung 
disease (e.g., sarcoidosis). The use of medication such as nasal corticosteroids, 
theophyllines, chronic use of acetylcysteine, and all other bronchodilators was allowed (19).  
None of the patients were vaccinated with pneumococcal vaccines before entering the 
study. Sputum samples were retrieved at 0, 4, 7, and 10 months, provided that the disease 
was stable, and during exacerbation. Serum was collected during acute exacerbation 
(acute-phase serum) and 2 weeks after exacerbation (convalescent-phase serum). The 
diagnosis of exacerbation was made based on the following criteria: (i) an objective 
exacerbation, with a >15% decrease in lung function (FEV1) and/or a 300-ml decrease in 
FEV1; (ii) a subjective exacerbation assessed by means of a symptom checklist and a 2-
week diary; and (iii) a clinical exacerbation, as judged by the patient's own chest physician 
(19).  
Sputum cultures. Sputa were collected at scheduled visits to the outpatient department and 
in cases of exacerbation. The sputum samples were collected in sterile vials and transported 
to the microbiology laboratory within 4 h. Sputum samples were judged microscopically with 
a low-magnification lens (x100) and had to contain <10 epithelial cells and >25 leukocytes 
per field to be considered representative bronchial samples. A fixed volume of a 1:100 
dilution of sputum was plated onto blood agar, chocolate agar, MacConkey agar, and 
Sabouraud agar. The identification of bacterial growth was performed by standard 
techniques (10). S. pneumoniae, H. influenzae, M. catarrhalis, Pseudomonas aeruginosa, 
Staphylococcus aureus, Aspergillus, and Candida species and other gram-negative rods 
were considered to be potential pathogens. Other bacterial species were classified as 
normal flora.  
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Bacterial colonization was defined as the presence of bacteria in a culture retrieved from the 
lower respiratory tract of a clinically stable COPD patient (5). A bacterial infection was 
defined by the presence of one or more potential pathogens in a COPD patient with a 
clinical exacerbation. A monoculture was defined as the growth of a single bacterial species, 
whereas the presence of multiple bacterial species was defined as a mixed culture.  
Serotyping of pneumococcal isolates. In total, 115 pneumococcal isolates were cultured 
and serotyped by the capsular swelling method (Quellung reaction), using commercially 
available antisera (Statens Serum Institute, Copenhagen, Denmark) and microscopic 
observation.  
EIA for measuring anti-pneumococcal polysaccharide IgG concentrations.  
Concentrations of IgG antibodies were measured by an enzyme immunoassay (EIA) method 
as described previously (9). The results are given in micrograms per milliliter, calculated 
from the officially assigned IgG values of the 89-SF reference serum (15), or were converted 
into units per milliliter by comparison with the 89-SF reference serum, which was considered 
to contain 100 U/ml, in cases for which no IgG values were available.  
EIA for measuring the avidity of anti-pneumococcal polysaccharide antibodies.  
The relative avidities of IgG antibodies for pneumococcal capsular polysaccharides were 
determined by the EIA method as described by Anttila et al. (1), with some minor 
modifications. Briefly, microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were coated 
overnight with 100 µl of coating solution, containing capsule polysaccharides at a 
concentration of 10 µg/ml (LGC Promochem, Teddington, United Kingdom), per well. Sera 
were diluted 1:50 in phosphate-buffered saline (PBS) containing 5% cell wall 
polysaccharides (Statens Serum Institute) and incubated at 4°C overnight. Sera were diluted 
1:100 in PBS-0.05% Tween 20, and threefold serial dilutions were incubated for 2 h at 37°C. 
After washing, 0.5 M sodium thiocyanate in PBS was added to dissociate antibody-antigen 
complexes. After 15 min of incubation at room temperature, the plates were washed and 
antibody binding was detected by the addition of alkaline-phosphatase-conjugated anti-
human IgG (Sigma, St. Louis, Mo.). The color was developed by the substrate p-nitrophenyl 
phosphate (Sigma). The absorbance was measured at 405 nm on an EIA reader 
(SpectraMAX; Molecular Devices, Sunnyvale, Calif.). Results were expressed as avidity 
index (AI) values, assigned as the percentages of antibodies that remained bound to the 
antigens after thiocyanate treatment. The high-avidity antibody concentration was calculated 
by multiplying the antibody concentration by the AI value. The reproducibility of the assay 
was checked by including a control serum in each plate.  
Data analysis. The results were analyzed with the statistical software SPSS 10. The effect 
of pneumococcal colonization on the time to the first exacerbation episode was assessed by 
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using multivariate Cox proportional hazard analyses. We adjusted for potential confounding 
variables, including age, sex, smoking status, number of exacerbation episodes in the 
preceding year, and FEV1% predicted, as found previously (P. van der Valk, D. Bogaert, E. 
Monninkhof, J. van der Palen, P. Hermans, G. Zielhuis, C. van Herwaarden, and R. 
Hendriks, submitted for publication). The initial concentrations of antibodies are depicted as 
geometric mean concentrations (GMC). Avidities are given as the means of the AI values 
and high-avidity antibody concentrations. Statistical comparisons between antibody levels 
were performed by analysis of variance and independent sample t tests. The maximum 
increase in antibody titer was tested for significance by using the one-sample t-test. 
Statistical significance was set at P values of <0.05.  
 
 
RESULTS   
Sputum samples from 269 patients were obtained at 0, 4, 7, and 10 months in cases of 
stable disease. An additional sputum sample was collected at each hospital visit for an acute 
exacerbation of COPD. In total, 55% of the patient group developed at least one 
exacerbation episode during the follow-up period. In total, 918 stable state sputa and 241 
exacerbation sputa were collected. Of the stable state sputa, 603 cultures were negative for 
potential pathogens, whereas 315 cultures were positive for at least one microorganism 
(34%). The exacerbation sputa showed significantly more positive cultures (49%). Mixed 
cultures were found in 9 and 5% of the sputum cultures during stable state and 
exacerbation, respectively. Monocultures were found significantly more often during 
exacerbation episodes (41%) than during stable states (26%). The three predominant 
bacterial species cultured during a stable state and exacerbation were H. influenzae (19 and 
26%, respectively), S. pneumoniae (13 and 13%, respectively), and M. catarrhalis (9 and 
7%, respectively).  
We calculated the effect of the colonization status at the time of randomization on the time to 
the next exacerbation episode for 209 patients from whom sputum was available at that 
time. We adjusted for potential confounding variables, including age, sex, smoking status, 
number of exacerbations in the preceding year, and FEV1% predicted. Bacterial colonization 
in general did not increase the risk of a first exacerbation compared to noncolonized 
patients, nor did pneumococcal colonization in general (hazard ratio, 1.31; 95% confidence 
interval [CI], 0.743 to 2.305). However, the adjusted hazard ratio for the development of 
exacerbations in patients with a pneumococcal monoculture was 2.93 (95% CI, 1.41 to 
6.07).  
We investigated all 115 pneumococcal isolates in detail by means of serotyping. The most 
prevalent serotypes were serotypes 19F and 3 (13 and 10%, respectively), followed by 
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serotypes 14, 9L/N/V, 23A/B, and 11 (9% each) (Table 1). The theoretical vaccine 
coverages for the 7-valent and 11-valent pneumococcal conjugate vaccines and the 23-
valent polysaccharide vaccine were 34, 47, and 70%, respectively. Inclusion of the expected 
cross-reactive serotypes increased the theoretical coverages to 60, 73, and 88%, 
respectively. A separate analysis of the potential vaccine coverage of pneumococcal 
isolates found during a stable state and exacerbation showed no significant difference 
(Table 1).  
 
Table 1. Most prevalent pneumococcal serotypes observed in COPD patients. 
VT serotype Total number  
of isolates (%) 
Stable state  
isolates (%) 
Exacerbation  
Isolates (%) 
14 10 8.7% 5 5.5% 5 20.0% 
19F 15 13.0% 12 13.3% 3 12.0% 
23F 
 
8 7.0% 7 7.8% 1 4.0% 
NVT serotype 
 
      
3 12 10.4% 11 12.2% 1 4.0% 
6A* 9 7.8% 7 7.7% 2 8.0% 
9 L/N* 10 8.7% 5 5.6% 5 20.0% 
11 9 7.8% 6 6.7% 3 12.0% 
23A/B* 10 8.7% 9 10.0% 1 4.0% 
       
7-valent 39 33.9% 30 33.3% 9 36.0% 
7-valent** 69 60.0% 52 57.7% 17 68.0% 
11-valent 54 47.0% 44 48.9% 10 40.0% 
11-valent** 84 73.0% 66 73.3% 18 72.0% 
23-valent 80 69.6% 61 56.8% 19 76.0% 
23-valent** 101 78.8% 78 67.8% 23 92.0% 
       
Total 115 100% 90 100% 25 100% 
* cross-reactive serotypes  
** including cross-reactive serotypes 
 
   
We investigated the presence of IgG antibodies and the AI of these antibodies for the 
serotypes included in the 7-valent conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) for 
serum samples obtained from 92 patients. For this purpose, we included all first serum 
samples obtained during the study period. Antibody levels against all seven serotypes were 
detectable in all patients. The GMCs of antibodies against the seven serotypes for the 
COPD patients as well as for 10 healthy adult volunteers before and after vaccination with 
the 7-valent conjugate vaccine are depicted in Table 2. The GMCs ranged from 5.04 µg/ml 
for serotype 4 to 55.76 for serotype 6B, with a large variability (Fig. 1A). The GMCs for 
healthy adults ranged from 1.7 (serotype 4) to 21.9 (serotype 6B) µg/ml before vaccination 
to 13.4 (serotype 9V) to 76.7 (serotype 6B) µg/ml after conjugate vaccination. The mean AIs 
as  well  as the mean high-avidity  antibody concentrations  with 95% CIs  are also shown in  
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Table 2. GMC (µg/ml) of anti-pneumococcal antibodies against the 7 conjugate vaccine pneumococcal serotypes. 
 
Pneumococcal 
serotype 
COPD 
patients 
(95% CI) healthy 
adults 
(95% CI) healthy adults 
after conjugate  
vaccination 
(95% CI) 
4 5.04 (3.93-6.15) 1.65* (0.48-2.81) 19.95** (5.99-33.92) 
6B 55.76 (40.83-70.70) 21.9 (7.02-36.84) 76.70 (46.87-106.53) 
9V 16.38 (12.22-20.54) 3.39* (0.85-5.95) 13.41 (8.51-18.31) 
14 7.06 (5.11-9.01) 3.37 (0.28-6.47) 30.74** (14.22-47.26) 
18C 17.49 (12.59-22.40) 9.37 (3.80-22.54) 56.53** (27.23-85.83) 
19F 36.34 (26.29-46.40) 18.40 (4.97-31.82) 66.76 (34.61-98.90) 
23F 18.08 (13.13-23.04) 4.08 (0.64-7.50) 55.43** (17.65-93.21) 
 
* significantly lower antibody level compared to patient group  
** significantly higher antibody level compared to patient group 
 
  
Table 3. Serotype-specific IgG concentration in initial and convalescent serum and the maximum increase in serotype-
specific IgG of  15 COPD patients with positive sputum cultures for S.pneumoniae during exacerbation 
 
Patient Serotype Male/ 
Female 
Age 
(years) 
Flixotide 
(yes/no) 
Serotype specific IgG (U/ml) 
 
     Initial serum Convalescent 
serum 
Increase  
1 14 M        66 Yes 97,92 81,25 0,83 
2 14 M        73 Yes 95,24 428,57 4,50 
3 9N     M        47 No 156 146,43 0,94 
4 19F    V        66 No 1000 1300 1,30 
5 19F     M        57 No 75 100 1,33 
6 9N     M        58 Yes 7000 9066,67 1,30 
7 19F     M        73 No 1000 1800 1,80 
8 9V       M        64 No 971,43 1540 1,59 
9 9V     M        67 Yes 1500 9500 6,33 
10 9N     M        56 No 500 5000 10,00 
11 14 M        61 Yes 105,87 95,24 0,90 
12 9N     M        61 Yes 15733,33 9066,67 0,58 
13 11 M        60 Yes 950 450 0,47 
14 14 M        63 Yes 31,67 50 1,58 
15 9V       M        63 Yes 2000 5250 2,63 
 
 
Fig. 1B and C. The AIs ranged from 55% for serotype 6B to 78% for serotype 18C. The 
high-avidity antibody titers ranged from 3.4 µg/ml for serotype 4 to 30.7 µg/ml for serotype 
6B.  
Because the studied serum samples were collected randomly, i.e., during both a stable state 
and exacerbation, we reanalyzed our data with respect to this variable. No significant 
difference in antibody titers against the seven tested serotypes was observed between 
samples obtained during exacerbation and during a stable state (data not shown).  
We investigated the development of antibodies in response to colonization with 
pneumococci  during  acute  exacerbation.  In total, 15  patients,  who  were  colonized  with 
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Figure 1. Capsular antibody titers against the seven pneumococcal conjugate vaccine serotypes in 92 COPD patients 
at the start of the study. Error bars show 95% CIs for the GMCs for IgG antibodies (A), AIs (B), and high-avidity 
antibody titers (C). (D) Error bars show 95% CIs for mean maximum antibody increases and mean maximum high-
avidity antibody increases for the homologous serotype during exacerbation. 
  
 
serotypes 14 (4), 9N (4), 9V (3), 19F (3), and 11 (1), were studied during an exacerbation. 
We investigated the antibody levels in serum and the AIs of the antibodies against the 
capsular polysaccharides of the pneumococcal serotypes isolated from the patients. When 
available, two or three consecutive serum samples were analyzed, as initial, acute-phase, 
and convalescent-phase samples. Furthermore, we calculated the maximum increase in 
antibody titer in the consecutive sera for individual patients (Table 3). We observed a 
significant rise in antibodies as well as in high-avidity antibodies, with an average 2.5-fold 
increase (Fig. 1D). The mean avidity, which was 70%, did not change significantly.  
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DISCUSSION   
We investigated the effect of pneumococcal colonization on the development of 
exacerbation in COPD patients. Although patients colonized with bacteria in general did not 
show an increased risk of a first exacerbation episode compared to patients without bacterial 
colonization, colonization with S. pneumoniae, specifically when present as a monoculture, 
did increase the risk of a first exacerbation, with a hazard ratio of 2.91. Our data support the 
findings of Sethi et al., who also showed a significant increase in exacerbations when S. 
pneumoniae was isolated (18), which underscores the role of S. pneumoniae in the 
pathogenesis of exacerbations of COPD. Surprisingly, the presence of pneumococci in 
combination with other pathogens in sputum did not cause an increased risk of a next 
exacerbation. This might indicate that monocultures merely represent an infectious state, 
whereas mixed cultures are more representative of a stable state of colonization. This is 
supported by our data, which show that during exacerbations of COPD, monocultures of 
potential pathogenic microorganisms, in particular, are increased. Because this specific 
correlation has never been investigated, it will be worthwhile to include this variable in future 
analyses.  
Subsequently, we calculated the theoretical coverage of the 7-valent, 11-valent, and 23-
valent pneumococcal vaccines. The most prevalent serogroups among the 115 isolates 
investigated were serogroups 3, 9, 11, 14, 19, and 23 (10, 9, 8, 9, 14, and 16%, 
respectively). Because most of these serogroups are included in the conjugate vaccine, the 
theoretical coverage for these vaccines is 34 to 49% of all pneumococci, but is even higher 
(60 to 73%) when cross-reactive serotypes are considered. An analysis of just exacerbation 
cultures showed comparable coverage rates. This is in agreement with the data of Flamaing 
et al., who investigated the serotype distribution among pneumococcal isolates obtained 
from individuals 65 years of age and older with invasive disease in Belgium (6). The 
potential coverage of the 23-valent conjugate vaccine is even higher, with 70 to 88% 
coverage. Unfortunately, most previous studies could not find a protective effect of this 
vaccine against mucosal diseases.  
Secondly, we investigated whether natural antibodies were already present in COPD 
patients but failed to protect these patients from pneumococcal colonization. GMCs for the 
92 COPD patients investigated were normal to high when compared to healthy adults (M. 
Sluijter, unpublished observations). Moreover, as in healthy adults, GMCs for serotypes 4 
and 14 were relatively low compared to the other serotypes. Finally, the quality of the 
antibodies, as measured by means of AIs, was sufficient. Therefore, we conclude that these 
patients are able to elicit an immunological response to pneumococcal challenge and thus 
are not immunologically deficient with respect to antibody development. The trend towards 
higher titers compared to healthy unvaccinated adults may represent the increased 
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pneumococcal contacts in this patient group, although a difference in gender (50 and 98% 
male, respectively) and smoking history (0 and 100%, respectively) between the healthy 
adults and the patient group may also be of influence (16).  
Healthy adults vaccinated once with the 7-valent conjugate vaccine displayed higher GMCs 
than the patient group, although they were only significant for serotypes 4, 14, 18C, and 23F 
due to the relatively large CIs. Because a similar response from our patient group can be 
expected upon vaccination, we suggest that vaccination of our patient group may increase 
antibody levels and hence may elicit a higher level of protection against pneumococcal 
disease. This is in agreement with the results of Jonsson et al., who have shown that 
vaccination of COPD patients with a serotype 6B conjugate vaccine or a 23-valent 
polysaccharide vaccine elicits antibody levels comparable to those in vaccinated healthy 
adults (8). One might question, however, whether the present levels of antibodies prevent 
both colonization and infection with pneumococci in our patients. It has been hypothesized 
that the prevention of mucosal disease requires higher levels of anti-pneumococcal 
antibodies than the prevention of invasive disease. Previous work has shown that higher 
antibody levels are necessary to protect children against acute otitis media than against 
invasive diseases (13). Alternatively, one might suggest that anatomical damage to the 
lungs and the thick mucous layers prevents the immune system from recognizing or 
attacking colonizing bacteria. This is supported by the data of Davis et al., who have shown 
that vaccination of COPD patients with a 14-valent pneumococcal polysaccharide vaccine 
induces significant antibody responses but not protection against pneumonia and death (4). 
In contrast to our findings, most pneumococci observed during infection in that study were 
nonvaccine serotypes, which may explain the observed vaccine failure. We determined 
whether the presence of pneumococci during exacerbation elicits a natural immune 
response to the homologous serotype. Overall, a 2.5-fold increase in IgG antibody levels 
and high-avidity antibody levels was found. Although a small patient group was studied and 
a small number of consecutive sera per patient were available, these data suggest that the 
immune systems of two-thirds of the COPD patients were capable of mounting an antibody 
response towards pneumococci, whereas one-third of the patients did not show an increase 
in antibodies upon the presence of pneumococci. Obviously, one could argue whether these 
antibodies protect COPD patients against pneumococcal reinfection. Follow-up studies are 
necessary in which the protective potentials of these antibodies are investigated in order to 
speculate about the effect of pneumococcal conjugate vaccination in COPD patients.  
In conclusion, our data indicate that pneumococcal colonization in COPD patients is 
frequently caused by vaccine serotype strains. Moreover, pneumococcal colonization is a 
risk factor for exacerbations in these patients. Finally, our findings show that the majority of 
COPD patients mount an anticapsular immune response during pneumococcal colonization 
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and infection. Clinical studies are needed to investigate the protective potentials of 
conjugate vaccination for COPD patients.  
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ABSTRACT  
Pneumococcal conjugate vaccination is highly efficacious against invasive diseases in 
young children. Since host protection is mainly mediated by opsonin-dependent 
phagocytosis, the in vitro measurement of opsonophagocytic activity of the anti-capsular 
antibodies is assumed to be a reliable correlate of protection to monitor vaccine efficacy. 
Unfortunately, the methods used so far are all tedious to perform and material consuming. 
Therefore, we modified the multi-specificity opsonophagocytosis killing assay (MSOPKA) 
into a high throughput method, which simultaneously measures the opsonophagocytosis 
against the seven serotypes covered by the current conjugate vaccine in a single assay. In 
the so called multiplex opsonophagocytosis assay (MOPA), a mixture containing equal 
numbers of colony forming units (CFUs) of chloramphenicol-resistant serotype 4, 
spectinomycin-resistant serotype 6B, streptomycin-resistant serotype 9V, erythromycin-
resistant serotype 14, rifampicin-resistant serotype 18C, tetracycline-resistant serotype 19F, 
and trimethoprim-resistant serotype 23F pneumococci was used as a target mixture and 
incubated with serial dilutions of test serum. After opsonophagocytosis by differentiated HL-
60 cells in the presence of complement, the samples were spotted onto different blood agar 
plates containing the 7 selective antibiotics, respectively. Opsonophagocytosis was 
calculated as the highest serum dilution resulting in 90% or more reduction in CFUs. The 
data obtained by this assay correlated well with the data obtained by the MSOPKA. In 
conclusion, the MOPA simultaneously measures opsonophagocytosis capacity of serum 
against the capsular serotypes included in the 7-valent pneumococcal conjugate vaccine in 
a high-throughput fashion, requiring low volumes of patient sera. 
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INTRODUCTION 
Streptococcus pneumoniae is one of the major pathogens causing serious respiratory tract 
and invasive infections [1]. Risk groups for these infections are young children under the age 
of two years, immunocompromised patients and elderly people. Therefore, prevention of 
pneumococcal infections by a 23-valent polysaccharide vaccine has been recommended by 
the Advisory Committee on Immunization Practices (ACIP) in these risk groups from the age 
of two years [2]. However, the 23-valent polysaccharide vaccine has shown to be less 
immunogenic in children under two years of age. Therefore, conjugate vaccines have been 
developed which contain the capsular polysaccharides of the seven to eleven most 
predominant pneumococcal serotypes linked to a protein carrier. These vaccines have 
shown to be immunogenic in risk groups and protect against invasive diseases in young 
children [3,4]. One of the vaccines, the 7-valent pneumococcal conjugate vaccine from 
Wyeth, has been released in the United States and Europe as preventive strategy against 
invasive pneumococal diseases.  
Because host protection is mainly mediated by opsonin-dependent phagocytosis, the in vitro 
measurement of opsonophagocytic activity of the anti-capsular antibodies is believed to be a 
reliable correlate of protection to evaluate the vaccine efficacy [5,6]. Several techniques 
have been standardized and validated so far, and they all have shown to be comparable [7]. 
Replacement of human blood leucocytes with HL-60 cell-line derived granulocytes as 
effector cells and frozen aliquots of bacteria as target cells have improved the 
opsonophagocytosis assay significantly [8]. However, the current techniques are still time- 
and material consuming, and require large volumes of serum to test protection against all 
vaccine serotypes. The latter problem is certainly relevant for the main target group for the 
vaccines, i.e. young children. Therefore, Nahm et al. have modified the classical 
opsonophagocytosis assay (OPA) into a multi-specificity opsonophagocytic killing assay 
(MSOPKA) [9]. In this assay, a mixture of two antibiotic-resistant pneumococci of different 
serotypes is used as target in a single opsonophagocytosis assay, thus reducing the amount 
of labor time, volume of serum and reagents needed. However, this assay is still fairly time-, 
serum- and material consuming, and thus less suitable for high-throughput use in children. 
Therefore, we extended the assay to seven antibiotic-resistant serotypes, i.e. the seven 
serotypes covered by the 7-valent conjugate vaccine, which can be used in a single assay. 
Furthermore, we modified the read-out method by incorporating the method used in the 
classical complement-killing assay for N. meningitidis [10]. 
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MATERIAL AND METHODS 
Pneumococcal strains. Six S. pneumoniae strains of serotype 6B, 9V, 14, 18C, 19F and 
23F, respectively, were kindly provided by R. Veenhoven, Spaarne Hospital, Haarlem, The 
Netherlands. These strains were nasopharyngeal isolates obtained from children 
participating in the OMAVAX study [11]. Strain 1124478 (serotype 19F), strain 1474912 
(serotype 14), strain 1212458 (serotype 23F) and strain 1026409 (serotype 18C) were 
selected because of single drug resistance to tetracycline, erythromycin, trimethoprim and 
rifampicin, respectively.  
Strain 1344387 representing serotype 6B and strain 1081748 representing serotype 9V 
were fully susceptible strains. A spectinomycin-resistant variant of strain 1344387 displaying 
a minimal inhibitory concentration (MIC) of > 400 mg/L (strain R6BSPCR) was obtained by 
natural selection on 5% blood agar plates with increasing concentrations of spectinomycin. 
A streptomycin-resistant variant of strain 1081748 was obtained by natural selection on 5% 
blood agar plates with increasing concentrations of streptomycin, resulting in a mutant strain 
with a MIC of > 400 mg/L (strain R9VSPCR). A chloramphenicol-resistant strain of serotype 
4 (RT4CHLOR) was obtained by natural transformation of the serotype 4 strain KNR.7/87 
with the chloramphenicol resistance cassette as described previously [12].  
MICs of the pneumococcal strains were determined for the antibiotics tetracycline, 
erythromycin, trimethoprim, spectinomycin, chloramphenicol, rifampicin and streptomycin by 
the agar dilution test as described previously [13]. 
The serotypes of the pneumococci were confirmed by the capsular swelling method 
(Quellung reaction) observed microscopically using commercially available antisera (Statens 
Serum institute, Copenhagen, Denmark). 
Pneumococcal cultures. The seven drug-resistant strains were plated on 5% sheep blood 
agar plates with the respective selective antibiotics and grown overnight under reduced 
oxygen conditions at 37ºC. The next day, several colonies were selected from the plate and 
grown to early logarithmic phase (OD 0.1-0.2) in Todd Hewitt broth supplemented with 0.5% 
yeast extract (THY broth). The bacteria were aliquoted in 17% glycerol and stored at -80ºC 
until use. Spot counts of the stocks were made on 5% blood agar plates as well as on the 
respective selective antibiotic plates to determine the number of viable CFUs/ml and to 
confirm the resistance profile. Pneumococci were stored for a maximum period of 3 months 
without any detectable decrease in viability.  
Serum samples. Six adult volunteers were immunized with the 7-valent pneumococcal 
conjugate vaccine Prevenar (Wyeth, The Netherlands). Serum samples were obtained from 
the vaccinated volunteers 28 days after the vaccination was administered, as well as from 3 
non-vaccinated adult controls.  
                                                 Multiplex opsonophagocytosis assay 301 
Growth and differentiation of HL-60 cell line. Growth and differentiation of HL-60 cells 
was performed as described previously [8]. Briefly, undifferentiated HL-60 cells were grown 
in RPMI-1640 culture medium with 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin. Differentiation was performed by incubating the cells in the presence 
of 0.8% dimethylformamide (Fisher Scientific, Pittsburgh, USA) for 7 days with renewal of 
the medium at day 5. Before use in the opsonophagocytosis assay, the cells were washed 
twice with and resuspended in RPMI-1640 containing 10% FCS.  
Opsonophagocytosis assay. The opsonophagocytosis assay is modified from the 
MSOPKA described by Nahm et al. [9]. In summary, serial dilutions of test sera in the range 
of 1:2 to 1:128 were made in RPMI-1640 in a 96-well cell culture plate with 30 µl of (diluted) 
serum per well. Stocks of the seven pneumococcal serotype strains were washed once in 
RPMI-1640, and a bacterial mixture was made containing 2 x 105 CFUs/ml of each strain. 15 
µl of this bacterial mixture was added to the serum dilutions and incubated for 20 minutes at 
37°C. After incubation, 60 µl of HL-60 suspension and 15 µl of rabbit complement 
(Pelfreeze, Browndeer, USA) were added to each well. The mixtures containing final serum 
dilutions within the range of 1:16 to 1:1024, and bacteria and granulocytes in a ratio of 1:400 
were incubated for 1 h at 37°C.  After incubation, the mixtures were plated onto blood agar 
plates. Two read-out systems were tested: (i) 10 µl of each mixture was spotted onto each of 
7 omni-trays (Nunc, Naperville, IL) containing 5% blood agar with 400 mg/L of streptomycin, 
4 mg/L of chloramphenicol, 400 mg/L of spectinomycin, 1.5 mg/L of rifampicin, 16 mg/L of 
tetracycline, 1 mg/L of erythromycin and 32 mg/L of trimethoprim, i.e the multiplex 
opsonophagocytosis assay (MOPA), and  (ii) 10 µl of mixture was spotted and carefully run 
out on the antibiotic-containing agar plates allowing counting of the individual colonies up to 
100%, according to the original method, i.e. MSOPKA. In addition, 10 µl of the serial dilution 
of the bacterial mixture without serum was spotted onto each of the 7 different antibiotic 
plates to calculate the exact CFUs per well. Finally, the seven resistant strains were spotted 
individually onto the antibiotic trays to confirm monoresistance and selectivity of the 
antibiotic plates. The selective plates were incubated overnight under reduced oxygen 
conditions. Colonies counted on the streptomycin-containing blood agar trays were identified 
as those of the 9V serotype. Similarly, colonies present on the chloramphenicol, 
spectinomycin, rifampicin, tetracycline, erythromycin and trimethoprim trays were exclusively 
of the serotypes 4, 6B, 18C, 19F14 and 23F, respectively. Using the MOPA, the 
opsonophagocytosis titer was expressed as the reciprocal of the highest serum dilution with 
90% killing of bacteria as compared to the number of bacteria counted in the controls 
without serum (range 16 to 1024). The MSOPKA method expressed the 
opsonophagocytosis titer as the reciprocal of the highest serum dilution with 50% killing as 
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compared to the bacterial growth in the controls without serum. Serum samples with titers of 
<16 were reported as a titer of 8 for the purpose of data analysis. 
The assay was tested for non-specific killing of bacteria by serum, complement and HL-60 
cells. Non-specific interference of serum or complement did not occur. Repeated washing of 
the HL-60 cells with RPMI-1640 was required to eliminate the toxic effect of the 
dimethylformamide and penicillin and/or streptomycin from the culture medium on 
pneumococcal growth. Washing of the bacterial stocks before use eliminated the 
interference of dead bacteria and/or degradation products during opsonophagocytosis. 
Enzyme-immunoassay (EIA) for measuring anti-pneumococcal polysaccharide IgG 
concentrations. Concentrations of IgG antibodies were measured from the test sera by EIA 
method as described previously [14]. The results are given as µg/ml calculated from the 
officially assigned IgG values of the 89-SF reference serum [15].  
Statistical analysis. Antibody titers from controls and vaccinees were compared using the 
Mann-Whitney U test. The opsonophagocytosis titers and ELISA IgG titers were converted 
to a log2 base and analyzed for correlation by the Pearson’s correlation coefficient using the 
statistical software SPSS 11. Significance was set at a p-value < 0.05. 
 
Table 1. MICs (mg/L) of the seven serotype strains for the seven selective antibitiotics used in the MOPA. 
 MIC (mg/L) 
 
 14 4 19F 6B 18C 9V  23F 
Erytromycin 4.0 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 
Chloramphenicol 1.0 9.0 1.0 1.0 2.0 1.0 1.0 
Tetracycline <1.0 <1.0 32 <1.0 <1.0 <1.0 <1.0 
Spectinomycine 50 35 100 >400 50 25 100 
Rifampicin <0.25 0.5 0.5 0.5 4.0 0.25 0.25 
Streptomycin 50 65 50 50 50 >400 50 
Trimethoprim 4.0 <2.0 4.0 4.0 <2.0 2.0 >32 
 
 
RESULTS 
We developed a multiplex opsonophagocytosis assay to test the opsonophagocytosis 
activity of serum against the seven capsular serotypes included in the 7-valent 
pneumococcal conjugate vaccine.  
The seven pneumococcal strains representing the vaccine serotypes used in the multiplex 
assay were first tested for cross resistance. The MICs of the seven vaccine serotype strains 
for the seven different antibiotics are depicted in Table 1. The concentration of antibiotics 
used for the selective growth of the seven strains was one-fourth of the MIC of the resistant 
strains. The culture plates were demonstrated to be selective for the individual strains. 
We tested the MOPA using sera from nine adult volunteers. The sera were obtained from six 
volunteers one month after vaccination with the 7-valent pneumococcal conjugate vaccine 
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and from three non-vaccinated volunteers. We determined the serotype-specific IgG 
concentration against the seven conjugate vaccine serotypes for the sera of both the 
vaccinees and the controls (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Average IgG antibody titers for vaccinees and controls for the 7 conjugate vaccine serotypes. The standard 
deviations are depicted. * Mann-Whitney U test: p < 0.05,  ** Mann-Whitney U test: p = 0.05 
 
 
gG antibodies were detectable for all sera. On average, the vaccinees showed 3-11 times 
higher serotype-specific IgG titers compared to the controls, which was significant for all 
serotypes except for the serotypes 9V and 23F.  
We tested the opsonophagocytosis activity of the sera using the MOPA (Figure 2). The 
assay was performed twice. The reproducibility of the assay was high and varied within only 
one dilution for most analyses. Opsonophagocytosis activity was highest for the capsular 
serotypes 14, 18C, 19F and 23F, and lowest for the serotypes 6B and 9V (Table 2). From 
the vaccinated persons 6 out of 42 determinations were below the MOPA detection limit. 
From the unvaccinated volunteers 20 out of the 21 determinations were below the MOPA 
detection limit. Undetectable serotype-specific titers were seen merely in individuals with low 
serotype-specific IgG titers.  
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Figure 2. MOPA for serotype 23F. Opsonophagocytosis results for six vaccinees and three controls; two serial dilutions 
of bacteria incubated with (+) and without (-) complement and HL-60 cells are also depicted. 
 
 
We determined the correlation between opsonophagocytosis and IgG antibody titer per 
capsular serotype. The R-values for the correlation between opsonophagocytosis and IgG 
for the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were 0.70 (p=0.05), 0.17 (p=0.70), 0.58 
(p=0.13), 0.52 (p=0.19), 0.83 (p=0.01), 0.43 (p=0.29) and 0.86 (p<0.01), respectively.  
We also tested the read-out system used in the MSOPKA, i.e. the standard plating method 
allowing the counting of all CFUs in the suspension. By this method the opsonophagocytosis 
titer is defined as the highest dilution of serum resulting in 50% or more reduction in CFUs, 
in contrast to the MOPA, which requires the calculation of 90% or more reduction in CFUs. 
Higher titers were calculated using the MSOPKA compared to the MOPA (Table 2). We 
tested whether the results obtained by the MOPA and MSOPKA read-out systems 
correlated well. A scatter plot was made of all paired results obtained per serum and per 
serotype (Figure 3). The correlation between both methods was high with an R-value of 
0.94. The difference in opsonophagocytosis titer between both methods was determined by 
calculating the best fit line drawn through the paired data. The best fit line for all serotypes is 
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defined by logMOPA = 0.86(logMSOPKA) + 0.3. This indicates that there is on average a 
difference of one log between both methods. Obviously, the MSOPKA method is slightly 
more sensitive because of the lower cut-off used. This is reflected in the number of 
undetectable serotype-specific opsonophagocytosis titers found in vaccinees: for the 
MSOPKA only 2 out of 40 determinations were below the detection limit, whereas for the 
MOPA 6 out of the 42 determinations were below the detection limit (Table 2). 
 
 
Table 2. Opsonophagocytosis titers for the individual sera for both the vaccinees and controls. 
 
Serotype 4 6B 9V 14 
 MOPA MSOPKA MOPA MSOPKA MOPA MSOPKA MOPA MSOPKA 
Vaccinees         
1 64 1024 16 48 16 64 128 1024 
2 48 512 32 64 16 64 128 1024 
3 24 256 16 64 8 8 128 1024 
4 32 256 12 32 8 32 128 1024 
5 12 48 12 48 8 16 128 1024 
6 8 32 16 128 16 48 16 64 
         
Controls         
1 8 16 8 8 8 8 8 128 
2 8 32 8 8 8 8 12 64 
3 8 8 8 8 8 8 8 8 
    
Serotype 18C 19F 23F 
 MOPA MSOPKA MOPA MSOPKA MOPA MSOPKA 
Vaccinees       
1 128 ND 96 1024 96 768 
2 128 1024 96 256 128 768 
3 96 1024 128 1024 128 768 
4 24 256 16 96 32 64 
5 12 128 32 128 128 768 
6 48 ND 8 8 8 16 
       
Controls       
1 8 8 8 16 8 64 
2 8 24 8 32 8 8 
3 8 64 8 8 8 8 
ND: not done 
 
DISCUSSION 
The 7-valent pneumococcal conjugate vaccine has shown to be highly immunogenic in 
young children and is highly protective against invasive pneumococcal diseases [4]. 
However, the efficacy of this vaccine against pneumonia and otitis media is limited 
[11,16,17]. Host protection against Streptococcus pneumoniae is mainly mediated by 
opsonin-dependent phagocytosis. Therefore, the in vitro measurement of opsonophagocytic 
activity of the anti-capsular antibodies is considered to be a reliable correlate of protection, 
and consequently of value to monitor unclear vaccine responses [6,7]. Unfortunately, this 
correlate of protection is seldom studied. This is mainly because the current techniques are 
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time-, and material consuming, and require large volumes of serum to test for the different 
pneumococcal serotypes. For example, the killing assay is very labor-intensive, and requires 
a separate titration curve of serum for each serotype tested [9]. The flow-cytometry assay is 
much less labor-intensive, but still requires 10 µl of serum per single titration curve [18]. In 
particular in the main target group for vaccination, i.e. young children, the amount of serum 
obtained is often limited. Therefore, Nahm et al. have developed a double serotype assay 
called the MSOPKA allowing the testing of opsonophagocytosis killing capacity of serum 
against two different serotypes in a single assay [9]. Nahm et al. have validated the double 
serotype assay method by direct comparison with the single opsonophagocytosis assay 
(OPA) and observed a high correlation between the two assays with R-values of 0.92 and 
0.99. Furthermore, no specific ‘bystander killing‘ was observed, and the MSOPKA provided 
equivalent results to those obtained with the single assays.  
We developed a multiplex opsonophagocytosis assay, MOPA, extending the simultaneously 
investigated capsular serotypes from two to seven serotypes, hereby reducing the required 
volume of serum to 30 µl to test opsonophagocytosis against all vaccine serotypes. We 
tested the assay for non-specific killing of bacteria by serum, complement or by the HL-60 
cells, and did not find non-specific interference of the individual components. Moreover, 
similarly to the previous opsonophagocytosis assays, the reproducibility of the test was high 
[8,9].  
We simplified the read-out system using the method applied in the complement-killing assay 
for N. meningtidis [10]. Because the MOPA uses spotting of reaction mixture instead of 
plating, this assay requires the use of a higher degree of killing as cut-off (i.e. 90% killing  
instead of 50%), since only the growth of approximately 10-15 colonies can be 
distinguished, which matches with 85-90% killing of the initial CFUs. However, this method 
does not require detailed counting of large numbers of colonies for the individual serum 
dilutions, and therefore, the read-out time for the opsonophagocytosis capacity per serum is 
reduced significantly. In addition, spotting of droplets of reaction mixture is less time-
consuming then plating the mixtures. Finally, the number of selective agar plates used is 
decreased significantly. To test whether the two read-out systems correlated well, we tested 
both systems within a single assay. A high correlation was found for all serotypes with an 
overall correlation coefficient of 0.94 (p < 0.001). Because the read-out system of the MOPA 
requires a cut-off for phagocytosis of 90%, the sensitivity of this test is lower compared to 
the read-out system of the MSOPKA, where the mixture is run out, allowing the exact 
counting of the individual colonies up to 100%, and, hence, the calculation of 50% reduction 
in phagocytosis. On average, a log difference between both methods is measured. As a 
result, opsonophagocytosis titers of vaccinees are more frequently found to be below the 
detection  limit  in  case  of  the  MOPA  method (14%) compared to when MSOPKA method  
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(5%). As no data are available regarding the minimal opsonophagocytic titers necessary for 
protection against pneumococcal disease, we cannot speculate about the consequence of 
this difference in detection limit. Therefore, we recommend further studies to evaluate both 
the spectrum of protective opsonophagocytic titers as well as the sensitivity of the assays to 
detect this spectrum. 
We tested whether the phagocytosis capacity correlated with the serotype-specific IgG 
antibody titers. Possibly as a consequence of the limited number of sera tested, we only 
found high correlations for IgG antibody titers and opsonophagocytosis capacity (R-value 
>0.70, p<0.05) for the serotypes 4, 18C and 23F. The lowest correlations between serotype-
specific IgG titers and opsonophagocytosis capacity were observed for the serotypes 6B 
and 19F, which is in line with the findings of Romero-Steiner et al. [8]. However, Jansen et 
al. have observed higher correlations for the latter serotypes using the flow-cytometry assay 
[19]. This might be explained by the difference in effector cells used. In the cytometric assay 
human leucocytes were used as effector cells instead of HL-60 cells. Leucocytes can be 
selected for a high-affinity IgG2 receptor allotype of FcγRIIa, whereas the HL-60 cells display 
the low-affinity variant of this receptor. Use of human leucocytes in the MOPA, however, is 
hardly possible due to the high number of cells required. Besides antibody titers, additional 
variables may influence opsonophagocytosis activity. Furthermore, our findings underline 
the importance of testing opsonophagocytosis activity in addition to the measurement of 
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Figure 3. Scatter plot of the individual opsonization titers. MSOPKA titers are depicted on the x-axis and MOPA titers 
on the y-axis. Best fit line for all serotypes is logMOPA = 0.86(logMSOPKA)+0.3. The R-value is 0.94 (p<0.001). 
Note: some paired results are identical and therefore multiple measurements can be represented by a single data point. 
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antibody titers when monitoring vaccination. Obviously, the number of sera tested in this 
study is too small to draw conclusions about the exact correlations between the amount of 
serotype-specific antibodies and their capacity to elicit opsonophagocytosis. 
In conclusion, the MOPA accurately measures the opsonophagocytosis capacity of serum 
against all serotypes included in the 7-valent conjugate vaccine in a high-throughput 
multiplex fashion, requiring low volumes of serum. Importantly, this assay is easily 
adjustable to measure the opsonophagocytosis capacity of antibodies raised against 
antigens other than the seven capsular polysaccharides, present in the current 7-valent 
conjugate vaccine.  
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ABSTRACT 
Surface associated pneumococcal proteins α-enolase (Eno), immunoglobulin A1 protease 
(Iga), streptococcal lipoprotein rotamase A (SlrA), and putative proteinase maturation protein 
A (PpmA) have potential as candidates for future protein-based anti-pneumococcal 
vaccines. The immunogenicity of these proteins were studied in a cohort of 329 children 
during their first two years of life. During the first recorded episode of otitis media, acute and 
convalescent phase sera were available from 151 children. Concentrations of antibodies 
against Eno, Iga, SlrA and PpmA were measured by EIA and detected in 99% (300/302), 
95% (288/302), 95% (288/302), and 83% (251/302) of the sera, respectively. There were no 
statistically significant differences between the groups of children with and without a history 
of pneumococcal contact or with respect to the type of pneumococcal contact. Despite a 
mean overall decrease in the antibody titers in the convalescent sera following AOM, several 
children were able to respond with a more than 2-fold increase in antibody titer in response 
to AOM. The majority of the children with increased antibody concentrations appeared in the 
groups, which were colonized with pneumococci at the time of serum collection, but were 
recorded as having no prior contact with pneumococci. In conclusion, SlrA, PpmA, Eno and 
Iga are immunogenic proteins that elicit antibody responses early in life. No significant 
correlation between antibody titers to these proteins and pneumococcal carriage or infection 
was found. Presumably, this results from the presence of cross-reactive epitopes on 
commensal bacteria. 
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INTRODUCTION 
Streptococcus pneumoniae is a commensal bacterium of the human nasopharynx (4). It is a 
leading etiological agent of mucosal disease such as acute otitis media (AOM), and of 
severe invasive disease such as septicemia, pneumonia and meningitis. Invasive 
pneumococcal disease may have fatal consequences: over three million deaths per year 
worldwide of which a million are young children (5). Little is known about the immunogenicity 
of pneumococcal proteins in relation to age, colonization, and disease status. Antibodies to 
pneumococcal proteins PspA, PsaA, and pneumolysin have been shown to develop early in 
life, moreover, adult levels of antibodies to PsaA, Pneumolysin, and PspA are reached by 
the ages of six months, two years and five years, respectively (10, 13). In addition, 
concentrations of antibodies against these proteins in young children are strongly associated 
with pneumococcal contact by colonization or infection (AOM) (10, 11). The relationship 
between antibodies against pneumococcal proteins and disease is less clear. In adults with 
severe pneumococcal infection, the immune response in the acute and convalescent phase 
serum to the pneumococcal proteins PspA, PrtA and SpuA shows no significant changes in 
relation to normal adult levels. A small increase in the titer was observed in the early 
convalescent phase serum to pneumococcal proteins PrtA and SpuA (16). In adults, titers of 
anti-PspA antibodies increase during colonization, and pre-existing low titers of anti-PspA 
antibodies were associated with pneumococcal colonization (6). In children over the age of 
nine months, higher titers of antibodies to PsaA were associated with a lowered risk of the 
development of pneumococcal AOM during pneumococcal carriage (12). 
Pneumococcal proteins α-enolase (Eno), immunoglobulin A1 protease (Iga), streptococcal 
lipoprotein rotamase A (SlrA), and putative proteinase maturation protein A (PpmA) have 
been suggested to play a role in virulence of S. pneumoniae (1, 2, 8, 15). Due to their 
surface location they have been proposed as potential vaccine candidates. The glycolytic 
enzyme Eno has been identified both in the cytoplasm, and in significant quantities on the 
surface of pneumococci, and has been shown to be involved in virulence by the activation of 
plasmin into plasminogen, a host collagen-degrading enzyme (2). Iga has been shown to 
play an important role in pneumococcal colonization by cleaving the Fc receptor from 
secreted immunoglobulin A1, thus preventing opsonophagocytosis. The cleaved IgA1 
fragments have been shown to increase the adherence properties of the pneumococcus 
(15). PpmA and SlrA are lipoproteins belonging to a class of chaperones, the peptidyl prolyl 
isomerases, which are thought to be involved in the secretion and activation of cell surface 
molecules (1, 8). PpmA shares homology with the parvulin group of peptidyl prolyl 
isomerases, and SlrA shares homology with the cyclophilins.  
No data are available yet on the prevalence of antibodies to PpmA, SlrA, Eno and Iga in 
young infants or their natural development in response to pneumococcal colonization or 
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disease. There are also no data to indicate whether such antibodies are protective against 
pneumococcal infection. To fill such gaps in the background knowledge needed when 
considering the use of a future protein-based pneumococcal vaccine, we present data on 
the development of antibodies to PpmA, SlrA, Eno and Iga in young children and evaluate 
the association of the antibody titers with culture-proven pneumococcal carriage and 
disease. 
 
 
METHODS 
Study cohort and sample schedule. The study population comprised 329 children who 
were enrolled in the Finnish Otitis Media (FinOM) Cohort Study (10, 11). For the analysis, 
151 pairs of serum samples from the acute and convalescent phase were taken from 
children, which presented with symptoms of a respiratory tract infection, and suspected 
AOM. The study population was divided into three groups according to whether or not they 
had a current contact with S. pneumoniae and according to the nature of the current contact. 
The three groups were: (1) current pneumococcal AOM: S. pneumoniae was cultured from 
the MEF and NPA sample obtained at the diagnosis of the evaluated AOM; (2) current 
pneumococcal carriage: S. pneumoniae was cultured from NPA but not from MEF; (3) no 
current pneumococcal contact: NPA and MPF cultures negative for S. pneumoniae. Each 
group was further divided into two subgroups according to whether the children had a history 
of previous pneumococcal contact (NP or NPA culture positive for S. pneumoniae). Thus the 
anti-PpmA, anti-SlrA, anti-Iga, and anti-Eno concentrations and responses were evaluated in 
the 6 groups of children.  
Clinical samples and culture methods. The NP swabs, NPA samples and MEF were 
obtained as described previously (10, 11). Pneumococci were identified by standard 
methods (14). Serum samples were stored at -20°C at National Public Health Institute of 
Finland and a small aliquot was shipped frozen to the Laboratory of Pediatrics at Erasmus 
MC for antibody determinations. 
Recombinant antigens. The PpmA and Iga protein antigens were prepared as described 
previously (7). The genes used for the production of the recombinant antigens Eno, and SlrA 
were amplified by PCR and cloned into a pET11a expression vector (Stratagene, LaJolla, 
CA). A His6 tag was incorporated onto the C-terminal peptide sequences for Eno. The N-
terminal signal peptide of SlrA was replaced with an N-terminal His6 tag. The recombinant 
plasmids were electrotransformed into E. coli BL21 (DE3). The expression of recombinant 
protein was induced by the addition of IPTG, and the recombinant proteins were purified by 
Ni+ affinity chromatography with the HisTrapTM Kit (Amersham Pharmacia, Uppsala, 
Sweden) according to the manufactures recommendations. The purity of the recombinant 
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proteins was determined by SDS-PAGE gel electrophoresis with CBB staining. The 
sequence of the purified peptides was confirmed with MALDI-TOF mass spectrometry. 
Serologic methods. IgG antibodies to Eno, Iga, PpmA and SlrA were measured by EIA. 
Microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with 100µl/well, with a 
coating concentration of 5µg/ml of antigen in PBS and incubated overnight at 37°C. The 
plates were blocked with 1% bovine serum albumin (BSA) and 0.05% Tween 20 in PBS at 
37°C for 1 h. The samples were serially diluted (starting at 1:100) in the dilution buffer (1% 
BSA, 0.05% Tween 20 in PBS). Duplicates (100µl/well) were incubated at 37°C for 2 h. 
Polyclonal alkaline phosphatase-conjugated antisera to human IgG (Sigma Chemicals, St. 
Louis) was diluted 1:3000 in the dilution buffer, pipetted at 100µl/well, and incubated for 2 h 
at 37°C. Finally, 100µl/well of MUP (Sigma, CAT#M8883) substrate solution (0.2 mM 4-
methylumbelliferyl phosphate, 0.05 M NaCO3, 0.05 mM MgCl2) was added, and the plates 
were incubated for 1 h at 37°C. The fluorescence was measured with an excitation 
wavelength of 365nm, and an emission wavelength of 450 nm with a Molecular Devices 
SpectraMAX (Sunnyvale, USA) microplate reader. The serum endpoint antibody titer was 
interpolated from the intersection of the absorbance-versus-serum dilution curve at the 
background fluorescence plus four times the standard deviation. The end-point titer was 
then converted into antibody concentration (EIA units of immunoglobulin per milliliter) by 
comparison with a standard serum consisting of pooled healthy adult volunteers, and was 
considered to contain 100 U/mL of anti-α-enolase, Iga, PpmA or SlrA. Samples with 
antibody concentrations below the detection limit (30 U/mL for Eno, 4 U/mL for Iga, 4 U/mL 
for SlrA, and 5 U/mL for PpmA) were assigned the values equivalent to half the detection 
limit.  
Statistical methods. We used SPSS software (SPSS, USA) for analysis of log-transformed 
data. The antibody concentrations in the groups of children are reported as geometric mean 
concentrations (GMC, units/ml) with 95% confidence intervals (95% CI) and compared by 
one way ANOVA followed by a LSD post hoc test. Statistical comparisons between antibody 
levels in acute and convalescent phase sera were carried out using a paired Student’s t test. 
Fisher’s exact test was used when the proportions of variables were compared. A logistic 
regression was used to evaluate the effects of the acute phase antibody concentration, age 
and the nature of pneumococcal contact on the antibody response and to evaluate antibody 
concentrations (logarithm base e of antibody concentration) as a risk factor for the 
involvement of pneumococci as a risk factor for the development of AOM. Children were 
grouped into eight 3-month groups according to the age at which the acute serum was 
sampled. To determine whether there were any significant differences in relation to age, 
groups were analyzed by 1-way ANOVA followed by a Tukey’s HSD test. 
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RESULTS 
One hundred and fifty one children for whom a MEF sample and paired sera were available 
had at least one attack of AOM (Table 2). Of the 151 AOM events occurring at the median 
age of 267 days (range 49 to 723 days), 37 children had S. pneumoniae in the MEF culture, 
and in all of them it was also cultured from the NPA sample. S. pneumoniae was recovered 
only from the NPA sample in 43 cases, and in 71 cases, the MEF and NPA samples were 
negative for S. pneumoniae. Of the 37 children with current pneumococcal AOM, 15 had no 
known previous pneumococcal contact (Group 1) and 22 had at least one proven previous 
pneumococcal contact (Group 2). Of the 43 children with current pneumococcal carriage, 12 
had no previous cultures positive for S. pneumoniae (Group 3), whereas 31 had a previous 
pneumococcal contact (Group 4). Of the 71 children with no current contact with 
S. pneumoniae (Group 5), 53 had no detected previous pneumococcal contacts, and 18 had 
a history of previous pneumococcal contact (Group 6) (Table 2). Measurable concentrations 
of antibodies against Eno, SlrA, Iga and PpmA were found in 99% (292/294), 97% 
(288/298), 95% (288/302), and 83% (251/302) of the sera respectively. 
Antibodies in acute phase sera. Previous pneumococcal contact appeared to have no 
influence on antibodies against Eno in the acute phase serum (Table 1). Furthermore, there 
were no significant differences in anti-enolase concentrations in relation to the type of 
pneumococcal contact. The GMC of antibodies to IgA1 protease showed no statistically 
significant differences between pneumococcal contact groups. In general, mean anti-Iga 
concentrations tended to be higher in the groups who had previous contact with 
pneumococci, however, in the children from which pneumococci were isolated from MEF 
(Groups 1 and 2), antibody titers were 2-fold higher in the group with no previous 
pneumococcal contacts (Group 1). With respect to antibodies against SlrA in the acute 
phase sera, there were no statistically significant differences in the titers of anti-SlrA 
antibodies between groups in relation to the type of pneumococcal contact, and in relation to 
the history of detection of pneumococci in the nasopharynx prior to the development of 
AOM. The highest titers of anti-SlrA antibodies were recorded in the group of children from 
whom pneumococci were recovered from MEF, but from who no previous contact with 
pneumococci was detected (Group 1). In this group a more than 2-fold difference in the 
GMC of anti-SlrA antibodies was recorded in relation to the other pneumococcal contact 
groups. With respect to antibodies against PpmA in the acute phase sera, there were no 
statistically significant differences in the titers of anti-PpmA antibodies between groups in 
relation to the type of pneumococcal contact, and the history of detection of pneumococci in 
the nasopharynx prior to the development of AOM.  There was, however, a trend towards 
higher titers of anti-PpmA antibodies being associated with previous pneumococcal contact. 
The GMC of anti-PpmA antibodies tended to be higher in the children from whom
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pneumococci were isolated from MEF.   
Antibody responses to AOM. Despite the fact that a number of children showed positive 
antibody responses to AOM, there was an overall decrease in the mean titer of antibodies 
against Eno, SlrA, Iga and PpmA antigens in the convalescent serum compared to the acute 
phase serum (Table 1). Of the different pneumococcal contact groups, the highest incidence 
of children, which showed a more than 2-fold increase in the response to AOM in the 
convalescent serum, was (Group 3), from which pneumococci were isolated from the NPA 
only, but which had no previous record of pneumococcal colonization. In this group, the 
percentage of children from which a more than 2-fold increase in the antibody titer following 
AOM in the convalescent serum was measured, was 42%, 25%, 17% and 33% for Eno, 
SlrA, Iga, and PpmA, respectively. In a logistic regression model, higher concentrations of 
antibodies to Eno, SlrA, Iga, and PpmA antigens were not associated with a decreased risk 
of pneumococcal AOM in any age groups (data not shown). 
Age specific differences. There were no statistically significant differences between the 
antibody titers of the different age groups of children. However, for most pneumococcal 
antigens the GMC of antibodies were higher in the 0-3 months age group than for the 
remainder of the first year of life. This was most noticeable for anti-PpmA antibodies. Titers 
of antibodies against PpmA and SlrA antigens showed a trend towards increasing after 18 
months of age. 
 
 
DISCUSSION 
A major contributing factor in the development of antibodies against pneumococcal antigens 
Eno, Iga, SlrA and PpmA, is the fact that several antigens that were tested may share 
common epitopes with the antigens present on the surface of other bacteria. This is 
especially true for Eno, which is a conserved essential glycolytic enzyme, which has 
epitopes that are able to ross-react with different species of streptococci and the human 
enzyme (3). Similarly, with Iga, despite it having a unique structure among bacterial 
proteases, homology searches have indicated that the Iga gene of S. pneumoniae is also 
found in the Viridans streptococci, the gene fragment used in this study shared >90% 
homology between viridans streptococci, and is unrelated to the serine IgA1 proteases of 
other commensal bacteria of the nasopharynx such as Neisseria meningitidis and 
Haemophilus influenzae (9). This suggests that the rapid colonization of children by 
commensal bacteria such as the viridans streptococci soon after birth is a likely source of 
cross-reactive epitopes of Eno and Iga. Furthermore, it helps to explain why anti-Eno and 
anti-Iga antibodies were present in almost all the serum samples, and indeed why the 
history  of  pneumococcal  exposure, current pneumococcal  colonization and AOM had little  
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impact on the serum concentrations of anti-Eno and -Iga antibodies in comparison to 
pneumococcal proteins PsaA, PspA and Pneumolysin for which the increase in antibody 
concentrations is associated with pneumcoccal contacts (10, 11). The influence of past or 
current pneumococcal contact appears to play little role in influencing concentrations of 
serum antibodies against SlrA. It is difficult to predict whether the presence of cross-reacting 
epitopes plays a hand in masking a noticeable response to pneumococcal contact. BLAST 
searches of all the bacterial genomes sequenced to date show that lipidated forms of the 
cyclophilin SlrA occur in all sequenced streptococcal genomes, and SlrA shares between 
60% and 70% amino acid identity with its corresponding viridans streptococcal homologues. 
PpmA is a member of the ubiquitous family of parvulin-like peptidyl prolyl isomerases, but 
despite being widely represented among bacteria, homology searches have shown that 
proteins of closely related bacteria share less than 52% homology with pneumococcal 
PpmA. In addition, polyclonal sera raised against purified PpmA has failed to recognize any 
epitopes of related streptococcal species by Western blot (unpublished data), and is unable 
to elicit  opsonophagocytic activity against other streptococcal species (8). Anti-PpmA 
antibody titers showed a trend towards responsiveness to contact with pneumococci in a 
similar way as the pneumococcal antigens PspA, PsaA and Pneumolysin.  
In conclusion, although the investigated proteins Iga. SlrA, Eno and PpmA showed to be 
immunogenic early in life, no correlation between colonization and infection with 
pneumococci and antibody titers directed against these proteins was found. These data 
suggest the presence of cross-reactive epitopes on commensal bacteria co-colonizing the 
nasopharyngeal niche. Since pathogen-specific epitopes are less likely to cross-react with 
epitopes of commensal bacteria of the nasopharynx, such proteins might have more 
potential as vaccine candidates. Finally, the effect of antibodies cross-reacting with vaccine 
epitopes on commensal bacteria warrants further study. 
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Streptococcus pneumoniae is a major cause of invasive diseases such as meningitis, 
septicemia and pneumonia. Approximately 1 million children under 5 years of age die of 
pneumococcal disease annually 1. In countries where the incidence of Neisseria meningitidis 
and Haemophilus influenzae infections has drastically decreased through the introduction of 
vaccines against meningococcus group C and H. influenzae type B, S. pneumoniae has 
become the major remaining cause of meningitis and septicemia in children. In addition, the 
morbidity by S. pneumoniae through respiratory tract infections such as otitis media and 
sinusitis is enormous.  30-50% of all patients with otitis media and a substantial percentage 
of cases of sinusitis and pneumonia are caused by pneumococci. Risk groups for serious 
pneumococcal disease include children under the age of 2 years, the elderly and patients 
with immunodeficiencies 2. 
Nasopharyngeal colonization by S. pneumoniae is common: probably all humans are 
colonized with this organism at least once early in life. Especially in circumstances of 
crowding, in day-care centers, nursing homes, hospitals and jails, the risk of colonization 
with pneumococci is high 3-5. Colonization is not usually followed by disease, since this is 
prevented by both the innate and adaptive immune systems. However, disturbance of 
homeostasis between host and pathogen, for example through viral infections, malnutrition 
or local damage of the mucosa, is associated with the development of (invasive) diseases 6-
8.  
In 1999, Engelen and coworkers investigated colonization in Amsterdam among 259 
children attending 16 day-care centers (DCCs) and among 276 children who did not attend 
day-care centers (NDCCs). A 1.6-3.4 fold increased risk for nasopharyngeal colonization 
was observed in children attending day-care compared with non-day-care center children. 
We investigated the serotype and genotype distribution of 305 nasopharyngeal S. 
pneumoniae isolates collected in the latter study (Chapter 3.1). The predominant serotypes 
in both the DCC and the NDCC group included serotypes 19F, 6B, 6A, 23F, and 9V. The 
theoretical vaccine coverage of the 7-valent conjugate vaccine was for both groups similar, 
i.e 56-59%. However, genetic analysis of the pneumococcal isolates revealed 75% 
clustering among pneumococci isolated from DCC attendees versus 50% among the NDCC 
children. The average pneumococcal cluster size in the DCC group was 3.8 and 4.6 isolates 
for two respective sample dates (range 2 to 13 isolates per cluster), while the average 
cluster size for the NDCC group was 3.0 (range 2 to 6 isolates per cluster). Similar to 
observations made in other countries, these results indicate a higher risk for horizontal 
spread of pneumococci in Dutch day-care centers in comparison with the general 
population, however this is not related to serotype distribution. A second risk factor for 
pneumococcal colonization is antibiotic consumption. However in our study, only 2% of the 
pneumococcal isolates were resistant to erythromycin and no resistance to penicillin, 
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cotrimoxazole, and tetracycline was found, therefore the enhanced horizontal spread within 
day-care centers was not related to antibiotic resistance. The RFEL patterns of the isolates 
were compared with the first sixteen international (multidrug-resistant) clones described by 
the pneumococcal epidemiology network (http://www.pneumo.com/ physician/pmen/pmen_ 
history.asp).  Twenty-five isolates (10%) in the DCC group were homologous to three of the 
reference clones (100% identical), whereas six isolates (10%) in the NDCC group matched 
with four of these clones. In contrast to the multidrug-resistant reference clones, all Dutch 
isolates but one were fully susceptible or mono-resistant. These results suggest that the 
Dutch isolates represent members of the ancestor lineages of the resistant reference clones. 
The absence of the original resistant clones in The Netherlands may be explained by the 
reserved antibiotic prescription behavior of doctors in this country for many years, which 
starts with the hospitals of which over 50% have implemented restrictive formulary 
agreements. In addition, most general practioners follow guidelines of the Dutch College of 
General Practioners, which results in restrictive and selective prescription behavior 
compared to international colleagues.  
In 2002, we had the opportunity to investigate the prevalence and determinants of 
nasopharyngeal carriage of S. pneumoniae and S. aureus in 3198 healthy children 1-19 
years of age (Chapter 3.2). Determinants of nasopharyngeal carriage of S. pneumoniae 
(19%) were age and day-care attendance. All of these factors were previously reported as 
determinants of carriage. Other variables which were reported in the literature to be 
determinants for pneumococcal carriage, such as passive smoking at home, large 
households and crowding among teenagers, did not correlate with carriage in our study, 
when corrected for the remaining determinants by means of multivariate logistic regression 
9. Analysis of the age-related distribution of vaccine and non-vaccine serotypes showed an 
initial predominance of vaccine-type pneumococci in the first 3 years of life, followed by a 
subtle shift towards non-vaccine type pneumococci after the age of 3 years. These findings 
are in agreement with those of Dagan et al., who showed a similar reversal after the age of 2 
years in children who attended day-care centers 10. Risk-factors for Staphylococcus aureus 
carriage (36%) were age (peak incidence: 10 years), sex, family size and passive smoking, 
whereas active smoking was inversely related to S. aureus carriage. Furthermore, passive 
smoking was associated with an increased risk while active smoking decreased this risk. We 
hypothesize, that tobacco smoke damages the epithelium of the upper airways. With initial 
exposure to smoke adherence of bacteria to host cell surfaces may be enhanced, while 
increased exposure may ultimately damage the surfaces such that colonization is prevented, 
as was shown by in vitro assays 11. Pneumococcal serotype analysis showed 42% vaccine 
type and 58% non-vaccine type pneumococci. After correction for the independent 
determinants  of colonization  by  multivariate  logistic  regression  analysis,  we  observed  a  
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negative correlation for co-colonisation of S. aureus and vaccine-type pneumococci, but not 
for S. aureus and non-vaccine serotypes. Because children under 5 years of age are 
considered to be representative for the target population for pneumococcal conjugate 
vaccination, bacterial interaction is particularly relevant in this age group. For this sub-
cohort, the negative correlation for co-colonisation of vaccine type pneumococci and S. 
aureus was even stronger. Our findings are in agreement with the data of Veenhoven et al. 
(Chapter 7.1) 12, who demonstrated a significant increase in S. aureus-induced AOM 
episodes in otitis prone children vaccinated with the 7-valent conjugate vaccine. This 
interference has already been described in 1922 in an in vitro model by Mc Leod and 
Gordon. These investigators showed that S. aureus growth is inhibited in the presence of 
culture supernatant of S. pneumoniae 13. At that time, this effect was thought to be caused 
by the presence of hydrogen peroxide in the supernatant. This hypothesis was later 
supported by studies of Dahiya et al. and Repine et al. 14,15. Whether only pneumococci, or 
also other streptococcal species are involved in this competitive balance remains unclear, 
although the investigations of Uehara et al. suggest a similar competitive corrrelation 
between viridans streptococci and S. aureus 16. This interspecies competition is also 
observed for streptococcal species and other nasopharyngeal bacteria 17,18. These studies 
suggest that host factors are also involved in the complex process of inter-species 
competition and interaction. Why the observed interaction between S. pneumoniae and S. 
aureus is serotype-dependent remains uncertain. We hypothesise, that this interaction is 
primarily genotype related. This assumption is supported by findings of Pericone et al. who 
have shown strain variability in the expression of SpxB and consequently, in the production 
of hydrogen peroxide 19. Differences in hydrogen peroxide concentrations generated by the 
pneumococcal strains might explain different inhibitory effects on other bacterial species. 
Extensive in vitro and in vivo research on the observed serotype-related interaction between 
S. pneumoniae and S. aureus is required to obtain insight in the molecular basis of the 
observed bacterial inhibitory interaction. In addition, the potential effect of pneumococcal 
conjugate vaccination on S. aureus carriage also requires further study. 
We also investigated the prevalence and determinants of nasopharyngeal carriage of N. 
meningitidis in the same group of children in Rotterdam, The Netherlands. These children 
were vaccinated with a meningococcal group C vaccination because of a recent outbreak 
with meningococcal group C disease (Chapter 3.3). We observed meningococcal carriage 
in 46 children (1.5%). Subtyping of the meningococcal strains showed 8 group B isolates, 9 
group C isolates, 24 type xyzw 135 isolates and 8 others. Peak-incidences were seen in the 
first year of life (3.2% carriage) and after the age of 15 years (3.7% carriage). We therefore 
concluded that nasopharyngeal carriage of N. meningitidis was low at the time of the Dutch 
national meningococcal vaccination campaign in the summer of 2002. One might argue that 
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this is caused by differences in the method of sampling, i.e. nasopharyngeal instead of 
oropharyngeal cultures. At present, there is still uncertainty about the most optimal method 
of meningococcal sampling 20-24. More importantly, the time of sampling, i.e. the summer, 
might explain the low incidence in carriage. Most often, a peak in meningococcal 
colonization and infection is observed in autumn and winter when the crowding factor 
increases 25. Independent determinants of N. meningitidis carriage included age, 
pneumococcal carriage and regular visits of youth clubs and dancings, as was also 
observed by Dominguez et al. 24. Together with season, most of these determinants lead to 
the same consequence, i.e. enhanced horizontal spread of meningococci within the 
population. 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality 
in adults. According to the Global Burden of Disease Study, COPD is the fifth most common 
disease and fourth leading cause of death in the world. Both prevalence and mortality are 
still expected to increase in the coming decades 26. The chronic course of this disease is 
frequently interrupted by acute exacerbations, which have a major impact on the morbidity 
and mortality of COPD patients 27. Bacterial infections are thought to contribute to the 
pathogenesis and clinical course of COPD 28. Therefore, we investigated the effect of 
bacterial colonization during stable disease on time to first exacerbation in COPD patients 
(Chapter 3.4). In a randomized controlled trial, 244 COPD patients were followed for  period 
of 10 months. Sputum samples were collected at randomization and during exacerbations. 
We calculated the time to development of an exacerbation in colonized compared to non-
colonized patients. At randomization 36% of the patients were colonized with potentially 
pathogenic microorganisms. We found that overall bacterial colonization in COPD patients is 
not an independent risk factor for the development of acute exacerbations. However, we 
hypothesized that monocultures might indicate a prestadium of infection in contrast to the 
presence of mixed cultures. Therefore, we performed a subsidiary analysis on monocultures 
of pneumococci, H. influenzae and M. catarrhalis in the latter study (Chapter 8.3). We found 
that colonization with merely pneumococci (monocultures) increased the risk of an 
exacerbation with a hazard ratio of 2.93. The most prevalent pneumococcal serotypes found 
were the serotypes 19F, 3, 14, 9L/N/V, 23A/B and 11 with a theoretical coverage for the 7-, 
and 11- valent pneumococcal vaccine of 60% and 73%, respectively. These results support 
a causative role of pneumococci in exacerbations of chronic obstructive pulmonary disease. 
In addition, we have shown that pneumococcal colonization in COPD patients is frequently 
caused by vaccine serotype strains. More detailed studies are necessary to determine a 
potential role for pneumococcal vaccination in the prevention of exacerbations in COPD 
patients. 
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Since the discovery of the antibacterial properties of penicillin by Fleming in 1929, many 
antibiotics have been used for treatment of pneumococcal infections. Recently, antibiotic 
resistance has become a worldwide problem, which limits the choice of antimicrobial agents. 
A majority of the resistant strains belongs to a limited number of multidrug-resistant 
pandemic clones, which have spread rapidly throughout Europe, Asia and the United States. 
To evaluate the genetic background of penicillin-resistant pneumococcal isolates from Greek 
children, we performed antibiotic susceptibility testing, serotyping, restriction fragment end 
labeling (RFEL), and penicillin binding protein (PBP) genotyping (Chapter 4.1). The 
serotypes 23A/23F, 19A/19F, 9V, 15A/15B/15C, 6A/6B and 21 were most prevalent in this 
collection. Fifty-three distinct RFEL types were identified. Sixteen different RFEL clusters, 
harboring 2 to 32 strains each, accounted for 82% of all strains. Eight of these genetic 
clusters representing 60% of the strains were previously identified in other countries. One 
predominant lineage (46% of the strains) representing serotype 19F and 23F isolates was 
closely related to the pandemic clone Spain23F-1 (genetic relatedness ≥ 85%). Another 
lineage representing 11 strains, showed close genetic relatedness to the pandemic clone 
France9V-3. Another lineage of 8 serotype 21 strains was Greece-specific as the RFEL types 
were not observed in an international collection of 193 genotypes from 16 different 
countries. Characterization of the PBP genes pbp1a, pbp2b and pbp2x revealed 20 distinct 
PBP genotypes of which PBP type 1-1-1, initially observed in the pandemic clones 23F and 
9V, was predominantly present in 11 RFEL types in this Greek collection of penicillin-
nonsusceptible strains (55%). Sixteen PBP types covering 52 strains (36%) were Greece-
specific. This study underlines the strong contribution of penicillin-resistant international 
clones to the prevalence and spread of penicillin-nonsusceptible pneumococci among young 
children in Greece. 
In addition, Syrogiannopoulos et al. observed a significant spread of serotype 6B multidrug-
resistant (MDR) pneumococci, susceptible to penicillin and resistant to erythromycin, 
clindamycin, tetracycline, chloramphenicol and trimethoprim-sulfamethoxazole in young 
carriers living in Central and Southern Greece since 1996. Using RFEL and PBP genotyping 
we studied 41 serotype 6B penicillin-susceptible MDR pneumococci isolated during two 
independent studies in Greece (Chapter 4.2). Forty (98%) of these 41 isolates were strongly 
related, representing a single lineage (genetic relatedness ≥ 91%). The Greek isolates were 
closely related (genetic relatedness ~91%) to the penicillin-resistant MDR clone of serotype 
6B that has spread from Spain to Iceland in the late 1980s. Moreover, the Greek group of 
isolates was genetically distinct (genetic relatedness ≤ 83%) from other penicillin-susceptible 
or -resistant serotype 6B strains from various parts of the world. All serotype 6B penicillin-
susceptible MDR isolates displayed a penicillin-susceptible PBP 1A-2B-2X genotype. These 
data suggest that the penicillin-susceptible MDR 6B clone that was found in Greece 
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between the years 1996 and 1999 represents the ancestor of the penicillin-resistant 
pandemic MDR clone 6B, which already has a high potency to spread horizontally within the 
population.  
To evaluate the genetic relatedness of pneumococcal isolates, susceptible to penicillin but 
resistant to non-β-lactam agents representing non-serotype 6B isolates, we also 
investigated hundred-twenty-eight S. pneumoniae isolates from young carriers in Greece by 
antibiotic susceptibility testing, serotyping, RFEL and antibiotic resistance genotyping 
(Chapter 4.3). The serotypes 6A/B, 14, 19A/F, 11A, 23A/F, 15B/C, and 21 were most 
prevalent in this collection. Of the isolates, 65% was  erythromycin-resistant, while the 
remaining isolates were tetracycline- and/or trimethoprim-sulfamethoxazole-resistant. Fifty-
nine distinct RFEL types were identified. Twenty different RFEL clusters, harboring 2 to 19 
strains each, accounted for 76% of all strains. Confirmatory multi locus sequence typing 
(MLST) analysis of the genetic clusters showed the presence of 3 international clones 
(Tennessee23F-4, England14-9 and Greece6B-22) representing 30% of the isolates. The 
erm(B), mef(A) and mef(E) genes were all present and belonged to distinct genetic clusters. 
The majority of the tetracycline-resistance was related to the Tet(M) gene. We concluded 
that penicillin-susceptible pneumococci resistant to non-β-lactams are a genetically 
heterogeneous group displaying a variety of genotypes, resistance markers and serotypes. 
This suggests multiple genetic events leading to non-β-lactam resistant pneumococci in 
Greece. Importantly, most of these genotypes are capable to disseminate within the 
community.  
Until now, antibiotic resistance among pneumococci in The Netherlands is uncommon. In 
1995 and 1996, a nation-wide molecular epidemiologic survey of penicillin-nonsusceptible S. 
was performed in The Netherlands, which showed less than 2% penicillin resistance. We 
analyzed the pbp genes from these clinical isolates in detail (Chapter 4.4). The 
pneumococcal strains were selected on the basis of differences in restriction fragment 
length polymorphism (RFLP) patterns of the complete genes pbp1a, pbp2b and pbp2x, 
representing 8, 7 and 10 distinct patterns, respectively. We characterized specific gene parts 
of pbp1a, pbp2b and pbp2x. Classification based upon sequence analysis of these pbp 
fragments correlated well with the classification according to RFLP analysis. Sequence 
analysis of pbp2b enables a refinement of the classification based on RFLP analysis. 
However, sequence analysis of pbp1a and pbp2x was less discriminatory compared to 
RFLP analysis. The mutations in the pbp sequences of the Dutch isolates invariably 
matched with the mutations described in pbp sequences of penicillin-nonsusceptible 
pneumococci isolated in other countries. This observation supports the hypothesis that 
multiple clones of penicillin-resistant pneumococci have been imported and spread in The 
Netherlands. Interestingly, novel combinations of mosaic structures were also identified 
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indicating horizontal exchange of pbp gene parts among penicillin-nonsusceptible 
pneumococci. This is in line with previous findings of Coffey et al. They concluded that the 
pbp mosaic genes have emerged by recombinational events between the pbp genes of 
pneumococci and their homologues in closely related streptococcal species. These 
recombinational genes may have disseminated among pneumococci by horizontal gene 
transfer, presumably mediated by genetic transformation between different pneumococcal 
lineages to produce new resistant clones 29. However, these events seem to occur seldom 
as can be concluded from the persisting low percentages of penicillin resistance. Obviously, 
this can be explained by the limited antibiotic pressure within the community as a result of 
the restricted antibiotic prescription behavior of physicians in The Netherlands.  
Because of the persistent high morbidity and mortality due to pneumococcal disease, and 
the rapid acquisition and spread of antibiotic resistance among pneumococci worldwide, 
prevention of pneumococcal disease has become of great interest. Until now, many 
research groups have focused on the development of new effective vaccines to be used in 
particular risk groups including immunocompromised patients and children. One of these 
vaccines, the 7-valent pneumococcal conjugate vaccine, has shown to be highly effective 
against invasive disease caused by the included pneumococcal serotypes 30. The 7-valent 
conjugate vaccine has also shown to be partially effective against pneumonia and otitis 
media 31-34. Moreover, several investigators have shown a significant reduction in 
nasopharyngeal carriage of vaccine type pneumococci in infants as a result of different 
conjugate vaccinations 10,35-37. However, the coverage is limited and varies per country or 
continent 38. In order to evaluate the theoretical coverage of the vaccines and the effect of 
vaccination on future serotype distribution we need to monitor in detail and at large scale the 
molecular epidemiology of pneumococcal colonization and infection before and after the 
implementation of these vaccines. So far, the coverage of the conjugate vaccine has been 
investigated in several parts of the world. Recently, the Asian Network for Surveillance of 
Resistant Pathogens (ANSORP) has studied nasal carriage of pneumococci in healthy 
children in Taiwan, Korea, Sri Lanka and Vietnam. The most common serogroups were 
serogroup 6, 23, 19, 14 and 15. Because no subtypes were determined, the exact vaccine 
coverage could not be calculated 39. Therefore, we investigated the molecular epidemiology 
of 84 pneumococcal carriage isolates of children attending several outpatient departments in 
Hanoi, Vietnam, with acute respiratory tract infections (Chapter 5.1). The serotypes 23F, 
19F, 6B and 14 were found most often. A significant number of strains was antibiotic-
resistant. Fifty-two percent of the strains was (intermediate) resistant to penicillin, 87% 
(intermediate) resistant to cotrimoxazole, 76% resistant to tetracycline, 73% resistant to 
erythromycin and 39% intermediate resistant to cefotaxim. Seventy-five percent was 
resistant to three or more classes of antibiotics. A high degree of genetic heterogeneity 
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among the penicillin resistance genes was observed. In addition, the tetracycline resistance 
gene tetM and the erythromycin resistance gene ermB were predominantly observed among 
the isolates. Molecular analysis of the 84 isolates by RFEL revealed 35 distinct genotypes. 
Twelve of these genotypes represented in total 8 genetic clusters and consisted of 61 of the 
isolates (73%). The two largest clusters represented 24 isolates and 12 isolates were 
identical to the two internationally spreading multi-drug resistant clones Spain 23F-1 and 
Taiwan 19F-14 clones, respectively. The remaining RFEL types were Vietnam-specific. 93% 
of the horizontally spreading isolates were covered by the 7-valent conjugate vaccine, 
whereas this vaccine covered only 43% of the unique genotypes. According to the serotype 
distribution of the nasopharyngeal pneumococcal isolates, this study suggests a high 
potential benefit of the 7-valent pneumococcal conjugate vaccine for children in Hanoi, 
Vietnam.  
We also characterized the potential vaccine coverage, the genetic background and 
resistance profiles of 578 pneumococcal isolates from healthy Dutch children aged 1-19 
years by means of serotyping, RFEL genotyping and susceptibility testing (Chapter 5.2). 
The most prevalent serotypes found were the serotypes 6B, 19F, 23F, 6A, 3, 11 and 14. In 
total, 42% of the strains represented vaccine type and 58% non-vaccine type pneumococci. 
The vaccine and cross-reactive serotypes showed peak-incidences at the age of 1-2 years. 
The non-vaccine serotype 11 showed a peak-incidence at the age of 3-6 years whereas the 
non-vaccine serotypes 3, 8, and 10 showed peak-incidences at the age of 7-10 years. In 
total, 337 genotypes were observed, which consisted of 153 unique genotypes and 184 
genotypes comprising 92 genetic clusters. In contrast to the observed age-related serotype 
distribution, the genetic background of the strains was not age-related. Comparison of our 
population to the PMEN database revealed the presence of 5 international clones, i.e. 
Spain9V-3, England 14-9, Tennesee23F-4, CSR14-10 and Sweden15A-25 in 18 strains. In total, 
19% of all strains showed resistance to one or more antibiotics. Resistance to 
cotrimoxazole, tetracycline, erythromycin and penicillin was found in 13.9%, 6.4%, 5.0% and 
3.4%, respectively. Multidrug resistance was found in 2.4% of all strains. These data 
implicate that most pneumococci found have a high tendency to spread horizontally. 
Moreover, these data indicate that the internationally recognized pandemic clones do not 
significantly contribute to colonization and spread of pneumococci among children in The 
Netherlands. Finally, because the majority of the strains is fully susceptible to the most 
common antibiotics, these data underline that a high tendency to spread is not automatically 
related to (multi)drug resistance. 
To illustrate the possible consequences of infections with multidrug-resistant pneumococci, 
we describe in Chapter 5.3 the follow-up of a nosocomial outbreak with a multidrug-resistant 
strain of S. pneumoniae among 36 patients with chronic obstructive pulmonary disease in 
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The Netherlands. To limit the outbreak, barrier nursing and a short-term ceftriaxone-rifampin 
eradication therapy were started. Rifampin, a semisynthetic derivative of the rifamycins that 
is primarily prescribed for the treatment of tuberculosis was used because of broad-
spectrum activity, efficient (mucosal) tissue penetration, and a low side-effect profile. 
Because of the possibility for rapid emergence of resistance, rifampin was prescribed in 
combination with a third-generation cephalosporins 40,41. Although the epidemic rapidly 
ceased, eradication therapy failed in 3 patients, and follow-up investigation of these patients 
showed the emergence of rifampin-resistant isolates. Microbiologic analysis confirmed that 
the studied isolates were of clonal origin and were identical to the initial outbreak strain. The 
mutations occurred in 2 different regions in the rpoB gene and displayed 3 distinct amino 
acid substitutions. We conclude that inadequate therapy caused by inaccurate prescription 
resulted in a primary rpoB-mediated rifampin resistance on 2 occasions. The use of rifampin 
monotherapy in patients 1 and 3 contributed to the acquisition of rifampin resistance, and 
these patients did not respond to treatment. Patient 2 manifested primary resistance despite 
accurate therapy. We hypothesize that the pathological lung structure of these COPD 
patients has contributed to inadequacy of treatment by the treatment protocol. This study 
indicates the importance of accurate bacteriologic monitoring of patients with COPD who are 
colonized or infected with MDR pneumococci and suggests extension of the current 
eradication regimen with an additional (β-lactam) antibiotic.   
As we discussed so far, next to the rapid horizontal dissemination of drug-resistant 
pneumococcal strains 42,43, several of our studies have suggested a high level of horizontal 
dissemination of susceptible pneumococci as well. To study this in more detail, we 
investigated the molecular epidemiological characteristics of S. pneumoniae from all patients 
with pneumococcal meningitis in The Netherlands in 1994 (Chapter 5.4). RFEL analysis 
demonstrated 52% genetic clustering among these penicillin-susceptible strains, a value 
substantially lower than the percentage of clustering among Dutch penicillin-nonsusceptible 
strains 42-46. Different serotypes were found within 8 of the 28 genetic clusters, suggesting 
that horizontal transfer of capsular genes is common among penicillin-susceptible strains. 
The degree of genetic clustering was much higher among serotype 3, 7F, 9V, and 14 
isolates than among isolates of other serotypes, i.e., 6A, 6B, 18C, 19F, and 23F. We further 
studied the molecular epidemiological characteristics of pneumococci of serotype 3, which is 
considered the most virulent serotype and which is commonly associated with invasive 
disease in adults. Fifty epidemiologically unrelated penicillin-susceptible serotype 3 invasive 
isolates originating from the United States (n = 27), Thailand (n = 9), The Netherlands (n = 
8), and Denmark (n = 6) were analyzed. The vast majority of the serotype 3 isolates (74%) 
belonged to two genetically distinct clades that were observed in the United States, 
Denmark, and The Netherlands. In line with previous studies, these data indicate that two 
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penicillin-susceptible serotype 3 clones have been independently disseminated 
internationally, suggesting strong genetic homogeneity and limited genetic heterogeneity 
within the serotype 3 pneumococci 47,48. We hypothesize that this serotype has recently 
evolved or has remained unchanged for a prolonged period. The few serotype 3 isolates not 
belonging to the main clusters are presumably derived from horizontal transfer of capsular 
genes.  
As mentioned earlier, the 7-valent conjugate vaccine has shown, besides an efficacy of 
97.4% against invasive diseases caused by vaccine serotypes, a significant though less 
efficient impact on pneumonia and otitis media 31-34. The pneumococcal vaccine reduced the 
number of infants suffering from recurrent episodes of AOM by 9% in both the American and 
the Finnish trial. The largest effect, a reduction of 23%, was observed in the number of 
children developing a severely otitis-prone condition with 5 episodes in 6 months or 6 
episodes per year. This was also reflected in a 20% reduction in the number of children 
receiving tympanostomy tubes. Moreover, several investigators have shown a significant 
reduction in nasopharyngeal carriage of vaccine type pneumococci in infants as a result of 
different conjugate vaccinations 10,35-37. Mucosal immunity in addition to systemic immunity 
would explain these effects. This is supported by the results of a second Finnish study, 
showing that a tetravalent pneumococcal conjugate vaccine induces both mucosal and 
systemic antibody responses in toddlers 49. Because of these promising data, the ACIP 
recommended pneumococcal conjugate vaccination for all children under the age of 24 
months, and children 24-59 months of age when at risk of pneumococcal disease 50,51. In 
addition, the American Academy of Pediatrics (AAP) issued the advice to immunize children 
with recurrent or severe acute otitis media (AOM) and children with tympanostomy tubes 
because of recurrent AOM with 7-valent pneumococcal conjugate vaccine (PCV7) 52. 
However, the prevention of recurrent acute otitis media (AOM) by the pneumococcal 
conjugate vaccine was only proven in infants immunized at 2, 4, 6 and 12-15 months of age. 
It has not been established whether pneumococcal conjugate vaccine also prevents AOM in 
older children with previous episodes of  AOM. Therefore, a double-blind, randomized study, 
including 383 patients aged 1 to 7 years with two or more episodes of AOM in the year 
before entry was performed (Chapter 7.1). Randomization was stratified in 4 groups 
according to age (12-24 months versus 25-84 months) and the number of previous AOM 
episodes (2-3 AOM versus 4 or more AOM). The children received either 7-valent 
pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide 
vaccine or hepatitis A or B vaccines. They were followed for 18 months for recurrence of 
AOM. Additional outcomes included pneumococcal cultures of middle ear fluid and 
nasopharyngeal pneumococcal carriage. We observed no reduction in AOM episodes in the 
pneumococcal vaccine group as compared to the control group.  Although nasopharyngeal 
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carriage of conjugate-vaccine pneumococcal serotypes was significantly reduced after 
pneumococcal vaccinations, we found immediate and complete replacement by non-vaccine 
pneumococcal serotypes. We suggest that interference in an existing balance between host 
and pathogen by means of vaccination may induce pneumococcal strain replacement. The 
appearance of a new pathogen, in turn, increases the risk of acute otitis media 53,54. This 
might explain the different results of the two landmark studies in California and Finland 
investigating the effect of conjugate vaccination on otitis media in infants: at infant age 
conjugate vaccination may prohibit or delay nasopharyngeal acquisition of the most 
prevalent pneumococcal serotypes, thus preventing or delaying early pneumococcal AOM 
until a later age. Therefore replacement will not occur in young children, in contrast to older 
children where full replacement of vaccine type pneumococci with non-vaccine type strains 
was observed. With ongoing follow-up, more studies have reported this phenomenon 10 ,34,55. 
The effect of replacement to the burden of invasive diseases still remains unknown, 
although one conjugate vaccination trial in the US recently reported 25% increase in 
invasive diseases caused by non-vaccine serotypes. Though this was not yet statistically 
significant, in the future it may become clinically relevant 56. This hypothesis is supported by 
data of Brueggemann et al., who have shown a high invasive capacity for certain non-
vaccine serotypes, which may also imply that replacement of carriage will lead to 
replacement of disease 57. 
To evaluate the effect of 7-valent pneumococcal conjugate vaccination on carriage in the 
different age-groups, we performed additional analysis on the OMAVAX colonization data 
(Chapter 7.2). After vaccinations overall pneumococcal carriage rates did not change and 
remained around 50% in both pneumococcal and control group during 18 months of follow-
up. However, in children who had received two conjugate vaccinations followed by a 
polysaccharide booster (age 12 to 24 months) a significant shift from conjugate vaccine type 
pneumococci to non-vaccine type pneumococci was observed. The most pronounced 
reduction in carriage was found for serotype 18C and the most important increase in 
colonization was noted for the serotypes 11, 15, and 16 as compared to the controls. In 
contrast, pneumococcal carriage was not influenced in children older than 24 months, who 
received the conjugate vaccine once followed by the polysaccharide booster. Therefore, we 
concluded that vaccination with at least twice the conjugate vaccine also after 2 years of age 
may be mandatory for carriage reduction of conjugate vaccine serotypes in children with 
recurrent otitis media. In addition, the natural shift in carriage of VT to non-VT S. 
pneumoniae by increasing age may limit the impact of the pneumococcal conjugate vaccine 
on pneumococcal carriage in older children, as concluded by previous studies 10.  
We decided to study the molecular epidemiological dynamics and resistance profiles of the 
pneumococcal strains collected from both children in the pneumococcal vaccine (PV) and 
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the hepatitis control vaccine group (CV) of the latter study in order to obtain insight in the 
effect of conjugate vaccination on the genetic background of the pneumococcal population 
(Chapter 7.3). We investigated the  molecular epidemiology of 921 pneumococcal isolates 
retrieved from both the pneumococcal vaccine (PV) and control vaccine (CV) group during 
the vaccination study. Within individuals a high turnover rate of pneumococcal genotypes 
was observed, which was unaffected by vaccination. Comparison of the genetic structure 
before and after completion of the vaccination scheme revealed, despite a shift in serotypes, 
genetic homology between 70% of the pneumococcal populations. The remaining isolates 
(30%) were equally observed in the PV and the CV group. In addition, the degree of genetic 
clustering was unaffected by vaccination. However, within the population genetic structure, 
non-vaccine serotype clusters with the serotypes 11, 15 and 23B became predominant over 
vaccine-type clusters as a result of vaccination. Finally, overall pneumococcal resistance 
was low (14%), and, albeit not significant, a reduction in pneumococcal resistance as a 
result of pneumococcal vaccination was observed. We therefore concluded that 
pneumococcal conjugate vaccination did not induce a shift in the population-based structure 
of the pneumococci, nor decreased their tendency to spread horizontally. Our observations 
combined with the vaccine efficacy data (Chapter 7.1) suggest that pneumococcal 
conjugate vaccination is not very useful for prevention of pneumococcal colonization in 
Dutch children older than 1 year of age.  
In Chapter 7.2, we found replacement of colonizing strains at the nasopharynx as a result of 
pneumococcal conjugate vaccination, followed by a polysaccharide booster. This 
replacement may seriously complicate the efficacy of pneumococal conjugate vaccines. This 
depends on whether this phenomenon is caused by unmasking of pneumococcal serotypes 
which are already present at the nasopharynx or by replacement, i.e. the acquisition of other 
serotypes, remains unknown 58. We therefore developed a colony blot assay, which allows 
the detection of multiple serotypes within clinical specimens (Chapter 7.4). This method can 
assess whether re-colonization with novel serotypes (replacement), overgrowth by minor co-
colonizing serotypes (unmasking) or masking of previously predominant vaccine serotype 
strains occurs at the nasopharynx as a result of vaccination. We found that this method 
allows the identification of multiple serotypes in a single specimen in a ratio of 1:1000. In 
order to demonstrate the potential of our method, we investigated the consecutive 
nasopharyngeal samples of 26 children who had shown a shift in pneumococcal colonization 
after conjugate vaccination. Unmasking and masking were found in 1 out of 15 and 4 out of 
26 cases, respectively. In the remaining children ‘true replacement’ had presumably 
occurred. We hypothesize, that the persistence of vaccine type strains accompanied by 
immunological pressure due to vaccination and the availability of non-vaccine serotype 
strains for replacement might create ideal circumstances for recombinational exchange of 
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capsular genes 59. Assuming that this phenomenon occurs as a result of vaccination, future 
vaccine failures with respect to prevention of disease and elimination of multidrug-resistant 
clones may take place. To study the true effect of conjugate vaccination on replacement, 
obviously a larger study should be performed. For such study, the colony blot assay will be a 
useful additional tool. 
So far, we have described studies with respect to the pathogen-related aspects of 
colonization and infection. However, pneumococcal colonization and infection as well as the 
efficacy of pneumococcal vaccination are determined by host, pathogen, and environmental 
factors. In Chapter 8, we describe several studies with respect to the host-response to 
pneumococcal vaccination and infection. First, because colonization with vaccine serotype 
strains had decreased in pneumococcal vaccine recipients but not otitis media, we 
questioned whether pneumococcal vaccination had provoked a mucosal immune response 
in our study population. We compared the IgG and IgA antibody concentration in saliva of 
children of the pneumococcal vaccine group with children of the control vaccine group 
(Chapter 8.1). IgA and IgG antibody concentrations to vaccine serotypes 6B, 14, 18C and 
19F were measured by enzyme immunoassay in 38 saliva samples of children vaccinated 
with pneumococcal conjugate vaccine and 45 control samples. In the pneumococcal vaccine 
group, 12 samples were received prior to vaccination, 12 samples 4 weeks after the 
polysaccharide booster and 14 samples 7 months after the last vaccination. In the control 
group 15 children were sampled at each of these 3 time points. We observed a trend 
towards increased salivary IgG antibody concentrations 14 months after the primary 
vaccination for the serotypes 6B, 14, and 18C in the vaccinated children but not the control 
children. This increase in IgG antibodies was seen only in children vaccinated with 
pneumcoccal conjugate vaccine twice followed by a polysaccharide booster. The IgA 
antibody titers increased significantly after 8 and after 14 months for all serotypes in both 
pneumococcal vaccine recipients and controls. However, the mean antibody titer increased 
significantly more in control children compared to children vaccinated with pneumococcal 
conjugate vaccine. Our data suggest that repeated pneumococcal conjugate vaccination is 
obligatory for persisting elevated salivary IgG antibodies in children.. However, because a 
significantly higher increase in mucosal IgA response is observed in control children 
compared to vaccinated children, we hypothesize that this is provoked by ongoing carriage 
rather then by vaccination. Therefore, we conclude that combined pneumococcal conjugate 
and polysaccharide vaccination does not induce a mucosal IgA response. 
Because recent studies suggest a role for bacteria like Streptococcus pneumoniae in the 
development of acute exacerbations of chronic obstructive pulmonary disease, we 
investigated the epidemiology of pneumococcal colonization and infection, the effect of 
pneumococcal colonization on the development of exacerbation, and the immunological 
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response against S. pneumoniae in COPD patients (Chapter 8.2). To this purpose, we 
cultured sputa of 269 COPD patients during stable state and exacerbations of COPD and 
we characterized the 115 pneumococcal isolates by means of serotyping. Moreover, we 
studied serum IgG antibodies, avidity and functional antibody titers against the seven 
conjugate-vaccine serotypes in these patients. Although overall carriage was not associated 
with exacerbations of COPD, we found that colonization with merely pneumococci 
(monocultures) increased the risk of an exacerbation with a hazard ratio of 2.93. The most 
prevalent pneumococcal serotypes found were the serotypes 19F, 3, 14, 9L/N/V, 23A/B and 
11 with a theoretical coverage for the 7-, and 11- valent pneumococcal vaccine of 60% and 
73%, respectively. These data indicate that pneumococal colonization in COPD patients is 
frequently caused by vaccine serotype strains. All patients had detectable IgG levels against 
the 7 conjugate-vaccine serotypes. These antibody titers were significantly lower than in 
vaccinated healthy adults. On average, a 2.5-fold rise in serotype-specific and functional 
antibodies was observed during exacerbations with S. pneumoniae positive sputum cultures. 
These data demonstrate that COPD patients are able to mount a significant immune 
response to pneumococcal infection. However, one could question whether these antibodies 
protect COPD patients against pneumococcal re-infection. Follow-up studies in which the 
protective potentials of these antibodies are investigated, are necessary in order to estimate 
the effect of pneumococcal conjugate vaccination of COPD patients.  
Host protection against S. pneumoniae is mainly mediated by opsonin-dependent 
phagocytosis. Therefore, the in vitro measurement of opsonophagocytic activity of the anti-
capsular antibodies is considered to be a reliable correlate of protection to evaluate vaccine 
responses 60,61. Unfortunately, the methods used so far are all tedious to perform and 
material consuming. In Chapter 8.3, we describe the modification of the multi-specificity 
opsonophagocytosis killing assay (MSOPKA) into a high throughput method, which 
simultaneously measures the opsonophagocytosis against the seven serotypes covered by 
the current conjugate vaccine in a single assay. In the so called multiplex 
opsonophagocytosis assay (MOPA), a mixture containing equal numbers of colony forming 
units (CFUs) of chloramphenicol-resistant serotype 4, spectinomycin-resistant serotype 6B, 
streptomycin-resistant serotype 9V, erythromycin-resistant serotype 14, rifampicin-resistant 
serotype 18C, tetracycline-resistant serotype 19F, and trimethoprim-resistant serotype 23F 
pneumococci was used as a target mixture and incubated with serial dilutions of test serum. 
After opsonophagocytosis by differentiated HL-60 cells in the presence of complement, the 
samples were spotted onto different blood agar plates containing the 7 selective antibiotics, 
respectively. Opsonophagocytosis was calculated as the highest serum dilution resulting in 
90% or more reduction in CFUs. We tested whether the phagocytosis capacity is correlated 
to the serotype-specific IgG antibody titers. Despite the limited number of sera tested, we 
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found high correlations for opsonophagocytosis capacity and IgG antibody titers for the 
serotypes 4, 6B, 9V, 18C and 23F. For the remaining serotypes, i.e. 14 and 19F, lower 
correlations were found for opsonophagocytosis and serotype-specific IgG. These data 
suggest that besides antibody titers, additional variables may influence opsonophagocytosis 
activity. Furthermore, our findings underline the importance of testing opsonophagocytosis 
activity in addition to the measurement of antibody titers when monitoring vaccination.  
The current 7-valent conjugate vaccine is highly efficacious against invasive disease caused 
by the vaccine type strains. However, the vaccine coverage is limited and replacement by 
non-vaccine serotypes resulting in disease is a serious threat for the near future. Therefore, 
the search for new vaccine candidates that will elicit protection against a broader range of 
pneumococcal strains is still ongoing. To this purpose, several surface-associated protein 
vaccines are under investigation. Surface associated pneumococcal proteins α-enolase 
(Eno), immunoglobulin A1 protease (Iga), streptococcal lipoprotein rotamase A (SlrA), and 
putative proteinase maturation protein A (PpmA) have potential as candidates for future 
protein-based anti-pneumococcal vaccines. In Chapter 8.4, the immunogenicity of these 
proteins was studied in a cohort of 329 children during their first two years of life. During the 
first recorded episode of otitis media, acute and convalescent phase sera were available 
from 151 of these children. Concentrations of antibodies against Eno, Iga, SlrA and PpmA 
were measured by EIA and detected in 83-99% of the sera, respectively. There were no 
statistically significant differences between the groups of children with and without a history 
of pneumococcal contact or with respect to the type of pneumococcal contact. No significant 
correlation between antibody titers to these proteins and pneumococcal carriage or infection 
was found. These data suggest the presence of cross-reactive epitopes on commensal 
bacteria co-colonizing the nasopharyngeal niche. Since pathogen-specific epitopes are less 
likely to cross-react with epitopes of commensal bacteria of the nasopharynx, such proteins 
might have more potential as vaccine candidates.  
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  Chapter 10 
In this final chapter we seek to provide answers to the five research objectives, which were 
put forward in the introductory chapter (Chapter 1). We have summarized our most relevant 
findings and propose future directions for clinical and laboratory research. 
 
Question 1. What is the prevalence and which are the determinants of 
nasopharyngeal colonization with S. pneumoniae and other pathogenic bacteria in 
children? 
Major conclusions. Nasopharyngeal carriage with S. pneumoniae is most frequently 
observed during the first three years of live with a peak incidence of 55% at the age of three 
years followed by a general decline to 10% after the age of 10 years. Nasopharyngeal 
colonization with S. aureus also shows an age-related distribution with the highest 
colonization rate of 50% at the age of 10 years. N. meningitidis was found rarely among 
Dutch children in the summer of 2002. The highest prevalence was seen in the second year 
of life and after the age of 15. Determinants of nasopharyngeal carriage with these bacteria 
are mainly environmental and include smoking (passive and active), and crowding (day-
care, discotheque). Importantly, we observed a natural competitive balance between 
vaccine-type pneumococci and S. aureus during colonization, which may explain the 
increase in S. aureus-related otitis media events found after vaccination. In addition, we 
found a positive correlation between N. meningitidis and S. pneumoniae for colonization of 
the nasopharynx  (Chapter 3.1, Chapter 3.2, Chapter 3.3). 
Future directions. Age-related distributions of and species-specific interactions between 
the colonizing bacteria of the nasopharynx should be further investigated. To this respect, 
both extensive in vitro assays (competition and interaction) and follow-up studies (natural 
dynamics and interference) should be performed. Importantly, host, pathogen, as well as 
environmental factors should be considered in such studies.  
 
Question 2. Is nasopharyngeal colonization with S. pneumoniae during health and 
(mucosal) infection a static or dynamic process? 
Major conclusions. Pneumococcal colonization during asymptomatic colonization and 
disease is a highly dynamic process allowing the rapid acquisition, spread and elimination of 
pneumococcal isolates in individuals and within the population. This process is enhanced in 
case of crowding as occurs in day-care centers and hospitals. The tendency to spread 
horizontally is serotype and genotype related (Chapter 3.1, Chapter 5.1, Chapter 5.2, 
Chapter 5.3, Chapter 5.4).  
Future directions. Continued molecular surveillance of nasopharyngeal colonization is 
indicated in risk groups for pneumococcal colonization and infection allowing us to study the 
                                                   Conclusions and future perspectives  
 
 
339 
dissemination of pneumococcal clones, possible changes in serotype distribution and the 
acquisition and spread of resistance among pneumococci. 
 
Question 3. How efficient do antibiotic-resistant pneumococci spread within the 
population and which events are involved in the acquisition and spread of resistance 
and resistance genes in pneumococci?  
Major conclusions. Antibiotic-resistant pneumococci, specifically the internationally 
recognized multidrug-resistant clones, have shown a rapid worldwide spread. However, their 
non-resistant relatives of similar chromosomal genotype also display a high capacity to 
spread within the community, which suggests a prevailing genotype-related influence. 
Antibiotic resistance has evolved by the horizontal transfer of resistance genes between 
related species and pneumococcal strains and recombinational events within resistance 
genes of pneumococci. The acquisition of antibiotic resistance in individuals is enhanced by 
the level and type of antibiotic pressure as well as by the condition of the patient (Chapter 
4.1, Chapter 4.2, Chapter 4.3, Chapter 4.4, Chapter 5.2).  
Future directions. Restrictive and selective antibiotic prescription behavior is warranted to 
minimize the selection and spread of (multi)drug resistance among pneumococcal isolates. 
Close monitoring of (multi)drug resistance among pneumococcal isolates is necessary to 
provide a timely change in therapy and to prevent treatment failures. In case of a 
nosocomial outbreak with a multidrug resistant strain among COPD patients, adequate 
combination therapy should be given to ensure eradication and to avoid persistent carriage 
and horizontal spread. 
 
Research question 4. What is the effect of pneumococcal vaccination on colonization 
and infection with S. pneumoniae?  
Major conclusions. Administration of a pneumococcal conjugate vaccine followed by a 
polysaccharide booster has no effect on the prevalence of otitis media in children with 
recurrent acute otitis media. In addition, this vaccination regimen induces nasopharyngeal 
replacement of vaccine serotype strains with non-vaccine serotype pneumococci. This 
phenomenon occurs specifically in children under two years of age. In older children no 
effect of vaccination on colonization was observed. The genetic make-up of the replacement 
strains is closely related to the pneumococcal vaccine serotype strains. Therefore, 
pneumococcal conjugate vaccination followed by a polysaccharide booster has no effect on 
colonization, otitis media and genetic background of the pneumococcal population. (Chapter 
7.1, Chapter 7.2, Chapter 7.3, Chapter 7.4).  
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Future directions. Future research should focus on the effect of pneumococcal conjugate 
vaccination on the first acquisition of pneumococci, and the potential influence on the 
occurrence of the first otitis media event. Moreover, such a study should investigate whether 
a delay in colonization with pneumococci is of influence on the composition of the 
nasopharyngeal flora. 
 
Question 5. What is the response of the host immune system and what type of 
response occurs with respect to pneumococcal colonization, infection and 
vaccination? 
Conclusions. Airway colonization with S. pneumoniae is a risk factor for the development of 
exacerbations in patients with chronic obstructive pulmonary disease (COPD). Colonization 
of sputum is frequently observed in this patient group and often involves vaccine serotype 
strains. The majority of the COPD patients mount an anti-capsular immune response during 
pneumococcal colonization and infection, which suggests a potential role for conjugate 
vaccination in the prevention of exacerbations of COPD. 
In children, a significant systemic IgG response can be found in response to pneumococcal 
conjugate vaccination followed by a polysaccharide booster. Small increases in IgG antibody 
titers can be found in saliva of these children, suggesting the transudation of IgG from blood 
to saliva. This is only found after repeated conjugate vaccinations. We observed a significant 
increase in mucosal IgA antibodies after pneumococcal conjugate vaccination. Since this 
increase was higher in the control children we conclude this is the result of colonization and 
infection rather than of vaccination. 
In the search for potential candidates for future protein-based anti-pneumococcal vaccines 
we found several pneumococcal proteins to elicit antibody responses early in life. However, 
no significant correlation between antibody titers to these proteins and pneumococcal 
carriage or infection could be found, which presumably results from the presence of cross-
reactive epitopes on commensal bacteria (Chapter 8.1, Chapter 8.2, Chapter 8.4). 
Future directions. Future research should be performed to evaluate what type of immune 
response protects against pneumococcal colonization and mucosal infection. In addition, 
detailed research has to be done with respect to mucosal vaccination (oral/nasal) and 
prevention of carriage and mucosal diseases. The exact role of pneumococcal colonization 
on exacerbations of COPD should be investigated. Moreover, a pneumococcal conjugate 
vaccine study should be performed to evaluate the potential effect of vaccination on 
exacerbations of COPD. Finally, future studies investigating the effect of (new) conjugate 
vaccines on colonization and infection with S. pneumoniae should consider side effects with 
respect to co-colonizing pathogens and the commensal flora. 
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Streptococcus pneumoniae is een belangrijke verwekker van hersenvliesontsteking, sepsis 
(bloedvergiftiging) en longontsteking. Deze bacterie, bekend onder de naam pneumokok, is de 
belangrijkste oorzaak van hersenvliesontsteking en sepsis bij kinderen sinds deze als onderdeel van het 
Rijksvaccinatie programma worden ingeënt tegen Neisseria meningitidis serogroep C en Haemophilus 
influenzae type B. Gemiddeld sterven er elk jaar wereldwijd 1 miljoen kinderen onder de leeftijd van 5 
jaar ten gevolge van infecties door pneumokokken. Daarnaast veroorzaakt de bacterie veelvuldig 
bovenste luchtweginfecties zoals middenoorontsteking en voorhoofd- en bijholteontsteking. Ook 
ouderen en patiënten met afweerstoornissen hebben een verhoogd risico op het oplopen van infecties 
met deze bacterie. 
Pneumokokken komen vaak asymptomatisch voor in de neus-en-keel holte. Vrijwel alle kinderen 
worden reeds in hun vroege jeugd ‘gekoloniseerd’ met deze bacterie. De kans op kolonisatie is met 
name groot op plaatsen waar veel mensen langdurig samenkomen, zoals in kinderdagverblijven, 
ziekenhuizen, verpleeghuizen of gevangenissen. De mens heeft van nature voldoende afweer om niet 
ziek te worden ten gevolge van dragerschap met deze bacterie. Echter, in geval van een (tijdelijk) 
verminderde afweer  kunnen pneumokokken infectie en ziekte veroorzaken. Personen met een 
verhoogd risico op dragerschap hebben derhalve een verhoogde kans op infecties met pneumokokken. 
De pneumokok is een diplokok; de bacterie komt in paren van twee voor omgeven door een 
suikerkapsel. Er zijn inmiddels 90 verschillende kapseltypen en subtypen bekend, ook wel serotypen 
genoemd. In de laatste decennia zijn er vaccins ontwikkeld om infecties met de meest voorkomende 
kapseltypen te voorkomen. Het 23-valente suikervaccin, waarin de meest voorkomende kapseltypen 
zijn opgenomen, is echter niet effectief in kinderen onder de leeftijd van 2 jaar omdat deze nog niet in 
staat zijn antistoffen te maken tegen suikers. Sinds kort is er echter een conjugaatvaccin op de markt 
dat werkzaam is tegen de 7 meest voorkomende serotypen. De suikers zijn hierbij gekoppeld aan een 
eiwit waardoor jonge kinderen wel antistoffen tegen de suikers kunnen maken. Dit vaccin heeft echter 
als nadeel dat het werkzaam is tegen slechts 7 van de 90 serotypen.  
In 1999 werd de invloed van kinderdagverblijfbezoek op dragerschap met pneumokokken in Nederland 
bestudeerd (hoofdstuk 3.1). Hiervoor werden 259 kinderen uit 16 kinderdagverblijven in Amsterdam 
onderzocht op dragerschap met pneumokokken. Daarnaast onderzochten we een controle groep van 
276 kinderen die geen kinderdagverblijf bezochten. De kinderen uit de kinderdagverblijven bleken 2 tot 
3 keer zo vaak gekoloniseerd te zijn met pneumokokken dan de controle populatie. We hebben ook de 
verdeling van de serotypen bestudeerd om te kunnen berekenen hoeveel pneumokokkeninfecties 
voorkomen zouden kunnen worden met de introductie van het 7-valente conjugaatvaccin in Nederland. 
Verder werd de genetische achtergrond van de pneumokokken bestudeerd middels het DNA. De 
zogenaamde genetische ‘vingerafdruk’ die met deze techniek wordt verkregen wordt ook wel genotype 
genoemd (hoofdstuk 3.1). Bij zowel de kinderdagverblijfkinderen als bij de controle kinderen werden de 
serotypen 19F, 6B, 6A, 23F, and 9V het meest frequent gevonden. De theoretische bescherming van 
het 7-valente conjugaatvaccin was voor beide groepen kinderen 55 tot 59%. Bestudering van de 
genetische achtergrond van de pneumokokken toont aan dat de pneumokokken bij de 
kinderdagverblijfkinderen veel vaker genetisch op elkaar lijken dan de pneumokokken in de controle 
groep. Dit wijst er op dat pneumokokken zich sneller van kind tot kind verspreiden binnen 
kinderdagverblijven dan erbuiten, maar dat dit fenomeen niet afhankelijk is van het kapseltype.  
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In 2002 werden de risicofactoren voor dragerschap met pneumokokken en S. aureus onderzocht in 
3200 gezonde kinderen in de leeftijd van 1 tot 19 jaar (hoofdstuk 3.2). De belangrijkste variabelen voor 
dragerschap met pneumokokken bleken leeftijd en het bezoeken van kinderdagverblijven. In de groep 
kinderen tot 3 jaar kwamen vooral pneumokokken serotypen voor die in het 7-valente vaccin 
vertegenwoordigd zijn. Bij de oudere kinderen werden vooral niet-vaccinserotypen gevonden. We 
concludeerden hieruit dat er gedurende de jeugd een natuurlijke verschuiving plaatsvindt van 
vaccintype pneumokokken naar niet-vaccinserotypen met de leeftijd.  
S. aureus is een bacterie die een breed scala aan infecties kan veroorzaken waaronder wondinfecties. 
Risicofactoren voor dragerschap met S. aureus bleken leeftijd, het hebben van het mannelijk geslacht, 
het leven in grote gezinnen en passief roken, terwijl actief roken (gemeten vanaf de leeftijd van 12 jaar) 
de kans op dragerschap verminderde. Tevens werden pneumokokken en S. aureus minder vaak samen 
in de neus-en-keelholte gevonden dan ieder afzonderlijk. Deze resultaten suggereren dat er een 
natuurlijke vorm van competitie tussen deze twee bacteriën bestaat. Bovendien blijkt deze competitie 
alleen te bestaan tussen vaccintype pneumokokken en S. aureus, maar niet tussen niet-
vaccinserotypen en S. aureus. Deze bevindingen komen overeen met de resultaten van eerder 
onderzoek, waarbij kinderen met recidiverende middenoorontstekingen gevaccineerd werden met het 7-
valente conjugaatvaccin (hoofdstuk 7.1). Deze studie toont niet alleen aan dat de vaccintype 
pneumokokken na vaccinatie worden vervangen door niet-vaccinserotypen, maar ook dat er in de 
gevaccineerde groep meer oorontstekingen veroorzaakt worden door S. aureus. Verder onderzoek is 
nodig om het mechanisme van deze interactie en de consequenties hiervan voor vaccinatie te 
bestuderen. 
In dezelfde groep Nederlandse kinderen werd tevens dragerschap met N. meningitidis ofwel de 
meningokok bestudeerd (hoofdstuk 3.3). Omdat in de periode voorafgaand aan deze studie een 
toename van hersenvliesontsteking door meningokokken was geconstateerd, werden alle kinderen op 
het moment van ons onderzoek gevaccineerd tegen groep C meningokokken. We vonden echter 
relatief weinig dragerschap met deze bacterie: bij slechts 1.5% van de kinderen werd een meningokok 
gekweekt. Dit werd mogelijk veroorzaakt door de invloed van het zomerseizoen. Het hoogste risico op 
dragerschap werd gevonden bij kinderen onder de leeftijd van 2 jaar en bij jongeren ouder dan 15 jaar. 
Daarnaast bleken pneumokokkendragerschap en regelmatig bezoek van uitgaansgelegenheden 
(gemeten vanaf de leeftijd van 12 jaar) de kans op dragerschap met meningokokken te verhogen. 
Samenvattend kan gesteld worden dat leeftijd en “crowding” de belangrijkste risicofactoren vormen voor 
dragerschap van meningokokken. 
Een andere risicogroep voor het krijgen van pneumokokkeninfecties is de groep volwassen patiënten 
met chronisch obstructief longlijden (COPD). Dit is een veel voorkomende en ernstige ziekte onder 
volwassenen met een hoog risico op overlijden. Bij deze ziekte treden regelmatig acute 
verslechteringen (exacerbaties) op die invaliderend zijn voor de patiënt en tevens het ziekteverloop 
kunnen versnellen. Er waren aanwijzingen dat bacteriële ontstekingen een rol spelen bij het ontstaan 
van deze exacerbaties. Daarom  hebben we in 244 COPD patiënten de relatie onderzocht tussen de 
aanwezigheid van bacteriën in de longen tijdens stabiele perioden en het ontstaan van exacerbaties 
(hoofdstuk 3.4). We vonden bij aanvang van de studie dat 36% van de COPD patiënten gekoloniseerd 
was met potentieel ziekmakende bacteriën. In het algemeen bleek dit geen invloed te hebben op het 
ontstaan van exacerbaties. Echter, wanneer pneumokokken dominant aanwezig waren bleken de 
patiënten wel een verhoogd risico te hebben op exacerbaties van COPD, waarbij het relatieve risico 3 
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maal groter was (hoofdstuk 8.2). De meest voorkomende kapseltype pneumokokken in deze 
patiëntengroep waren de serotypen 19F, 3, 14, 9L/N/V, 23A/B en 11. Het 7-valente 
pneumokokkenvaccin beschermt theoretisch tegen 60% van de infecties door deze bacteriën. Ook 
bleek dat alle COPD patiënten IgG antistoffen maakten tegen de pneumokok, en dat de concentratie 
aan IgG in bloed stijgt bij aanwezigheid van pneumokokken tijdens exacerbaties. Verder onderzoek 
naar het effect van pneumokokkenvaccinatie op het ontstaan van exacerbaties van COPD is derhalve 
gewenst. 
De behandeling van infecties door pneumokokken wordt gecompliceerd door de ontwikkeling van 
ongevoeligheid van de bacterie voor antibiotica, ook wel resistentie genoemd. De resistentie tegen 
antibiotica is wereldwijd enorm toegenomen: in sommige landen zijn 60% van de 
pneumokokkenstammen ongevoelig geworden voor het meest gebruikte antibioticum, penicilline. Veel 
van deze pneumokokken behoren tot een beperkt aantal genetische ‘families’. 
Wij hebben de genetische achtergrond van de voor penicilline resistente pneumokokken onderzocht in 
een groep kinderen uit Griekenland (hoofdstuk 4.1). We vonden dat een hoog percentage van de 
pneumokokken tot een beperkt aantal genetische families ofwel clusters behoord. Tevens werd 
vastgesteld dat een beperkt aantal internationaal aanwezige clusters ook in Griekenland voor een groot 
deel verantwoordelijk zijn voor de verspreiding van voor penicilline resistente pneumokokken. Tijdens 
de studie werd een pneumokokkenfamilie gevonden die gevoelig was voor penicilline maar resistent 
tegen 5 andere klassen van antibiotica (hoofdstuk 4.2). Met behulp van aanvullende genetische 
studies bleek deze stam zich breed verspreid te hebben in Griekenland. Wij stelden tevens vast, dat 
deze bacteriestam een voorouder is van de penicillineresistente stam die zich in de tweede helft van de 
jaren 90 zeer snel verspreid heeft in IJsland. Hieruit kan geconcludeerd worden dat deze endemische 
stam reeds de potentie had zich snel te verspreiden vóór ongevoeligheid voor penicillines werd 
verkregen. 
Er wordt veel onderzoek gedaan naar de preventie van pneumokokkeninfecties door middel van 
vaccinatie. Het reeds eerder genoemde 7-valente vaccin bleek in kinderen zeer effectief bij het 
voorkomen van invasieve ziekten zoals sepsis en hersenvliesontsteking, redelijk efficiënt in het 
voorkomen van longontsteking en slechts beperkt effectief tegen middenoorontstekingen. Daarnaast 
bleek dit vaccin ook het dragerschap met pneumokokken te verminderen. Zoals reeds vermeld is het 
belangrijk om vóór het introduceren van dit vaccin te onderzoeken hoeveel circulerende pneumokokken 
theoretisch door dit vaccin kunnen worden geëlimineerd. In Azië was slechts weinig bekend over de 
serotypeverdeling onder pneumokokken. Daarom werd een collectie pneumokokken afkomstig van 
jonge kinderen met een bovenste luchtweginfectie in Vietnam getypeerd en nader bestudeerd met 
behulp van moleculaire technieken (hoofdstuk 5.1). Ook in dit onderzoek werden vooral de serotypen 
23F, 19F, 6B en 14 gekweekt. In 52% van de pneumokokken werd penicillineresistentie aangetoond. 
Resistentie tegen andere antibiotica zoals cotrimoxazol, tetracycline, erytromycine en cefotaxim werd 
gevonden bij 39-87% van de stammen. 75% van de pneumokokken was resistent tegen 3 of meer 
soorten antibiotica. De meeste pneumokokken in Vietnam behoren tot een beperkt aantal families. 
Twee van de grootste clusters bleken onderdeel te zijn van internationaal bekende en wijdverspreide 
families. Tevens bleek 93% van de stammen uit deze clusters een kapseltype te hebben dat behoort tot 
de serotypen uit het 7-valente vaccin. Van de unieke genotypen was dit percentage veel lager. 
Samenvattend kan geconcludeerd worden dat introductie van het 7-valente vaccin in Vietnam potentieel 
een significante reductie van het aantal infecties zal geven. 
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Hetzelfde onderzoek werd tevens uitgevoerd met de pneumokokken afkomstig van Nederlandse 
kinderen (hoofdstuk 5.3). De meest voorkomende kapseltypen in ons land zijn de serotypen 6B, 19F, 
23F, 6A, 3, 11 en 14. In totaal behoorden 42% van de gevonden pneumokokken tot de 7-valente 
vaccintypen. Vaccintype pneumokokken werden vooral aangetroffen bij de kinderen tussen 1 en 5 jaar 
terwijl niet-vaccintypen  pas na de leeftijd van 3 tot 6 jaar werden gevonden. In de studie werd een groot 
aantal verschillende genetische typen pneumokokken gevonden, waaronder veel genetische clusters. 
Met andere woorden, veel van de pneumokokken bleken in staat zich makkelijk onder kinderen te 
verspreiden. In de Nederlandse studie werden maar zelden internationaal bekende 
pneumokokkenfamilies aangetroffen. Resistentie werd gevonden in 19% van de isolaten, hetgeen 
internationaal gezien zeer laag is.  
In de jaren 1995 en 1996 was in Nederland slechts 2% van de pneumokokken resistent tegen 
penicilline. De genetische achtergrond van deze stammen is verder onderzocht met behulp van diverse 
methoden (hoofdstuk 5.4). Het bleek dat de genen verantwoordelijk voor penicillineresistentie zeer 
divers waren, maar duidelijk overeenkwamen met die in andere landen. De import van meerdere 
penicillineresistente stammen uit het buitenland bleek vooral verantwoordelijk te zijn voor het optreden 
van penicillineresistentie in Nederland. Er werden echter ook nieuwe combinaties van genen gevonden 
hetgeen suggereert dat pneumokokken deze genen of fragmenten hiervan onderling uitwisselen. Het 
lage aantal pneumokokken dat resistent is tegen penicilline is waarschijnlijk te danken aan het 
restrictieve voorschrijfgedrag van antibiotica door artsen in Nederland.  
In hoofdstuk 5.2 hebben we de gevolgen beschreven van een ziekenhuisuitbraak onder patiënten met 
COPD in Veldhoven met een pneumokokkenstam die resistent was voor meerdere antibiotica. Na 
behandeling met het antibioticum rifampicine bleken 3 patiënten nog steeds dezelfde stam bij zich te 
dragen, ditmaal ook resistent tegen dit antibioticum. Met behulp van moleculaire technieken werd 
aangetoond dat de resistentie tegen rifampicine in de drie stammen op een afzonderlijke plaats in het 
hiervoor verantwoordelijke gen, het rpoB gen, was ontstaan. De resultaten van deze studie tonen aan 
dat ongevoeligheid voor rifampicine snel ontstaat, en dat behandeling met dit antibioticum alleen mag 
plaatsvinden indien dit wordt gecombineerd met meerdere klassen van antibiotica.   
Zoals eerder besproken beschermt het 7-valente conjugaat vaccin bij toediening aan zuigelingen tegen 
invasieve ziekten, longontsteking en, zij het beperkt, middenoorontsteking. De effectiviteit van 
vaccinatie bij oudere kinderen was echter nog niet aangetoond. Daarom werd er een studie verricht 
naar het effect van vaccinatie met het 7-valente vaccin op het aantal middenoorontstekingen bij 
kinderen tussen 1 en 7 jaar oud met een voorgeschiedenis van recidiverende middenoorontstekingen 
(OMAVAX studie) (hoofdstuk 7.1). Hierbij kreeg de helft van de kinderen één of twee conjugaat 
vaccinaties gevolgd door een booster injectie met het 23-valente suikervaccin. De andere helft van de 
kinderen, de controle groep, kreeg een vaccin tegen hepatitis A of B. Voor zowel de behandelaars als 
de kinderen en hun ouders was het niet bekend welk vaccin er bij welk kind werd toegediend. Na het 
beëindigen van de studie bleken de kinderen die het pneumokokken vaccin gekregen hadden niet 
minder, maar zelfs meer middenoorontstekingen te hebben dan de kinderen uit de controle groep. Er 
werd een reductie gevonden in het aantal dragers van vaccintype pneumokokken, maar tevens een 
stijging in het aantal dragers met niet-vaccintypen. Met andere woorden, er was een verschuiving 
opgetreden van vaccintype dragerschap naar niet-vaccintype dragerschap, waarbij het totale 
percentage dragers gelijk was gebleven.  
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Bij nadere bestudering van dragerschap binnen de verschillende groepen kinderen in het OMAVAX 
onderzoek bleek dat de verschuiving zich vooral had voorgedaan bij de jongste groep kinderen 
(hoofdstuk 7.2). Omdat het conjugaatvaccin bij deze groep twee keer in plaats van één keer was 
toegediend concluderen wij dat herhaalde vaccinatie nodig is om eliminatie van pneumokokken in de 
neus-en-keelholte te realiseren. Dit wordt ondersteund door de aanwezigheid van antistoffen tegen de 
vaccintype pneumokokken in het speeksel van de gevaccineerde kinderen (hoofdstuk 8.1). Opnieuw 
hadden de jongste kinderen een verhoogde concentratie van IgG antistoffen na vaccinatie, terwijl bij de 
oudere kinderen geen toename in IgG antistoffen gevonden werd. De concentraties van een ander 
antistof, het pneumokokken-specifieke IgA, steeg eveneens in de gevaccineerde kinderen. Echter, in de 
controle groep steeg de hoeveelheid IgA antistoffen nog sterker dan bij de gevaccineerde kinderen. Op 
basis hiervan werd geconcludeerd dat dit veroorzaakt wordt door dragerschap in plaats van door 
vaccinatie.  
De geobserveerde verschuiving in dragerschap van vaccinserotypen naar niet-vaccinserotypen werd 
door ons bestudeerd met behulp van de colony blot methode (hoofdstuk 7.4). Deze methode werd 
ontwikkeld om de aanwezigheid van verschillende serotypen pneumokokken in één monster aan te 
tonen. Door meerdere pneumokokkenserotypen aan te tonen wilden wij de vraag oplossen of de 
verschuiving in dragerschap na vaccinatie een verschuiving van dominante stam binnen een bestaand 
evenwicht van meerdere pneumokokken serotypen betreft, of een daadwerkelijke vervanging van de 
aanwezige stam. De eerste situatie heeft mogelijk minder consequenties dan de tweede, omdat in het 
eerste geval het immuunsysteem van het kind de aanvankelijk onderdrukte stam al herkent en er 
daarom geen ernstige infecties met deze stam meer kunnen ontstaan, terwijl in de tweede situatie 
mogelijk sprake is van het verkrijgen van een nieuwe en potentieel schadelijke bacterie. Wij hebben de 
verschuiving van een vaccinserotype pneumokok naar een niet-vaccinserotype stam onderzocht in 29 
gevaccineerde kinderen. Bij de meerderheid van de kinderen was de vaccintype pneumokok 
daadwerkelijk vervangen door een niet-vaccinserotype en werd alleen sporadisch gemengd 
dragerschap gevonden.  
Uit het onderzoek kan geconcludeerd worden dat vaccinatie met het 7-valente pneumokokkenvaccin 
middenoorontstekingen bij kinderen ouder dan één jaar niet voorkomt. Verder onderzoek zal nodig zijn 
om het effect van verschuiving in dragerschap van vaccintype naar niet-vaccintype pneumokokken op 
de frequentie van voorkomen van ernstige infecties te bestuderen.  
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Het is zover, dit proefschrift is nu toch echt een feit! Een mijlpaal eerder dan een einde, want het 
onderzoek is nog zeker niet af! In tegendeel, voor mijn gevoel moet het allemaal nog beginnen. Toch is 
het een mooi moment om stil te staan bij wat we tot nu toe bereikt hebben en hoe dat alles tot stand is 
gekomen. Een dankwoord hoort daarbij maar is tegelijkertijd zo ontoereikend: wie moet je bedanken? 
Net als wanneer je bij een wielerwedstrijd terugblikt zie je ook in dit geval dat vroeg in de race al vele 
mensen terdege invloed op het koersverloop hebben gehad. Naarmate de finish meer in zicht komt, 
wordt de menigte wellicht steeds groter, maar niet persé belangrijker, met andere woorden alle 
supporters en toeschouwers verdienen dank! Het zijn bovendien niet alleen de mensen die je direct aan 
het hart gaan, maar ook vele (on)opvallende passanten zonder wie het resultaat wel degelijk anders 
zou zijn geweest. Terug naar ‘mijn koers’. Misschien moet ik al beginnen bij de kleuterjuffrouw Zuster 
Augusta die middels de vouwblaadjes en ontwerpjes mijn ‘exacte kant’ heeft gestimuleerd. Ook de 
lagere en middelbare school zijn een thuishaven geweest met stimulerende en motiverende leraren. 
Dan spreek ik nog niet over de stimulans van de dubbeltjes, kwartjes en guldens die gul werden 
gedoneerd door familie, kennissen en buren bij een goed rapport. Naarmate ik verder ga zie ik een 
steeds grotere massa van professoren, leraren, student-assistenten, vrijwilligers, begeleiders, 
amenuensissen, cateringjuffrouwen, treinconducteurs en buschauffeurs (bedankt voor het altijd eerder 
stoppen dan de echte bushalte op Overvecht, Bunnik), collega’s van weekend baantjes (bedankt voor 
het vertrouwen in mij), medestudenten, buren en huisbazen voorbijtrekken. Vergeet daarnaast ook niet 
de invloed van alle mensen die mijn buitenlandse stages hielpen regelen en verwezenlijken, en de 
mensen die daar terplekke tijdelijk maar onvoorwaardelijk mijn vrienden zijn geweest (bedankt voor 
barbecues, kaartjes, winkelmiddagen, tripjes, en troostende woorden (Texas), de dierbare warmwater 
douche, ‘echte cola’, het uitwisselen van ervaringen en niet te vergeten maaltijden met echt vlees 
(Zimbabwe). Op het moment dat je student af bent en het ‘echte leven’ instapt realiseer je je misschien 
niet altijd hoeveel mensen daar zorgen dat je het toch allemaal net wel volhoudt: de portier (bedankt 
voor de vriendelijke goedemorgens), de schoonmaakster, de secretaresse, de verpleegkundigen 
(bedankt voor de nachtelijke snoepfestijnen en film uurtjes), laboranten, caissières, ouders, studenten, 
patiënten (bedankt voor het surprise ei en de tekeningen), paramedici, typisten (voor het tot ? maal toe 
herstellen van brieven) en secretaresses. Collega’s van buiten, collega’s van binnen, chefs, mentoren, 
medeassistenten en onderzoekers, en ook die toevallige passant. En natuurlijk, niet te vergeten, mijn 
(schoon)familie! Een offer was nodig, ook van jullie kant! Dat in ogenschouw nemend lijkt het moeilijk 
om te besluiten wie ik nu daarvan in het bijzonder moet noemen. Maar omdat ik toch ook maar een 
mens ben, kan (durf) ik het niet laten om wat mensen persoonlijk te danken. 
Prof. Dr. R. de Groot, beste Ronald, 5½ jaar geleden kwam ik solliciteren en toen zag je het wel zitten 
met mij. Dankzij jou heb ik de mogelijkheid gekregen om kindergeneeskunde en wetenschap te 
combineren. Ik hoop dan ook van harte dat ik aan je verwachtingen heb voldaan! Jouw enthousiasme 
werkt absoluut aanstekelijk en is zelfs, tegen wil en dank, besmettelijk!  
Dr. P.W.M. Hermans, beste Peter, diezelfde 5½ jaar geleden moest je het nog maar zien. Wie had toen 
kunnen denken dat medici een significant onderdeel zouden gaan vormen van het laboratorium 
kindergeneeskunde in het algemeen en jouw groep in het bijzonder. Ik weet zeker dat ik jou niet heb 
teleurgesteld. We hebben tot op heden een aantal mooie studies gerealiseerd en “ who knows what the 
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future will bring…….? Thanks so far!” (En zeker voor de vele marathon sessies manuscripten 
corrigeren!). 
Marcel Sluijter, lieve Marcel, mijn paranimf, mijn buddy, mijn partner in crime (research)! Alles hebben 
we samen gedaan. Uniek denk ik. Ik zal je de komende jaren missen, maar wie weet komt er nog eens 
een nieuwe uitdaging  waar we samen onze tanden in kunnen zetten..........Dank! 
Mijn 2e paranimf en grote broer, lieve Roy, vroeger een twee-eenheid, nu rijdt ieder van ons zijn eigen 
koers. Desondanks absoluut wederzijds respect. Ik ben trots op jou en op je gezin, enneh....... die twee 
roodharige monstertjes van je zijn goud waard! 
Drs. R.H. Veenhoven, beste Reinier, nog even en je bent een zeergeleerde heer! Voor mij ben je dat 
toch al. Ik heb bewondering voor de manier waarop en het enthousiasme waarmee je de OMAVAX 
studie en alles eromheen hebt gerund. Bedankt dat ik daar onderdeel van mocht zijn, ik had het voor 
geen goud willen missen!! 
Prof. Dr. E.A.M. Sanders, beste Lieke, een mens kiest altijd bewust of onbewust zijn rolmodel, en jij 
bent de mijne! Dank voor je onvoorwaardelijke hulp, je persoonlijke benadering was een enorme steun! 
Prof. Dr. A. van Belkum, beste Alex, maar weinigen hebben het vermogen om puur op zichzelf te 
vertrouwen en tegelijkertijd zichzelf te zijn, maar jij bent zo’n persoon! Het was een eer om jouw advies 
en commentaar te mogen ontvangen. Bedankt dat je in de commissie wilde plaatsnemen. 
Prof. Dr. H. Hooijkaas en Prof. Dr. A. Finn, thank you for being committee members! I’m honored.... 
Dr. D.A.Watson and Dr. F.N. Watson. Dear Fay and David, beyond all doubt you were the supporting 
bystanders in the beginning of ‘my race’. Even in one of the toughest periods of my live, you kept on 
believing in me. Without any personal benefit, you teached, motivated and supported me. Without you, 
this work would not have been initiated. I will always be grateful for that! All the best to you, Emily, Ross, 
Jon and Zach. 
De samenwerkende groepen uit binnen en buitenland, zonder hen was dit boekje er niet geweest en 
was het werk zeker niet zo uitdagend en leuk geweest. Bedankt alle mensen van OMAVAX, en COPE; 
in het bijzonder dank aan de groep van Prof. Dr. H.A. Verbrugh, Hans Rümke en medewerkers van 
Vaxinostics en alle anderen die zich voor onze eigen AHOY studie hebben ingezet; bedankt Kees 
Elzenaar en collega’s van het LIS, RIVM; thanks to our foreign colleagues Nguen Ha en coworkers from 
Vietnam, Prof. Dr. George Syrogiannopoulos and colleagues from Greece, Dr. Helena Kayhty and co-
workers from Finland and Dr. Tim Mitchell and collegues from Scotland. Maybe we will be able to 
continue our cooperation in the future.... 
Dan kom ik toch ook op een aantal groepen mensen uit. Allereerst alle mensen van de subgroep 
infectieziekten en immunologie, bedankt voor de gemoedelijke sfeer tijdens zowel de 
maandagochtendbesprekingen als onze congressen en uitjes! De medewerkers van het lab 
kindergeneeskunde, het was leuk, leerzaam en gezellig. Ik mis ze nu al, de lab dagen, de kerstfeestjes, 
de taartenbakwedstrijden, de wijnproeverijen en de toertoto’s. Ik hoop dat ik af en toe nog eens langs 
mag komen.......  
‘De partij’, opgericht uit baldadigheid, uitgegroeid tot vriendenclub. Bedankt voor de vele borrels, met als 
hoogtepunt onze Hurricanes. Dat er nog vele vergaderingen mogen volgen....... 
De AIO’s, arts-onderzoekers en tegenwoordig ook AGIKO’s; een zeer heterogene groep gemotiveerde 
mensen die de afgelopen jaren een behoorlijk verloop heeft gekend. Vanwege de fysieke afstand was 
er geen frequent contact, maar op de weekendjes, borrels  en promoties hebben we heel wat gedeeld 
met elkaar. Ik zou zeggen......tot de volgende promotie en ‘we will meet’ in de kliniek!  
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De arts-assistenten groep; ook jullie hebben een enorm verloop gekend, velen zijn gekomen, vanuit 
kliniek of onderzoek, en velen zijn gegaan, als kinderarts of anderszins. Als je samen assistent bent 
merk je dat dat allemaal niet uitmaakt, samen moet je het tenslotte doen. Die bewustwording heeft de 
laatste jaren geresulteerd in een hechte groep mensen, die met elkaar kunnen lachen en huilen, die 
elkaar steunen en in elkaar geïnteresseerd zijn. Ik hoop dat dat nog lang zo blijft!  
Dan ons eigen clubje, Lieve Peter A., je bent nu alweer bijna een jaar weg maar we missen je nog 
steeds! Dank voor de mopperpraatjes, brainstormsessies en gezelligheid. Laten we snel weer gaan 
zeilen....... Beste Anja, ook jij bent al weer een paar jaar weg! Wat gaat de tijd toch snel..... Bedankt 
voor al je hulp! Theo, kamergenoot en hart van de groep, bedankt voor alles. Ingrid, ook wij hebben het 
laatste half jaar samen mogen werken. Bedankt voor je hulp en ‘keep up the good work’. Lieve Sylvia, 
ondertussen ook alweer een aantal jaren in het lab. Een constante factor die zo nu en dan verrassend 
uit de hoek kan komen. Bedankt voor onder andere onze petekind praatjes! Beste Marieke, opvolgster 
in de lijn der promovendi en in de lijn der AGIKO’s. Ik hoop dat ik het pad een beetje voor je geëffend 
heb. Succes met alles, en ik zie je....... Vishal en Wouter, succes met de staven en kokken! Saskia, 
helaas hebben onze wegen elkaar net gekruist, maar ik zal zeker met interesse ‘de competitie’ 
volgen....! De stagiaires die de afgelopen jaren allemaal op eigen wijze hebben bijgedragen aan dit 
boekje; Peter van T, Nayat, Maartje, Michiel, Nicole en Reshmi, ook jullie enorm bedankt voor al het 
mooie werk. Veel succes met jullie toekomst en geniet ervan! 
De stafleden en mede assistenten van het MCRZ locatie Zuider, ik had geen betere perifere 
opleidingsplek kunnen bedenken! Bedankt voor alle leermomenten, blijken van interesse en 
gezelligheid.  
Dan heb je natuurlijk met sommige mensen nog een bijzondere band: Marjolein, Marli, en Natasja, 
bedankt voor onze gezellige ‘stedentripjes’, hopelijk volgen er nog vele. Ingrid, Wendy en Esther, een 
gemeenschappelijke jeugd verbind ons, fantastisch toch? Ik hoop dat we deze band nog lang 
volhouden. Simone en Martijn, het is leuk om samen met jullie op te gaan in het leven. Onze etentjes 
zou ik dan ook niet willen missen! Lieve Clementien, de rust en tegelijkertijd openheid waarmee je in het 
leven staat, knap hoe jij moeder, dokter en onderzoeker zijn combineert! Ik hoop dat onze vriendschap, 
nog  lang mag blijven bestaan. Lieve Annemarie, we zijn erachter gekomen dat we toch echt hetzelfde 
willen! Dat schept een band die we ondertussen omgezet hebben in vriendschap. Op onze toekomst 
duo fio! Lieve Mariëlle, recent werden we maatjes, ik mis je enorm nu jij in het Sophia zit! Ik ben blij dat 
we collega’s zijn....... 
Lieve mam. Het leven is niet altijd even rooskleurig voor je geweest, maar het feit dat je kinderen en 
zeker ook je kleinkinderen het zo goed doen geven je zichtbaar energie! Alhoewel je waarschijnlijk niet 
altijd meer begrijpt waar je dochter mee bezig is,  ben je toch onvoorwaardelijk trots op me. Bedankt 
daarvoor, enneh........... geniet van het leven! 
Mijn lieve vader, jij bent een van de weinigen die de laatste jaren mijn ups en downs, mijn 
onzekerheden, zorgen, maar ook mijn overwinningen heeft gekend. Bedankt voor je altijd luisterende 
oor, de momenten van reflectie en de motiverende woorden. Samen met Marjolein en Pim wens ik je 
veel geluk!  
Lieve Tonny, deze koers hebben we samen gereden, dit keer liet ik de wielen draaien en reed jij 
ernaast, adviserend, steunend en nu en dan stiekem duwend als ik er even doorheen zat. Vandaag is 
de finish bereikt. Nu even nagenieten, en morgen .......... gewoon weer verder. Een nieuwe dag, een 
nieuwe etappe, nieuwe kansen en nieuwe uitdagingen. De wereld is mooi. Let’s go on .............. 
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